---
document_datetime: 2023-09-21 18:09:09
document_pages: 138
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/nerventra-epar-refusal-public-assessment-report_en.pdf
document_name: nerventra-epar-refusal-public-assessment-report_en.pdf
version: success
processing_time: 93.7483691
conversion_datetime: 2025-12-17 15:20:18.028102
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 May 2014 EMA/451905/2014 Committee for Medicinal Products for Human Use (CHMP)

## Nerventra

laquinimod

Procedure No. EMEA/H/C/002546

Applicant: Teva Pharma GmbH

Assessment report as adopted by the CHMP with all commercially confidential information deleted

●

7 Westferry Circus

Canary Wharf

+44 (0)20 7418 8400

●

London E14 4HB

Facsimile

●

United Kingdom

+44 (0)20 7523 7455

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................8                                |                                                                                                           |
|---------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier .....................................................................................8     |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                        | ........................................................9                                                 |
| 1.3. Steps taken for the re-examination procedure                                                                         | ....................................................... 10                                                |
| 2. Scientific Discussion..............................................................................11                  |                                                                                                           |
| 2.1. Introduction                                                                                                         | ...................................................................................................... 11 |
| 2.2. Quality aspects..................................................................................................    | 12                                                                                                        |
| 2.2.1. Introduction ...................................................................................................   | 12                                                                                                        |
| 2.2.2. Active Substance.............................................................................................      | 12                                                                                                        |
| 2.2.3. Finished Medicinal Product................................................................................         | 14                                                                                                        |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects                                                      | ............................. 16                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                 | ...................... 16                                                                                 |
| 2.2.6. Recommendation(s) for future quality development.............................................                      | 16                                                                                                        |
| 2.3. Non-clinical aspects............................................................................................     | 17                                                                                                        |
| 2.3.1. Introduction ...................................................................................................   | 17                                                                                                        |
| 2.3.2. Pharmacology.................................................................................................      | 17                                                                                                        |
| 2.3.3. Pharmacokinetics ............................................................................................      | 19                                                                                                        |
| 2.3.4. Toxicology......................................................................................................   | 20                                                                                                        |
| 2.3.5. Ecotoxicity/environmental risk assessment.........................................................                 | 26                                                                                                        |
| 2.3.6. Discussion on non-clinical aspects .....................................................................           | 27                                                                                                        |
| 2.3.7. Conclusion on the non-clinical aspects ...............................................................             | 34                                                                                                        |
| 2.4. Clinical aspects..................................................................................................   | 34                                                                                                        |
| 2.4.1. Introduction                                                                                                       | ................................................................................................... 34    |
| 2.4.2. Pharmacokinetics ............................................................................................      | 36                                                                                                        |
| 2.4.3. Pharmacodynamics..........................................................................................         | 39                                                                                                        |
| 2.4.4. Discussion on clinical pharmacology ..................................................................             | 40                                                                                                        |
| 2.4.5. Conclusions on clinical pharmacology.................................................................              | 41                                                                                                        |
| 2.5. Clinical efficacy..................................................................................................  | 42                                                                                                        |
| 2.5.1. Dose response studies .....................................................................................        | 42                                                                                                        |
| 2.5.2. Main studies ...................................................................................................   | 43                                                                                                        |
| 2.5.3. Discussion on clinical efficacy............................................................................        | 77                                                                                                        |
| 2.5.4. Conclusions on the clinical efficacy ....................................................................          | 84                                                                                                        |
| 2.6. Clinical safety .................................................................................................... | 84                                                                                                        |
| 2.6.1. Patient exposure                                                                                                   | ............................................................................................. 84          |
| 2.6.2. Adverse events                                                                                                     | ............................................................................................... 85        |
| 2.6.3. Serious adverse event/deaths/other significant events.........................................                     | 87                                                                                                        |
| 2.6.4. Laboratory, ECG findings, Vital signs .................................................................            | 93                                                                                                        |
| 2.6.5. Safety in special populations.............................................................................         | 96                                                                                                        |
| 2.6.6. Safety related to drug-drug interactions and other interactions.............................                       | 96                                                                                                        |
| 2.6.7. Discontinuation due to adverse events...............................................................               | 96                                                                                                        |
| 2.6.8. Post marketing experience ...............................................................................          | 97                                                                                                        |
| 2.6.9. Additional analyses..........................................................................................      | 97                                                                                                        |
| 2.6.10. Discussion on clinical safety............................................................................         | 98                                                                                                        |
| 2.6.11. Conclusions on the clinical safety...................................................................             | 101                                                                                                       |

<div style=\"page-break-after: always\"></div>

| 2.7. Pharmacovigilance ...........................................................................................   | 101                                                                                                     |
|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 2.8. Risk Management Plan......................................................................................      | 101                                                                                                     |
| 2.9. User consultation ............................................................................................. | 106                                                                                                     |
| 3. Benefit-Risk Balance ........................................................................... 106              | 3. Benefit-Risk Balance ........................................................................... 106 |
| 4. Recommendations...............................................................................111                 | 4. Recommendations...............................................................................111    |
| 5. Re-examination of the CHMP opinion of 23 January 2014 ...................111                                      | 5. Re-examination of the CHMP opinion of 23 January 2014 ...................111                         |
| 5.1. Detailed grounds for re-examination submitted by the applicant ............................                     | 112                                                                                                     |
| 5.2. Additional expert consultation............................................................................      | 122                                                                                                     |
| 5.3. Overall conclusion on grounds for re-examination ................................................               | 127                                                                                                     |
| 5.4. Updated Benefit-Risk Balance............................................................................        | 132                                                                                                     |
| 5.5. Recommendations following re-examination........................................................                | 137                                                                                                     |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| 9-HPT   | 9-Hole Peg Test                                                            |
|---------|----------------------------------------------------------------------------|
| ACTH    | Adrenocorticotropic Hormone                                                |
| AE      | Adverse Event                                                              |
| AhR     | Aryl hydrocarbon receptor                                                  |
| ALT     | Alanine transaminase/Alanine Aminotransferase                              |
| ANCOVA  | Analysis of Covariance                                                     |
| AST     | Aspartate transaminase/Aspartate Aminotransferase                          |
| AUC     | Area Under Curve                                                           |
| AV      | Atrioventricular                                                           |
| BCS     | Biopharmaceutical Classification System                                    |
| CALUX   | Chemically-Activated Luciferase Expression                                 |
| CDP     | Confirmed Disability Progression                                           |
| CEP     | Certificate of Suitability to the monographs of the European Pharmacopoeia |
| CGR     | Country and Geographical Region                                            |
| CHMP    | Committee for Medicinal Products for Human Use                             |
| CI      | Confidence Interval                                                        |
| Cmax    | Maximum Plasma Concentration                                               |
| Cmin    | Minimum Plasma Concentration                                               |
| CNS     | Central Nervous System                                                     |
| CO      | Completers (cohort)                                                        |
| CPRD    | Clinical Practice Research DataLink                                        |
| CQA     | Critical Quality Attribute                                                 |
| CRP     | C-Reactive Protein                                                         |
| CTCAE   | Common Terminology Criteria for Adverse Events                             |
| CYPs    | Cytochromes                                                                |
| DELAQ   | N-deethylated metabolite                                                   |
| DLC     | Dioxin-like compounds                                                      |
| DMSO    | Dimethyl sulfoxide                                                         |
| DMT     | Disease Modifying Therapy                                                  |
| DOE     | Design of Experiments                                                      |
| DVT     | Deep Venous Thrombosis                                                     |
| EAE     | Experimental Autoimmune Encephalomyelitis                                  |
| EC      | European Commission                                                        |
| EC20    | Effective concentration at 20%                                             |
| ECG     | Electrocardiogram                                                          |
| ED50    | Effective dose at 50% (Median Effective Dose)                              |
| ED90    | Effective dose at 90%                                                      |
| EDSS    | Expanded Disability Status Scale                                           |
| EMA     | European Medicines Agency                                                  |
| EQ-5D   | European Quality of Life-5 Dimensions Health Survey                        |

<div style=\"page-break-after: always\"></div>

| ER        | Estrogen Receptor                                                            |
|-----------|------------------------------------------------------------------------------|
| ERA       | Environmental Risk Assessment                                                |
| ESR       | Erythrocyte Sedimentation Rate                                               |
| EU        | European Union                                                               |
| EV        | Evaluable (cohort)                                                           |
| FMEA      | Failure Mode Effect Analysis                                                 |
| GA        | Glatiramer Acetate                                                           |
| GC        | Gas Chromatography                                                           |
| GCP       | Good Clinical Practices                                                      |
| GD        | Gestation Day                                                                |
| Gd        | Gadolinium                                                                   |
| GdE       | Gadolinium Enhancing                                                         |
| GGT       | Gamma Glutamyl Transferase                                                   |
| GI        | Gastrointestinal                                                             |
| GLP       | Good Laboratory Practices                                                    |
| GPRD      | General Practice Research Database                                           |
| HCT       | Hematocrit                                                                   |
| hERG      | human ether-a-go-go-related gene                                             |
| HIV       | Human Immunodeficiency Virus                                                 |
| HPLC      | High Performance Liquid Chromatography                                       |
| HR        | Hazard Ratio                                                                 |
| I3C       | Indol-3-Carbinol                                                             |
| ICH       | International Conference On Harmonization                                    |
| IFN       | Interferon                                                                   |
| Ig        | Immunoglobulin                                                               |
| IHD       | Ischaemic Heart Disease                                                      |
| IM or i.m | Intramuscular                                                                |
| IR        | Infrared                                                                     |
| ITT       | Intention to Treat                                                           |
| IV or i.v | Intravenous                                                                  |
| IVRS      | Centralised Interactive Voice Response System                                |
| IWRS      | Interactive Web Response System                                              |
| KF        | Karl Fisher                                                                  |
| KLH       | Keyhole Limpet Hemocyanin                                                    |
| Kow       | Octanol/water partition coefficient                                          |
| LAQ       | Laquinimod                                                                   |
| LC-MS/MS  | Liquid Chromatography Tandem Mass Spectrometry                               |
| LDPE      | Low density polyethylene                                                     |
| LOAEL     | Lowest Observed Adverse Effect Level                                         |
| MCQME     | methyl 5-chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-quinoline-3-carboxylate |
| MCV       | Mean Cell Volume                                                             |
| MFIS      | Modified Fatigue Impact Scale                                                |
| MNAR      | Missing Not At Random                                                        |
| MNBN      | Micronucleated Binucleated (cell)                                            |

<div style=\"page-break-after: always\"></div>

| MRI    | Magnetic Resonance Imaging                                        |
|--------|-------------------------------------------------------------------|
| MS     | Multiple Sclerosis                                                |
| MSFC   | Multiple Sclerosis Functional Composite                           |
| MTD    | Maximum Tolerated Dose                                            |
| Nb     | Number                                                            |
| NF κ B | Nuclear Factor kappa Light-Chain-Enhancer of Activated B          |
| NK     | Natural Killer (cell)                                             |
| NMR    | Nuclear magnetic resonance                                        |
| NOAEL  | No-Observed-Adverse-Effect-Level                                  |
| NOEL   | No-Observed-Effect-Level                                          |
| NONMEM | Nonlinear Mixed Effects Modeling Methodology                      |
| NRU    | Neutral Red Uptake                                                |
| NTP    | National Toxicology Program                                       |
| p.o    | Per os                                                            |
| PAR    | Proven Acceptable Ranges                                          |
| PASAT  | Paced Auditory Serial Addition Test                               |
| PBMC   | Peripheral Blood Mononuclear Cells                                |
| PBVC   | Percent brain volume change                                       |
| PD     | Pharmacodynamic                                                   |
| PDCO   | Paediatric Committee                                              |
| PECsw  | Predicted Environmental Concentration in the surface water        |
| Ph Eur | European Pharmacopoeia                                            |
| PHA    | Phytohemagglutinin                                                |
| PIP    | Paediatric Investigation Plan                                     |
| PK     | Pharmacokinetic                                                   |
| PML    | Progressive multifocal leukoencephalopathy                        |
| PND    | Post Natal Day                                                    |
| PP     | Per Protocol                                                      |
| PPMS   | Primary Progressive Multiple Sclerosis                            |
| PRAC   | Pharmacovigilance Risk Assessment Committee                       |
| PRL    | Prolactin                                                         |
| QbD    | Quality by Design                                                 |
| QTCB   | QT Interval Corrected For Heart Rate Using the Bazett Formula     |
| QTCF   | QT Interval Corrected For Heart Rate Using the Fridericia Formula |
| QTCI   | Individually Corrected QT Interval                                |
| QTPP   | Quality Target Product Profile                                    |
| RBC    | Red Blood Cell                                                    |
| RH     | Relative Humidity                                                 |
| RMP    | Risk Management Plan                                              |
| RMS    | Relapsing Multiple Sclerosis                                      |
| RR     | Rate Ratio                                                        |
| RRMS   | Relapsing Remitting Multiple Sclerosis                            |
| SAE    | Serious Adverse Event                                             |
| SD     | Sprague Dawley                                                    |

<div style=\"page-break-after: always\"></div>

| SD      | Standard Deviation                                          |
|---------|-------------------------------------------------------------|
| SEER    | Surveillance Epidemiology and End Results                   |
| SF-36   | Short Form 36 Health Survey                                 |
| SIR     | Standardized incidence ratio                                |
| SLE     | Systemic Lupus Erythematosus                                |
| SmPC    | Summary of Product Characteristics                          |
| SMQ     | Standardised MedDRA Queries                                 |
| SMR     | Standard Maintenance Diet                                   |
| SOC     | System Organ Class                                          |
| SPMS    | Secondary Progressive Multiple Sclerosis                    |
| SWP     | Safety Working Party                                        |
| T25FW   | Timed -25- Foot-Walk                                        |
| TCDD    | 2,3,7,8-tetrachlorodibenzo-p-dioxin                         |
| TK      | Toxicokinetic                                               |
| Tmax    | Time to maximum plasma concentration                        |
| TSE     | Transmissible spongiform encephalopathy                     |
| UDS     | Unscheduled DNA synthesis                                   |
| UGT     | UDP-glucuronosyltransferase                                 |
| UKNEQAS | United Kingdom National External Quality Assessment Service |
| ULN     | Upper Limit of Normal                                       |
| USA     | United States of America                                    |
| UV      | Ultraviolet                                                 |
| v.s     | Versus                                                      |
| WBC     | White Blood Cell                                            |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The  applicant  Teva  Pharma  GmbH  submitted  on  26  June  2012  an  application  for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMA)  for  Nerventra,  through  the  centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 14 April 2011.

The applicant applied for the following indication: treatment of patients with relapsing remitting multiple sclerosis (RRMS).

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application. The applicant indicated that laquinimod was considered to be a new active substance.

The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision, P/0027/2012, on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0027/2012 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## New active Substance status

The applicant requested the active substance laquinimod contained in the above medicinal product to be considered as a new active substance in itself, as the applicant claims that it is not a constituent of a product previously authorised within the Union.

## Scientific Advice

The applicant received Scientific Advice from the CHMP on 21 June 2007. The Scientific Advice pertained to non-clinical and clinical aspects of the dossier.

<div style=\"page-break-after: always\"></div>

## Licensing status

The product was not licensed in any country at the time of submission of the application.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur: Pierre Demolis Co-Rapporteur: Martina Weise

- The application was received by the EMA on 26 June 2012.
- The procedure started on 18 July 2012.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 8 October 2012. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 5 November 2012.
- During the meeting on 15 November 2012, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 16 November 2012.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 24 May 2013.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 3 July 2013.
- During the PRAC meeting on 11 July 2013, the PRAC adopted an RMP Advice and assessment overview.
- During the CHMP meeting on 25 July 2013, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant.
- The applicant submitted the responses to the CHMP List of Outstanding Issues on 18 October 2013.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on 31 October 2013 and 4 November 2013.
- On 13 November 2013, the PRAC adopted an RMP Advice and assessment overview via written procedure.
- During the CHMP meeting on 21 November 2013, the CHMP agreed on a Second list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant.
- The applicant submitted the responses to the Second CHMP List of Outstanding Issues on 29 November 2013.
- The Rapporteur circulated the Assessment Report on the applicant's responses to the Second List of Outstanding Issues to all CHMP members on 6 December 2013.
- During a meeting of a Safety Working Party (SWP) on 3 December 2013, experts were convened to address questions raised by the CHMP.
- On 12 December 2013, the PRAC adopted an RMP Advice and assessment overview via written procedure.

<div style=\"page-break-after: always\"></div>

- During the CHMP meeting on 17 December 2013, outstanding issues were addressed by the applicant during an oral explanation.
- During the meeting on 23 January 2014, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a negative opinion for granting a Marketing Authorisation to Nerventra.

## 1.3. Steps taken for the re-examination procedure

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur:

Greg Markey

Co-Rapporteur:

Arantxa Sancho-Lopez

PRAC Rapporteur: Julie Williams

PRAC Co-Rapporteur: Dolores Montero Corominas

- The applicant submitted written notice to the EMA on 4 February 2014 to request a re-examination of Nerventra CHMP opinion of 23 January 2014.
- During its meeting on 17-20 February 2014, the CHMP appointed Greg Markey as Rapporteur and Arantxa Sancho-Lopez as Co-Rapporteur.
- The applicant submitted the detailed grounds for the re-examination on 24 March 2014. The re-examination procedure started on 25 March 2014.
- The Rapporteur's Assessment Report was circulated to all CHMP members on 17 April 2014. The Co-Rapporteur's Assessment Report was circulated to all CHMP members on 16 April 2014.
- During a meeting of the Safety Working Party (SWP) on 30 April 2014, experts were convened to address questions raised by the CHMP.
- During a meeting of the Scientific Advisory Group (SAG) on 8 May 2014, experts were convened to consider the grounds for re-examination.
- During the PRAC meeting on 5-8 May 2014, the PRAC adopted a PRAC advice on the questions raised by the CHMP.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's detailed grounds for re-examination to all CHMP members on 13 May 2014.
- During the CHMP meeting on 19-22 May 2014, the detailed grounds for reexamination were addressed by the applicant during an oral explanation before the CHMP.
- During the meeting on 19-22 May 2014, the CHMP, in the light of the scientific data available and the scientific discussion within the Committee, the CHMP re-examined its initial opinion and in its final opinion concluded that the application did not satisfy the criteria for authorisation and did not recommend the granting of the  marketing authorisation.

<div style=\"page-break-after: always\"></div>

## 2. Scientific Discussion

## 2.1. Introduction

Laquinimod  (Nerventra)  is  an  oral  quinoline-3-carboxamide  and  is  a  derivative  of  a  parent compound,  roquinimex,  a  drug  previously  evaluated  in  clinical  trials  for  Multiple  Sclerosis  (MS) treatment and that had been discontinued due to safety concerns (see 2.6). Laquinimod showed beneficial effects in animal models of experimental autoimmune encephalomyelitis (EAE) used in MS  drug  development.  However,  the  mechanism  of  action  of  laquinimod  is  not  fully  elucidated because the molecular target is not known.

The  following  indication  was  initially  applied  for:  treatment  of  patients  with  relapsing  remitting multiple sclerosis (RRMS). The proposed posology was a single oral daily dose of 0.6 mg.

Multiple  sclerosis  is  a  chronic,  progressive,  autoimmune,  debilitating  neurodegenerative  disorder with  multifocal  demyelination  affecting  the  brain,  optic  nerves,  and  spinal  cord  and  this  process leads to neurological impairment and severe disability. It is one of the most common neurological diseases in young adults and the leading cause of non-traumatic disability in young and middleaged adults. Typically, it begins in the second or third decade of life. In 2008, the global incidence was  estimated  at  2.5  individuals  per  100 000  and  the  global  prevalence  was  estimated  at  30 individuals per 100 000, with women being at a two times higher likelihood to develop MS than men. Regionally, the estimated median prevalence of MS is greatest in Europe (80 per 100 000), followed by the Eastern Mediterranean (14.9 per 100 000), the Americas (8.3 per 100 000), the Western Pacific (5 per 100 000), Southeast Asia (2.8 per 100 000), and Africa (0.3 per 100 000).

The  classification  of  MS  into  4  distinct  clinical  categories  was  suggested  by  Lublin  and  Reingold shortly after the availability of the first disease-modifying treatments as a means to aid physicians in providing care. The following categories were included: relapsing-remitting (RR) MS, with clearly defined disease relapses (clinical attacks) with full recovery or with sequelae and residual deficit upon recovery, and with periods between relapses characterized by a lack of disease progression; secondary-progressive (SP) MS, with continuous neurological decline with or without superimposed relapses, that follows an initial period of RR disease; Primary-progressive (PP) MS, characterized by a slow worsening from onset, without superimposed relapses; and progressive-relapsing (PR) MS, indicating slow worsening from the onset, but with superimposed relapse events as well.

Relapsing forms of MS are the most frequent clinical presentation of the disease. Eighty-two (82) to  85  %  of  all  patients  present  with  relapsing-remitting  MS  (RRMS),  which  is  characterised  by unpredictable  acute  episodes  of  neurological  dysfunction  named  relapses,  followed  by  variable recovery  and  periods  of  clinical  stability.  Within  ten  years  more  than  50%  of  patients  who presented with a RR form eventually develop sustained deterioration with or without superimposed relapses; this form is called the secondary progressive variety of MS (SPMS).

The term relapsing MS (RMS) applies to those patients either with a RRMS form or a SPMS form that  are  suffering  relapses.  Patients  with  RMS,  in  spite  of  suffering  from  different  MS  forms, constitute a common target for current treatments.

Available  disease  modifying  therapies  (DMT)  for  MS  aim  to  prevent  relapses  and  ultimately  to diminish the accumulation of disability. Laquinimod is a novel orally administered therapy intended for the treatment of patients suffering from relapsing-remitting multiple sclerosis. Currently, three oral  MS  drugs  received  positive  opinions  by  the  CHMP  for  granting  their  initial  marketing authorisations in the European Union (EU), fingolimod (Gilenya) and teriflunomide (Aubagio) which were authorised respectively in March 2011 and August 2013; and dimethyl fumarate (Tecfidera) which is awaiting Commission Decision. The other available MS drugs are parenteral formulations

<div style=\"page-break-after: always\"></div>

and  include  first  line  interferons-beta  therapies,  glatiramer  acetate,    natalizumab  (Tysabri)  and Alemtuzumab  (Lemtrada).  Lemtrada  was  recently  authorised  in  September  2013.  Tecfidera, together with Aubagio were recommended an indication for treatment of adult patients with RRMS by the CHMP. Lemtrada is specifically indicated for adult patients with relapsing remitting multiple sclerosis  with  active  disease  defined  by  clinical  or  imaging  features.  Due  to  their  safety  profiles (e.g.  risk  of  opportunistic  infections  and  secondary  malignancies),  Gilenya  and  Tysabri  were considered as second line options at the time of their initial marketing authorisations.

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as immediate release hard gelatin capsules containing 0.6 mg of laquinimod, as laquinimod sodium, as active substance.

Other ingredients are: mannitol, meglumine and sodium stearyl fumarate. The capsules shells are made of gelatin and titanium dioxide (E171); and the printing ink is composed of shellac, ethanol, iron oxide black (E172), propylene glycol (E1520), and ammonium hydroxide (E527).

The  product  is  available  in  aluminum/aluminum  blisters  or  high-density  polyethylene  bottles capped with child-resistant closure.

## 2.2.2. Active Substance

The chemical name of laquinimod sodium is sodium 5-chloro-3-(ethylphenylcarbamoyl)-1-methyl2-oxo-1,2-dihydroquinolin-4-olate and has the following structure:

<!-- image -->

The  structure  of  laquinimod  sodium  has  been  confirmed  by  elemental  analysis  (C/H/N/Cl)  and spectroscopic analysis (UV, IR,  1 H-NMR and  13 C-NMR) and mass spectrometry.

Laquinimod is a white to off-white slightly hygroscopic crystalline powder.

It is a BCS Class I (highly soluble-highly permeable) compound. It is slightly soluble in DMF and ethanol; sparingly soluble in DMSO and methanol; and practically insoluble in acetone, acetonitrile and isopropanol.

Laquinimod has a non-chiral molecular structure.

Polymorph screening studies of laquinimod sodium identified several possible crystalline forms. It has been demonstrated that the proposed route of synthesis leads to crystalline form A, which is the most physically stable solid form.

The other forms , all convert to Form A under exposure to elevated temperatures.

<div style=\"page-break-after: always\"></div>

## Manufacture

Laquinimod  sodium  is  synthesized  in  five  main  steps  using  commercially  available  well-defined starting materials with acceptable specifications. The main steps include preparation of laquinimod, preparation of crude laquinimod sodium and purification.

The  manufacturing  process  has  been  developed  using  a  combination  of  conventional  univariate studies  and  elements of  QbD  such  as  risk  assessment  and  design  of  experiment  (DOE)  studies. Based  on  these  studies,  proven  acceptable  ranges  have  been  defined  for  the  five  steps  of  the manufacturing  process  of  the  active  substance.  The  available  development  data,  the  proposed control strategy and batch analysis data from commercial scale batches fully support the proposed proven acceptable ranges (PARs).

The  characterisation  of  the  active  substance  and  its  impurities  are  in  accordance  with  the  EU guideline on chemistry of new active substances. Potential and actual impurities, including potential genotoxic impurities, have been well discussed with regards to their origin and characterised, and they  are  controlled  by  appropriate  limits.  However,  further  information  regarding  the  limit  of detection  of  the  analytical  methods  used  to  characterize  two  potential  impurities  has  not  been provided at the time of opinion. The applicant is recommended to provide this information postapproval. This is considered acceptable since the maximum daily dose of the product is very low (0.6 mg/day) and these impurities do not contain any structural alert of genotoxicity. In addition, these  impurities  were  either  not  detected  in  stability  studies  carried  under  long  term  and accelerated conditions, or detected at levels below 0.05%.

Adequate  in-process  controls  are  applied  during  the  synthesis.  The  specifications  and  control methods for intermediate products, starting materials and reagents have been presented.

Validation of the process has been performed on three consecutive commercial scale batches.

## Specification

The  active  substance  specification  includes  tests  for  description,  identification  (HPLC,  IR,  UV, sodium), assay (HPLC), impurities (HPLC), water content (KF), heavy metals (Ph. Eur.), sodium content  (potentiometric  titration),  colour  of  solution  (Ph.  Eur.),  free  chloride  (Ph.  Eur.),  residual solvents (GC) and microbial purity test (Ph. Eur.).

The exclusion of polymorphism and particle size distribution from the specification is justified since laquinimod sodium is completely dissolved during the first step of the drug product manufacturing process.

The analytical methods used have been adequately described and non-compendial methods have been appropriately validated in accordance with the ICH guidelines.

The proposed specifications are considered adequate. However, the applicant is recommended to tighten the specification limits for one of the solvents  used in the manufacturing process of the active substance to bring them in line with the manufacturing capability, and further develop and revalidate its analytical method.

Batch analysis data six pilot scale and six commercial scale batches of the active substance are provided. The results are within the specifications and consistent from batch to batch.

## Stability

Stability data on four production scale batches of active substance from the proposed manufacturer stored for 24 months (3 batches) or 12 months (one batch) under long term conditions at 25 ºC / 60% RH and for up to 6 months under accelerated conditions at 40 ºC / 75% RH according to the ICH guidelines were provided.

<div style=\"page-break-after: always\"></div>

The  container  closure  of  the  batches  used  for  the  stability  studies  consisted  in  one  low  density polyethylene (LDPE) bag inserted into an aluminium bag, simulating the container closure proposed for storage and distribution (low density double polyethylene (LDPE) bag inserted in an aluminium bag).

The  following  parameters  were  tested:  appearance,  identification  (HPLC),  related  substances (HPLC),  water  content  (KF),  assay  (HPLC),  and  colour  of  solution.  The  analytical  methods  used were the same as for release and were stability indicating.

No significant changes or trends were observed in any of the parameters tested after storage at long term or accelerated conditions.

A photostability study performed in accordance with the ICH guideline Q1B was performed on one commercial scale batch, demonstrating that laquinimod sodium is photostable in the solid state.

Forced  degradation  studies  were  performed  by  treatment  with  heat,  acidic,  base  or  oxidizing conditions. The results from these studies showed that the drug substance is intrinsically stable in the powder form, with moderate degradation occurring for the drug in solution exposed to extreme conditions.

The  stability  results  indicate  that  the  drug  substance  manufactured  by  the  proposed  supplier  is sufficiently stable. The stability results justify the proposed retest period in the proposed container.

## 2.2.3. Finished Medicinal Product

## Pharmaceutical Development

A comprehensive  overview on the history of laquinimod 0.6 mg  hard  gelatine capsules development has been provided. The first Phase I studies were performed with an aqueous oral solution of laquinimod free acid. For the Phase II studies, laquinimod tablets of 0.05 mg, 0.25 mg and  0.3  mg  laquinimod  (as  the  sodium  salt)  were  developed.  The  proposed  commercial  is  the capsule formulation, which was used successfully for both Phase III trials and for the open-label extension of Phase IIb.

Bioequivalence  of  the  early  clinical  formulations  (oral  aqueous  solution  and  tablets)  and  the proposed commercial formulation, which was used in the pivotal trials, was shown by bioequivalence studies.

The selected excipients for laquinimod 0.6 mg capsules are mannitol used as a filler, meglumine used  as  an  alkalinizing  agent  to  improve  the  stability  of  the  formulation,  and  sodium  stearyl fumarate  used  as  a  lubricant,  all  of  which  are  well  known  pharmaceutical  ingredients  and  their quality  is  compliant  with  Ph.  Eur  standards.  There  are  no  novel  excipients  used  in  the  finished product formulation.

The  pharmaceutical  development  of  the  finished  product  was  based  on  the  Quality  by  Design principles.

The quality target product profile (QTPP) was defined as immediate release oral dosage form for a once  daily  administration  that  meets  compendial  and  other  relevant  quality  standards,  and  is packaged protected from light and moisture in a bottle and a blister configuration. The formulation should be stable for 24 or 36 months at room temperature.

Based on the QTPP, a number of quality attributes of the drug product that could potentially affect the  product  quality  were  identified.  In  accordance  with  ICH  Q6A,  and  taking  scientific  and  prior knowledge  into  consideration  when  evaluating  the  impact  of  the  quality  attributes  on  the  drug product safety and efficacy, several attributes were identified as Critical Quality Attributes (CQAs).

<div style=\"page-break-after: always\"></div>

The manufacturing process has been developed through the use of risk assessment to identify the critical  product  quality  attributes  and  critical  process  parameters.  A  risk  analysis  was  performed using the failure mode effect analysis (FMEA) method in order to define critical process steps and process parameters that may have an influence on the finished product quality attributes. The risk identification  was  based  on  the  prior  knowledge  as  well  as  on  the  experience  from  formulation development. Based on the outcome of the FMEA, a series of Design of Experiments (DOEs) were performed  in  order  to  gain  better  and  more  insightful  knowledge  of  the  formulation  and manufacturing process. The critical process parameters have been adequately identified.

The primary packaging is either aluminium/aluminium blisters or high density polyethylene bottles with child-resistant caps. The materials comply with Ph.Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## Adventitious agents

Gelatine obtained from bovine sources is used in the product. Valid TSE CEP from the supplier of the gelatine used in the manufacture is provided.

No other excipients derived from animal or human origin have been used.

## Manufacture of the product

The manufacture of laquinimod capsules is performed by two alternative manufacturers using a wet granulation procedure.

The  manufacturing  process  consists  of  several  steps:  wet  granulation,  fluid  bed  drying,  milling, capsule  filling  and  packaging.  Although  the  product  is  a  very  low  dosage  form,  it  has  been demonstrated that a uniform distribution of the drug substance in the drug product is obtained and the manufacturing process can be considered to be a standard process.

Proven  acceptable  ranges  have  been  defined  for  several  steps  of  the  medicinal  product.  The available development  data,  the proposed  control strategy and  batch  analysis data from commercial scale batches fully support the proposed PARs.

Process  validation  has  been  performed  on  four  and  three  production  scale  batches  at  the  two proposed manufacturing sites, respectively. The process validation data indicate that the manufacturing process is capable of consistently producing hard capsules of suitable quality which meet the release specifications.

## Product specification

The  finished  product  release  specifications  include  appropriate  tests  for  this  dosage  form  and include:  description,  identification  (HPLC,  UV),  dissolution  (HPLC),  uniformity  of  dosage  units (HPLC), assay (HPLC), impurities/degradation products (HPLC), water content (KF), identification of color  (Ph.  Eur.)  and  microbial  purity  (Ph.  Eur.).    The  finished  product  is  released  on the  market based on the above release specifications, through traditional final product release testing.

Batch analysis results are provided for 4 commercial scale batches from one manufacturer and 5 commercial scale batches from another manufacturer confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

## Stability of the product

Stability data on eight commercial scale batches, manufactured at the two proposed manufacturing sites,  stored  under  for  up  to  24  months  long  term  conditions  (25  ºC/60%  RH  ),  for  up  to  12 months under intermediate conditions (30 ºC/60% RH) and for up to 6 months under accelerated conditions  (40  ºC/75%  RH)  according  to  the  ICH  guidelines  were  provided.  The  batches  of Nerventra  are  representative  to  those  proposed  for  marketing  and  were  packed  in  the  primary packagings proposed for marketing (HDPE bottles and Alu/Alu blisters).

<div style=\"page-break-after: always\"></div>

Samples  were  tested  for  appearance,  dissolution  (HPLC),  assay  (HPLC),  impurities/degradation products,  water  content  (KF),  microbial  purity  (Ph.  Eur.).  The  analytical  procedures  used  are stability indicating.

All stability results are within specification with exception of two out of specification assay results observed at accelerated storage conditions at 6 month time point, which led to the inclusion of the special storage condition 'Do not store above 30 ºC'.

A  photostability  study  was  conducted  according  to  ICH  Q1B.  The  study  showed  that  the  drug product  is  not  stable  when  unpackaged  capsules  are  directly  exposed  to  light.  However,  all  the results  on  laquinimod  capsules  packaged  in  the  proposed  commercial  packaging  configurations were satisfactory and well within the specifications. Therefore, a statement to protect the capsules from exposure to direct light has been included in the product label.

In addition, an in-use stability study was performed as per Note for Guidance on in-use stability testing of human medicinal products (CPMP/QWP/2934/99) on capsules packed ion HDPE bottles. As no significant changes were observed in any of the test parameters, no declaration of an in-use shelf life or additional storage conditions is required.

Based on available stability data, the shelf-life and storage conditions as stated in the SmPC are acceptable.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

The applicant has applied QbD principles in the development of the active substance and finished product  and  their  manufacturing  process.  However,  no  design  spaces  were  claimed  for  the manufacturing process of the active substance, nor for the finished product.

At the time of the CHMP opinion, there were a number of minor unresolved quality issues having no impact on the Benefit/Risk ratio of the product.

The limits of detection of the analytical methods used to characterize two potential impurities of the active substance have not been provided. The specification limits of one of the solvents used in the synthesis of the active substance should be revised in the active substance specification based on the batch data results, and its analytical method should be revised and validated.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The  quality  of  this  product  is  considered  to  be  acceptable  when  used  in  accordance  with  the conditions proposed in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.2.6. Recommendation(s) for future quality development

In  the  context  of  the  obligation  of  the  MAHs  to  take  due  account  of  technical  and  scientific progress, the CHMP recommends the following points for investigation:

-To  determine  the  limits  of  detection  of  the  analytical  methods  used  to  characterize  the  two potential impurities.

<div style=\"page-break-after: always\"></div>

-To tighten the specification limits for one of the solvents used in the manufacturing process of the active substance to bring them in line with the manufacturing capability, and further develop and revalidate its analytical method.

## 2.3. Non-clinical aspects

All  main  safety  pharmacology  and  pivotal  toxicology  studies  were  performed  according  to  Good Laboratory Practices (GLP), as stated by the applicant.

## 2.3.1. Introduction

The non-clinical documentation for laquinimod consisted of primary and secondary pharmacological studies,  as  well  as  safety  pharmacology.  Furthermore,  pharmacokinetic  data  in  various  species were  provided.  The  toxicological  testing  programme  consisted  of  studies  addressing  general toxicity, genotoxicity, reproductive toxicity, carcinogenicity, local tolerance, immunotoxicity, phototoxicity and qualification of impurities.

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

The effect  of laquinimod was evaluated in the acute, chronic-relapsing, and chronic progressive experimental  autoimmune  encephalomyelitis  rodent  model.  In  these  studies,  the  effect  of laquinimod on disease progression was assessed using clinical evaluation of ascending paralysis.

In mouse and rat models of acute EAE, laquinimod reduced disease severity and was more potent than the structurally-related compound roquinimex. The ED50 and ED90 of laquinimod determined in the  murine  acute  EAE  model  were  approximately  20-fold  lower  than  that  of  roquinimex  ( ≈ 0.2 mg/kg  and  1  mg/kg  vs. ≈ 5  mg/kg  and  25  mg/kg,  respectively).  In  chronic  models  of  EAE, laquinimod  caused  reduction  in  the  severity  of  the  disease  either  in  prophylactic  or  therapeutic settings. In addition, the prophylactic treatment regimen led to a decrease in the incidence of the disease at the highest dose tested (25 mg/kg). The minimal doses showing effect were 1 mg/kg and 5 mg/kg in the prophylactic and therapeutic settings, respectively. An additional pharmacokinetic/pharmacodynamic  (PK/PD)  study  performed  in  a  mouse  model  of  chronic  EAE suggested that  the  effect  of  laquinimod  is  minimum  plasma  concentration  (Cmin)-driven.  Further investigations  in  these  models  of  chronic  EAE  showed  that  laquinimod-related  reductions  in demyelination of white matter in the spinal cord at ≥ 5 mg/kg/day in the prophylactic regimen and at 25 mg/kg/day in the therapeutic regimen. The data also provided support of myelin and axonal protecting  activity  of  laquinimod  in  animal  models  of  demyelinating  disease  ('chronic  EAE  and cuprizone-induced demyelinating disease in mice). It should be noted that the minor metabolite DELAQ was a more potent inhibitor of disease development than laquinimod.

It  was  shown  that  treatment  with  laquinimod  decreases  inflammatory  cell  infiltration  into  the Central  Nervous  System  (CNS)  in  different  models  of  MS,  as  well  as  the  secretion  of  proinflammatory cytokines. It was suggested that laquinimod is not acting as a general immunosuppressive/ immunotoxic agent, as there was no evidence of an effect of treatment on the primary (IgM) and secondary (IgG) humoral immune response against Keyhole Limpet Hemocyanin (KLH), on T- and B- cell numbers, and on cardiac allograft survival. In immunohistochemical acute EAE  studies  with  mice  and  rats  it  was  demonstrated  that  laquinimod  significantly  reduces  the infiltration of leukocytes in the central nervous system and inhibited the inflammation of both CD4 + T  cells  and  macrophages  into  central  nervous  tissues.  In  another  set  of  studies  laquinimod's

<div style=\"page-break-after: always\"></div>

potency  to  modulate  immune  responses  was  investigated.  A  dose-dependent  reduction  of  proinflammatory cytokines by antigen-specific T-cells was found. In addition, as the nuclear factor-κB (NF-κB)  is  an  important  transcription  factors,  which  can  activate  inflammatory  responses,  the putative  effects  of  laquinimod  on  NF-κB  activation  has  been  studied.  Some  data  also  suggested that  laquinimod  modulates  signalling  through  NF κ B  pathway  which  is  often  associated  with inflammatory diseases.

While acknowledging that the molecular target of laquinimod has not been identified, the applicant presented data on cellular effects or activities downstream this unidentified target to characterise the  mechanism  of  action  of  laquinimod  in  MS.  The  potential  of  quinolone-3  carboxamide compounds to bind to protein S100A9 has been described by Björk et  al, (2009)  as  a  target  of quinoline-3-carboxamide  compounds  underlying  their  immunomodulatory  activity.  Other  data obtained  with  compounds  of  similar  chemical  structures  suggest  that  laquinimod  could  bind  to S100A9. The CHMP also noted that recent publications pointed  out to  a  dual  role  of  S100A9  in inflammation and cancer (Gebhardt et al 2006, Ghavami et  al. ,  2009,  Goyette and Geczy 2011, Srikrishna et  al., 2012). In view of the claimed properties of laquinimod and the carcinogenicity findings (see 2.3.4), the CHMP requested further investigation of this protein and other proteins of S100 family as potential target for laquinimod. Additional experimental data were provided by the applicant  showing  that  laquiminod  was  still  active  in  animal  models  of  EAE  in  S100A9  knockout mice (which lack also S100A8) suggesting that S100A9 was not the molecular target of efficacy of laquinimod  in  this  model.  A  screening  for  the  binding  of  laquinimod  to  S100A8  (which  is  the dimerization  partner  of  S100A9  originally  hypothesized  as  the  target  of  laquinimod),  using  the technique of surface plasmon resonance was negative. The applicant committed to perform further testing of the binding of laquinimod to cells transfected with S100A8 cDNA to confirm the above results. Overall, the CHMP concluded that the mode of action of laquinimod remains unknown.

## Secondary pharmacodynamic studies

Data on other inflammatory/autoimmune disease models (inflammatory bowel disease; rheumatoid arthritis;  type  I  diabetes;  Guillain-Barre  Syndrome;  systemic  lupus  erythematosus  /  lupus nephritis)  were  presented  to  further  support  the  immunomodulatory  properties  of  laquinimod. Overall, laquinimod showed dose-dependent activity in these inflammatory disease models in the oral  dose  range  of  1-25  mg/kg  when  administered  prophylactically  or  semi-prophylactically whereas reduced activity or no effect was detected when administered after disease onset.

## Safety pharmacology programme

No potential effects of laquinimod on the CNS function (Irwin Test) and on gastrointestinal transit time were observed.

In vitro data using the hERG assay and in the Purkinje fiber assay (at concentrations approximately 30-fold  and  1.4-fold  the  clinical  maximum  plasma  concentration  (Cmax),  respectively  and considering total plasma drug concentration) did not identify any concerns on the cardiovascular function. Although the GLP-compliant in vivo cardio-respiratory study was conducted in anaesthetized dogs by the intravenous route and may therefore be viewed as not fully clinically relevant, no effect of laquinimod on cardiovascular parameters was reported at up to 20 mg/kg. Since  at  this  dose  level,  animals  were  288-  and  7.7-fold  more  exposed  than  humans  based  on Cmax and AUC, respectively, and in view of the in vitro data, the data seem sufficient to consider that  there  is  no  preclinical  concern  a  drug-related  arrhythmogenic  potential.This  is  supported further by the negative outcome of the QT/QTc study (see 2.4.3).

<div style=\"page-break-after: always\"></div>

At 20 mg/kg intravenous (i.v.), decreased peak expiratory and peak inspiratory flows were noted in anaesthetised dogs. These effects of laquinimod on the respiratory function were considered minor.

In male rats, there were some effects of laquinimod in urinary electrolyte concentrations (reduced sodium,  potassium,  chloride)  and  decreased  urine  volume  at  90  mg/kg.  At  30  mg/kg,  reduced sodium and chloride concentration in urine were reported. No effect was seen at 10 mg/kg. Based on toxicokinetic data obtained in rats, there is considerable safety margin for this effect.

## Pharmacodynamic drug interactions

No  pharmacodynamic  drug  interaction  studies  were  carried  out  with  laquinimod.  This  was considered acceptable based on available data from clinical studies and in view of the intended use as monotherapy in MS population.

## 2.3.3. Pharmacokinetics

The pharmacokinetics and toxicokinetic (TK) studies of laquinimod were performed in mice, rats, rabbits,  dogs  and  monkeys.  Several  bioanalytical  methods  were  developed  and  validated  to characterize  the  disposition  of  total  laquinimod  in  plasma  including  an  HPLC  assay  using  UV detection and LC-MS/MS methods with lower levels of sensitivity. Some of the studies were also conducted with its metabolites (DELAQ, DMLAQ and N-4'HLAQ). The metabolic profile of laquinimod and formation of protein adducts was also studied in mice, rats, rabbits, dogs and humans.

After oral administration, the absorption of laquinimod is relatively rapid in the mouse, rat, and dog (Tmax within 2 hours) while it was slower in the rabbit (Tmax within 4-8 hours). In vitro bi-directional permeability  was  tested,  using  Caco-2  model.  High  equal  permeability  was  observed  in  both directions, suggesting that laquinimod is absorbed passively.

In these species, oral bioavailability was high (82-93%). The half life of laquinimod was found to be longer in humans (71 hours) than in the tested animal species (3 to 14 hours).

Exposure data measured following the first dose in toxicology studies showed that the kinetics is linear over the 2-160 mg/kg dose range in mice, over the 0.15-90 mg/kg dose range in rats, and over the 1-10 mg/kg dose range in dogs. In general, the kinetic remained linear after repeated administrations in toxicity studies performed in mice at up to 40 mg/kg. In rats, linearity was also observed at up to 10 mg/kg; at higher dose levels, the data suggested less than dose proportional increase  in  exposure.  In  some  studies,  the  kinetics  was  time-dependent  in  mice  and  rats (decreased systemic exposure in relation to increased clearance). This was not clearly shown in dogs. A significant time-dependency on the kinetics of laquinimod at the proposed posology (0.6 mg/day) in man was also not suggested. Systemic exposure was also found to be 3-4-fold higher in female rats as compared male rats suggesting a gender related difference in this animal species.

Laquinimod is highly bound to mouse, rat, rabbit, dog and human plasma proteins (&gt; 97%), with a free fraction of 1.8% in humans.

The  volume  of  distribution  in  the  different  species  was  relatively  low,  0.12  L/kg  in  rabbits, 0.17 L/kg in rats, 0.26 L/kg in dogs, and 0.45 L/kg in mice, suggesting that laquinimod is mainly distributed into the extracellular space. In dogs, the blood/plasma ratio was found to be about 0.6. These data further  indicated  that  laquinimod  does  not  substantially  bind  to,  or  enter,  the  blood cells but is rather distributed to plasma.

After  dosing 14 C-labeled  laquinimod  in  mice  (i.v)  and  rats  (p.o),  drug  related  radioactivity distributed mainly to the liver and kidney cortex and was generally slowly cleared from tissues (t1/2 ranging  from  20  to  50  hours,  and  even  up  to  84  hours  in  kidney  cortex).  According  to  the

<div style=\"page-break-after: always\"></div>

applicant, the slow clearance from tissues may be related to the formation of drug-protein adducts, that  were  specifically  studied  in  the  characterisation  of  the  metabolic  profile  (see  below).  Brain penetration was also noted in both species with brain to blood ratios ranging from 0.04 to 0.08 and lower ratios at later time points. After i.v or p.o dosing in dogs, the level of radioactivity found in liver was more than 2-fold higher than levels found in blood; levels in lung and kidney were slightly lower and the levels in brain were about 7% of those in blood.

In  murine  EAE  model  (cerebellum  of  mice  with  compromised  blood-brain-barrier),  drug-related radioactivity was also shown to distribute into the CNS with brain: blood ratios up to 0.18.

In rats and rabbits, laquinimod-related radioactivity crosses the placenta and distributes homogenously within fetal tissues. In both species, the fetal radioactivity uptake is increased in the late gestational period.

Laquinimod was found to be primarily metabolised by CYP3A4 enzymes. In vitro and in vivo data suggested that the major metabolic pathway was quinoline hydroxylation at 2 positions (6-HLAQ and 8-HLAQ) followed by N-demethylation of the quinoline ring (DMLAQ), aniline hydroxylation (N4'-HLAQ), and to a lesser extent N-deethylation at the aniline moiety (DELAQ) and dechlorination of  the  quinoline  ring  (DCLAQ).    The  liver  extraction  ratio  is  low.  Both  the  parent  compound  and hydroxylated metabolites undergo also glucuronidation. In vivo data did not show significant interspecies differences in the qualitative and quantitative metabolic profile, and therefore the toxicity species are considered validated. In addition, no metabolite could be considered as major, since most were found to have circulating concentrations well below (&lt;1% in most cases) that of the parent  compound  in  all  investigated  species  and  humans.  All  human  circulating  and  excreted metabolites  have  been  observed  and  are  well-represented  in  animal  species.  The  metabolites (ABR-215818, ABR-215791, ABR-218287) and their conjugates are much more abundant in the excretaes  than  laquinimod.  Their  pharmacological  activity  was  evaluated  using  the  EAE  mouse model.  The  results  and  metabolic  patterns  of  laquinimod  indicated  that  its  metabolites,  at circulating levels following clinical doses, did not contribute to the pharmacological activity of the drug.

Laquinimod  is  mainly  eliminated  by  metabolism  and  therefore  only  low  levels  of  unchanged laquinimod  were  recovered  in  excreta  of  animal  species  including  humans.  The  main  route  of excretion was the feces in rats and dogs (50 to 70%) and the urine in rabbits and humans (5060%). Laquinimod and/or its metabolites are also excreted in the milk of lactating rats.

In  all  animal  species,  laquinimod  was  shown  to  form  tissue  adducts.  Data  suggested that  these adducts  were  the  results  of  covalent  binding  of  laquinimod  drug  material  to  lysine  residues  of plasma and liver microsome proteins after a reaction of N-deethylation (formation of DELAQ). In rats, such covalent binding was much higher in plasma than in the liver. In the plasma, 0.4-2% of the dose was covalently bound to proteins, and elimination of such adducts was low (t1/2 = 7 days). The formation of adducts was also found to be dose-dependent in rats.

## 2.3.4. Toxicology

## Single dose toxicity

Single-dose toxicity studies were conducted in rats and dogs. In rats, lethality was reported at 400 mg/kg. In dogs, laquinimod was not well tolerated at 60 mg/kg since it induced acute inflammatory reactions  e.g.  increased  erythrocyte  sedimentation  rate  (ESR)  and  fibrinogen  in  both  sexes,

<div style=\"page-break-after: always\"></div>

leukocytosis in females. At the No-Observed- Effect Levels (NOAELs), animal-to-human exposure ratios reached 200 and 100 in rats and dogs, respectively.

## Repeat dose toxicity

The pivotal repeat-dose toxicity studies were conducted in rats and dogs for up to 26 weeks and to 52  weeks,  respectively.  Dose  finding  studies  for  carcinogenicity  evaluation  were  also  performed and used two mouse strains (CD-1; C57BL/6).

Toxicity studies in rats have identified the haematopoietic tissue (erythroid cell line), liver, thymus, and  thyroid  as  target  organs  of  laquinimod.  In  general,  the  findings  occurred  with  dose-related incidence and/or severity and consisted mainly in pro-inflammatory effects and lymphoid atrophy. In the 26-week study, the effects noted from the low dose level of 1 mg/kg/day were decreased body weight and Red Blood Cell (RBC) parameters, hepatocyte vacuolation/hypertrophy/degeneration, inflammatory infiltrates in the liver, deposits of pigmented macrophages in the liver, liver fibrosis, bile duct hyperplasia in females, thymic atrophy, thyroiditis, and  capsular  fibrosis  of  the  spleen.  High  toxicity  was  shown  at  the  high-dose  level  ( ≥ 50-fold human  exposure),  with  mortality  associated  with  a  marked  anaemia,  principally  due  to  bone marrow and liver toxicity. In this dose-group, additional inflammatory findings in the pancreas and joints/skin, and proliferative lesions in lungs (broncho-alveolar hyperplasia) were observed. In line with  finding  in  mice,  laquinimod  induced  hyperplasia  and  hyperkeratosis  of  the  squamous epithelium  at  the  limiting  ridge  of  the  stomach.  The  incidence  of  this  lesion  was  both  dose  and time-related. According to the applicant, this finding is related to the irritant effect of laquinimod deposited in the stomach after gavage. Findings reported in the thymus, spleen, thyroid and liver were not fully reversed after a 4-week treatment free period. A NOAEL could not be determined due to findings in the liver, thymus and thyroid. Total drug exposure at 1 mg/kg/day was about 11 (males)  and  33    (females)  fold  higher  than  that  at  the  intended  clinical  dose  of  0.6  mg/day  in humans based on Cmax, and 5 (males) and 18.3 (females) fold higher than humans based on AUC. Concerning thyroiditis, there is no safety margin to the mid dose exposure level in the 52-week dog study where thyroiditis was observed. In rats, thyroiditis was present down to the low dose group  (1  mg/kg)  in  the  26-week  study,  and  also  in  high  dose  males  (1  mg/kg)  in  the carcinogenicity study.

In dogs, laquinimod was also shown to induce inflammatory reactions as shown by the occurrence of  peritonitis,  encephalitis,  and  myelitis  in  the  28-day  study  at ≥ 26-fold  the  human  exposure. Furthermore, the interpretation of the 39-week study was complicated due to the occurrence of inflammatory episodes and arteritis in all groups, thus a 52-week study was conducted at the same dose levels. It showed that systemic inflammatory response occurred in two dogs at the high dose level (0.6 mg/kg/day)  on  isolated  occasions  with  both  clinical,  haematological  (leucocytes increase),  and  biochemical  (fibrinogen  and  CRP  increased  levels)  manifestations.  One  of  these animals,  and  also  two  others  in  the  mid-  and  high-  dose  groups  showed  minimal  to  marked thyroiditis, one case being associated with increased levels of anti-T3 and anti-thyroglobulin autoantibodies. Based on these results, it is concluded that laquinimod induced inflammation in dogs. These studies also showed that haematopoietic tissue (erythroid cell line) and thymus (atrophy) are target organs of laquinimod.

Principal  findings  in  the  mouse  were  dose-related  increase  in  liver  weight,  inflammatory  foci  of minimal to moderate intensity with single cell necrosis of the liver, gastritis and decreased thymus weight.  The  toxicity  profile  of  laquinimod  in  mice  is  characterized  mainly  by  liver  toxicity (centrilobular  hypertrophy,  inflammation,  degeneration)  and  inflammatory  findings  in  various tissues.  In  the  stomach,  chronic  gastritis  and  hyperkeratosis  of  the  squamous  epithelium  at  the

<div style=\"page-break-after: always\"></div>

limiting  ridge  were  reported  after  13  weeks  of  treatment.  Centrilobular  hypertrophy/eosinophilia was observed in the liver of males and females in this study and is considered to be related to laquinimod's ability to induce enzymes involved in phase I and II metabolism. These findings were fully  reversible  on  cessation  of  treatment.  In  CD-1  mice,  a  31-38%  decrease  in  CD161+  cells (including NK cells) in the immunotoxicity subset was observed and is in line with the decrease in NK  cells  observed  in  the  specific  immunotoxicity  study  conducted  in  rats.  No  NOAEL  could  be determined in  these  studies.  At  the  identified  Lowest  Observed  Adverse  Effect  Levels  (LOAELs), animal-to-human exposure ratios ranged from 1.2 to 5.

The  above  mentioned  toxicity  findings  are  suggestive  of  an  Aryl  hydrocarbon  receptor  (AhR) agonist-like  effect  of  laquinimod.  This,  together  with  the  mechanistic  data  supportive  of  AhR activation (e.g. the metabolite DELAQ, although being present in minute levels, is a very potent agonist of this receptor) raise concerns on human safety.

In  addition,  in  repeated  dose  studies,  a  myeloid-directed  shift  in  the  myeloid/erythroid  ratio  of bone marrow cells was observed in mice, rats and dogs; although the effects in rodents were not significant..  The  bone  marrow  changes  observed  in  laquinimod-treated  dogs  indicate  a  small myeloid shift that was observed at very high doses relative to the clinical exposure, and are most likely secondary to the effects of laquinimod on cytokines that regulate hematopoiesis.

## Genotoxicity

Laquinimod was not mutagenic in the Ames assay and did not induce unscheduled repair of DNA in the  unscheduled  DNS  synthesis  (UDS)  test.  The  genotoxicity  test  was  positive  in  the  mouse lymphoma TK assays with a long treatment of the cells without metabolic activation at high doses levels. In vitro test in V79 Chinese hamster cells and human peripheral lymphocytes revealed an increase of  micronucleated  cells.  Using  a  pan-centromeric  DNA  probe,  the  mechanism  of micronucleus induction in the in vitro study in human lymphocytes was suggested at the only one concentration  that  was  analyzed  (194.5  µg/mL)  to  be  in  favor  of  an  aneugenic  mechanism; however, these data cannot be used to rule out a clastogenic activity.

As aneuploidy is not considered to result from direct damage to DNA, it is generally accepted that a threshold for aneuploidy can be identified. The concentration of 65.61 μg/mL was identified by the applicant  as  the in  vitro No  Observed  Effect  Level  (NOEL)  using  primary  human  lymphocytes. However, this was not endorsed by the CHMP since a statistically significant increase in micronuclei frequency  was  shown  at  the  lowest  concentration  of  53.14  µg/mL.  Therefore,  no  NOEL  was identified in vitro for  micronuclei induction. The CHMP was also concerned about the use of pancentromeric  probes  to  demonstrate  a  loss  of  chromosome  as  a  good  marker  of  aneugenicity. Actually,  laquinimod  has  a  clear  clastogenic  potential  with  a  predominantly  aneugenic  mode  of action.  According  to  Kirsch-Volders et  al .  (2003)  the  increase  of  micronucleus  frequency  in  the micronucleus assay demonstrates chromosome loss, but aneugens that induce chromosome loss induce  also  chromosome  non-disjunction.  As  described  by  Kirsch-Volders et  al. (2003),  this determination should be performed using probes for at least 2 chromosomes in binucleated human lymphocytes.

In  the  acute  (2-day)  rat  bone  marrow  assay,  a  statistically  significant  increase  of  micronucleus frequency  was  also  reported  vs.  study  controls  at  the  highest  dose  levels,  but  vs.  historical negative control data at 30 mg/kg/day. Therefore, the NOEL in this study was downgraded from 90 to 10 mg/kg/day. In the 28-day repeat-dose micronucleus study a statistically significant increase in  bone  marrow  micronuclei  compared  to  controls  was  seen  at  the  highest  dose  tested  (90

<div style=\"page-break-after: always\"></div>

mg/kg/day). In the 28-day repeat-dose chromosome  aberrations study, no indication of chromosome  damage/breakage  (clastogenicity)  was  detected  at  up  to  90  mg/kg/day.  This response is in favor of a non-clastogenic effect and of a pure aneugenic effect. Overall, the in vivo NOEL for genotoxicity identified by the applicant (30 mg/kg) was also not endorsed by the CHMP in view of the results of the 2-day in vivo micronucleus test. A new reading of the slides obtained in the 28-day micronucleus test was requested to increase the sensitivity of the observation, and the confidence in the result of the dose used to determine the threshold. However, the specimens of the original 28-day in vivo micronucleus rat study were found to be too old to allow a valid analysis and the applicant decided to repeat two of the studies performed for NOEL determination.

Based on the repeated studies, the in vitro data showed that laquinimod was both aneugenic and clastogenic.  Laquinimod  cannot  be  considered  as  a  pure  aneugen  since  no  supporting  mode  of action  is  available,  and  because  the  threshold  for  chromosome  loss  is  lower  than  that  for  nondisjunction (for aneugens, the threshold for non-disjunction is lower or equal to the threshold for chromosome loss).

The  repeated  acute in  vivo micronuclei  rat  study  demonstrated  a  NOEL  between  60  and  90 mg/kg/day,  consistent  with  the  estimation  of  this  value  as  90  mg/kg/day  in  the  original  study. Overall, the results were consistent with those obtained previously in the original study. Therefore, the  NOEL  of  30  mg/kg/day  obtained  in  the  28-day  rat  bone  marrow  micronucleus  study  was selected for determination of safety margin, which reached 100 based on AUC levels.

Although  the  exact  genotoxic  mode  of  action  of  laquinimod  remains  to  be  established,  the threshold  of  genotoxic  effect  and  the  safety  margin  for  this  risk  is  considered  acceptable  at  the present time. This however may require further reevaluation in the case of decrease in the safety margin (e.g. use of higher dose level in patients).

## Carcinogenicity

Carcinogenicity was tested in a conventional 104 week study in rats, testing dose levels of 0.1, 0.3 and 1 mg/kg/day. Furthermore, a 26 weeks study in p53+/- mice, testing doses of 0, 1, 5, 15 and 40 mg/kg/day in male groups and 0, 2, 10, 30 and 80 mg/kg/day in female groups.

Laquinimod  was  shown  to  be  carcinogenic  in  rats.  Significant,  dose-dependent  increases  of tumours were observed; namely neoplastic lesions in the uterus, in the thyroid in males and oral cavity squamous cell carcinoma in females. In addition to these findings, a range of proliferative lesions  (hyperplasia)  were  observed  in  the  kidney  and  urinary  bladder  at  all  dose  levels.  These were not associated with inflammatory processes.

An increased incidence of uterine adenocarcinomas was seen in high dosed females (1 mg/kg) and the margin to the NOAEL, No Observed Adverse Effect Level (0.3 mg/kg/day) was found to be low (5.8). The mechanism underlying these findings suggested by the applicant was a possible relation with a decrease in prolactinomas/prolactin (PRL) levels and age related changes in the regulation of prolactin secretion in rats. The applicant argued for an association between reduced body weight gain and lower prolactin levels. However, careful review of the available data did not support the claimed mechanism, and thus this hypothesis was not considered convincing by the CHMP. This aspect is further discussed below (see 2.3.6).

Thyroid  gland  was  identified  as  a  target  organ  for  toxicity,  both  in  rats  and  dogs.  An  increased incidence of thyroid follicular cell adenomas was noted in high dose rat males in the carcinogenicity study, which was suggested by the applicant to be a rat specific finding due to laquinimod's ability to  increase  the  activity  of  two  rat  thyroxin  UGTs  that  glucuronidate  T3  and  T4.  The  applicant

<div style=\"page-break-after: always\"></div>

provided experimental evidence that follicular thyroid adenomas are species specific in the male rat. .

Increased incidence of oral cavity squamous cell carcinoma was noted in rats dosed at ≥ 0.3 mg/kg (both  sexes).  The  applicant  suggested  that  this  effect  may  be  related  to  a  direct  effect  of laquinimod  on  the  oral  cavity  tissue  during  repeated  gavage  procedures  and  not  to  a  systemic effect  of  the  drug  as  suggested  by  dose-related  increased  incidence  and/or  severity  of  nonneoplastic  proliferative/  inflammatory  findings  in  the  oral  and  nasal  cavities,  lungs,  larynx,  and fore-stomach.  It  was  also  mentioned  that  such  direct  exposure  was  not  relevant  to  humans  as laquinimod is administered in a capsule, and that excretion in saliva in rats and humans is well below cytotoxic concentrations. However the CHMP was not convinced that an effect via systemic exposure  can  be  excluded  as  an  explanation  for  these  findings.  Additional  studies  with  local application of laquinimod to the cheek pouch of hamsters and to the buccal mucosa of rats were conducted. Local  inflammatory  /  proliferative  /  degenerative  findings  were  observed  in  both species.  In  addition,  in  the  hamster,  discolouration  of  the  incisor  teeth  was  observed  and associated  with  atrophy  and  disorganization  of  the  ameloblastic  cells  at  the  base  of  the  incisor teeth. In rat, despite inflammatory effect observed in treated and in non-treated animals, dental effects were also reported.

In  the  26-week  carcinogenicity  study  conducted  in  p53+/-  mice,  there  was  no  significant treatment-related  increased  incidence  of  neoplastic  lesions.  A  non-significant  increase  in  skin sarcoma was reported at the high dose level. Similar findings were observed at lower dose levels and in the control group. This is considered as a common background tumour in this mouse strain, and  all  sarcomas  identified  in  these  studies  were  qualitatively  comparable.  The  liver,  heart (females), and skeletal muscles were considered to be target organs due to the presence of nonneoplastic inflammatory lesions. There was no safety margin for liver findings in both sexes, and skeletal  muscle  findings  in  females.  The  safety  margin  reached  4.3  and  8.6  times  for  cardiac (females) and skeletal muscle (males) findings, respectively. Mandibular lymph node hyperplasia was  also  observed  at  all  dose  levels.  According  to  the  applicant,  mandibular  lymph  node hyperplasia was not considered as a generalized or systemic lymphoid reaction as no treatment related changes were noted in the morphology or lymphoid populations of the mesenteric lymph node, thymus and spleen. For the applicant, this finding is considered as a loco-regional response. No correlation was observed between incidence of local inflammation and mandibular lymph node hyperplasia in the treated animals.This finding was also not seen in other studies in mice, rats and dogs and may also be related to a response of mandibular lymph nodes following exposure to a variety of stimuli in the oropharyngeal region. However no firm conclusion could be drawn by the CHMP on this aspect.

## Reproduction Toxicity

Laquinimod did not impair the fertility of male and female rats at doses inducing marked toxicity (mortality  in  males  at  15  mg/kg,  effects  on  body  weight  and  consumption  parameters  at 1.5 mg/kg).  An  embryolethal  effect  was  noted  at  the  high  dose  level  (15  mg/kg).  The  safety margin for this effect reached 12.

Conventional embryo-fetal toxicity studies in rats and rabbits showed that laquinimod is embryofeto-toxic and abortive (rabbits) at maternotoxic high doses. In rats, maternal toxicity was shown from  6 mg/kg/day.  Developmental  toxicity  was  evidenced  from  the  dose  of  6  mg/kg/day  by  a decrease  in  fetal  weights,  and  increased  incidence  of  skeletal  variations.  At  18  mg/kg/day,  this toxicity  was  increased  as  shown  by  embryo-feto-lethality  and  increased  pelvic  cavitation  of  the kidney.  In  rabbits,  both  maternal  and  fetal  toxicities  were  noted  from  0.5  mg/kg  (mortality  and

<div style=\"page-break-after: always\"></div>

effects  on  body  weights  and  food  consumption  in  dams,  abortions,  embryo  and  fetal  mortality, decreased fetal weight, increased skeletal variations). The NOAELs determined from these studies were 2 mg/kg/day in rats and 0.1 mg/kg/day in rabbits, yielding safety margins of 22 and 1.8, respectively.

Laquinimod  is  considered  as  teratogenic  in  female  rats  because  it  induced  abnormalities  of  the urogenital tract occurring at non-maternotoxic dose levels (from 0.1 mg/kg/day). These abnormalities consisted of hypospadias (cleft phallus at macroscopic examination) which could be associated with hypertrophy/protrusion of the clitoris. A mechanistic study showed that the most sensitive  period  for  the  development  of  hypospadias  in  females  exposed  in  utero  was  between gestation days (GD) 18 to 21, although this was also noted at lower frequency in offspring exposed on GD6-9, GD10-13 and GD14-17. Exposure before implantation or during lactation did not induce this type of malformation.

In  the  pre  &amp;  postnatal  study,  hypospadias  were  also  reported  in  F1  males  on  postnatal  day  4 (PND4)  of  the  pivotal  study,  but  not  confirmed  on  PND35  nor  in  the  mechanistic  study.  Other findings consisted of dose-dependent delayed growth which persisted up to adult age in the high dose group, a clear dose-dependent delay in onset of puberty, and decreased fertility in spite of normal sperm parameters. In addition, the absolute weight of prostate and seminal vesicles were decreased  at  the  high  dose  level  (6mg/kg/day).  In  F1  females,  in  addition  to  the  urogenital abnormalities, there were also treatment-related effects on growth, delayed vaginal opening at the high dose level only, prolonged estrous cycle length, decreased fertility at the mid and high dose levels. Treatment also had an impact on F2 generation as seen from decreased viability of F2 pups born from F1 females (high-dose group).

DELAQ, but not laquinimod, shows anti-estrogenic potential in the CALUX in  vitro model system through the AhR-ER cross-talk pathway, and the EC20 of DELAQ (0.041 nM) was in the range of concentrations  reached  in  patients  following  a  single  dose  of  laquinimod.  Taken  together,  an endocrine-disrupting  potential  of  laquinimod  involving  this  pathway  could  not  be  excluded. Additional  data  were  provided  but  they  are  not  sufficient  to  exclude  a  mechanism  involving  the AhR-ER cross-talk  pathway.  According  to  the  applicant,  some  differences  in  malformations  were seen after exposure to laquinimod or TCDD and the applicant claims that there is no mechanistic relation  between  these  two  compounds.  However,  TCDD  is  known  to  cause  also  very  species specific malformations, thus some variations in the malformation pattern between laquinimod and TCDD would be expected even though the common mechanistic factor is an activation of AhR. Also, dioxin like substances which are known to interact via the AhR, have been shown to differ in their malformation patterns. Considering the complexity of interaction between various substances and the AhR, a complete overlap in malformation pattern is unlikely. However, striking similarities were observed in the malformation patterns comparing the teratogenic effects of laquinimod and TCDD in rat, and a mechanism involving the AhR-ER cross-talk pathway could not be excluded.

In pregnant cynomolgus monkeys, a treatment-related increase in pre-natal losses was observed at  the  high  dose  level  (8mg/kg/day),  shown  as  slightly  maternotoxic.  At  the  low-dose  level (1mg/kg/day),  abortions  were  reported  at  an  increased  frequency  vs.  both  study  controls  and spontaneous  abortion  rate  in  cynomolgus  monkeys  (17.8%  according  to  Walker et  al. ,  2007). Therefore, there is some uncertainty regarding the determination of a NOAEL at 1 mg/kg/day. As a result of the increased abortions, number of infants examined post-natally was limited, particularly at  the  high  dose  level  and  the  fact  that  no  treatment-related  malformations  were  observed  in monkeys should be interpreted with caution. The CHMP considered that no definitive conclusions could be drawn regarding the teratogenic potential of laquinimod in cynomolgus monkeys.

<div style=\"page-break-after: always\"></div>

## Local Tolerance

In rabbits, studies were conducted after single and repeated administration to investigate dermal and  ocular  tolerance,  respectively.  Laquinimod  was  not  shown  to  induce  either  skin  or  ocular irritation.

## Other toxicity studies

In a 4-week immunotoxicity study in rats, CD161+ cells (including NK cells) were decreased, and this  caused  reduced  cytotoxic  NK  activity  in  high  dosed  animals  (4  mg/kg).  Based  on  the  data collected in the 26-week toxicology rat study on week 13 in males, the safety margin for this effect is 4 at the proposed therapeutic dose. Furthermore, no clinical evidence to support treatment effect on NK cell activity is available to date.

Laquinimod  was  positive  in  the  3T3  NRU  phototoxicity  test,  but  was  shown  to  be  devoid  of phototoxic potential in a single-dose phototoxicity study performed in rats at up to 200 mg/kg. The limitation of this study (raised by the CHMP during the scientific advice) was that single doses were administered in comparison to the chronic administration schedule planned for humans. However, given  the  systemic  exposure  in  the  animals  and  also  in  view  of  the  fact  that,  data  do  not demonstrate potential accumulation of laquinimod and/or its metabolites in eyes and skin tissues upon repeated dosing, laquinimod is not anticipated to be phototoxic in humans.

No evidence of a mutagenic potential or toxicity of the impurities was shown except for a weak mutagenic effect for one impurity. The specifications limits for the impurities were set at acceptable levels.

## 2.3.5. Ecotoxicity/environmental risk assessment

Table 1. Summary of main study results

| Substance: laquinimod                                               | Substance: laquinimod                          | Substance: laquinimod                          | Substance: laquinimod                          |
|---------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| CAS-number (if available):                                          | CAS-number (if available):                     | CAS-number (if available):                     | CAS-number (if available):                     |
| PBT screening                                                       |                                                | Result                                         | Conclusion                                     |
| Bioaccumulation potential- log K ow                                 | pH-metric method                               | 2.78 (neutral species) -0.51 (anionic species) | Potential PBT: No                              |
| pKa                                                                 |                                                | 4                                              |                                                |
| Bioaccumulation potential- log D                                    | Liquid-Liquid Distribution Chromatography      | 2.56 (pH 2.5) <1 (pH 7.4)                      |                                                |
| Phase I                                                             |                                                |                                                |                                                |
| Calculation                                                         | Value                                          | Unit                                           | Conclusion                                     |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | default: 0.003 refined*: 0.0003                | µ g/L                                          | < 0.01 threshold                               |
| Phase II Physical-chemical properties and fate                      | Phase II Physical-chemical properties and fate | Phase II Physical-chemical properties and fate | Phase II Physical-chemical properties and fate |
| Study type                                                          | Test protocol                                  | Results                                        | Remarks                                        |
| Ready Biodegradability Test                                         | OECD 301A                                      | Not readily biodegradable                      |                                                |

Whilst, the potential endocrine disruption of DELAQ cannot be ruled out, this metabolite was not detected in human excreta and therefore the CHMP considered that no phase II was required to conclude on the ERA. On the basis of the presented data, laquinimod is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.3.6. Discussion on non-clinical aspects

In  animal  models  of  experimental  autoimmune  encephalomyelitis,  it  was  shown  that  treatment with laquinimod decreases inflammatory cell infiltration into the Central Nervous System (CNS) in different  models  of  MS,  as  well  as  the  secretion  of  pro-inflammatory  cytokines.  Some  data  also suggested that laquinimod modulates signalling through NF κ B pathway which is often associated with inflammatory diseases. There was no evidence of an effect of treatment on the primary and secondary humoral immune responses suggesting the absence of immunosuppressive/immunotoxic properties.  However,  the  mechanism  of  action  of  laquinimod  is  not  fully  elucidated  because  the molecular target  is  not  known.  Data  on  other  inflammatory/autoimmune  disease  models  further supported the immunomodulatory properties of laquinimod.

The safety pharmacology studies suggested that laquinimod had a low or no potential to acutely affect the function of vital organ systems.

The pharmacokinetics properties of laquinimod were thoroughly evaluated in mice, rats, rabbits, and dogs and showed: relatively rapid oral absorption (slower in rabbits), main distribution into the plasma, crossing of the blood brain and placenta barriers, high protein binding. Laquinimod drug material is excreted both in urine and faeces and notably in milk. In all animal species, it was also found that laquinimod forms tissue adducts. Data suggested that these adducts were the results of covalent  binding  of  laquinimod  drug  material  to  lysine  residues  of  plasma  and  liver  microsome proteins after a reaction of N-deethylation (formation of DELAQ). Covalently bound material was not found in human plasma after therapeutic dosing. However these clinical data were very limited (n=6  healthy  volunteers,  dosed  once)  and  could  not  exclude  this  risk  considering  the  chronic intended use of laquinimod and slow elimination of these adducts. Thus, the occurrence of drug hypersensitivity  reactions  could  not  be  ruled  out,  and  this  safety  concern  is  considered  as  a potential risk (see 2.6.10). In addition, laquinimod was found to be a potent inducer of CYP1A and this  could  be  likely  due  to  an  interaction  of  laquinimod  and  metabolite  DELAQ  with  the  AhR transcription factor. CYP1A1 and 1A2 play critical roles in the metabolic activation of carcinogenic polycyclic aromatic hydrocarbons and heterocyclic aromatic amines/amides that lead to toxicity and cancer. A literature review was performed by the applicant suggesting that the role of CYP1A in the activation  of  procarcinogens  to  carcinogens  is  overestimated  due  to  results  obtained in  vitro . However, CYP1A induction was reported in  vivo in  patients  treated  with  laquinimod  and  no  data were  presented  to  exclude  the  potential  carcinogenicity  of  laquinimod,  in  relation  to  CYP1Amediated activation of PAHs and other carcinogens.

Laquinimod induced inflammatory reactions in various tissues in mice, rats, and dogs. In rodents, the  liver  was  shown  as  a  target  organ.  In  rats  and  dogs,  decreased  RBC  parameters,  thymic atrophy and thyroiditis were also observed. The applicant indicated that thyroid toxicity as seen in dogs and rats is rather a species-specific effect, is not dose-dependent and occurs even in controls. However, the CHMP did not agree with the applicant, given the effects also noted in the lowest dose  groups.  No  NOAEL  could  be  determined  in  rodents,  whereas  it  reached  0.2 mg/kg/day  in dogs. The safety margins were low, i.e. &lt;1.2 in mice, &lt;5 in rats, and approximately 2 in dogs. The bone marrow changes observed in laquinimod-treated dogs indicated a small myeloid shift that was observed at very high doses relative to the clinical exposure, and are most likely secondary to the effects of laquinimod on cytokines that regulate hematopoiesis.

In  genotoxicity  testing,  laquinimod  was  both  aneugenic  and  probably  clastogenic.  Although  the exact genotoxic mode of action of laquinimod remains to be established, the threshold of genotoxic effect  and  the  safety  margin  for  this  risk  is  considered  acceptable  at  the  present  time.  This however may require further reevaluation in the case of decrease in the safety margin (e.g. use of higher dose level in patients).

<div style=\"page-break-after: always\"></div>

There is currently a considerable level of uncertainty on the carcinogenic potential of laquinimod. The  pharmacology  of  laquinimod  is  unclear  thus  making  difficult  the  full  appreciation  of  any pharmacology-driven  proliferative  or  metaplastic  processes.  The  mechanisms  proposed  by  the applicant to explain the occurrence of the neoplastic lesions found in the oral cavity and uterus of rats  in  the  carcinogenicity  study  were  not  convincing  to  exclude  a  relevance  of  the  findings  in animals with respect to human safety. For the oral cavity tumours, alternative explanations to a local  effect,  as  claimed  by  the  applicant,  cannot  currently  be  ruled  out.  For  the  uterine adenocarcinomas, the mechanism proposed by the applicant involving indirect, via reduced body weight, reductions of PRL, was not supported following careful review of the available data.  This is further elaborated on below (see additional expert consultation).

On this basis, the CHMP requested, at their November 2013 Plenary meeting, the Safety Working Party  (SWP)  to  address  a  number  of  questions  related  to  these  toxicological  findings  The  SWP overall  conclusions  are  presented  below  (see  additional  expert  consultation).  Further  discussion from the applicant on this issue was also requested by the CHMP. A comparison was provided by the applicant between laquinimod, TCDD and DLCs with regard to major non-neoplastic toxicity, taking  all  repeat  dose  toxicity  studies  of  laquinimod  into  consideration.  These  data  showed  that the histopathological findings did not show a complete overlap, however, from this analysis, the CHMP  was  of  the  opinion  that  it  can  be  concluded  that  laquinimod  shares  a  general  proinflammatory,  hyperplastic  (forestomach,  oral  cavity  and  kidney),  hepatic  and  thyroid  toxicity profile  with  TCDD  and  DLCs.  Considering  the  complexity  and  diversity  of  AhR-mediated  toxic responses,  complete  overlap  between  laquinimod  and  TCDD  is  not  to  be  expected.  Moreover, striking similarities were observed in the malformation patterns comparing the teratogenic effects of laquinimod and TCDD in rat, and a mechanism involving the AhR-ER cross-talk pathway could not be excluded.

Laquinimod did not impair the fertility of male and female rats at doses inducing marked toxicity. However an embryo-feto-toxic and -lethal effect was observed and laquinimod was also found to be abortive in rabbits. The NOAELs determined from these studies were 2 mg/kg/day in rats and 0.1 mg/kg/day in rabbits, yielding safety margins of 22 and 1.8, respectively.

Laquinimod was teratogenic in rats at non-maternotoxic dose levels (above 0.1 mg/kg/day). These abnormalities consisted of hypospadias (cleft phallus at macroscopic examination) which could be associated  with  hypertrophy/protrusion  of  the  clitoris.  Exposure  before  implantation  or  during lactation  did  not  induce  this  type  of  malformation.  In  F1  males,  hypospadias  were  also  reported and other findings consisted of dose-dependent delayed growth which persisted up to adult age in the high dose group, a clear dose-dependent delay in onset of puberty, and decreased fertility in spite  of  normal  sperm  parameters.  In  addition,  the  absolute  weight  of  prostate  and  seminal vesicles  were  decreased  at  the  high  dose  level.  In  F1  females,  in  addition  to  the  urogenital abnormalities, there were also treatment-related effects on growth, delayed vaginal opening at the high dose level only, prolonged estrous cycle length, decreased fertility at the mid and high dose levels. Treatment also had an impact on F2 generation as seen from decreased viability of F2 pups born  from  F1  females  (high-dose  group).  Most  of  the  findings  obtained  in  F1  animals  were suggestive of a hormonal effect of laquinimod. An effect of laquinimod on the AhR-ER cross-talk pathway cannot be excluded as possible mechanism underlying its potential endocrine-disrupting effects.

No  definitive  conclusions  could  be  drawn  regarding  the  teratogenic  potential  of  laquinimod  in cynomolgus monkeys.

<div style=\"page-break-after: always\"></div>

## Additional expert consultation

On 3 December 2013, the SWP overall concluded by majority that:

-  The  mechanisms proposed by the applicant for uterine adenocarcinoma and, in particular, oral squamous cell carcinoma are not considered sufficiently substantiated by data. In contrast, there are pieces of evidence that speak against that these proposed mechanisms are plausible:

· The mechanistic hypothesis proposed by the applicant for the uterine adenocarcinoma is based  on  the  observation  that  long-term  decreased  food  consumption/body  weight/body  weight gain  has  been  shown  to  influence  the  incidence  of  pituitary  hyperplasia/adenoma  (Greaves; Hargreaves &amp; Harleman 2011). This, in turn, results in a relative reduction in circulating prolactin (relative  hypoprolactinemia).  In  rats,  but  not  humans,  prolactin  is  a  luteinizing  hormone  that stimulates ovarian production of progesterone and maintains progesterone dominance (Hargreaves &amp; Harleman, 2011).  Accordingly, a decrease in prolactin levels in rats leads to the opposite, i.e. estrogen dominance and associated risk for endometrial proliferation.

Although  prolactin  levels  were  not  measured  in  the  laquinimod  rat  carcinogenicity  study,  the applicant argues that a number of indirect findings and associations are highly suggestive of this rat-specific mechanism being at play. A statistically significant decrease in pituitary adenomas was observed  for  high  dose  females  (1  mg/kg/day)  compared  to  vehicle  controls.  At  the  high  dose level, there was also an increased incidence of uterine adenocarcinoma (9% relative to controls). It was suggested that the decrease in the incidence of pituitary adenomas could be related to the uterine  findings.  As  these  adenomas  typically  produce  prolactin,  a  higher  incidence  of  pituitary adenomas in control females would produce higher prolactin levels in controls and fewer estrogenrelated lesions in the uterus, such as adenocarcinomas, compared to high dose females.

It  was  further  proposed  that  an  inverse  relationship  between  uterine  and  mammary  tumours existed  in  the  rat  carcinogenicity  study,  i.e.  fewer  mammary  tumours  in  the  laquinimod-treated females as compared to controls. Since prolactin has a profound influence upon the promotion of mammary  gland  neoplasia  in  rodents,  this  would  support  the  notion  of  a  hypoprolactinemic mechanism [Hargreaves &amp; Harleman, 2011].

It is agreed that there was an association between decreased body weight gain in female high-dose rats  and  a  decreased  incidence  of  pituitary  adenomas  in  the  same  dose  group.  With  regard  to mammary tumours, the incidence of total mammary tumours was somewhat lower in laquinimodtreated females as compared to controls. However, there was no clear dose response relationship, mammary  fibroadenoma  were  present  in  4/7  high-dose  females  with  uterine  adenocarcinoma. Since prolactin is known to be the main driving force in the development of rat mammary tumours (Hargreaves &amp; Harleman , 2011), the presence of mammary fibroadenoma in these rats argues against  these  rats  being  hypoprolactinemic.  Clearly,  there  was  no  evidence  of  an  inverse relationship between uterine and mammary tumours.

The most important argument put forward by the applicant to constitute the most plausible and direct experimental evidence for an inverse correlation between pituitary and uterine tumours - is the statement that none of the 7 high-dose females with uterine adenocarcinoma had prolactinoma. However, when taking a closer look at the histopathology and immunohistochemistry data  this  statement  appears  somewhat  ambiguous.  Of  the  7  high-dose  females  with  uterine adenocarcinoma  no  less  than  4  had  pituitary  neoplasms  (adenoma).  In  addition,  2  rats  had pituitary hyperplasia ranging from minimal to moderate.

Immunohistochemistry (IHC) for the detection of prolactin was performed on all 4 tumours. The result is said to be negative for 3 tumours (animals N o  514, 519, 539), and 'not possible to judge' for  1  tumour  (animal  N o 525).  According  to  the  study  report  [Study  8244655],  the  following grading system was used to evaluate the IHC results:

<div style=\"page-break-after: always\"></div>

-  The  tumour  is  negative  for  prolactin.  '1':  indicates  a  few  of  the  tumour  cells  are  positive  for prolactin,  '2':  Indicates  many  of  the  tumour  cells  are  positive  for  prolactin,  '3':  indicates  the majority of the tumour cells are positive for prolactin

Although the tumors from animals No 525 and 539 were graded 1, they were in the final analysis judged to be 'not possible to judge' and 'negative', respectively. Photographs of the IHC stainings in the report, especially Figure 13 showing a close-up of N o  525, convey a different message. There are evidently several positively stained tumor cells, and it is not clear what the 'not possible to judge' and 'negative' diagnoses are based upon. For a third tumor judged negative (animal N o 514) autolytic changes are present and there is no normal pituitary gland to compare the staining results with; thus the result cannot be considered conclusive.

Furthermore, it should be noted that 3 control animals also had uterine adenocarcinoma. These rats  (N o 324,  545  and  559)  all  had  pituitary  adenomas  that  were  judged  positive  for  prolactin (grade 3) for the two tumours that were investigated by IHC (N o  545 and 559). Thus, there was no correlation  between  absence  of  prolactinoma  and  presence  of  uterine  adenocarcinoma  in  these rats.

It  is  important  to  consider  that  there  are  rat  strain  differences  with  respect  to  the  background incidence of uterine and mammary tumours, and to the response to decreased prolactin levels. All published  articles  regarding  a  relationship  between  uterine  adenocarcinoma  and  decreased prolactin levels following reduced body weights and reduced number of pituitary tumors come from studies  in  Wistar  rats  (Harleman  H et  al. ,  2012).  In  contrast,  the  carcinogenicity  study  with laquinimod was undertaken in Sprague-Dawley (SD) rats. In dietary restriction studies, both SD and Wistar rats have shown reduced number of pituitary and mammary tumours; however, only Wistar  rats  show  an  increase  in  uterine  tumours  (Keenan  KP et  al. ,  1995;  Harleman  H et  al., 2012). The authors of a review on &gt; 5000 Wistar rats and &gt; 2000 SD rats from the RITA database state that there is an apparent specific sensitivity for this effect in the Wistar strain, which is not present in SD rats (Harleman H et al. , 2012). These data further question the mechanism proposed by the applicant.

In summary, since prolactin levels were not measured in the rat carcinogenicity study there is no direct  evidence  to  show  that  the  7  high-dose  females  with  uterine  adenocarcinoma  were hypoprolactinemic. Indirect evidence of hypoprolactinemia is not particularly convincing: 4 of these rats  had  mammary  tumors  (suggesting  prolactin  stimulation)  and  4  had  pituitary  adenoma  (3 animals  had  both  types  of  tumours)  with  at  least  2  pituitary  tumors  showing  some  degree  of prolactin-positive  IHC  staining.  Furthermore,  a  relationship  between  reduced  body  weight  and uterine adenocarcinoma via reduced number of prolactinoma has not been found in SD rats.

Even assuming that the applicant's hypothesis is correct, i.e. that these rats were hypoprolactinemic as a consequence of lower body weight gain and associated lower incidence of prolactinoma,  it  should  be  noted  that  an  increase  in  uterine  tumors  has  only  been  verified  for compounds causing a direct effect on prolactin secretion, e.g. bromocriptine. Such an association has  not  been  confirmed  for  relative  hypoprolactinemia  due  to  decreased  incidence  of  pituitary neoplasia (Hargreaves &amp; Harleman, 2011). Assuming that the applicant's hypothesis is correct, i.e. that  the  occurrence  of  uterine  adenocarcinomas  in  high-dosed  animals  is  driven  by  a  lower incidence in prolactinemia inducing in turn an 'hypoprolactinemic state', it is surprising that none of the 37 control females not presenting any prolactinoma was diagnosed with uterine adenocarcinoma (vs. 6/46 in the high dose group, according to the applicant's hypothesis).

The applicant refers to the Biosure study (Roe et al. , 1995) where the feeding of a high fibre diet (LMA) to Wistar rats led to  an  increased incidence  of  uterine carcinomas. However, the authors of that  study  concluded  that  it  could  not  be  excluded  that  the  effect  might  be  due  to  a  higher

<div style=\"page-break-after: always\"></div>

exposure of the LMA-fed rats to dietary phyto-estrogens in some way associated with the fibre. Rats in the same study that were fed with a restricted standard maintenance diet (SMR) did not show  an  increase  in  uterus  adenocarcinoma,  although  they  had  a  lower  incidence  of  pituitary tumors.

Furthermore,  there  is  no  strong  regulatory  acknowledgement  of  this  mechanism.  The  examples provided by the applicant (fingolimod and ticagrelor) illustrate that regulatory bodies (FDA, CHMP) have  come  to  different  conclusions  regarding  the  link  between  prolactin  decrease  and  uterine tumors. It should be noted that the carcinogenicity studies with fingolimod as well as ticagrelor were conducted in Wistar rats.

In the absence of convincing data to support the applicant's hypothesis, alternative mechanisms have to be considered. AhR activity can modulate prolactin expression in the pituitary, which could theoretically result in similar hormonal disturbances as seen in true and relative hypoprolactinemia (Moran et al. , 2012). However, there are no findings (e.g. implantation failure, decreased fertility) suggestive of direct hypoprolactinemia in the repeat dose toxicity or reproductive toxicity studies with laquinimod.

On the other hand, TCDD and DLCs have been shown to induce a number of effects on female reproductive  organs  in  rats,  e.g.  chronic  inflammation  in  the  ovary,  acute  and/or  chronic inflammation of the uterus, cystic endometrial hyperplasia and uterine carcinoma (Yoshizawa K et al. ,  2009b). These effects were possibly via anti-estrogenic mechanisms, endocrine disruption of the  reproductive  organs,  or  a  local  retinoid  deficiency  pathway  resulting  in  abnormal  epithelial differentiation.

In conclusion, for the majority, the applicant's proposed rat-specific mechanism is not considered sufficiently  supported  by  data.  Alternative  mechanisms,  e.g.  mediated  via  the  AhR,  cannot  be excluded.

· The  applicant's  proposed  mechanism  for  oral  squamous  cell  carcinoma  observed  in  the laquinimod rat carcinogenicity study is as follows: during withdrawal of the gavage tube from the animal,  reflux  or  leakage  of  residual  dosing  solution  may  lead  to  direct  contact  with  high concentrations of drug in the oral cavity. Since laquinimod is cytotoxic to keratinocytes in vitro this high local concentration is likely to cause irritation, which in turn may progress to hyperplasia and carcinoma. If the above outlined hypothesis would be correct one would assume that many drugs would  exert  the  same  effect  in  rodent  carcinogenicity  studies;  however,  few  if  any  therapeutic agents  have  been  shown  to  cause  oral  cavity  tumours  in  rodent  bioassays  [Greaves,  2007].  In contrast, a number of chemical carcinogens including TCDD and DLCs have been reported to induce squamous carcinomas in the oral cavity of rats.

TCDD and DLCs caused gingival hyperplasia as well as squamous cell carcinoma in Sprague-Dawley rats  (Yoshizawa  K et  al. ,  2005).  These  tumours  occurred  within  the  oral  mucosa  of  the  palate, located mainly lateral to the molar teeth. The gingival area in the vicinity of the molars was also the location of the proliferative oral findings in the laquinimod rat carcinogenicity study.

In mink, gingival hyperplasia characterized by cystic nests and infiltrative squamous epithelial cells in periodontal  ligaments  appeared  during  TCDD  exposure  (Haynes et al. , 2009). Similar histopathological  lesions  (periodontal/palatal  cysts  and  gingival  hyperplasia)  were  present  in  the laquinimod rat carcinogenicity study.

Although the exact mechanism whereby TCDD and DLCs induce oral squamous carcinoma is not known,  one  hypothesis  relates  to  a  disruption  of  retinoid  homeostasis,  leading  to  abnormal epithelial  differentiation  and  a  keratinized  squamous  phenotype (Lancillotti F et  al. ,  1992).  From

<div style=\"page-break-after: always\"></div>

this perspective it is of interest to note that laquinimod caused forestomach squamous hyperplasia, and squamous metaplasia in the urinary bladder and larynx.

Furthermore, dental lesions such as ameloblast degeneration and tooth developmental abnormalities  have  been  reported  in  both  animals  and  humans  exposed  to  TCDD  and  DLCs (Yoshizawa  K et  al. ,  2005).  In  view  of  the  well-known  dental  toxicity  of  TCDD  and  DLCs  it  is interesting to note that distinct dental lesions were observed in the applicant's two local tolerance studies in hamsters and rats [Study 39926; Study 39924].

In  these  studies,  laquinimod  was  directly  applied  to  the  oral  mucosa  for  up  to  13  weeks,  at concentrations 5 and 20-fold higher than the top concentration of the dosing solution used in the rat carcinogenicity study. In the hamster study, laquinimod caused hyperplasia, hyperkeratosis and inflammation at the application site as well as in other sites of the oral cavity (oral mucosa, gingiva and  palate).  In  addition,  discolouration  of  the  incisor  teeth  was  observed  and  associated  with atrophy and disorganization of the ameloblastic cells at the base of the incisor teeth. The results of the rat study were confounded by inflammatory changes in both control and drug-treated animals. However,  there  were  clear  treatment-related  dental  effects  in  the  form  of  discolouration  of  the incisor teeth and degeneration/necrosis of the pulp.

It  should  be  noted  that  AhR  is  detectable  in  molar  teeth  buds  and  palatal  epithelial  cells,  in particular from the late embryonic stage in rodents and humans (Yoshisawa K et al. , 2005).

In  conclusion,  for  the  majority,  the  applicant's  proposed  mechanism  for  the  oral  squamous carcinomas is considered highly unlikely. Taking into account the similarities between oral/dental proliferative and degenerative lesions caused by TCDD/DLCs and laquinimod, a mechanism related to AhR activation cannot be excluded.

- Laquinimod has an overall toxicity profile (general toxicity, immune system effects, reproductive toxicity and carcinogenicity) that correlates well with what has been shown for AhR agonists such as  e.g.  2,3,7,8-tetrachlorodibenzo-p-dioxin  (TCDD).  It  is  acknowledged  that  not  all  effects  are completely overlapping; however, this is to be expected considering the complexity and diversity of AhR-mediated toxic responses. Thus, it cannot be excluded that the tumours were caused by the interaction of laquinimod or its metabolites with the AhR receptor. Such mechanism(s) can be of relevance  for  humans.  Alternatively,  although  no  obvious  suggestion  can  be  made,  some  other unidentified mechanism of unknown relevance to humans could be causing the tumours identified in the rat carcinogenicity study. The low exposure margins should then be considered.

-  There  are  data  showing  that  the  human  is  less  sensitive  than  animals  for  certain  effects associated with activation of the AhR ( Connor &amp; Aylward Toxicol Environ Health B Crit Rev. 2006 Mar-Apr;9(2):147-71 ) .  However,  there  are  data  showing  that  different  AhR  ligands  affect  the human and animal AhR differently, and some are more potent at the human receptor than the animal and vice versa (e.g. Moriguchi et al. , PNAS  2003, 5652-5657; Flaveny &amp; Perdew;  Mol Cell Pharmacol. 2009, 1(3): 119-123). Thus, it is not possible to in a general manner estimate that the human will be less sensitive AhR activation. It is thus not possible to conclude on larger margins of exposure than those established based on pharmacokinetic data.

Taken together, there are concerns related to carcinogenic risk associated with long-term human use of laquimimod.

- the SWP did not find it meaningful to recommend specific additional studies to be undertaken at this stage. There are several possible studies that could be considered to explore the interaction with  laquinimod  and  its  metabolites  at  the  AhR.  For  instance,  additional  in  vitro  studies,  in  the same models as already used for testing of laquinimod and DELAQ, could be undertaken with other metabolites of laquinimod. The rationale for doing so, despite that other metabolites have been

<div style=\"page-break-after: always\"></div>

observed in humans at very low levels only, would be the finding that DELAQ was very potent at the AhR (EC50 in the picomolar range), and that there are metabolites downstream of DELAQ with close structural similarity. Furthermore, there is a knock-out mouse available; and studies in AhR /-  mice  could  be  used  to  dissect  which  effects  of  laquinimod  are  AhR  dependent  and  which  are AhR- independent.

- Regarding effects on the immune system, further exploration of the primary mechanism of action could be of interest. In addition, a reported reduction in IL-17 levels after laquinimod exposure in vivo (in  the EAE model) confirmed in in vitro experiment on human PBMCs possibly indicates an direct or an indirect effect on Th17 differentiation or function and might be considered for further investigation.

-  Further  data  on  the  effects  of  laquinimod  on  prolactin  levels  are  not  meaningful  given  the considerable evidence speaking against reduced prolactin as a plausible mechanism for the uterine adenocarcinoma in the rat carcinogenicity study.

-  The  toxicity  profile  shown  in  the  general  and  reproductive  toxicity  studies,  in  addition  to  the tumours for which mechanistic explanations have not been possible to establish, and together with the available, although somewhat limited, mechanistic support for interaction with the AhR system, lead  to  serious  concerns  for  human  safety.  Based  on  that,  there  are  doubts  that  additional mechanistic data can help in excluding a human risk.

- The mechanisms proposed by the applicant for the uterine adenocarcinomas as well as the oral cavity tumours are not convincing; rather detailed review of available data speaks against these proposed mechanisms. Such interaction could be part of alternative mechanistic explanations for the development of these tumours. There are species differences between effects induced by AhR activation,  and  there  is  support  that  the  human  may  be  less  sensitive  for  certain  effects  than animals. However, there are also data showing the opposite. Thus, it is not possible to conclude on a  general  increase  in  margins  of  exposure  due  to  potential  species  differences.  Alternatively, although  no  obvious  suggestion  can  be  made,  some  other  unidentified  mechanism  of  unknown relevance to humans could be causing the tumours identified in the rat carcinogenicity study. The low exposure margins should then be considered, and thus the tumours are of concern for human safety.  Thus,  the  data  at  hand  cannot  be  used  to  conclude  a  lack  of  human  relevance  of  the tumours  observed  in  the  rat  carcinogenicity  study.  In  addition,  no  obvious  risk  minimisation activities could be proposed. Thus, there are concerns related to carcinogenic risk associated with long-term human use of laquinimod.

The  applicant  presented  at  an  Oral  Explanation  held  on  17  December  2013  the  details  of  their rationale  for  considering  AhR  activation  as  a  valid  pharmacological  target  and  their  position regarding  the  potential  risk  of  carcinogenicity  and  teratogenicity  based  on  animal  findings.  No major  changes  to  the  applicant  position  regarding  the  potential  risk  of  carcinogenicity  and teratogenicity were noted by the CHMP. According to the applicant, AhR has been acknowledged as a viable pharmacological target for inflammatory diseases and cancer and the profile of laquinimod resembles  to  indole-3-carbinol,  a  compound  found  as  nutrient  in  vegetables  and  used  as  food supplement.

Having considered the above SWP conclusions and the data submitted in the application, the CHMP concluded that:

the non-clinical aspects of laquinimod have not been adequately documented and do not meet the requirements to support this application for the following reasons:

-The  overall  toxicity  profile  (general  toxicity,  carcinogenicity  and  reproductive  toxicity)  of laquinimod correlates well with what has been shown for AhR agonists such as e.g. TCDD (dioxin).

<div style=\"page-break-after: always\"></div>

This,  in  addition  with  the  mechanistic  data  supportive  of  AhR  activation,  raised  some  serious concerns regarding the relevance of the findings in animals with respect to human safety.

-The mechanisms proposed by the applicant to explain the occurrence of neoplastic lesions found  in  the  oral  cavity  and  uterus  of  rats  in  the  carcinogenicity  study  were  not  convincing  to exclude a relevance of the findings in animals with respect to human safety.

-The mode of action of laquinimod has not been sufficiently investigated, and in particular, the  identification  of  the  molecular  target  remains  unknown,  contributing  to  the  insufficient characterization of the safety profile of laquinimod.

## Assessment of paediatric data on non-clinical aspects

During  the  evaluation,  data  on  the  juvenile  toxicity  study  in  rats  were  submitted  at  the  CHMP request  on  the  basis  that  the  study  was  completed  according  to  the  PIP.  The  CHMP  noted  that preliminary  data  were  reviewed  by  the  PDCO  in  the  context  of  a  PIP  modification  procedure  in January  2013.  These  data  showed  decreased  femur  width  in  males  dosed  with  laquinimod.  The effect seemed to be irreversible. Given the clinical relevance of the reduced femur width observed following exposure to laquinimod during maturation was unknown at that time, the PDCO agreed for  further  characterisation  of  this  issue.  Upon  availability  of  the  final  results,  findings  and conclusions were requested to be discussed with the PDCO prior to initiating any paediatric studies. On this basis, no further assessment was considered necessary by the CHMP at the present time.

## 2.3.7. Conclusion on the non-clinical aspects

Overall, the non-clinical aspects of laquinimod have not been adequately documented and do not meet the requirements to support this application for the following reasons:

-The  overall  toxicity  profile  (general  toxicity,  carcinogenicity  and  reproductive  toxicity)  of laquinimod correlates well with what has been shown for AhR agonists such as e.g. TCDD (dioxin). This,  in  addition  with  the  mechanistic  data  supportive  of  AhR  activation,  raised  some  serious concerns regarding the relevance of the findings in animals with respect to human safety.

-The mechanisms proposed by the applicant to explain the occurrence of neoplastic lesions found  in  the  oral  cavity  and  uterus  of  rats  in  the  carcinogenicity  study  were  not  convincing  to exclude a relevance of the findings in animals with respect to human safety.

-The mode of action of laquinimod has not been sufficiently investigated, and in particular, the  identification  of  the  molecular  target  remains  unknown,  contributing  to  the  insufficient characterization of the safety profile of laquinimod.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant

The  applicant  has  provided  a  statement  to  the  effect  that  clinical  trials  conducted  outside  the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

· Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

The clinical development program to evaluate laquinimod in patients with MS includes both ongoing and completed studies:

-Phase I studies: thirteen studies in healthy volunteers were completed (one also included MS patients)  and  an  ascending  dose,  sequential  cohort  study  (MS-LAQ-101)  is  ongoing  in  RRMS patients.

-Phase  II  studies:  one  placebo-controlled  (Study  ID  01506203)  and  one  open-label  (study  ID 03506207)  in  MS  patients  were  completed.  One  study  (LAQ/5062)  and  its  extension  study (LAQ/5063) were also completed. An extension of study LAQ/5063 is ongoing.

-Phase III studies, MS-LAQ-301 and MS-LAQ-302 studies were completed and extensions to both are currently ongoing.

Table 1. Summary of Clinical Studies Providing Efficacy Data

| Study ID              | No. of study centres, locations                                                                      | Design                          | Study Posology                                | Study Objective                             | Subjects by arm entered/ complete d           | Duratio n                                  | Gender M/F, Median Age                  | Diagnosis Inclusion criteria                        | Primary Endpoint                                                                                                                                                                                                        |
|-----------------------|------------------------------------------------------------------------------------------------------|---------------------------------|-----------------------------------------------|---------------------------------------------|-----------------------------------------------|--------------------------------------------|-----------------------------------------|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Phase II studies      | Phase II studies                                                                                     | Phase II studies                | Phase II studies                              | Phase II studies                            | Phase II studies                              | Phase II studies                           | Phase II studies                        | Phase II studies                                    | Phase II studies                                                                                                                                                                                                        |
| 01506203              | mc, 20 centers in UK, Russia, Sweden, and Netherlands                                                | Phase II r,p, db,pc (n=209 )    | 0.1mg LAQ/day 0.3mg LAQ/ day Placebo once/day | Efficacy and Safety in relapsing MS         | 0.1 mg: 68/65 0.3 mg: 74/69 placebo: 67/64    | 24 weeks treatme nt and 8 weeks follow- up | 54 M 155 F, mean age 40.2 (19-62) years | RRMS (84%) SPMS (15.3%) based on Mc Donald criteria | cumulative number of active lesions between week 0 and 24                                                                                                                                                               |
| LAQ/5062              | mn, mc, 51 centers in Italy, Germany, Spain, Czech Republic, Russia, Poland, UK, Hungary, and Israel | Phase IIb r, p, db, pc (n=306)  | 0.3mg LAQ/day 0.6mg LAQ/ day Placebo once/day | Efficacy, Tolerabilit y and Safety in RRMS  | 0.3 mg: 98/92 0.6 mg: 106/100 placebo: 102/91 | 36 weeks double- blind phase               | 115 M 191F mean age 33.0 (18-51) years  | RRMS based on Mc Donald criteria                    | cumulative number of GD- enhancing lesions on T1- weighted images, weeks 24,28,32 and 36                                                                                                                                |
| Phase III studies     | Phase III studies                                                                                    | Phase III studies               | Phase III studies                             | Phase III studies                           | Phase III studies                             | Phase III studies                          | Phase III studies                       | Phase III studies                                   | Phase III studies                                                                                                                                                                                                       |
| MS-LAQ- 301 (ALLEGRO) | mc, USA, Canada, Israel and Europe 139 centers in 24 countries                                       | Phase III r, p, db, pc (n=1106) | 0.6 mg LAQ/day Placebo once/day               | Efficacy, Tolera- bility and Safety in RRMS | 0.6 mg: 550/437 Placebo: 556/427              | 24 months                                  | 347 M 759 F mean age 38.7 (18-56) years | RRMS based on revised Mc Donald criteria (2005)     | Annualized Relapse Rate (ARR) secondary: -cumulative number of GD- enhancing lesions on T1- weighted images -cumulative number of new/enlargi ng T2 lesions -Time to confirmed EDSS progression -MSFC score at month 24 |
| MS-LAQ-               | mc, USA,                                                                                             | Phase III                       | 0.6 mg                                        | Efficacy,                                   | 0.6 mg:                                       | 24                                         | 421 M                                   | RRMS                                                | Number of                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| 302 (BRAVO)                              | Israel, South Africa and Europe 155, 154, 153 centers in 15, 18 countries   | r, p, ac, db for oral treatment arms (LAQ and Placebo) rb for inj. arm IFN-β 1a (Avonex) (n=1331)   | LAQ/day Placebo once/day 30 mcg Avonex im once weekly   | Tolera- bility and Safety in RRMS versus placebo and active c (Avonex)   | 434/353 Placebo: 450 /359 Avonex: 447/378   | months                       | 910 F mean age 37.6 (18-56) years   | based on revised Mc Donald criteria (2005)   | Annualized Relapse Rate (ARR) secondary: -brain atrophy -time to comfirmed EDSS progression -MSFC score at month 24   |
|------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|---------------------------------------------------------|--------------------------------------------------------------------------|---------------------------------------------|------------------------------|-------------------------------------|----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Open label extension studies             | Open label extension studies                                                | Open label extension studies                                                                        | Open label extension studies                            | Open label extension studies                                             | Open label extension studies                | Open label extension studies | Open label extension studies        | Open label extension studies                 | Open label extension studies                                                                                          |
| LAQ/5063 Extension of LAQ/5062           | mc                                                                          | Phase IIb, r, p, db extension study.                                                                | 0.3mg LAQ/day 0.6mg LAQ/ day                            | Efficacy, Tolera- bility and Safety in RRMS                              | 257 RRMS patients                           | complet ed                   | 103 M 154 F (18-51 years)           | RRMS                                         |                                                                                                                       |
| LAQ/5063 OL open label phase of LAQ/5063 | mc                                                                          | Phase IIb ol extension phase of study LAQ/506 3                                                     | 0.6mg LAQ/ day                                          | Safety, Tolerabilit y and Efficacy in RRMS                               | 209 RRMS patients                           | ongoing                      | 83 M 126 F (19.8- 52.5 years)       | RRMS                                         |                                                                                                                       |
| MS-LAQ- 301 E                            | mc                                                                          | phase III ol                                                                                        | 0.6mg LAQ/ day                                          | long-term Safety, Tolerabilit y and Efficacy                             | 837 com- pleters of MS- LAQ-301             | ongoing                      | 270 M 567 F 20-58.2 years           | RRMS                                         |                                                                                                                       |
| MS-LAQ 302 E                             | mc                                                                          | phase III ol                                                                                        | 0.6mg LAQ/ day                                          | long-term Safety, Tolerabilit y and Efficacy                             | 1047 completers of MS-LAQ- 302              | ongoing                      | 340 M 707 F 20.2- 57.9 years        | RRMS                                         |                                                                                                                       |

LAQ=laquinimod, r= randomized, p=parallel, db= double-blind, pc = placebo controlled, ol= open label, ac= active controlled, IFN-ß 1a = interferon-beta 1a, mc = multicenter, mn = multinational, rb = rater blinded, EDSS:Expanded Disability Status Scale

In addition, phase III studies in RRMS evaluating 1.2 mg dose are ongoing (CONCERTO) or planned (LIBRETTO) and one phase II study (ARPEGGIO) in PPMS is initiated by the applicant.

## 2.4.2. Pharmacokinetics

Pharmacokinetic  (PK)  data  were  derived  from  14  Phase  I  clinical  studies,  involving  a  total  of approximately 500 subjects as well as PK evaluation which was performed in four Phase II studies and one Phase III  study  in  MS  patients.  In  addition,  a  number  of  drug-drug  interaction  studies have been performed in healthy volunteers in order to investigate the potential effect of CYP3A4 modifiers and the effect of laquinimod on CYP1A2 and CYP3A4 substrates.

Concentrations  of  laquinimod  were  measured  in  the  human  plasma  and  urine  using  LC/MS/MS methods in the PK studies. Pharmacokinetic parameters were determined using non compartmental models.  In  addition,  one  population  PK  analysis  using  non  linear  mixed  effects  modeling methodology (NONMEM). The population PK analysis was  conducted using sparse data from phase II and phase III studies together with the phase I studies.

<div style=\"page-break-after: always\"></div>

## Absorption

The  absolute  oral  bioavailability  of  laquinimod  has  not  been  studied.  Based  on  the  human metabolism data, more than 90% of the drug was absorbed supporting a high level of absorption of laquinimod.  The  extent  of  absorption  of  laquinimod  is  not  significantly  modified  by  food  intake absorption. The impact on food-intake on the rate of absorption is less clear. A 30 % decrease in Cmax was observed high fat meals resulted in a prolongation of Tmax to approximately 5 hours. Laquinimod may be taken with or without food since the overall extent of absorption is not affected (AUC decrease by 10% only). The CHMP also noted that laquinimod was taken without regard to meals in phase III studies, thus supporting such recommendation.

All  phase  III  clinical  studies  were  conducted  using  the  formulation  intended  to  be  marketed.  In addition, bioequivalence was demonstrated between the earlier formulations used in phase I and II studies and the final formulation.

## Distribution

The steady-state apparent volume of distribution of laquinimod is small (~10 L) and independent of dose, thus the drug is suggested to be poorly distributed to the peripheral tissues. Laquinimod is reversibly bound to human plasma proteins, primarily to serum albumin. Plasma protein binding of laquinimod  is  high  in  humans  (&gt;98%).  After  single  dose  administration  of  a  dose  of  14Claquinimod  to  healthy volunteers, blood/  plasma  partition of radioactivity  was  0.6,  hence laquinimod was mainly distributed to plasma with minimal distribution to red blood cells.

## Elimination

Laquinimod is very slowly eliminated primarily by metabolization as only a marginal fraction of the unchanged parent drug is recovered in the excretae (1.57% in faeces and 1.88% in urine). The plasma  elimination  half-life  is  approximately  80  hours.  From  the  available  data,  laquinimod  is primarily  but  slowly  eliminated  by  oxidative  metabolism.  No  major  metabolite  was  identified  in plasma and consequently accumulation of metabolites in humans was not tested. The main route of excretion  was  via  the  urine  with  50.8±2.2  per  cent  of  the  dose  recovered.  Faecal  excretion accounted for 28.1±3.4 per cent resulting in a total recovery of 78.9±4.3 (mean±SEM, n=6) per cent.

## Dose proportionality and time dependencies

Laquinimod  PK  appeared  to    evolve  proportionally  to  the  dose  after  single  and  repeated  doses ranging  from  0.05  up  to  2.4  mg/day  in  healthy  volunteers  and  also  in  patients.  No  time dependency  was  observed.  Upon  once  daily  repeated  dosing,  laquinimod  reaches  steady  state concentrations within approximately 14 days of dosing, accumulates in plasma approximately 5-6 fold, and fluctuation during the 24 hours dosing interval is low (about 30%).

The intra-individual and inter-individual variability were relatively small, respectively less than 16% and 20%, respectively.

## Special populations

Specific  phases  I  studies  evaluating  renal  and  hepatic  functions  were  conducted.  Other  age  and gender related data were derived from the population PK analysis. The effects of race and weight could  not  be  evaluated  in  the  population  PK  analysis  because  Caucasians  were  accounted  from 90% of the population and the underweighted and obese patients were not adequately studied. Additional  analyses  were  therefore  performed  to  evaluate  the  effects  of  race  and  weight  using

<div style=\"page-break-after: always\"></div>

Bayesian estimation of the clearance and volume of distribution in the different race and weight subgroups.

A specific study was conducted in subjects with moderate renal impairment after 0.6 mg oral single dose. Exposure to laquinimod in moderate renal impaired subjects was found to be approximately 40% (1.4 fold)  higher  comparatively  to  healthy  volunteers.  No  difference  was  observed  for  the maximum  plasma  concentration,  Cmax.  The  influence  of  severe  renal  impairment  on  the pharmacokinetics of laquinimod has not been studied.

A specific study was conducted in subjects with mild/moderate hepatic impairment after 0.6 mg oral  single dose. The AUC for laquinimod was approximately 1.3 and 2.3 fold higher in subjects with  mild/moderated  hepatic  impairment.  No  difference  was  observed  for  the  maximum  plasma concentration,  Cmax.  The  influence  of  severe  hepatic  impairment  on  the  pharmacokinetics  of laquinimod has not been studied.

No data are available in the paediatric population as the clinical studies included in the PIP had been deferred at the time of initial submission. The elderly population was also not studied and there was a limited exposure to patients aged 55 years or above.

In the population pharmacokinetic analysis, laquinimod clearance was higher (about 8%) in males compared to females and its volume of distribution of the central compartment was approximately 21% higher in males compared to females of similar weight. These differences were not considered of clinical relevance. No effect of age was observed.

Bayesian  estimation  of  clearance  and  volume  of  distribution  did  not  reveal  any  significant differences across race and weight (obese, underweighted and normal patients) subgroups.

## Pharmacokinetic interaction studies

In vitro studies with human hepatocytes demonstrated a little or no inhibitory effect of laquinimod on  CYP1A2,  CYP2B6,  CYP2C8,  CYP2C9,  CYP2C19,  CYP2D6,  CYP2E1.  At  25  μM,  the  activity  of CYP2C8 and CYP3A4/5 were inhibited by laquinimod, up to 4 and 11%, respectively. At 10 μM , a moderate  effect  on  CYP2C9  activity  was  observed  at  a  concentration  of  10  μM,  i.e.  a  32% decrease.

Potential for induction effect of laquinimod was also studied in vitro evaluating a number of CYP450 enzymes.  No  induction  effect  was  observed  on  CYP3A4,  however  a  potent  induction  of  CYP1A2 activity  was  noted.  CYP2B6  activity  was  also  found  to  increase  2  to  4-fold  over  the  tested concentration range (0.1, 1 and 10 μM) whereas no clear change was seen in CYP2C8, CYP2C9 or CYP2C19 activity. The activity of CYP3A4/5 showed a 2-4- fold decrease at 1-10 μM associated with low change in the levels of CYP3A4 mRNA.  In vivo data suggested a potent induction effect of laquinimod in rats with a level of hepatic CYP1A1 increases of 20-, 130- and 600-fold following doses of 0.1, 1, and 10 mg/kg/day for 4 days, respectively. Hepatic CYP1A2 content increased 4, 9, and 10-fold at the corresponding doses. In the same studies no relevant change in the level of CYP3A2 (the rat analogue to the human CYP3A4) or CYP2B1/2 was detected.

The induction effect on CYP1A1 and CYP1A2 activities and inhibitory effect on CYP3A4 activity was further investigated in an additional study, evaluating both laquinimod and DELAQ metabolite. In this  study,  laquinimod  or  DELAQ  caused  increases  in  CYP1A2  activity  and  CYP1A1  and  CYP1A2 mRNA levels and a decrease in CYP3A4/5 activity and, in the case of DELAQ, a decrease in CYP3A4 mRNA levels was also noted. Laquinimod was found to be a more potent inducer of CYP1A2 activity than DELAQ but had no relevant effect on CYP3A4 mRNA levels.  According to the applicant, the CYP induction potential of laquinimod is likely related to its interaction with the AhR transcription factor, as shown in dioxin responsive CALUX bioassay and in human MCF7 cells.

<div style=\"page-break-after: always\"></div>

Laquinimod  was  also  shown  to  cause  a  concentration-dependent  induction  of  two  uridine diphosphate glucuronosyltransferase enzymes, UGT1A1/6 and UGT2B2, when examined in primary cultures of male rat hepatocytes. Laquinimod at 1, 10 and 100 μM caused up to 6.9-fold and 2.4fold concentration dependent increase in UGT1A1/6 and UGT2B2 activities, respectively.

When the inhibitory effect of laquinimod (10 μ M) on transport of substrate by P-gp, BCRP, OAT1, OAT3,  OCT1,  OCT2,  OATP1B1  and  OATP1B3  was  investigated,  no  decrease  in  the  transport  of probe substrates for these transporters was observed.

The  potential  interactions  were  studied  in  humans  for  the  following  drugs:  rifampin  (CYPA3A4 inducer),cimetidine (weak CYP3A4  inhibitor), fluconazole (moderate CYP3A4  inhibitor) and ketoconazole  (strong  CYP3A4  inhibitor).  In  addition,  the  effect  of  laquinimod  on  the  PK  of midazolam,  a  CYP3A4  substrate,  and  caffeine,  a  CYP1A2  substrate,  was  evaluated  in  healthy volunteers.

After receiving ketoconazole, at 400 mg once daily for 28 days or fluconazole, at 200 mg once daily for  21 days,  systemic  exposure  (AUC)  of  laquinimod  increased  approximately  3.1-fold  with ketoconazole and 2.5-fold with fluconazole.  No effect was observed on Cmax in both situations. After receiving cimetidine, at 1600 mg once daily for 21 days, systemic exposure (AUC and Cmax) of  laquinimod  was  found  not  to  be  affected.  Systemic  laquinimod  exposure  was  decreased approximately 5-fold with no effect on Cmax, after receiving rifampicin, at a dose of 600 mg once daily for 21 days.

After  receiving  caffeine  or  midazolam with repeated doses of laquinimod (0.6 mg), the AUC and Cmax  of  caffeine  were  decreased  approximately  5-fold  and  2-fold,  respectively,  the  AUC  of midazolam was increased approximately 1.5-fold, while its Cmax was not affected.

Considering the teratogenic properties of laquinimod, an additional vivo interaction study investigating the potentially inducing effect of laquinimod on oral contraceptives was recommended by the CHMP to be performed. Results were recommended by the CHMP to be available within a reasonable timeframe.

## 2.4.3. Pharmacodynamics

Limited data were provided regarding the pharmacodynamic effects of laquinimod in humans.

## Mechanism of action

The mechanism of action of laquinimod is not fully elucidated because the molecular target is not known. Data on various types of experimental autoimmune encephalomyelitis models, as well as in cuprizone  induced  demyelination  and  on  other  inflammatory/autoimmune  disease  models  were presented to support the immunomodulatory properties of laquinimod and therapeutic effect in MS population.

## Primary and Secondary pharmacology

Pharmacodynamic  effects  of  laquinimod  on  heart  (QT/QTc  study)  and  lymphocytes  counts  have been  specifically  investigated  in  healthy  volunteers  and  RRMS  patients  (phase  III  sub-study), respectively.

## Cardiac effects

The  presented  QT/QTC  study  was  well  conducted  and  is  considered  valid.  Laquinimod  (up  to 1.2 mg daily during 14 days) did not show an effect on the cardiac ventricular repolarization. The mean QTcI was not increased in a clinically meaningful manner during the study. The largest time

<div style=\"page-break-after: always\"></div>

matched QTcI against placebo was in the 3 ms range for 0.6 mg and in the 4 ms range around Cmax for the 1.2 mg. The upper limit of the confidence interval always remained within the 10 ms limit, defined by the ICH E14 guideline. One volunteer only experienced a QTcI prolongation &gt;60 ms. Moxifloxacin increases the QTcI in the 10 ms range, as expected, confirming the sensitivity of the assay. Analysis of QTcB and QTcF yields comparable results.

## Immunological tests

Immune analyses in a subgroup of patients enrolled in phase III ALLEGRO study were performed to identify  possible  immune  parameters  that  may  be  specifically  modified  in  patients  receiving laquinimod. Blood samples were collected prior to commencement of therapy, and again after 1, 3, 6,  12  and  24  consecutive  months  of  laquinimod  or  placebo  therapy.  Main  objectives  were  to examine 148 patients with regard to: 1) Immune cell type distribution analysis and 2) Immune cell proliferation  in  response  to  mitogen  and  recall  antigen.  Measures  collected  over  time  in  the laquinimod treated group were compared to baseline data, and to data obtained from the placebo control  cohort.  No  changes  from  baseline  were  observed  in  the  composition  of  Peripheral  Blood Mononuclear Cell (PBMC): i.e. none of the major populations of PBMC showed any changes over time of between groups. Similarly, there were no changes in the preponderance of any of the subpopulations thus far assessed. After simultaneous evaluation of the proliferative response of PBMC in the presence of PHA or tetanus toxoid, there were no changes from baseline in the proliferative response  of  PBMC  from  patients  receiving  laquinimod  therapy,  and  no  differences  between  the laquinimod treated and placebo control cohorts. According to the applicant, these data demonstrate that  patients  receiving  laquinimod  therapy  had  no  apparent  changes  in  their  peripheral  blood repertoire and retain their capacity to respond accordingly to immunological stimuli. However the CHMP was concerned that the presented results of this study were not adequately substantiating the applicant claim. Details of the CHMP position are presented in 1.7.4.

## 2.4.4. Discussion on clinical pharmacology

The  pharmacokinetic  profile  (absorption,  distribution,  metabolism  and  elimination)  of  laquinimod has been studied in healthy volunteers and multiple sclerosis patients and is considered sufficiently characterised in the intended patient population.

As laquinimod was almost completely metabolised, the CHMP considered that genetic polymorphism could be an important intrinsic factor. The potential impact of genetic polymorphism was thoroughly discussed by the applicant, in particular of the isoenzyme CYP3A4 and the CHMP agreed that the potential for genetic polymorphism could be considered low.

Bioequivalence was demonstrated between the earlier formulations used in phase I and II studies and the final formulation.

No dosage adjustment is required for patients with moderate renal impairment. In the absence of data  in  subjects  with  severe  renal  impairment,  the  use  of  laquinimod  should  be  avoided  in  this population.

Although data in subjects with mild/moderate hepatic impairment did not suggest a very significant increase in the systemic exposure of laquinimod (1.3 to 2.3 fold higher, respectively), the CHMP recommended strengthening the warning, initially proposed by the applicant, as to reflect that the use  of  laquinimod  should  be  avoided  in  this  population  as  well  as  in  severe  hepatic  impaired subjects due to the known and extensive hepatic metabolism.

<div style=\"page-break-after: always\"></div>

No data are available in the paediatric population as the clinical studies included in the PIP had been deferred at the time of initial submission. The elderly population was also not studied and there was a limited exposure to patients aged 55 years or above.

Population  pharmacokinetic  analyses  did  not  reveal  any  significant  effect  of  gender  nor  age. Bayesian  estimation  of  clearance  and  volume  of  distribution  did  not  reveal  any  significant differences across race and weight (obese, underweighted and normal patients) subgroups.

The  extent  of  exposure  of  laquinimod  depends  mainly  on  the  CYP3A4  activity.  Inhibition  of  the CYP3A4 increases the plasma levels of laquinimod depending on the potency of the inhibitor and a reverse  effect  is  observed  when  CYP3A4  is  induced.  Laquinimod  itself  is  a  strong  inducer  of CYP1A2.  Consequently,  a  number  of  recommendations  related  to  concomitant  use  with  CYP3A4 modifiers and CYP1A2 substrates should be considered as follows: 1) The concomitant prolonged (&gt; 1 month) use of moderate or strong CYP3A4 inhibitors and laquinimod should be avoided, 2) Concomitant use of strong CYP3A4 inducers with laquinimod is not recommended and 3) Dosage adjustment should be made in case of concomitant administration with CYP1A2 substrates with a narrow therapeutic index.

Laquinimod showed a weak effect on CYP3A4 substrates and is not expected to significantly impair their pharmacokinetic profiles. No dosage adjustment is required.

Considering the teratogenic properties of laquinimod, an additional vivo interaction study investigating the potentially inducing effect of laquinimod on oral contraceptives was recommended by the CHMP to be performed. Results were recommended by the CHMP to be available within a reasonable timeframe.

Laquinimod (up to 1.2 mg daily during 14 days) did not show an effect on the cardiac ventricular repolarization.

The  applicant  presented  data  to  demonstrate  that  patients  receiving  laquinimod  therapy  had  no apparent  changes  in  their  peripheral  blood  repertoire  and  retain  their  capacity  to  respond accordingly to immunological stimuli. Although, there were no statistically nor clinically significant differences in the composition or proliferative response of patient's Peripheral blood mononuclear cells  PBMCs  in  the  laquinimod-treated  group  as  compared  to  the  baseline  data,  and  to  data obtained from the placebo group, the CHMP questioned the relevance of the selected markers for the analysed cell subsets (e,g. CD83+ for dendritic cells,  CD57+ for NK-T cells). In its analysis, the CHMP was concerned about the lack of clear presentation of the data and recommended the applicant  to  provide  relevant  longitudinal  information  on  the  variations  of  lymphocytes  subsets such  as  the  absolute  values  and  percentages  (obtained  by  a  bead-based  standardized  flow cytometry  procedure  performed  on  whole  blood  and  carried  out  by  a  single  lab  registered  to  a recognized quality control such UKNEQAS). Overall, these issues remained to be addressed. The applicant claim was therefore not endorsed by the CHMP.

Overall,  limited  data  were  provided  regarding  the  pharmacodynamic  effects  of  laquinimod  in humans. Given the mechanism of action has not been sufficiently investigated and the molecular target remains unknown, the CHMP considered that no conclusion could be drawn on the clinical pharmacology of laquinimod.

## 2.4.5. Conclusions on clinical pharmacology

Overall,  the  pharmacological  profile  of  laquinimod  in  human  studies  has  not  been  adequately documented  and  does  not  meet  the  requirements  to  support  this  application  for  the  following reasons:

<div style=\"page-break-after: always\"></div>

- Whilst the pharmacokinetic profile has been sufficiently characterised, there is a lack of relevant data on the pharmacodynamic effects of laquinimod in humans reinforcing the uncertainties raised on its mechanism of action and potential risks.

## 2.5. Clinical efficacy

The  applicant  applied  for  the  following  indication:  treatment  of  patients  with  relapsing  remitting multiple sclerosis (RRMS).

The clinical development program comprises the following clinical studies:

-  a  phase  II,  24-week,  double-  blind,  randomised,  placebo-  controlled,  parallel-group,  study (01506203) evaluating the efficacy and safety of laquinimod 0.1 mg and 0.3 mg  versus placebo in patients with relapsing multiple sclerosis (RMS) patients;

-a phase  II, 36  week,  double-blind,  randomised,  placebo-controlled,  parallel-group  study ( LAQ/5062 )  evaluating the efficacy and safety of laquinimod 0.3 and 0.6 mg versus placebo in RRMS patients. LAQ/5062 had an extension study ( LAQ/5063 ) that has been completed and has been then subject to another extension study, which is currently ongoing.

- a phase III, 24-month, double-blind, randomised, placebo-controlled, parallel-group study (LAQ301), evaluating  the  efficacy  and  safety  of  0.6  mg  laquinimod  administered  once  daily  versus placebo  in  RRMS  patients.  LAQ-301  (also  called  ' ALLEGRO' )  has  an  ongoing  extension  study (LAQ-301E).

- a phase III, 24-month, randomised,parallel-group study (LAQ-302), evaluating the efficacy and safety of 0.6 mg laquinimod administered once daily versus placebo in a double-blind design and versus interferon β-1a (Avonex) administered i.m. once weekly in a rater-blinded design in RRMS patients. LAQ-302 (also called ' BRAVO' ) has an ongoing extension study ( LAQ-302E ).

## 2.5.1. Dose response studies

In  study  01506203,  2  doses  were  tested  (0.1  mg  and  0.3mg).  A  total  of  209  patients  were randomised (n=67 for placebo group, n=68 for 0.1 mg laquinimod group and n=74 for 0.3 mg group). The population study was representative of the MS population (RRMS, SPMS), with 74.2 % of  women and 98.6% of Caucasian patients. Around 15.3% were SPMS patients. The mean age was around 40, the mean duration of the disease was 5.82 years and patients had at least one documented clinical or subclinical (defined as a gadolinium-enhanced lesion on MRI examination or a  new  T2  lesion  demonstrated  on  two  consecutive  Magnetic  Resonance  Imaging  or  MRI examinations) exacerbation in the last year or two documented exacerbations in the last two years (one of which could be subclinical) or the presence of one gadolinium-enhanced lesion on the Week -4 MRI scan and had had at least nine T2 lesions on the Week -4 MRI scan or at least three T2 lesions and at least one gadolinium-enhanced lesion on a T1 weighted scan at Week -4.

In the primary analysis using Per Protocol (PP) population, the mean cumulative number of active lesions was reduced by 44% in the 0.3mg laquinimod group compared with placebo (5.24 vs 9.44) and there was a reduction in the geometric mean for the cumulative number of active lesions at Week  24  in  the  laquinimod  0.3  mg  group  (2.264)  as  compared  to  placebo  group  (3.164);  this difference was of borderline significance (p=0.0498). At 0.1 mg, this difference was not statistically significant (p=0.2615). The CHMP also noted that there was an imbalance at baseline regarding the number of active lesions (higher in the placebo group) which could introduce a bias in favour of the laquinimod  groups.  The  analysis  using  Intention  To  Treat  (ITT)  population  showed  a  nonstatistically significant difference between laquinimod (both 0.1 mg and 0.3 mg dose) and placebo groups (p=0.202 at 0.1 mg and p=0.172 at 0.3 mg).  No statistically significant differences were observed in any clinical parameters (e.g. number of relapses, time to first relapse or severity of

<div style=\"page-break-after: always\"></div>

relapse)  between  treatment  groups  over  the  treatment  period.  Taking  into  account  the  lack  of effect of the 0.1 mg dose and the inconclusive results for the 0.3 mg dose, study LAQ/5062 was conducted using higher dose of laquinimod.

In study LAQ/5062, only one higher dose was tested (0.6 mg) together with the 0.3 mg dose, that was  previously  investigated  and  only  RRMS  patients  were  included.  In  addition,  the  primary endpoint  was  changed  to  measure  the  cumulative  number  of  active  lesions  between  week  0  to week 14, as opposed to week 24. The number of randomized patients was 98 in the laquinimod 0.3 mg group,  106  in  the  laquinimod  0.6  mg  group  and  102  in  the  placebo  group.  The  population studied was representative of the RRMS population with 62.4% of it being women and 99.0% of it being Caucasian patients. The mean age was around 33 years; the mean duration of disease was short (3.7 years). Patients had 1.46 relapses in the previous one year and had a baseline EDSS of 2.3. A statistically significant treatment effect (p=0.0048) of laquinimod 0.6 mg  was observed as compared to placebo, with a reduction of 40% in the cumulative number of Gd-enhancing lesions at weeks 24, 28, 32 and 36 (primary endpoint). Results on a number of secondary MRI parameters (e.g. cumulative number of new T2 lesions, mean number of new hypointense lesions on T1) were positive and consistent with the primary efficacy analysis for the 0.6 mg dose. On the other hand, no significant effect on the  primary endpoint was observed with the 0.3 mg dose with a reduction of 8% as compared to placebo (p=0.6740) and no significant effects were observed on the other analysed MRI endpoints.  Regarding the proportion of relapse-free subjects, and clinical endpoints related to relapses and EDSS there was no effect of any of the laquinimod treatments compared to placebo. The mean number of relapses was decreased in the Laquinimod 0.6 mg group (0.40) as compared to placebo (0.54); however this result was not statistically significant (p=0.2079). In the laquinimod 0.3 mg group there was no difference in the number of relapses (0.56) compared to placebo.

## 2.5.2. Main studies

## 2.5.2.1. Study LAQ-301 - ALLEGRO

This  was  a  randomised,  double-blind,  parallel-group,  placebo-controlled  study  evaluating  the efficacy  and  safety  of  laquinimod  administered  orally  once  daily  versus  placebo  in  patients  with relapsing-remitting  multiple  sclerosis.  Treatment  duration  was  24  months  with  a  possibility  of extension to 36 months.

The study was conducted in a number of European countries and also in non-EU regions (e.g. the US, Canada, Israel, Russia, Ukraine, Turkey, Georgia, Serbia).

## 2.5.2.1.1. Methods

## Study Participants

## Main inclusion criteria

Males or females aged 18 to 55 years inclusive, with a diagnosis of MS as defined by 2005 revised McDonald criteria, with a relapsing-remitting course with at least one documented relapse during the previous year or two documented relapses during the previous 2 years, prior to screening or one  documented  relapse  between  12  and  24  months  prior  to  screening  with  at  least  one documented T1-Gadolinium enhancing (GdE) lesion in an MRI performed within 12 months prior to

<div style=\"page-break-after: always\"></div>

screening, with an Expanded Disability Status Scale score of 0 to 5.5 inclusive and with a disease duration of at least 6 months prior to screening.

## Main exclusion criteria

Patients who met any of the following criteria were excluded: subjects with progressive forms of MS; an onset of relapse, unstable neurological condition or any treatment with corticosteroids [iv, intramuscular or i.m, and/or per os or ACTH between Month -1 (screening) and 0 (baseline); use of immunosuppressive  including  mitoxantrone  or  cytotoxic  agents  within  6  months  prior  to  the screening  visit  ;  previous  use  of  either  of  the  following:  natalizumab,  cladribine,  laquinimod; previous treatment with glatiramer acetate, Interferon-β (either 1a or 1b) or IVIG within 2 months prior to screening visit; systemic chronic corticosteroid treatment (30 or more consecutive days) within  2  months  prior  to  screening  visit;  previous  total  body  irradiation  or  total  lymphoid irradiation;  previous  stem  cell  treatment,  autologous  bone  marrow  transplantation  or  allogenic bone marrow transplantation; a known history of tuberculosis; acute infection within two weeks prior to baseline visit; major trauma or surgery within two weeks prior to baseline; use of inhibitors of CYP3A4 within 2 weeks prior to baseline visit (1 month for fluoxetine) , use of amiodarone within 2 years prior to screening visit; pregnancy or breastfeeding; a ≥3x Upper Limit of Normal (ULN) serum  elevation  of  either  ALT  (Alanine  Transaminase)  or  AST  (Aspartate  Transaminase)  at screening; serum direct bilirubin  which  is  ≥2x  ULN  at  screening;  a  QTc  interval  which  is  ≥  450 msec (according to machine output), obtained from two ECG recordings at screening visit, or the mean  value  calculated  from  3  baseline  ECG  recordings;  subjects  with  a  clinically  significant  or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical exams, ECG, abnormal laboratory tests or chest X-ray, those included a cardiovascular or pulmonary disorder that could not be well-controlled by standard treatment  permitted  by  the  study  protocol,  a  gastrointestinal  disorder  that  could  affect  the absorption of laquinimod, renal or metabolic diseases, any form of acute or chronic liver disease, known human immunodeficiency virus (HIV) positive status, a family history of long-QT syndrome, an history of drug and/or alcohol abuse, major psychiatric disorder.

## Treatments

Laquinimod  was  given  for  24  months  at  an  oral  dose  of  0.6  mg  (capsules).  Patients  were randomized to one  of  the  two  treatment  groups  in  a  1:1  ratio.  They  received  fixed  once-a-day doses of study medication with no adjustment permitted.

## Objectives

The primary  objective was  to  evaluate  the  efficacy  of  a  daily  dose  of  laquinimod  0.6  mg compared  to  placebo,  as  measured  by  the  number  of  confirmed  relapses  during  the  24-month double blind study period.

The secondary objectives were as follows: 1) to compare the cumulative number of enhancing lesions on T1-weighted images taken on Months 12 and 24 (termination/early discontinuation visit after  Month  12)  between  the  laquinimod  0.6  mg  and  the  placebo  groups;  2)  to  compare  the cumulative number  of new/enlarging T2 lesions on scans taken on  Months 12 and 24 (termination/early  discontinuation  visit  after  Month 12)  between  the laquinimod  0.6 mg  and  the placebo groups; 3) to compare the accumulation of physical disability as measured by the time from  randomization  to  confirmed  progression  of  EDSS  during  the  24-Month  double  blind  study period, between laquinimod 0.6 mg and the placebo groups and 4) to compare the disability as assessed by the Multiple Sclerosis Functional Composite (MSFC) score at Month 24 (termination/early discontinuation visit) between the laquinimod 0.6 mg and the placebo groups.

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

## Primary outcome measure

The total  number of confirmed relapses observed during the double-blind treatment period as a mechanism  for  estimating  the  treatment  effect  on  the  annualized  relapse  rate.  The  primary analysis  was  aimed  at  the  comparison  of  the  annualized  relapse  rate  between  the  0.6  mg laquinimod arm and the placebo arm.

## Secondary outcome measures

-MRI variables: cumulative number of Gd-enhancing lesions on T1-weighted images taken on Months 12 and 24 (termination/early discontinuation visit after Month 12); cumulative number of new/enlarging (hyperintense) T2 lesions on scans taken on Months 12 and 24 (termination/early discontinuation visit after Month 12).

-Disability progression related variables: accumulation of physical disability measured at the time of confirmed progression of EDSS (progression was defined as at least 1 point increase from baseline on EDSS score if baseline EDSS was between 0 and 5.0, or at least 0.5 point increase if baseline EDSS was 5.5 or higher, confirmed 3 months later; progression could not be confirmed during an MS relapse); MSFC score at Month 24 (termination/early discontinuation visit after Month 12).

## Other outcome measures

Other  outcomes  measures  considered  as  exploratory  were:    time  to  the  first  confirmed  relapse during the study period; rate of confirmed relapses during the study period, requiring hospitalization and/or IV steroids; proportion of relapse free subjects;  total volume of T2 lesions at Month  12;  total  volume  of  T2  lesions  at  Month  24  (termination/early  discontinuation  visit  after Month 12); total  volume of  hypointense  lesions  on  GdE  T1  scans  at  Month  12;  total  volume  of hypointense  lesions  on  GdE  T1  scans  at  Month  24  (termination/early  discontinuation  visit  after Month 12); brain atrophy as defined by the percentage change in normalized brain volume from baseline to Months 12 and 24 (termination/early discontinuation visit after Month 12);  MSFC zscore at months 6, 12, and 18; cumulative number of new hypointense lesions on enhanced T1 scans  at  Months  12  and  24  (termination/early  discontinuation  visit  after  Month  12);  Modified Fatigue Impact Scale (MFIS) score at Month 24 (termination/early discontinuation visit after Month 12); EuroQoL (EQ5D) score at Month 24 (termination/early discontinuation visit after Month 12), Short-Form general health survey (SF-36)  change from baseline to Month 24 (termination/early discontinuation visit after Month 12); binocular low-contrast visual acuity assessment, using 100%, 2.5% and 1.25% contrast charts.

## Sample size

The  sample  size  considerations  for  the  study  are  based  on  the  following  assumptions:  1)  an individual  patient's  number  of  confirmed  relapses  during  a  one  year  period  reflects  a  Poisson process with an individual rate of λ i, and this individual patient rates λ i is exponentially distributed with mean 1/ θ , where θ is the population's annualized relapse rate (this approach models the total number  of  confirmed  relapses  as  an  Over  Dispersed  Poisson  distribution),  2)  the  expected annualized relapse rate in an untreated patient population is θ =0.65 relapses per year; 3) in the placebo treatment group, the expected annualized relapse rate is θ =0.6 relapses per year, due to a placebo  effect  and  4)  treatment  with  laquinimod  will  reduce  the  patient  population  annualized relapse  rate  by  25%  or  more  when  compared  to  the  placebo  group.  That  is,  the  expected annualized relapse rate of the laquinimod treated population is θ =0.45 relapses per year or less. Following simulation using the Quasi- Likelihood (over-dispersed) Poisson Regression, it was found

<div style=\"page-break-after: always\"></div>

that a total of 830 subjects (415 per treatment group) will provide approximately 90% power to detect a statistically significant difference in the total number of confirmed relapses between the treatment group and the placebo group, as described above. To correct for anticipated withdrawal rate of 20% over 24 months, the sample was adjusted and rounded to a total of 1000 patients (500 subjects per treatment group).

The  study  was  also  powered  to  show  a  statistically  significant  effect  on  the  time  to  confirmed progression  of  EDSS  under  the  following  assumptions:  1)  EDSS  progression  rate  of  untreated subjects is 30% over two years, 2) expected effect of treatment with laquinimod is 25% reduction of the untreated population progression rate, i.e. progression rate of laquinimod treated subjects will  be  22%  or  less  over  two  years.  This  assumption  reflects  a  relative  risk  of  0.75  and  3) Progression rate is constant over time in both treatment groups. Using SAS PROC POWER a sample size of 500 subjects per arm was calculated to provide the long-rank test a power of 82.7% detect a 25% reduction in progression rate of subjects treated with laquinimod with respect to subjects in the placebo group.

The  study  protocol  allowed  for  possible  extension  of  the  double  blind  placebo  controlled  phase duration to 30 months, depending on the results of a blinded variance analysis of the population disability  progression  rate  and  power  reassessment.  The  reassessment  was  performed  on  July 2009. The results of this assessment, according to the pre-defined decision rule, led to the decision to  end  the  study  as  planned,  at  the  end  of  24  months  of  treatment  and  not  to  extend  it  to  30 months.

## Randomisation

After meeting eligibility criteria, at the baseline visit, subjects were assigned to one of two possible treatment  groups  by  the  Centralised  Interactive  Voice/Web  Response  Systems  (IVRS/IWRS) according to the randomization scheme that employed a 1:1 assignment ratio. The randomization scheme used blocks stratified by center. Each subject was allocated a unique number in sequential chronological order per site. This number replaced the screening number. The randomization list and the seed used to generate were kept sealed in a fire-protected safe.

## Blinding (masking)

The  investigators,  the  sponsor  and  any  personnel  involved  in  subjects'  assessment,  monitoring, analysis and data management (excluding the designated Clinical Supplies Unit's personnel), were blinded to the subject assignment.

## Statistical methods

## Level of Significance

The  overall  significance  level  for  this  study  is  5%  using  two-tailed  tests  and/or  two-sided confidence  intervals  with  95%  confidence  level.  In  order  to  protect  the  study  from  type-I  error inflation,  the  secondary  endpoints  were  interpreted  inferentially  only  if  a  statistically  significant treatment effect was detected in the primary analysis. The study's overall type-I error was further controlled  in  the  analysis  of  the  secondary  endpoints  by  applying  the  following  gate-keeping procedure:  the  first  two  MRI-based  secondary  endpoint  were  analyzed  simultaneously  with  an overall type-I error of 5%, using the Hochberg's step-up modification to Bonferroni's method to the two  p-values  obtained  from  the  analyses  of  these  two  endpoints;  the  third  secondary  endpoint, accumulation of physical disability measured by the time to confirmed progression of EDSS was to be interpreted inferentially only if at least one of the 2 endpoints analyzed in the first step of the secondary  analysis  was  significant  under  Hochberg's  procedure,  the  fourth  secondary  endpoint, disability  as  assessed  by  MSFC  was  to  be  interpreted  inferentially  only  if  the  accumulation  of physical disability endpoint analyzed in the second step of the secondary analysis was significant.

<div style=\"page-break-after: always\"></div>

## Primary Endpoint

The principal statistical analysis of the annualized relapse rate during study was performed on the ITT cohort and was based on the outcome of a contrast (laquinimod 0.6 mg vs. placebo) derived from a baseline-adjusted, quasi-likelihood (over-dispersed) Poisson regression. Subject's number of relapses during the double blind placebo controlled phase served as the response variable. An offset  based  on  the  log  of  subject's  exposure  in  years  was  employed  to  adjust  for  variability  of treatment  exposure.  In  addition  to  the  treatment  group,  the  model  included  the  covariates: baseline EDSS score, log of prior 2-year number of relapses+1 and country or geographical region (CGR). The robustness of the results obtained by the principal analysis was explored by applying the  principal  model  (Poisson  regression)  on  completers  (CO)  and  evaluable  (EV)  analysis  sets. Additional models, negative binomial and ANCOVA (with and without covariates) and the Wilcoxon rank-sum test were applied to the ITT analysis set.

## Secondary Endpoints

Analyses  of  the  two  MRI  endpoints,  the  cumulative  number  of  Gd-enhancing  lesions  on  T1weighted  and  the  cumulative  number  of  New/Enlarging  T2  lesions  were  employing  the  negative binomial  regression  model.  An  offset  based  on  the  log  of  relative  exposure  in  the  study  (actual exposure  (years)/2  years)  was  employed  to  adjust  for  early  termination's  lack  of  exposure.  In addition  to  the  treatment  group,  the  model  included  the  number  of  T1  Gd-enhancing  lesions  at baseline and CGR as covariate, for both endpoints and in addition the baseline T2 volume for the new/enlarging T2 count endpoint. The third endpoint, time to EDSS progression confirmed after 3 months, was analyzed based on Cox Proportional Hazard model. The inference was based on the 95% confidence  limit  for  the  hazards  ratio  of  the  treatment.  The  model  also  included  baseline EDSS, log of the (prior 2-year number of relapses +1) and country/geographical region (CGR) as covariates. The  fourth endpoint, disability  as  assessed  by  the  MSFC  score  at  Month  24 (termination/early  discontinuation  visit  after  Month  12),  was  analyzed  based  on  Analysis  of Covariance, with baseline MSFC, baseline EDSS, log of the (prior 2-year number of relapses +1) and CGR as covariates.

<div style=\"page-break-after: always\"></div>

## 2.5.2.1.2. Results

## Participant flow

This is presented in Figure 1.

Figure 1

<!-- image -->

## Recruitment

The study period was from 13 November 2007 to 8 November 2010.

## Conduct of the study

The original protocol was amended 4 times and these changes mainly aimed at 1) cancelling some of the exclusion criteria (especially patients with a history of vascular thrombosis and patients with a carrier state of factor V Leiden mutation), 2) further emphasizing the issue of contraception   and intensifying the measures to detect pregnancies earlier, 3) maximizing the chances of success to demonstrate the effect in these measures, without reducing the chance to show an effect on either EDSS or MSFC scores and 4) changing the safety monitoring procedures regarding liver safety.

<div style=\"page-break-after: always\"></div>

A total of 176 subjects (15% of the subjects on laquinimod 0.6 mg and 17% on placebo) had at least one major protocol violation. The most frequent violations were related to use of disallowed medications.

## Baseline data

These are summarised in Tables 2 and 3.

Table 2. Baseline characteristics (randomized population)

|                                                        | Placebo           | Laquinimod 0.6 mg/day   | Total      |
|--------------------------------------------------------|-------------------|-------------------------|------------|
| Number of patients                                     | 556               | 550                     | 1156       |
| (%females/males)                                       | 66.2/33.8         | 71.1/28.9               | 68.6/31.4  |
| Age (mean±SD)                                          | 38.5 ± 9.1        | 38.9 ± 9.2              | 38.7 ± 9.1 |
| Race(%Caucasian)                                       | 96.0              | 97.1                    | 96.6       |
| BMI (mean ±SD)                                         | 25.3 ± 5.5        | 25.1 ± 5.5              | 25.2 ± 5.5 |
| Time from first symptoms (years) (mean±SD)             | 8.6 ± 6.7         | 8.7 ± 6.9               | 8.6 ± 6.8  |
| Previous use of MS medications N (%)                   | 221 (39.7)        | 210 (38.2)              | 431 (39)   |
| Relapses in the one year prior to screening (Mean ±SD) | 1.3 ± 0.7         | 1.2 ± 0.7               | 1.2 ± 0.7  |
| Relapses in the 2 years prior to screening (Mean±SD)   | 1.9 ±1.0          | 1.9 ±1.0                | 1.9 ±1.0   |
| Baseline EDSS (converted) Mean ±SD                     | 2.6 ±1.3          | 2.6 ±1.3                | 2.6 ±1.3   |
| Nb Gd enh.T1lesions Mean ± SD Median                   | N=556 2.0 ± 5.7 0 | N=547 1.7 ± 3.9 0       |            |
| Min, max                                               | 0 - 84            | 0 - 30                  |            |
| Vol hypointenseT1 lesions cm 3                         | N=556             | N=547                   |            |
| Mean (SD)                                              | 2.7 ± 3.7         | 2.8 ± 4.2               |            |
| Median                                                 | 1.3               | 1.3                     |            |
| Min, max                                               | 0 - 26.0          | 0 - 34.9                |            |
| T1 enhancing lesions vol cm 3 Mean (SD)                | N=556 0.2 ± 0.6   | N=547 0.2 ± 1.0         |            |
| Median                                                 | 0                 | 0                       |            |
| Min, max                                               | 0 - 8.2           | 0 - 22.6                |            |
| Tot vol T2 lesions cm 3                                | N=556             | N=547                   |            |
| Mean (SD)                                              | 9.7 ± 10.5        | 9.8 ± 10.4              |            |
| Median                                                 | 6.8               | 6.3                     |            |
| Min,                                                   | - 77.5            |                         |            |
| max                                                    | 0                 | 0 - 82.1                |            |
|                                                        | ±                 | 1578.9 ± 94.3           |            |
| Mean (SD) Median                                       | 1584.7 92.1       |                         |            |
|                                                        | 1590              | 1578                    |            |
| Min, max                                               | 1299 - 1824       | 1312-1823               |            |

<div style=\"page-break-after: always\"></div>

Table 3. Previous therapy taken by patients

| MS-LAQ-301 (ALLEGR0)   | MS-LAQ-301 (ALLEGR0)    | MS-LAQ-301 (ALLEGR0)      | Placebo (N=556, Subject Years=953.3)   | Placebo (N=556, Subject Years=953.3)   | Laquinimod 0.6 mg (N=550, Subject Years=965.6)   | Laquinimod 0.6 mg (N=550, Subject Years=965.6)   |
|------------------------|-------------------------|---------------------------|----------------------------------------|----------------------------------------|--------------------------------------------------|--------------------------------------------------|
|                        |                         |                           | No. of Subjects                        | % of Subjects                          | No. of Subjects                                  | % of Subjects                                    |
| TherapeuticSubgroup    | Chemical Subgroup       | Preferred Term/Generic    |                                        |                                        |                                                  |                                                  |
| ALL                    | ALL                     | ALL                       | 221                                    | 39.7                                   | 210                                              | 38.2                                             |
| Antineoplastic Agents  | ALL                     | ALL                       | 14                                     | 2.5                                    | 17                                               | 3.1                                              |
| Antineoplastic Agents  | Anthracyclines And      | ALL                       | 11                                     | 2.0                                    | 17                                               | 3.1                                              |
| Antineoplastic Agents  | RelatedSubstances       | Mitoxantrone              | 11                                     | 2.0                                    | 17                                               | 3.1                                              |
| Antineoplastic Agents  |                         | MitoxantroneHydrochloride |                                        |                                        | 1                                                | 0.2                                              |
| Antineoplastic Agents  | MonoclonalAntibodies    | ALL                       | 3                                      | 0.5                                    |                                                  |                                                  |
| Antineoplastic Agents  |                         | MonoclonalAntibodies      | 1                                      | 0.2                                    |                                                  |                                                  |
| Antineoplastic Agents  |                         | Rituxinab                 | 2                                      | 0.4                                    |                                                  |                                                  |
| Immune Sera And        | ALL                     | ALL                       | 4                                      | 0.7                                    | 5                                                | 0.9                                              |
| Imnunoglobulins        | Immunoglobulins         | ALL                       | 2                                      | 0.4                                    |                                                  |                                                  |
| Imnunoglobulins        |                         | Immunoglobulins           | 2                                      | 0.4                                    |                                                  |                                                  |
| Imnunoglobulins        | Immunoglobulins, Normal | ALL                       | 3                                      | 0.5                                    | 5                                                | 0.9                                              |
| Imnunoglobulins        | Human                   | Gammonativ                | 1                                      | 0.2                                    |                                                  |                                                  |
| Imnunoglobulins        |                         | Immunoglobulin            | 1                                      | 0.2                                    | 5                                                | 0.9                                              |
| Imnunoglobulins        |                         | ImmunoglobulinHunanNornal | 2                                      | 0.4                                    | 1                                                | 0.2                                              |
| Immunostimulants       | ALL                     | ALL                       | 212                                    | 38.1                                   | 206                                              | 37.5                                             |
|                        | Interferons             | ALL                       | 177                                    | 31.8                                   | 179                                              | 32.5                                             |
|                        |                         | Betaseron                 | 2                                      | 0.4                                    | 4                                                | 0.7                                              |
|                        |                         | Interferon                | 3                                      | 0.5                                    |                                                  |                                                  |
|                        |                         | Interferon Alfa           |                                        |                                        | 1                                                | 0.2                                              |
|                        |                         | InterferonBeta            |                                        |                                        | 3                                                | 0.5                                              |
|                        |                         | InterferonBeta-la         | 123                                    | 22.1                                   | 132                                              | 24.0                                             |
|                        |                         | InterferonBeta-1b         | 80                                     | 14.4                                   | 72                                               | 13.1                                             |
|                        | OtherImmunostimulants   | ALL                       | 89                                     | 16.0                                   | 84                                               | 15.3                                             |
|                        |                         | GlatiramerAcetate         | 89                                     | 16.0                                   | 84                                               | 15.3                                             |
| Immunosuppressants     | ALL                     | ALL                       | 21                                     | 3.8                                    | 13                                               | 2.4                                              |
|                        | Other                   | ALL                       | 19                                     | 3.4                                    | 12                                               | 2.2                                              |
|                        | Immunosuppressants      | Azathioprine              | 7                                      | 1.3                                    | 6                                                | 1.1                                              |
|                        |                         | Azathiprine               | 17                                     | 3.1                                    | 10                                               | 1.8                                              |
|                        |                         | Immunosuppresants         |                                        |                                        | 1                                                | 0.2                                              |
|                        |                         | Methotrexate              | 1                                      | 0.2                                    |                                                  |                                                  |
|                        | Selective               | ALL                       | 3                                      | 0.5                                    | 1                                                | 0.2                                              |
|                        | Immunosuppressants      | Mycophenolate Mofetil     | 3                                      | 0.5                                    | 1                                                | 0.2                                              |

The table presents data combined from the Medication Log and the field of 'previous use of disease modifying therapies' in the MS History form

## Numbers analysed

In total, 100% of randomized patients were included in the ITT population.

The completers analysis set included 864 subjects who completed the 24 months of double-blind treatment; 437 (79.5%) on laquinimod 0.6 mg and 427 (76.8%). All completers were included in the principal analysis of the primary analysis endpoint.

The  evaluable  (EV  analysis  set)  included  all  subjects  in  the  CO  analysis  set  who  complied  with major protocol guidelines. A total of 752 subjects were included in this analysis set; 382 subjects on laquinimod 0.6 mg, and 370 subjects on placebo All subjects in this analysis set were included in the principal analysis of the primary endpoint analysis. All subjects who had protocol violations are excluded from the primary endpoint analysis of this analysis set.

## Outcomes and estimation

## Primary outcome measure

Results are summarised in Table 4.

<div style=\"page-break-after: always\"></div>

## Table 4. Total number of confirmed relapses observed during the double-blind treatment period (24 months)

| Analysis Set         | Model                                                                         | Covariates                                                                            | Mean Annualized Relapse Rate   | Treatment Effect         | P-value              |
|----------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|--------------------------------|--------------------------|----------------------|
| Principal Analysis   | Principal Analysis                                                            | Principal Analysis                                                                    | Principal Analysis             | Principal Analysis       | Principal Analysis   |
| ITT                  | Principal Model: Analysis of Ammualized Relapse Rate - Poisson Regression     | 1) EDSS at Baseline 2) Log of prior 2-year mmber of relapses+1 3) CGR                 | Laq 0.6 =0.304 Placebo =0.395  | Risk Ratio= 0.770        | 0.0024               |
| Sensitivity Analysis | Sensitivity Analysis                                                          | Sensitivity Analysis                                                                  | Sensitivity Analysis           | Sensitivity Analysis     | Sensitivity Analysis |
| ITT                  | Uhadjusted Analysis of Amualized Relapse Rate Poisson Regression              | No Covaniates                                                                         | Laq 0.6 =0.307 Placebo=0.392   | Risk Ratio= 0.781        | 0.0057               |
| ITT                  | Analysis of Ammualized Relapse Rate --Negative Binomial Regression            | 1) EDSS at Baseline 2) Log of prior 2-year mmber of relapses+1 3) CGR                 | Laq 0.6 =0.307 Placebo=0.406   | Risk Ratio= 0.756        | 0.0018               |
| ITT                  | Unadjusted Analysis of Anmualized Relapse Rate - Negative Binomial Regression | No Covariates                                                                         | Laq 0.6 =0.313 Placebo=0.409   | Risk Ratio= 0.765        | 0.0045               |
| ITT                  | Analysis of Nuumber of Relapses- ANCOVA                                       | 1) EDSS at Baseline Log of prior 2-yea mmber of relapses+1 3) CGR 4) Exposure (Years) | Laq 0.6 =0.603 Placebo=0.738   | Means Difference= -0.135 | 0.0097               |
| ITT                  | Unadjusted Analysis of Number of Relapses-ANCOVA                              | Exposure (Years)                                                                      | Laq 0.6 =0.538 Placebo=0.673   | Means Difference= -0.135 | 0.0130               |
| ITT                  | Wilcoxon Rank Sum Test                                                        | NA                                                                                    | NA                             | NA                       | 0.0018               |
| Completers           | Principal Model: Analysis of Ammualized Relapse Rate - Poisson Regression     | 1) EDSS at Baseline 2) Log of prior 2-year mumber of relapses+1 3) CGR                | Laq 0.6=0.238 Placebo =0.294   | Risk Ratio= 0.810        | 0.0314               |
| Evaluable            | Principal Model: Analysis of Ammualized Relapse Rate - Poisson Regression     | 1) EDSS at Baseline 2) Log of prior 2-year mmber of relapses+1 3) CGR.                | Laq 0.6 =0.210 Placebo=0.269   | Risk Ratio= 0.782        | 0.0218               |

<div style=\"page-break-after: always\"></div>

## Secondary outcome measures

These are presented in Figures 2-4 and Tables 5-6.

Cumulative number of enhancing lesions/ number of New or Enlarging Lesions at Months 12 and 24 at months 12 and 24 (Termination/Early Discontinuation Visit After Month 12) - Figures 2 and 3

<!-- image -->

Table 5. Rate Ratio and 95% CI for Cumulative number of enhancing lesions/ number of New or Enlarging Lesions at Months 12 and 24 at months 12 and 24

| Cumulative number of enhancing lesions at months 12 and 24 (Termination/Early Discontinuation Visit After Month 12)   | Cumulative number of enhancing lesions at months 12 and 24 (Termination/Early Discontinuation Visit After Month 12)   | Cumulative Number of New or Enlarging Lesions at Months 12 and 24 (Termination/Early Discontinuation Visit After Month 12)   | Cumulative Number of New or Enlarging Lesions at Months 12 and 24 (Termination/Early Discontinuation Visit After Month 12)   |
|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| Comparison                                                                                                            | Laquinimod 0.6 mg vs placebo                                                                                          | Comparison                                                                                                                   | Laquinimod 0.6 mg vs placebo                                                                                                 |
| Rate ratio                                                                                                            | 0.629                                                                                                                 | Rate ratio                                                                                                                   | 0.704                                                                                                                        |
| SE                                                                                                                    | 0.081                                                                                                                 | SE                                                                                                                           | 0.067                                                                                                                        |
| Lower confidence limit                                                                                                | 0.488                                                                                                                 | Lower confidence limit                                                                                                       | 0.584                                                                                                                        |
| Upper confidence limit                                                                                                | 0.809                                                                                                                 | Upper confidence limit                                                                                                       | 0.849                                                                                                                        |
| P-value                                                                                                               | 0.0003                                                                                                                | P-value                                                                                                                      | 0.0002                                                                                                                       |

Table 6. Disability progression - Time to 3-month confirmed disability progression at Month 24

| Comparison                                 | Laquinimod 0.6 mg (N=550)   | Placebo (N=556)   |
|--------------------------------------------|-----------------------------|-------------------|
| Proportion of patients free of progression | 90.2%                       | 86%               |
| Hazard ratio (95% CI)                      | 0.641 (0.452, 0.908)        | -                 |
| p- value vs placebo                        | 0.0122                      | -                 |

<div style=\"page-break-after: always\"></div>

Figure 4. Time to 3-month confirmed disability progression at Month 24

<!-- image -->

No  effect  of  laquinimod  on  disability  assessed  by  the  MSFC  at  Month  24  was  demonstrated  as compared to placebo. The mean difference was 0.019 (p =0.5893).

## Other outcome measures

An  effect  of  treatment  with  laquinimod  0.6  mg  over  placebo  was  shown  for  the  relapse-related endpoints of time to first relapse, proportion of relapse-free subjects (64.5% in laquinimod group and 54.7% in placebo group) and rate of severe confirmed relapse.

Laquinimod 0.6 mg reduced brain atrophy over placebo at Months 12 and Month 24.

Regarding the cumulative number of new/enlarging hypointense lesions, the results showed rate ratio of 0.733 (95% CI: 0.593,0.905; p=0.0039), reflecting a reduction of 27% in the mean rate of developing New/enlarging hypointense T1 with laquinimod 0.6 mg as compared to placebo.

There  was  no  difference  between  laquinimod  and  placebo  at  Months  12  or  24  measurements, neither for the T2 lesions volume nor for the hypointense lesions volume.

Regarding MSFC at months 6, 12 or 18, there was no difference between the treatment groups similarly to the results of MSFC at Month 24 (secondary endpoint).

## 2.5.2.2. Study LAQ-302 - BRAVO

This  was  a  randomised,  parallel-group  study  evaluating  the  efficacy  and  safety  of  laquinimod administered orally once daily versus placebo in a double-blind design and versus interferon beta1a (Avonex) in a rater-blinded design.

The study was conducted in a number of European countries and also in non-EU regions (e.g. the US, Israel, Russia, Ukraine, Georgia, Macedonia and South Africa).

<div style=\"page-break-after: always\"></div>

## 2.5.2.2.1. Methods

## Study Participants

## Main inclusion criteria

The inclusion criteria were the same as for those for the LAQ-301 study except that the disease duration was not limited to at least 6 months (from the first symptom) prior to screening.

## Main exclusion criteria

The exclusion criteria were the same as for those for the LAQ-301 study except that subjects were excluded  in  case  of  previous  use  of  interferons,  regardless  of  the  timepoint  of  treatment.  The following exclusion criteria were also added: thyroid disease, and history of seizure disorder.

## Treatments

Subjects were administered either of the following: one capsule of laquinimod 0.6 mg taken orally; one matching placebo capsule taken orally ; an injection of Avonex 30 mcg given IM once weekly. In case of oral capsules, subjects were allowed to omit study drugs up to 3 consecutive days during the study. In the event of a delay of up to 5 days in the administration of the once-weekly Avonex treatment, the subject was administered the injection immediately and continued with the former treatment scheduling. In the event of a delay of 6 to 7 days in administration of the once-weekly Avonex treatment, one treatment was skipped.

## Objectives

The primary objective was to evaluate the efficacy of 0.6 mg daily dose of laquinimod in subjects with RRMS, as measured by the number of confirmed relapses during the treatment period.

The secondary  objectives were  as  follows:  1)  to  evaluate  the  effect  of  0.6  mg  daily  dose  of laquinimod on the development of brain atrophy as defined by the per cent brain volume change from baseline at the end of the treatment period; 2) to evaluate the effect of 0.6 mg daily dose of laquinimod  on  the  accumulation  of  physical  disability  as  measured  by  the  time  to  confirmed progression of EDSS during the treatment period (a confirmed progression of EDSS is defined as a 1 point increase from baseline on EDSS score if baseline EDSS was between 0 and 5.0, or a 0.5 point  increase  if  baseline  EDSS  was  5.5,  confirmed  3  months  later;  progression  cannot  be confirmed during a relapse) and 3) to evaluate the effect of 0.6 mg daily dose of laquinimod on the accumulation of disability, as assessed by the MSFC score at the end of the treatment period.

## Outcomes/endpoints

## Primary outcome measure

The total number of confirmed relapses during the treatment period as a mechanism for estimating the treatment effect on the annualized relapse rate.

## Secondary outcome measures

These included: brain atrophy, measured as the percent brain volume change from baseline to end of the treatment period; time to confirmed progression of EDSS sustained for 3 months during the treatment period (progression was defined as a 1.0 point increase if baseline EDSS was between 0 and  5.0,  or  a  0.5  point  increase  if  baseline  EDSS  was  5.5);  the  MSFC  score  at  the  end  of  the treatment period.

<div style=\"page-break-after: always\"></div>

## Other outcome measures

Other  outcomes  measures  considered  as  exploratory  were:  cumulative  number  of  enhancing lesions on T1-weighted images taken at Months 12 and 24 (termination/early discontinuation visit, if occurred after month 12); number of enhancing lesions on a T1-weighted image taken at Month 12, the number of enhancing lesions on a T1-weighted image taken at Month 24 (termination/early discontinuation  visit,  if  occurred  after  Month  12);  cumulative  number  of  new  or  enlarging hypointense  lesions  on  enhanced  T1  scans  taken  at  months  12  and  24  (termination/early discontinuation, if occurred after Month 12);number of new or enlarging hypointense lesions on an enhanced  T1  scan  taken  at  Month  12;  number  of  new  or  enlarging  hypointense  lesions  on enhanced T1 scans taken at Month 24 (termination/early discontinuation, if occurred after Month 12);  cumulative  number  of  new  or  enlarging  T2  lesions  on  scans  taken  at  months  12  and  24 (termination/early  discontinuation,  if  occurred  after  Month  12);  number  of  new  or  enlarging  T2 lesions on a scan taken at Month 12; number of new or enlarging T2 lesions on a scan taken at Month 24 (termination/early discontinuation, if occurred after Month 12); volume of T2 lesions at Month 24 (termination/early discontinuation, if occurred after Month 12); volume of T2 lesions at Month 12; volume of hypointense lesions on enhanced T1 scans at Month 24 (termination/early discontinuation visit, if occurred after Month 12); volume of hypointense lesions on enhanced T1 scans at Month 12; brain atrophy as defined by the per cent brain volume change from baseline to Month  12  and    Month  12  to  Month  24  (termination/early  discontinuation  visit,  if  occurred  after Month 12); Modified  Fatigue  Impact  Scale  change  from  baseline  to  Month  24  (termination/early discontinuation  visit,  if  occurred  after  Month  12);  time  to  the  first  confirmed  relapse  during  the study  period;    proportion  of  relapse-free  subjects;  rate  of  confirmed  relapses  during  the  study period requiring hospitalization and/or IV steroids; the EuroQoL (EQ-5D) change from baseline to Month  24  (termination/early  discontinuation  visit  if  occurred  after  Month  12);  the  Short-Form general health survey change from baseline to Month 24 (termination/early discontinuation visit if occurred  after  Month  12),  change  from  baseline  to  Month  24  (termination/early  discontinuation visit) in binocular visual acuity, as assessed by  the number of letters read correctly from 2 meters distance on 1.25%, 2.5% and 100% contrast Sloan letter/Tumbling E charts.

## Sample size

Using the same assumptions as in study LAQ-301, it was found that  a total of 666 subjects (333 subjects  per  arm)  will  provide  approximately  80%  power  to  detect  a  statistically  significant reduction of 25% in the total number of confirmed relapses between the placebo group and the laquinimod  group.  This  sample  size  also  enabled  92%  power  to  detect  a  statistically  significant reduction  of  30%  in  the  total  number  of  confirmed  relapses  between  the  laquinimod  0.6  mg treatment group and the placebo group. To correct for anticipated withdrawal rate of 20% over 24 months, the sample was adjusted and rounded to 400 subjects per arm. The size of the Avonex reference arm was set to be equal to the other study arms. Since the Avonex arm is included in the study  for  reference  only,  there  was  no  need  to  adjust  for  multiplicity  when  comparing  the laquinimod and Avonex arms to the placebo arm.

## Randomisation

The  study  had  a  screening  period  of  up  to  1  month,  during  which  the  subject  was  assigned  a screening  number  through  the  IVRS/IWRS.  At  the  baseline  visit,  subjects  were  assigned  by  the IVRS to one of three possible treatment groups in a 1:1:1 ratio, according to the randomization scheme. Each subject was allocated a unique number. This number replaced the screening number.

<div style=\"page-break-after: always\"></div>

## Blinding (masking)

For  oral  treatment  (laquinimod  or  placebo  capsules),  the  investigators,  the  sponsor  and  any personnel involved in subjects' assessment, monitoring, analysis and data management (excluding the designated Clinical Supplies Unit's personnel), were blinded to the subject assignment. For the injectable treatment (Avonex), the administration was not provided in a blinded manner. A subject assigned to injectable treatment was unblinded, as well as the site personnel involved in dispensing the drug. The Examining Neurologist/ Physician was blinded to the treatment assignment and was not present during the study drug dispensing process.

In order to maintain reliable evaluation and reduce the potential for bias the following actions were undertaken regardless of the treatment assignment: the Examining Neurologist/Physician was the only one to evaluate the subject neurologically; the Examining Neurologist/Physician had no access to the subject's file, including previous neurostatus forms and AEs; a decision as per treatment of a relapse  was  under  the  sole  responsibility  of  the  Treating  Neurologist/Physician;  the  subject  was neurologically assessed by the Examining Neurologist/Physician. It was verified that the subject, regardless of treatment assignment, was clothed in a manner that the arms (down to the elbows) and thighs (down to the knees) were fully covered. In addition, the subject was instructed not to discuss his/her well-being and AEs or the treatment route/assignment (oral or injectable) with the Examining  Neurologist/Physician.  These  activities  were  under  the  responsibility  of  the  Treating Neurologist/Physician/Study Coordinator and were recorded in the source documents.

## Statistical methods

## Level of Significance

The  overall  significance  level  for  this  study  is  5%  using  two-tailed  tests  and/or  two-sided confidence  intervals  with  95%  confidence  level.  In  order  to  protect  the  study  from  type-I  error inflation,  secondary  endpoints  were  interpreted  inferentially  only  if  a  statistically  significant treatment effect was detected in the primary analysis. The study's overall type-I error was further controlled in the analysis of the secondary endpoints by employing the hierarchical approach (i.e. each secondary endpoint was analyzed only in case the preceding endpoint had a p-value less or equal to 0.05 for laquinimod 0.6 mg over placebo comparison).

## Primary Endpoint

Same statistical  methods as  in  study  LAQ-301  for  the  comparison  of  laquinimod  0.6  mg  versus placebo were applied for the primary endpoint. A post-hoc exploratory comparison of laquinimod 0.6 mg versus Avonex was also conducted using the same model.

A  sensitivity  analysis  was  also  performed  to  address  the  issue  of  missing  values,  in  order  to estimate  the  amount  of  treatment  effect  preserved  under  the  Missing  Not  At  Random  (MNAR) assumption.

## Secondary Endpoints

Same statistical  methods as  in  study  LAQ-301  for  the  comparison  of  laquinimod  0.6  mg  versus placebo were applied for the time to EDSS progression confirmed after 3 months and MSFC score at  Month  24.  Brain  atrophy,  as  defined  by  the  per  cent  volume  change  from  baseline  to termination/early  discontinuation  visit  after  Month  12,  was  based  on  the  outcome  of  a  contrast (laquinimod 0.6 mg vs placebo) derived from a baseline-adjusted analysis of covariance (ANCOVA). In  addition  to  treatment  group,  the  model  also  included  as  covariates  the  number  of  enhancing lesions on T1-weighted images taken at baseline and CGR.

<div style=\"page-break-after: always\"></div>

Within the same models, additional exploratory contrasts were constructed to assess the treatment effect of Avonex vs placebo for all the secondary endpoints.

## 2.5.2.2.2. Results

## Participant flow

This is presented in Figure 5.

Figure 5

<!-- image -->

## Recruitment

The study period was from 24 April 2008 to 10 June 2011.

## Conduct of the study

The original protocol was amended 4 times and these changes mainly aimed at 1) modifying the inclusion  and  exclusion  criteria  and  the  safety  monitoring  of  inflammatory  conditions  2)  further emphasizing  the  issue  of  contraception      and  intensifying  the  measures  to  detect  pregnancies earlier,  3)  changing  the  safety  monitoring  procedures  regarding  liver  safety;  4)  changing  the hierarchy order of the secondary endpoints.

A total of 146 subjects had at least one major protocol violation: 51 (12%) on laquinimod 0.6 mg, 51 (11%) on placebo and 44 (9.8%) on Avonex .The most frequent violations were related to use of disallowed medications.

## Baseline data

These are summarised in Tables 7 and 8.

<div style=\"page-break-after: always\"></div>

Table 7. Baseline characteristics (randomized population)

|                                                                 | Placebo             | Laquinimod 0.6 mg/day   | Avonex              | Total         |
|-----------------------------------------------------------------|---------------------|-------------------------|---------------------|---------------|
| Number of patients (%females/males)                             | 321 71.3/28.7       | 282 65/35               | 307 68.7/31.3       | 910 68.4/31.6 |
| Age (mean±SD)                                                   | 37.5 ± 9.5          | 37.0 ± 9.3              | 38.2 ± 9.5          | 37.6 ± 9.5    |
| Race(%Caucasian)                                                | 98.4                | 98.2                    | 98.4                | 98.3          |
| BMI (mean ±SD)                                                  | 24.4 ± 4.6          | 24.1 ± 4.5              | 24.6 ± 5.0          | 24.4 ± 4.7    |
| Time from first symptoms (years) (mean±SD)                      | 6.9 ± 6.6           | 6.6 ± 6.0               | 7.0 ± 5.9           |               |
| Previous use of MS medications N (%)                            | 27 (6)              | 30 (6.9)                | 42 (9.4)            |               |
| Relapses in the one year prior to screening (Mean ±SD)          | 1.3 ± 0.6           | 1.3 ± 0.6               | 1.3 ± 0.6           |               |
| Relapses in the 2 years prior to screening (Mean±SD)            | 1.9 ±0.9            | 1.9 ±1.0                | 1.9 ±0.9            |               |
| Baseline EDSS (converted) Mean ±SD                              | 2.7 ±1.2            | 2.7 ±1.3                | 2.6 ±1.2            |               |
| Nb Gd enh.T1lesions Mean ± SD                                   | N=449 1.5 ± 5.7     | N=434 1.8 ± 5.2         | N=443 1.8 ± 6.7     |               |
| Proportion of subjects with number of Gd enh T1 lesions ≥ 1 (%) | N=150 33.4          | N=172 39.6              | N=169 38.1          |               |
| Vol hypointenseT1 lesions cm 3 Mean (SD)                        | N=449 2.8 ± 4.2     | N=434 3.5 ± 4.9         | N=440 3.0 ± 5.0     |               |
| Tot vol T2 lesions cm 3 Mean (SD)                               | N=449 7.9 ± 8.9     | N=434 9.6 ± 10.3        | N=440 8.6 ± 10.4    |               |
| Normalized brain vol (cm 3 ) Mean (SD)                          | N=449 1586.3 ± 93.3 | N=432 1581.5 ± 95.5     | N=441 1586.2 ± 84.4 |               |

Table 8. Previous therapy taken by patients

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Numbers analysed

In total, 100% of randomized patients were included in the ITT population.

The  completers'  analysis  set  included  1,090  subjects  who  completed  24  months  of  double-blind treatment:  353  (81.3%)  on  laquinimod  0.6  mg,  359  (79.8%)  on  placebo  and  378  (84.6%)  on Avonex. All completers were included in the principal analysis of the primary endpoint applied to the CO set. All subjects who terminated the study prematurely were excluded from the primary endpoint analysis of the CO analysis set.

The evaluable (EV analysis set) included 990 subjects from the CO analysis set who complied with major protocol guidelines: 321 (74.0%) to laquinimod 0.6 mg, 327 (72.7%) to placebo and 342 (76.5%) to Avonex. All subjects in this analysis set are included in the principal analysis of the primary  endpoint  applied  to  the  EV  set.  All  subjects  with  major  protocol  violations  or  early termination from the study were excluded from the primary endpoint analysis of the EV set.

## Outcomes and estimation

## Primary outcome measure

Results are summarised in Table 9 and Figure 6.

Table 9.Total Number of confirmed relapses observed during the double-blind treatment period (24 months)

| Analysis Set         | Analysis Model                                                                 | Covariates                                                                                                              | Adjusted Mean Values                      | Treatment Effect**                         | P-value              |
|----------------------|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|--------------------------------------------|----------------------|
| Principal Analysis   | Principal Analysis                                                             | Principal Analysis                                                                                                      | Principal Analysis                        | Principal Analysis                         | Principal Analysis   |
| 1.1I                 | Annualized RR: Negative Binomial (Primary Model)                               | 1)EDSS at BL 2) Log of prior 2-year number of relapses+1 3)CGR                                                          | Placebo = 0.344 Laq= 0.283 Avonex=0.255   | Risk Ratio Laq=0.823 Avonex* = 0.741       | 0.0746 0.0067        |
| Sensitivity Analysis | Sensitivity Analysis                                                           | Sensitivity Analysis                                                                                                    | Sensitivity Analysis                      | Sensitivity Analysis                       | Sensitivity Analysis |
| IIT                  | Annualized RR: Negative Binomial (Unadjusted)                                  | Treatment only                                                                                                          | Placebo = 0.367 Laq= 0.304 Avonex*=0.272  | Risk Ratio Laq=0.827 Avonex=0.740          | 0.0968 0.0089        |
| IIT                  | Annualized RR: Negative Binomial (Corrected Analysis, Additional Covariates*)  | 1) EDSS at BL 2) Log of prior 2-year number of relapses+1 3) CGR 4) Baseline T2 volume 5) ≥1 T1 GdE lesions at baseline | Placebo = 0.371 Laq=0.292 Avonex=0.265    | Risk Ratio Laq=0.787 Avonex= 0.714         | 0.0264 0.0021        |
| IIT                  | Annualized RR: Poisson Regression                                              | 1)EDSS at BL 2) Log of prior 2-year number of relapses+1 3) CGR                                                         | Placebo = 0.330 Laq = 0.277 Avonex”=0.250 | Risk Ratio Laq=0.839 Avonex\"=0.757         | 0.0744 0.0054        |
| IIT                  | Annualized RR: Poisson Regression (Unadjusted)                                 | Treatment only                                                                                                          | Placebo = 0.354 Laq= 0.299 Avonex=0.268   | Risk Ratio Laq = 0.844 Avonex=0.756        | 0.0947 0.0069        |
| IIT                  | Annualized RR: Poisson Regression (Corrected Analysis, Additional Covariates*) | 1) EDSS at BL 2) Log of prior 2-year number of relapses+1 3) CGR. 4) Baseline T2 volume 5)≥l T1 GdE lesions at baseline | Placebo = 0.357 Laq=0.284 Avonex=0.262    | Risk Ratio Laq = 0.796 Avonex=0.733        | 0.0192 0.0018        |
| IIT                  | No. of Relapses: ANCOVA                                                        | 1) EDSS at BL 3) CGR 4) Exposure (years)                                                                                | Placebo = 0.628 Avonex*=0.497 Laq= 0.541  | Adi. Mean Diff. Avonex*=-0.131 Laq= -0.087 | 0.1328 0.0231        |
| IIT                  | No. of Relapses:                                                               | Treatment and exposure only                                                                                             | Placebo = 0.620                           | Adi. Mean Diff.                            |                      |

ANCOVA

Laq =0.528

Laq =-0.092

0.1239

<div style=\"page-break-after: always\"></div>

| Analysis Set   | Analysis Model                                                              | Covariates                                                                                                                               | Adjusted Mean Values                           | Treatment Effect**                          | P-value       |
|----------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|---------------------------------------------|---------------|
| ITT (cont'd)   | (Unadjusted)                                                                |                                                                                                                                          | Avonex = 0.478                                 | Avonex= -0.142                              | 0.0171        |
| ITT (cont'd)   | No. of Relapses: ANCOVA (Additional Covariates*)                            | 1) EDSS at BL 2) Log of prior 2-year number of relapses+1 3) CGR 4) Exposure (years) 5)BaselineT2volume 6) ≥1 T1 GdE lesions at baseline | Placebo = 0.694 Laq = 0.579 Avonex = 0.549     | Adj. Mean Diff. Laq= -0.115 Avonex = -0.145 | 0.0454 0.0111 |
| ITT (cont'd)   | WilcoxonRankSums Testccc                                                    | NA                                                                                                                                       | NA                                             | NA                                          | 0.1381 0.0120 |
| CO             | Annualized RR: Negative Binomial (Primary Model)                            | 1) EDSS at BL 2) Log of prior 2-year number of relapses+1 3) CGR                                                                         | Placebo = 0.258 Laq = 0.229 Avonex = 0.210     | Risk Ratio Laq = 0.887 Avonex? = 0.816      | 0.3114 0.0875 |
| CO             | Annualized RR: NegativeBinomial (CorrectedAnalysis, AdditionalCovariates*)  | 1) EDSS at BL 2)Logofprior 2-yearnumberofrelapses+1 3) CGR 4)Baseline T2 volume 5)≥1 T1 GdE lesions at baseline                          | Placebo = 0.277 Laq = 0.236 Avonex = 0.220     | Risk Ratio Laq = 0.851 Avonex = 0.795       | 0.1670 0.0513 |
| EV             | Annualized RR: Negative Binomial (Primary Model)                            | 1) EDSS at BL 2) Log of prior 2-year number ofrelapses+1 3) CGR                                                                          | Placebo = 0.251 Laq = 0.209 Avonex? = 0.177    | Risk Ratio Laq =0.833 Avonex? = 0.708       | 0.1497 0.0079 |
| EV             | AnnualizedRR: NegativeBinomial (Corrected Analysis, Additional Covariates*) | 1) EDSS at BL 2) Log of prior 2-year number of relapses+1 3) CGR 4)Baseline T2 volume 5) ≥1 T1 GdE lesions at baseline                   | Placebo = 0.269 Laq 0.6 = 0.216 Avonex = 0.189 | Risk Ratio Laq = 0.804 Avonex = 0.701       | 0.0822 0.0058 |

* Model was corrected by adding MRI baseline covariates (baseline T2 lesions volume and indicator for subjects with T1 Gd-enhancing lesions ≥1 at baseline)

Abbreviations: RR, relapse rate; Laq, laquinimod 0.6 mg: BL, baseline; EDSS, Expanded Disability Status Scale; CGR, country/geographical region; GdE, gadolinium-enhancing

** Treatment effects were calculated based on the outcome of a contrast (either laquinimod O.6 mg vs placebo or Avonex? vs placebo)

Figure 6. Cumulative number of confirmed relapses

<!-- image -->

## Secondary outcome measures

These are presented in Table 10.

<div style=\"page-break-after: always\"></div>

Table  10.Secondary  Efficacy  Results  (brain  atrophy  at  Month  24,  time  to  confirmed progression of EDSS sustained for 3 months, MSFC score at Month 24)

| Analysis Results                                                                   | Laquinimod 0.6 mg vs Placebo                                                       | Laquinimod 0.6 mg vs Placebo                                                       | Avoner vs Placebo                                                                  | Avoner vs Placebo                                                                  |
|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
|                                                                                    | Original Analysis                                                                  | Corrected Analysis*                                                                | Original Analysis                                                                  | Corrected Analysis*                                                                |
| Brain Atrophy at Month 24 (Termination/Early Discontinuation Visit After Month 12) | Brain Atrophy at Month 24 (Termination/Early Discontinuation Visit After Month 12) | Brain Atrophy at Month 24 (Termination/Early Discontinuation Visit After Month 12) | Brain Atrophy at Month 24 (Termination/Early Discontinuation Visit After Month 12) | Brain Atrophy at Month 24 (Termination/Early Discontinuation Visit After Month 12) |
| Adjusted Mean Difference [95% C1]                                                  | 0.284 [0.139; 0.429] Reflecting a 27.6% reduction                                  | 0.313 [0.168; 0.459] Reflecting a 27.5% reduction                                  | -0.107 [0.249; 0.035] Reflecting a 10.4% increase                                  | -0.108 [-0.250; 0.035] Reflecting a 9.5% increase                                  |
| P-Value                                                                            | 0.0001                                                                             | <0.0001                                                                            | 0.1392                                                                             | 0.1380                                                                             |
| Time to Confirmed Progression of EDSS                                              | Time to Confirmed Progression of EDSS                                              | Time to Confirmed Progression of EDSS                                              | Time to Confirmed Progression of EDSS                                              | Time to Confirmed Progression of EDSS                                              |
| Hazard Ratio [10 %s6]                                                              | 0.687 [0.462; 1.020] Reflecting a 31.3% reduction                                  | 0.665 [0.447; 0.989] Reflecting a 33.5% reduction                                  | 0.742 [0.507; 1.088] Reflecting a 25.8% reduction                                  | 0.713 [0.484; 1.051] Reflecting a 28.7% reduction                                  |
| P-Value                                                                            | 0.0628                                                                             | 0.0440                                                                             | 0.1269                                                                             | 0.0878                                                                             |
| Disability as Assessed by MSFC                                                     | Disability as Assessed by MSFC                                                     | Disability as Assessed by MSFC                                                     | Disability as Assessed by MSFC                                                     | Disability as Assessed by MSFC                                                     |
| Adjusted Mean Difference [10 %s6]                                                  | 0.104 [0.038; 0.247] Reflecting a 77.0% reduction                                  | 0.115 [0.028; 0.258] Reflecting a 77.2% reduction                                  | 0.089 [-0.050; 0.229] Reflecting a 65.9% reduction                                 | 0.095 [-0.045; 0.235] Reflecting a 63.8% reduction                                 |
| P-Value                                                                            | 0.1505                                                                             | 0.1152                                                                             | 0.2083                                                                             | 0.1852                                                                             |

Analysis was performed post-hoc using original model corrected for the two additional MRI covariates (T2 lesions volume and indicator for subjects with number of T1 Gd-enhancing lesions ≥l at baseline)

## Other outcome measures

As compared to placebo, laquinimod 0.6 mg had no effect on time to first confirmed relapse  (HR= 0.835, 95% CI: 0.67, 1.040), the proportion of relapse-free subjects (65.7% in laquinimod group versus  61.3%  in  placebo  group)  and  rate  of  severe  relapses  requiring  hospitalization  and/or administration of steroids (RR= 0.835, 95% CI: 0.668, 1.045, p=0.1152). In contrast, an effect of Avonex over placebo was observed for all three relapse-related endpoints. In Avonex group, 68.9% of patients were relapse free.

A favourable effect of laquinimod 0.6 mg over placebo was observed for the reduction of enhancing T1 lesions at Month 24 (RR= 0.611, 95% CI: 0.439, 0.852, p=0.0037) but not at Month 12 (RR= 0.884, 95% CI: 0.658, 1.186, p=0.4099). There was a reduction in the mean rate of development of cumulative number of T1 Gd-enhancing lesions on laquinimod 0.6 mg over placebo but this was not  statistically  significant  (RR=  0.785,  95%  CI:  0.604,  1.019,  p=0.0691).  Avonex  showed  a reduction versus placebo in the number of enhancing T1 lesions at both Month 12 and Month 24 measurements (respectively, RR= 0.410, 95% CI: 0.299, 0.562, p&lt;0.0001 and RR=0.336, 95% CI: 0.237, 0.474, p&lt;0.0001) as well as for the cumulative lesion counts for Months 12 and 24 and this was statistically significant (RR= 0.385, 95% CI: 0.239, 0.505, p&lt;0.0001).

An effect of laquinimod 0.6 mg versus placebo was seen for reduction of new/newly T2 lesions at Month  12  (RR=  0.813,  95%  CI:  0.664,  0.996,  p=0.0462).  As  compared  to  placebo,  Avonex reduced the new T2 lesions at Months 12 and 24 (RR= 0.491, 95% CI: 0.400, 0.602, p&lt;0.001).

No  differences  between  laquinimod  0.6  mg  and  placebo  were  observed  for  T2  lesions  volume, either at Month 12 or Month 24 (respectively mean ratio= 0.996, 95% CI: 0.925, 1.071, p=0.9053 and  mean  ratio=  1.005,  95%  CI:  0.930,  1.085,  p=0.9019).  A  statistically  significant  effect  for Avonex  over  placebo  was  seen  for  both  endpoints  (respectively  p=0.0019  and  p=0.0104).  No differences  between  laquinimod  0.6  mg  and  placebo  were  observed  for  T1  hypointense  lesions volume, either at Month 12 or Month 24; there was no difference between the Avonex and placebo groups for either endpoint.

<div style=\"page-break-after: always\"></div>

Laquinimod 0.6 mg demonstrated a reduction in brain atrophy over placebo from baseline to Month 12 (adjusted mean difference=0.221, 95% CI: 0.125, 0.317, p&lt;0.001) , whereas no appreciable difference  between  the  two  groups  was  shown  between  Months  12  to  24(  adjusted  mean difference=0.033, 95% CI: -0.062, 0.127, p=0.4972). No treatment effects on reduction in brain atrophy were seen for Avonex over placebo for either measurement period  (Month 12: adjusted mean  difference=-0.134,  95%  CI:  -0.229,-0.040,  p=0.0053  and  Month  24:  adjusted  mean difference=0.018 , 95% CI: -0.074, 0.111, p=0.6975, respectively).

No difference between laquinimod 0.6 mg and placebo were observed for change from baseline to Month 24 in any of the following exploratory endpoints related to health status and quality of life: subject-reported  fatigue  (assessed  by  MFIS  score);  any  of  the  EQ-5D  dimensions  or  subjects' subjective  overall  health  assessment  scores;  general  health  status  assessed  by  SF-36  (both physical  and  mental  component  summary  scores);  and  binocular  visual  acuity.  Similarly,  no appreciable differences could be demonstrated between Avonex and placebo for these endpoints, with the exception of subjects' subjective overall health assessment scores, for which there was a lesser decline from baseline in health status at Month 24 for subjects on Avonex compared to those on placebo.

## 2.5.2.3. Ancillary analyses

During the evaluation, additional efficacy subgroup analyses were requested by the CHMP based on the  following  criteria:  prior  use  of  MS  treatment,  severity  of  relapses  at  baseline.  No  efficacy analysis based on the severity of relapses at baseline was provided by the applicant as the data were not collected in the clinical studies. At baseline, as per inclusion, patients were stable and free of relapses for at least 60 days. The applicant presented an analysis based on ALLEGRO study only due to the design of the other pivotal study BRAVO which excluded all patients with prior use of interferons and the small sample size for patients previously treated with glatiramer acetate (4% vs 4.8 in placebo and laquinimod groups, respectively. Data are presented in Tables 11 and 12.

<div style=\"page-break-after: always\"></div>

Table 11.  ALLEGRO: summary of treatment effects (laquinimod 0.6 mg vs placebo) by prior interferon use

|                                                        |                   | Prior use of interferon=No LAQ 0.6 mg n=371 (67.5%) Placeb0, n=379 (68.2%)   | Prior use of interferon=Yes LAQ 0.6 mg, n=179 (32.5%) Placebo, n=177 (31.8%)   |
|--------------------------------------------------------|-------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Annualized Relapse Rate                                | Risk Ratio        | 0.735 [0.596; 0.905]                                                         | 0.865 [0.647; 1.156]                                                           |
| Annualized Relapse Rate                                | Laquinimod Effect | 27%                                                                          | 13%                                                                            |
| Annualized Relapse Rate                                | p-value           | p=0.0038                                                                     | p=0.3257                                                                       |
| Brain Atrophy Defined by PBVC                          | Adj. Mean Diff.   | 0.466 [0.269; 0.663]                                                         | 0.209 [-0.092; 0.509]                                                          |
| Brain Atrophy Defined by PBVC                          | Laquinimod Effect | 34.6%                                                                        | 17.4%                                                                          |
| Brain Atrophy Defined by PBVC                          | p-value           | p=0.0001                                                                     | p=0.1731                                                                       |
| Time to Confirmed EDSS Progression (3m)                | Hazard Ratio      | 0.506 [0.324; 0.791]                                                         | 0.965 [0.542; 1.717]                                                           |
| Time to Confirmed EDSS Progression (3m)                | Laquinimod Effect | 49.4%                                                                        | 3.5%                                                                           |
| Time to Confirmed EDSS Progression (3m)                | p-value           | p=0.0028                                                                     | p=0.9029                                                                       |
| Time to Confirmed EDSS Progression (6m)                | Hazard Ratio      | 0.418 [0.239; 0.731]                                                         | 0.713 [0.364; 1.400]                                                           |
| Time to Confirmed EDSS Progression (6m)                | Laquinimod Effect | 58.2%                                                                        | 28.7%                                                                          |
| Time to Confirmed EDSS Progression (6m)                | p-value           | p=0.0022                                                                     | p=0.3260                                                                       |
| Cumulative GdE Tl Lesions at Months 12 and 24          | Rate Ratio        | 0.643 [0.472; 0.876]                                                         | 0.589 [0.378; 0.918]                                                           |
| Cumulative GdE Tl Lesions at Months 12 and 24          | Laquinimod Effect | 35.7%                                                                        | 41.1%                                                                          |
| Cumulative GdE Tl Lesions at Months 12 and 24          | p-value           | p=0.0052                                                                     | p=0.0193                                                                       |
| Cumulative New/EnlargingT2 Lesions at Months 12 and 24 | Rate Ratio        | 0.697 [0.556; 0.875]                                                         | 0.719 [0.515; 1.004]                                                           |
| Cumulative New/EnlargingT2 Lesions at Months 12 and 24 | Laquinimod Effect | 30.3%                                                                        | 28.1%                                                                          |
| Cumulative New/EnlargingT2 Lesions at Months 12 and 24 | p-value           | p=0.0018                                                                     | p=0.0525                                                                       |

Table 12.  ALLEGRO: summary of treatment effects (laquinimod 0.6 mg vs placebo) by prior glatiramer acetate (GA) use

|                                                        |                   | Prior use of GA=No LAQ 0.6 mg, n=466 (84.7%) Placebo, n=467 (84.0%)   | Prior use of GA=Yes LAQ 0.6 mg, n=84 (15.3%) Placebo, n=89 (16.0%)   |
|--------------------------------------------------------|-------------------|-----------------------------------------------------------------------|----------------------------------------------------------------------|
| Annualized Relapse Rate                                | Risk Ratio        | 0.734 [0.608; 0.886]                                                  | 0.987 [0.672; 1.449]                                                 |
| Annualized Relapse Rate                                | Laquinimod Effect | 27%                                                                   | 1%                                                                   |
| Annualized Relapse Rate                                | p-value           | p=0.0013                                                              | p=0.9470                                                             |
| Brain Atrophy Defined by PBVC                          | Adj. Mean Diff.   | 0.436 [0.266; 0.607]                                                  | 0.405 [-0.003; 0.812]                                                |
| Brain Atrophy Defined by PBVC                          | Laquinimod Effect | 32.8%                                                                 | 31.3%                                                                |
| Brain Atrophy Defined by PBVC                          | p-value           | p=0.0001                                                              | p=0.0516                                                             |
| Time to Confirmed EDSS Progression (3m)                | Hazard Ratio      | 0.631 [0.427; 0.930]                                                  | 0.690 [0.314; 1.518]                                                 |
| Time to Confirmed EDSS Progression (3m)                | Laquinimod Effect | 36.9%                                                                 | 31.0%                                                                |
| Time to Confirmed EDSS Progression (3m)                | p-value           | p=0.0201                                                              | p=0.3561                                                             |
| Time to Confirmed EDSS Progression (6m)                | Hazard Ratio      | 0.497 [0.311; 0.795]                                                  | 0.612 [0.221; 1.696]                                                 |
| Time to Confirmed EDSS Progression (6m)                | Laquinimod Effect | 50.3%                                                                 | 38.8%                                                                |
| Time to Confirmed EDSS Progression (6m)                | p-value           | p=0.0036                                                              | p=0.3452                                                             |
| Cumulative GdE Tl Lesions at Months 12 and 24          | Rate Ratio        | 0.617 [0.471; 0.809]                                                  | 0.645 [0.329; 1.262]                                                 |
| Cumulative GdE Tl Lesions at Months 12 and 24          | Laquinimod Effect | 38.3%                                                                 | 35.5%                                                                |
| Cumulative GdE Tl Lesions at Months 12 and 24          | p-value           | p=0.0005                                                              | p=0.2002                                                             |
| Cumulative New/EnlargingT2 Lesions at Months 12 and 24 | Rate Ratio        | 0.699 [0.570; 0.855]                                                  | 0.740 [0.452; 1.211]                                                 |
| Cumulative New/EnlargingT2 Lesions at Months 12 and 24 | Laquinimod Effect | 30.1%                                                                 | 26.0%                                                                |
| Cumulative New/EnlargingT2 Lesions at Months 12 and 24 | p-value           | p=0.0005                                                              | p=0.2309                                                             |

In addition, at the CHMP request, the applicant presented additional efficacy analysis in patients with high disease activity (see Figures 7-9). Indirect efficacy comparison with other MS treatments (interferons and glatiramer acetate) was also performed and is presented in Figures 10 and 11.

<div style=\"page-break-after: always\"></div>

## Figure 7: Efficacy results on ARR

|                                          | AnnualizedRelapseRate   | AnnualizedRelapseRate               | AnnualizedRelapseRate   | TreatmentEffect       |          |
|------------------------------------------|-------------------------|-------------------------------------|-------------------------|-----------------------|----------|
| Subgroup                                 | No.of Patients (%) LAQ  | PLC                                 |                         | RR (95% CI)           | P-Value* |
| Relapses(>=2) 1yr Prior SC               |                         |                                     |                         |                       | 0.9267   |
| >=2 Relapses                             | 257( 26)                | 273( 27)                            |                         | 0.793( 0.623,1.009)   |          |
| <2Relapses                               | 727( 74)                | 733( 73)                            | 王                       | 0.782 ( 0.664, 0.922) |          |
| Relapses(>=2)1yr Prior SC andGdE at BL   |                         |                                     |                         |                       | 0.4722   |
| >=2 Relapses and GdE at BL               | 117( 12)                | 120(12)                             |                         | 0.702 (0.504,0.980)   |          |
| Otherwise                                | 864( 88)                | 885(88)                             |                         | 0.803(0.692,0.931)    |          |
| Relapses(>=1) 1yr Prior SC and GdE at BL |                         |                                     |                         |                       | 0.1512   |
| >=1 Relapse and GdE at BL                | 370(38)                 | 380(38)                             | 工⊥                      | 0.710 (0.581,0.866)   |          |
| Otherwise                                | 611( 62)                | 625(62)                             |                         | 0.866 ( 0.721， 1.039) |          |
| Median T2 Lesion Volume at BL            |                         |                                     |                         |                       | 0.5816   |
| >=Median T2 Volume at BL                 | 508(52)                 | 485( 48)                            | 工H二                     | 0.752( 0.629,0.898)   |          |
| <Median T2 Volume at BL                  | 473( 48)                | 520( 52)                            | 工                       | 0.812( 0.660, 1.000)  |          |
| Number of GdE Lesions at BL              |                         |                                     |                         |                       | 0.7405   |
| >=2 GdE Lesions at BL                    | 247( 25)                | 239( 24)                            | T⊥                      | 0.810 (0.640,1.026)   |          |
| < 2 GdE Lesions at BL                    | 734( 75)                | 766( 76)                            | 王                       | 0.772( 0.655, 0.908)  |          |
| EDSS(>=2) at BL                          |                         |                                     |                         |                       | 0.7087   |
| >=2 EDSS                                 | 697( 71)                | 734( 73)                            | 王                       | 0.775(0.664,0.905)    |          |
| <2 EDSS                                  | 287( 29)                | 272( 27)                            | T⊥                      | 0.825 ( 0.620, 1.096) |          |
| EDSS(>=3) at BL                          |                         |                                     |                         |                       | 0.9738   |
| >=3 EDSS                                 | 430( 44)                | 452( 45)                            |                         | 0.788 (0.650,0.954)   |          |
|                                          |                         | 0.1                                 |                         |                       |          |
| <3 EDSS                                  | 554( 56)                | 554( 55)                            | 工HI                     | 0.784 ( 0.647, 0.950) |          |
|                                          |                         |                                     | 1                       | 10                    |          |
|                                          |                         | <---Favors LAQ-------Favors PLC.--> |                         |                       |          |

SubgroupVariableandTreatmentbySubgroupInteraction

*P-Valueisfrom theteststatisticofTreatment bySubgroupInteraction

## Figure 8: Efficacy results on 3 month confirmed disease progression (CDP)

|                                                                                                                                                                                                                      | CDP 3Months                                                                                                                                                                                                          | CDP 3Months                                                                                                                                                                                                          | CDP 3Months                                                                                                                                                                                                          | CDP 3Months                                                                                                                                                                                                          |                                                                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Subgroup                                                                                                                                                                                                             | No.of Patients (%)                                                                                                                                                                                                   | No.of Patients (%)                                                                                                                                                                                                   | No.of Patients (%)                                                                                                                                                                                                   | TreatmentEffect                                                                                                                                                                                                      | TreatmentEffect                                                                                                                                                                                                      |
|                                                                                                                                                                                                                      | LAQ                                                                                                                                                                                                                  | PLC                                                                                                                                                                                                                  |                                                                                                                                                                                                                      | HR (95% CI)                                                                                                                                                                                                          | P-Value*                                                                                                                                                                                                             |
| Relapses(>=2) 1yr Prior SC                                                                                                                                                                                           |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      | 0.2261                                                                                                                                                                                                               |
| >=2 Relapses                                                                                                                                                                                                         | 257( 26)                                                                                                                                                                                                             | 273( 27)                                                                                                                                                                                                             |                                                                                                                                                                                                                      | 0.851(0.522,1.388)                                                                                                                                                                                                   |                                                                                                                                                                                                                      |
| <2 Relapses                                                                                                                                                                                                          | 727( 74)                                                                                                                                                                                                             | 733( 73)                                                                                                                                                                                                             |                                                                                                                                                                                                                      | 0.594( 0.435,0.811)                                                                                                                                                                                                  |                                                                                                                                                                                                                      |
| Relapses(>=2)1yr Prior SC andGdE at BL                                                                                                                                                                               |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      | 0.9099                                                                                                                                                                                                               |
| >=2 Relapses and GdE at BL                                                                                                                                                                                           | 117( 12)                                                                                                                                                                                                             | 120( 12)                                                                                                                                                                                                             |                                                                                                                                                                                                                      | 0.680 ( 0.314, 1.475)                                                                                                                                                                                                |                                                                                                                                                                                                                      |
| Otherwise                                                                                                                                                                                                            | 864( 88)                                                                                                                                                                                                             | 885( 88)                                                                                                                                                                                                             |                                                                                                                                                                                                                      | 0.649 ( 0.491, 0.857)                                                                                                                                                                                                |                                                                                                                                                                                                                      |
| Relapses(>=1)1yrPriorSC andGdE at BL                                                                                                                                                                                 |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      | 0.7896                                                                                                                                                                                                               |
| >=1 Relapse and GdE at BL                                                                                                                                                                                            | 370( 38)                                                                                                                                                                                                             | 380(38)                                                                                                                                                                                                              |                                                                                                                                                                                                                      | 0.624( 0.409,0.951)                                                                                                                                                                                                  |                                                                                                                                                                                                                      |
| Otherwise                                                                                                                                                                                                            | 611(62)                                                                                                                                                                                                              | 625(62)                                                                                                                                                                                                              |                                                                                                                                                                                                                      | 0.672 ( 0.480, 0.939)                                                                                                                                                                                                |                                                                                                                                                                                                                      |
| Median T2 Lesion Volume at BL                                                                                                                                                                                        |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      | 0.029                                                                                                                                                                                                                |
| >=Median T2 Volume at BL                                                                                                                                                                                             | 508(52)                                                                                                                                                                                                              | 485( 48)                                                                                                                                                                                                             |                                                                                                                                                                                                                      | 0.864 ( 0.602, 1.240)                                                                                                                                                                                                |                                                                                                                                                                                                                      |
| <Median T2 Volume at BL                                                                                                                                                                                              | 473( 48)                                                                                                                                                                                                             | 520(52)                                                                                                                                                                                                              |                                                                                                                                                                                                                      | 0.475 ( 0.321,0.705)                                                                                                                                                                                                 |                                                                                                                                                                                                                      |
| Number of GdE Lesions at BL                                                                                                                                                                                          |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      | 0.5769                                                                                                                                                                                                               |
| >=2 GdE Lesions at BL                                                                                                                                                                                                | 247( 25)                                                                                                                                                                                                             | 239( 24)                                                                                                                                                                                                             |                                                                                                                                                                                                                      | 0.731 ( 0.452, 1.182)                                                                                                                                                                                                |                                                                                                                                                                                                                      |
| < 2 GdE Lesions at BL                                                                                                                                                                                                | 734( 75)                                                                                                                                                                                                             | 766( 76)                                                                                                                                                                                                             |                                                                                                                                                                                                                      | 0.621(0.454,0.849)                                                                                                                                                                                                   |                                                                                                                                                                                                                      |
| EDSS( >=2) at BL                                                                                                                                                                                                     |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      | 0.7606                                                                                                                                                                                                               |
| >=2 EDSS                                                                                                                                                                                                             | 697( 71)                                                                                                                                                                                                             | 734( 73)                                                                                                                                                                                                             |                                                                                                                                                                                                                      | 0.641 ( 0.471, 0.872)                                                                                                                                                                                                |                                                                                                                                                                                                                      |
| <2 EDSS                                                                                                                                                                                                              | 287( 29)                                                                                                                                                                                                             | 272( 27)                                                                                                                                                                                                             |                                                                                                                                                                                                                      | 0.702( 0.428, 1.153)                                                                                                                                                                                                 |                                                                                                                                                                                                                      |
| EDSS(>=3) at BL                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      |                                                                                                                                                                                                                      | 0.6434                                                                                                                                                                                                               |
| >=3 EDSS                                                                                                                                                                                                             | 430( 44)                                                                                                                                                                                                             | 452( 45)                                                                                                                                                                                                             |                                                                                                                                                                                                                      | 0.700 (0.480,1.021)                                                                                                                                                                                                  |                                                                                                                                                                                                                      |
| <3 EDSS                                                                                                                                                                                                              | 554( 56)                                                                                                                                                                                                             | 554(55)                                                                                                                                                                                                              |                                                                                                                                                                                                                      | 0.618 ( 0.429,0.891)                                                                                                                                                                                                 |                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                      |                                                                                                                                                                                                                      | 0.1                                                                                                                                                                                                                  | 1                                                                                                                                                                                                                    | 10                                                                                                                                                                                                                   |                                                                                                                                                                                                                      |
| <---FavorsLAQ-------FavorsPLC.--> Results are generated by Cox regression analysis adjusted to: Log(No. of Relapses in 2 years prior SC), EDSS at BL,Country/Geographical Region, Treatment group, Subgroup Variable | <---FavorsLAQ-------FavorsPLC.--> Results are generated by Cox regression analysis adjusted to: Log(No. of Relapses in 2 years prior SC), EDSS at BL,Country/Geographical Region, Treatment group, Subgroup Variable | <---FavorsLAQ-------FavorsPLC.--> Results are generated by Cox regression analysis adjusted to: Log(No. of Relapses in 2 years prior SC), EDSS at BL,Country/Geographical Region, Treatment group, Subgroup Variable | <---FavorsLAQ-------FavorsPLC.--> Results are generated by Cox regression analysis adjusted to: Log(No. of Relapses in 2 years prior SC), EDSS at BL,Country/Geographical Region, Treatment group, Subgroup Variable | <---FavorsLAQ-------FavorsPLC.--> Results are generated by Cox regression analysis adjusted to: Log(No. of Relapses in 2 years prior SC), EDSS at BL,Country/Geographical Region, Treatment group, Subgroup Variable | <---FavorsLAQ-------FavorsPLC.--> Results are generated by Cox regression analysis adjusted to: Log(No. of Relapses in 2 years prior SC), EDSS at BL,Country/Geographical Region, Treatment group, Subgroup Variable |

*P-Value is from the test statistic of Treatment by SubgroupInteraction

<div style=\"page-break-after: always\"></div>

Figure 9: Efficacy results on 6 month confirmed disease progression (CDP)

<!-- image -->

Figure 10: ARR (Point Estimates, 95% CI)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 11: 3-Month Disability Progression (Point Estimates, 95% CI)

<!-- image -->

Furthermore, additional data were presented to support the efficacy profile of laquinimod in the subsets of RRMS population that would benefit from laquinimod according to the applicant. These included efficacy data in the following patient groups: patients who completed 2 years of Avonex treatment then switched to laquinimod (Figure 12), patients with baseline EDSS scores ≥4 (Table 13),  patients  who  were  relapse-free  throughout  the  studies  (Tables  14  and  15),  patients  in  the 25% quartile of the MSFC z-score (i.e. patients in the bottom quartile of the MSFC change, Table 16, Figure 13), treatment naïve patients per baseline characteristics (Figure 14 ).

Figure 12: Annualised relapse rate in BRAVO for the original Avonex arm over 4 years (switch to laquinimod occurred in the beginning of year 3)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 13: subgroup analysis of pooled data: summary of treatment effects (laquinimod 0.6 mg vs placebo) by EDSS baseline score

|                                                    |                   | EDSS <4 LAQ 0.6 mg, n=769 (78.2%) Placebo, n=814 (80.9%)   | EDSS ≥4 LAQ 0.6 mg, n=215 (21.8%) Placebo, n=192 (19.1%)   |
|----------------------------------------------------|-------------------|------------------------------------------------------------|------------------------------------------------------------|
| AnnualizedRelapseRate                              | Risk Ratio        | 0.804 [0.688; 0.941]                                       | 0.747 [0.567; 0.984]                                       |
| AnnualizedRelapseRate                              | Laquinimod Effect | 19.6%                                                      | 25.3%                                                      |
| AnnualizedRelapseRate                              | p-value           | p=0.0064                                                   | p=0.0382                                                   |
| Brain Atrophy As Defined By PBVC                   | Adj. Mean Diff.   | 0.342 [0.223; 0.462]                                       | 0.423 [0.184; 0.661]                                       |
| Brain Atrophy As Defined By PBVC                   | Laquinimod Effect | 29.6%                                                      | 31.0%                                                      |
| Brain Atrophy As Defined By PBVC                   | p-value           | p<0.0001                                                   | p=0.0005                                                   |
| TimeToConfirmedEDSS Progression (3m)               | Hazard Ratio      | 0.647 [0.479; 0.875]                                       | 0.654 [0.383; 1.117]                                       |
| TimeToConfirmedEDSS Progression (3m)               | Laquinimod Effect | 35.3%                                                      | 34.6%                                                      |
| TimeToConfirmedEDSS Progression (3m)               | p-value           | p=0.0047                                                   | p=0.1201                                                   |
| Disability As Assessed By MSFCZ-ScoreAtMonth 24    | Adj. Mean Diff.   | 0.007 [-0.084; 0.099]                                      | 0.311 [0.128; 0.494]                                       |
| Disability As Assessed By MSFCZ-ScoreAtMonth 24    | p-value           | p=0.8747                                                   | p=0.0009                                                   |
| CumulativeGdETLesionsAt Months 12 and 24           | Rate Ratio        | 0.688 [0.563; 0.840]                                       | 0.801 [0.537; 1.193]                                       |
| CumulativeGdETLesionsAt Months 12 and 24           | Laquinimod Effect | 31.2%                                                      | 19.9%                                                      |
| CumulativeGdETLesionsAt Months 12 and 24           | p-value           | p=0.0002                                                   | p=0.2749                                                   |
| Cumulative New/Enlarging T2 LesionsAtMonths12and24 | Rate Ratio        | 0.77 [0.661; 0.898]                                        | 0.778 [0.571; 1.058]                                       |
| Cumulative New/Enlarging T2 LesionsAtMonths12and24 | Laquinimod Effect | 23%                                                        | 22.2%                                                      |
| Cumulative New/Enlarging T2 LesionsAtMonths12and24 | p-value           | p=0.0009                                                   | p=0.1098                                                   |

Table 14: ITT Analysis Set - EDSS Data

<!-- image -->

ISE-DoubleBlindITT

Table 15: Statistical Analysis of Time to Confirmed Progression by Relapse-Free Additional Covariates

SAS PHREG -Cox Model （Hazard Ratio and 9596confidence intervals)

<!-- image -->

| Companison                             |   Hazard Ratio |   LowerConfidence Limit | Upper Confidence Limit   |   value |
|----------------------------------------|----------------|-------------------------|--------------------------|---------|
| Laquinimod0.6mgvs.Placebo Relapse-Free |          0.611 |                   0.385 | 0.969                    |  0.0362 |
| Laquinimod0.6mgVs.Placebo Relapsing    |          0.733 |                   0.531 | LTO'T                    |  0.0581 |

<div style=\"page-break-after: always\"></div>

Table 16: Proportions of Patients by MSFC's Quartile vs. the Risk for EDSS Confirmed Progression Per Treatment Group

|               | Treatment Group   | Treatment Group   | Treatment Group   | Treatment Group   | Treatment Group   | Treatment Group   | Treatment Group   | Treatment Group   |                  |                  |            |            |
|---------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|------------------|------------------|------------|------------|
|               | Placebo           | Placebo           | Placebo           | Placebo           | Laquinimod 0.6 mg | Laquinimod 0.6 mg | Laquinimod 0.6 mg | Laquinimod 0.6 mg | All              | All              | All        | All        |
|               | Did not progress  | Did not progress  | Progressed        | Progressed        | Did not progress  | Did not progress  | Progressed        | Progressed        | Did not progress | Did not progress | Progressed | Progressed |
|               | N                 | %                 | N                 | %                 | N                 | %                 | N                 | %                 | N                | %                | N          | %          |
| MSFC Quartile |                   |                   |                   |                   |                   |                   |                   |                   |                  |                  |            |            |
| MSFC Q25%     | 159               | 73.61             | 57                | 26.39             | 162               | 81.82             | 36                | 18.18             | 321              | 77.54            | 93         | 22.46      |
| MSFC Q50%     | 202               | 90.58             | 21                | 9.42              | 172               | 89.58             | 20                | 10.42             | 374              | 90.12            | 41         | 9.88       |
| MSFC Q75%     | 183               | 88.41             | 24                | 11.59             | 190               | 91.79             | 17                | 8.21              | 373              | 90.10            | 41         | 9.90       |
| MSFC Q100%    | 165               | 87.30             | 24                | 12.70             | 212               | 93.81             | 14                | 6.19              | 377              | 90.84            | 38         | 9.16       |

Figure 13: Proportions of Patients by MSFC's Quartile vs. the Risk for EDSS Confirmed Progression Per Treatment Group

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 14: Subgroup analysis dichotomized by baseline parameters of disease activity for ARR and CDP

<!-- image -->

<!-- image -->

According  to  the  applicant,  reduction  in  time  to  3,  6,  9  and  12  month  confirmed  disability Progression has been observed with laquinimod with a large magnitude, higher than predicted by the corresponding effect on relapse reduction. Based on laquinimod effect on ARR, 5% reduction in 3 month confirmed disability progression was predicted. However, 36% was observed. See Figures 15 and 16.

<div style=\"page-break-after: always\"></div>

Figure 15. Laquinimod 3,6,9,12 month CDP effect versus placebo

<!-- image -->

600 000

Figure 16. Effect on 3 month confirmed disability in the Sormani Equation relating effect on relapses to the effect on disability progression

<!-- image -->

The green regression line depicts the relationship between ARR and CDP and its 95% confidence bounds based on all available clinical RRMS trial data. The green dot signifies the point estimate of the predicted CDP effect of laquinimod by this Sormani equation; the black dot is the actual effect observed for laquinimod, well outside the 95%CI. The ARR effect of laquinimod is not predictive of its more pronounced CDP effect.

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

## Table 17.Summary of efficacy for trial Laq-301 (ALLEGRO)

| Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)   | Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)   | Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)   | Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)                                      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                              | Laq-301 (ALLEGRO)                                                                                                                                                                                                                                                             | Laq-301 (ALLEGRO)                                                                                                                                                                                                                                                             | Laq-301 (ALLEGRO)                                                                                                                                                                                                                                                                                                |
| Design                                                                                                                                                                                                                                                                        | Multicentre,Randomized, double-blind, parallel-group, placebo-controlled                                                                                                                                                                                                      | Multicentre,Randomized, double-blind, parallel-group, placebo-controlled                                                                                                                                                                                                      | Multicentre,Randomized, double-blind, parallel-group, placebo-controlled                                                                                                                                                                                                                                         |
| Design                                                                                                                                                                                                                                                                        | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                | 24 months not applicable ongoing                                                                                                                                                                                                                                                                                 |
| Hypothesis                                                                                                                                                                                                                                                                    | Hypothesis                                                                                                                                                                                                                                                                    | Hypothesis                                                                                                                                                                                                                                                                    | Hypothesis                                                                                                                                                                                                                                                                                                       |
| Treatments groups                                                                                                                                                                                                                                                             | Laquinimod                                                                                                                                                                                                                                                                    | Laquinimod                                                                                                                                                                                                                                                                    | 0.6 mg p.o. daily (capsule) N=550 (ITT )                                                                                                                                                                                                                                                                         |
| Treatments groups                                                                                                                                                                                                                                                             | Placebo                                                                                                                                                                                                                                                                       | Placebo                                                                                                                                                                                                                                                                       | capsule N=556 (ITT)                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                                                                                                                                                                                                                                                     | Co-primary endpoint                                                                                                                                                                                                                                                           | Relapse rate                                                                                                                                                                                                                                                                  | A relapse was defined as the appearance of one or more new neurological abnormalities or the reappearance of one or more previously observed neurological abnormalities, lasting at least 48 hours and immediately precede by an improved neurological state of at least 30 days from onset of previous relapse. |
| Endpoints and definitions                                                                                                                                                                                                                                                     | Secondary endpoint                                                                                                                                                                                                                                                            | Cumulative Nb of GdE T1lesions                                                                                                                                                                                                                                                | Sum of T1 enhancing lesions at M12 and number of T1 enhancing lesions at M24                                                                                                                                                                                                                                     |
| Endpoints and definitions                                                                                                                                                                                                                                                     | Secondary endpoint                                                                                                                                                                                                                                                            | Cumulative Nb of new or enlarging T2 lesions                                                                                                                                                                                                                                  | Sum of new T2 lesions count at M12 and new T2 lesions count at M24                                                                                                                                                                                                                                               |
| Endpoints and definitions                                                                                                                                                                                                                                                     | Secondary endpoint                                                                                                                                                                                                                                                            | Time to confirmed EDSS progression                                                                                                                                                                                                                                            | A confirmed progression of EDSS is defined as at least 1 point increase from baseline on EDSS score if baseline EDSS was between 0 and 5.0 or at least 0.5 point increase if baseline EDSS was 5.5 or higher, confirmed 3 months later.                                                                          |

## Results and Analysis

Analysis description

Analysis population and time point

description

Descriptive statistics and estimate

variability

Primary and secondary Endpoint Analysis

ITT set (all randomized patients from baseline to last day in the study)

Time point : 24 months

Treatment group

Number of subject

Relapse rate

(Annualized relapse rate)

SE

Cumulative Nb of

GdE T1lesions

SE

Laquinimod

550

0.304

0.022

1.332

0.142

Placebo

556

0.395

0.027

2.119

0.218

<div style=\"page-break-after: always\"></div>

|                                | Cumulative Nb of new or enlarging T2 lesions   | 5.032             | 7.148                 |
|--------------------------------|------------------------------------------------|-------------------|-----------------------|
|                                | SE                                             | 0.400             | 0.536                 |
|                                | EDSS (3 months)                                | 2.8 (N=551)       | 2.7 (N=543)           |
|                                | SD                                             | 1.5               | 1.5                   |
| Effect estimate per comparison | Annualized relapse rate                        | Comparison groups | Laquinimod vs placebo |
| Effect estimate per comparison | Annualized relapse rate                        | Rate Ratio        | 0.770                 |
| Effect estimate per comparison | Annualized relapse rate                        | 95% CI            | 0.650;0.911           |
| Effect estimate per comparison | Annualized relapse rate                        | Risk reduction    | 23%                   |
| Effect estimate per comparison | Annualized relapse rate                        | P value           | 0.0024                |
| Effect estimate per comparison | Cumulative Nb of GdE T1lesions                 | Comparison groups | Laquinimod vs placebo |
| Effect estimate per comparison | Cumulative Nb of GdE T1lesions                 | Rate Ratio        | 0.629                 |
| Effect estimate per comparison | Cumulative Nb of GdE T1lesions                 | 95% CI            | 0.488 ; 0.809         |
| Effect estimate per comparison | Cumulative Nb of GdE T1lesions                 | Risk reduction    | 37.1%                 |
| Effect estimate per comparison | Cumulative Nb of GdE T1lesions                 | P value           | 0.0003                |
|                                | Cumulative Nb of new or enlarging T2 lesions   | Comparison groups | Laquinimod vs placebo |
|                                | Cumulative Nb of new or enlarging T2 lesions   | Rate Ratio        | 0.704                 |
|                                | Cumulative Nb of new or enlarging T2 lesions   | 95% CI            | 0.584 ; 0.849         |
|                                | Cumulative Nb of new or enlarging T2 lesions   | Risk reduction    | 29.6%                 |
|                                | Cumulative Nb of new or enlarging T2 lesions   | P value           | 0.0002                |
|                                | Time to confirmed EDSS progression (3 months)  | Comparison group  | Laquinimod vs placebo |
|                                | Time to confirmed EDSS progression (3 months)  | Hazard Ratio      | 0.641                 |
|                                | Time to confirmed EDSS progression (3 months)  | 95% CI            | 0.452;0.908           |
|                                | Time to confirmed EDSS progression (3 months)  | Risk reduction    | 35.9%                 |
|                                | Time to confirmed EDSS progression (3 months)  | P value           | 0.0122                |

<div style=\"page-break-after: always\"></div>

Table 18. Summary of efficacy for Laq-302 (BRAVO)

| Title: A multinational, multicenter, randomized, parallel-group study performed in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of interferon β-1a (Avonex) in   | Title: A multinational, multicenter, randomized, parallel-group study performed in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of interferon β-1a (Avonex) in   | Title: A multinational, multicenter, randomized, parallel-group study performed in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of interferon β-1a (Avonex) in   | Title: A multinational, multicenter, randomized, parallel-group study performed in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of interferon β-1a (Avonex) in                     | Title: A multinational, multicenter, randomized, parallel-group study performed in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of interferon β-1a (Avonex) in                     | Title: A multinational, multicenter, randomized, parallel-group study performed in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of interferon β-1a (Avonex) in                     | Title: A multinational, multicenter, randomized, parallel-group study performed in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of interferon β-1a (Avonex) in   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                           | Laq-302 (BRAVO)                                                                                                                                                                                                                                                                                            | Laq-302 (BRAVO)                                                                                                                                                                                                                                                                                            | Laq-302 (BRAVO)                                                                                                                                                                                                                                                                                                              | Laq-302 (BRAVO)                                                                                                                                                                                                                                                                                                              | Laq-302 (BRAVO)                                                                                                                                                                                                                                                                                                              | Laq-302 (BRAVO)                                                                                                                                                                                                                                                                                            |
| Design                                                                                                                                                                                                                                                                                                     | Multicentre, Randomized, parallel-group, placebo-controlled in a double-blind design, with a reference arm in a rater blinded design                                                                                                                                                                       | Multicentre, Randomized, parallel-group, placebo-controlled in a double-blind design, with a reference arm in a rater blinded design                                                                                                                                                                       | Multicentre, Randomized, parallel-group, placebo-controlled in a double-blind design, with a reference arm in a rater blinded design                                                                                                                                                                                         | Multicentre, Randomized, parallel-group, placebo-controlled in a double-blind design, with a reference arm in a rater blinded design                                                                                                                                                                                         | Multicentre, Randomized, parallel-group, placebo-controlled in a double-blind design, with a reference arm in a rater blinded design                                                                                                                                                                                         | Multicentre, Randomized, parallel-group, placebo-controlled in a double-blind design, with a reference arm in a rater blinded design                                                                                                                                                                       |
| Design                                                                                                                                                                                                                                                                                                     | Duration of main phase:                                                                                                                                                                                                                                                                                    | Duration of main phase:                                                                                                                                                                                                                                                                                    | 24 months                                                                                                                                                                                                                                                                                                                    | 24 months                                                                                                                                                                                                                                                                                                                    | 24 months                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                            |
| Design                                                                                                                                                                                                                                                                                                     | Duration of Run-in phase:                                                                                                                                                                                                                                                                                  | Duration of Run-in phase:                                                                                                                                                                                                                                                                                  | not applicable                                                                                                                                                                                                                                                                                                               | not applicable                                                                                                                                                                                                                                                                                                               | not applicable                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                            |
| Design                                                                                                                                                                                                                                                                                                     | Duration of Extension phase:                                                                                                                                                                                                                                                                               | Duration of Extension phase:                                                                                                                                                                                                                                                                               | ongoing                                                                                                                                                                                                                                                                                                                      | ongoing                                                                                                                                                                                                                                                                                                                      | ongoing                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                            |
| Hypothesis                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                                                                                                                                                          | Laquinimod                                                                                                                                                                                                                                                                                                 | Laquinimod                                                                                                                                                                                                                                                                                                 | 0.6 mg p.o. daily (capsule) N=434 (ITT )                                                                                                                                                                                                                                                                                     | 0.6 mg p.o. daily (capsule) N=434 (ITT )                                                                                                                                                                                                                                                                                     | 0.6 mg p.o. daily (capsule) N=434 (ITT )                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                                                                                                                                                          | Placebo                                                                                                                                                                                                                                                                                                    | Placebo                                                                                                                                                                                                                                                                                                    | One capsule matching placebo p.o daily N=450 (ITT)                                                                                                                                                                                                                                                                           | One capsule matching placebo p.o daily N=450 (ITT)                                                                                                                                                                                                                                                                           | One capsule matching placebo p.o daily N=450 (ITT)                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                                                                                                                                                          | Avonex                                                                                                                                                                                                                                                                                                     | Avonex                                                                                                                                                                                                                                                                                                     | 30 mcg i.m. once weekly                                                                                                                                                                                                                                                                                                      | 30 mcg i.m. once weekly                                                                                                                                                                                                                                                                                                      | 30 mcg i.m. once weekly                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                                                                                                                  | Co-primary endpoint                                                                                                                                                                                                                                                                                        | Relapse rate                                                                                                                                                                                                                                                                                               | N=447 (ITT) A relapse was defined as the appearance of one or more new neurological abnormalities or the reappearance of one or more previously observed neurological abnormalities, lasting at least 48 hours and immediately precede by an improved neurological state of at least 30 days from onset of previous relapse. | N=447 (ITT) A relapse was defined as the appearance of one or more new neurological abnormalities or the reappearance of one or more previously observed neurological abnormalities, lasting at least 48 hours and immediately precede by an improved neurological state of at least 30 days from onset of previous relapse. | N=447 (ITT) A relapse was defined as the appearance of one or more new neurological abnormalities or the reappearance of one or more previously observed neurological abnormalities, lasting at least 48 hours and immediately precede by an improved neurological state of at least 30 days from onset of previous relapse. |                                                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                                                                                                                  | Secondary endpoint Brain                                                                                                                                                                                                                                                                                   | atrophy                                                                                                                                                                                                                                                                                                    | Percent brain volume change (PBVC) in normalized brain volume from baseline to                                                                                                                                                                                                                                               | Percent brain volume change (PBVC) in normalized brain volume from baseline to                                                                                                                                                                                                                                               | Percent brain volume change (PBVC) in normalized brain volume from baseline to                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                            | Disability measured by Time to confirmed progression of EDSS                                                                                                                                                                                                                                               | month 24 A confirmed progression of EDSS is defined as at least 1 point increase from baseline on EDSS score if baseline EDSS was between 0 and 5.0 or at least 0.5 point increase if baseline EDSS was 5.5 or higher, confirmed 3 months later                                                                              | month 24 A confirmed progression of EDSS is defined as at least 1 point increase from baseline on EDSS score if baseline EDSS was between 0 and 5.0 or at least 0.5 point increase if baseline EDSS was 5.5 or higher, confirmed 3 months later                                                                              | month 24 A confirmed progression of EDSS is defined as at least 1 point increase from baseline on EDSS score if baseline EDSS was between 0 and 5.0 or at least 0.5 point increase if baseline EDSS was 5.5 or higher, confirmed 3 months later                                                                              |                                                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                            | .A 3 dimensional clinical measure which includes cognitive function in addition to leg                                                                                                                                                                                                                                       | .A 3 dimensional clinical measure which includes cognitive function in addition to leg                                                                                                                                                                                                                                       | .A 3 dimensional clinical measure which includes cognitive function in addition to leg                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                            | Disability as assessed by MSFC score                                                                                                                                                                                                                                                                       | function/ambulation and arm/hand function.                                                                                                                                                                                                                                                                                   | function/ambulation and arm/hand function.                                                                                                                                                                                                                                                                                   | function/ambulation and arm/hand function.                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                            |
| Results and Analysis                                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                                         | Results and Analysis                                                                                                                                                                                                                                                                                                         | Results and Analysis                                                                                                                                                                                                                                                                                                         | Results and Analysis                                                                                                                                                                                                                                                                                       |
| Analysis description                                                                                                                                                                                                                                                                                       | Primary and secondary Endpoint Analysis                                                                                                                                                                                                                                                                    | Primary and secondary Endpoint Analysis                                                                                                                                                                                                                                                                    | Primary and secondary Endpoint Analysis                                                                                                                                                                                                                                                                                      | Primary and secondary Endpoint Analysis                                                                                                                                                                                                                                                                                      | Primary and secondary Endpoint Analysis                                                                                                                                                                                                                                                                                      | Primary and secondary Endpoint Analysis                                                                                                                                                                                                                                                                    |
| Analysis population and time point description                                                                                                                                                                                                                                                             | ITT set (all randomized patients from baseline to last day in the study) Time point : 24 months                                                                                                                                                                                                            | ITT set (all randomized patients from baseline to last day in the study) Time point : 24 months                                                                                                                                                                                                            | ITT set (all randomized patients from baseline to last day in the study) Time point : 24 months                                                                                                                                                                                                                              | ITT set (all randomized patients from baseline to last day in the study) Time point : 24 months                                                                                                                                                                                                                              | ITT set (all randomized patients from baseline to last day in the study) Time point : 24 months                                                                                                                                                                                                                              | ITT set (all randomized patients from baseline to last day in the study) Time point : 24 months                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                            | Treatment group                                                                                                                                                                                                                                                                                            | Laquinimod                                                                                                                                                                                                                                                                                                 | Laquinimod                                                                                                                                                                                                                                                                                                                   | Placebo                                                                                                                                                                                                                                                                                                                      | Avonex                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                            | Number of subject                                                                                                                                                                                                                                                                                          | 434                                                                                                                                                                                                                                                                                                        | 434                                                                                                                                                                                                                                                                                                                          | 450                                                                                                                                                                                                                                                                                                                          | 447                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                            | Relapse rate (Annualized relapse rate)                                                                                                                                                                                                                                                                     | 0.283                                                                                                                                                                                                                                                                                                      | 0.283                                                                                                                                                                                                                                                                                                                        | 0.344                                                                                                                                                                                                                                                                                                                        | 0.255                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                            | SE                                                                                                                                                                                                                                                                                                         | 0.025                                                                                                                                                                                                                                                                                                      | 0.025                                                                                                                                                                                                                                                                                                                        | 0.029                                                                                                                                                                                                                                                                                                                        | 0.023                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                            | Brain atrophy (PBVC)                                                                                                                                                                                                                                                                                       | -0.746                                                                                                                                                                                                                                                                                                     | -0.746                                                                                                                                                                                                                                                                                                                       | -1.030                                                                                                                                                                                                                                                                                                                       | -1.137                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                                | SE                                                                      | 0.058                    | 0.057                 | 0.056             |
|--------------------------------|-------------------------------------------------------------------------|--------------------------|-----------------------|-------------------|
|                                | EDSS (3months )                                                         | 2.7 (N=428)              | 2.9 (N=447)           | 2.7 (N=438)       |
|                                | SE                                                                      | 1.4                      | 1.4                   | 1.3               |
|                                | Disability as assessed by MSFC score                                    | -0.030                   | -0.135                | -0.045            |
|                                | SE                                                                      | 0.057                    | 0.056                 | 0.055             |
| Effect estimate per comparison | Annualized relapse rate                                                 | Comparison groups        | Laquinimod vs placebo | Avonex vs placebo |
| Effect estimate per comparison | Annualized relapse rate                                                 | Rate Ratio               | 0.823                 | 0.741             |
| Effect estimate per comparison | Annualized relapse rate                                                 | 95% CI                   | 0.664;1.020           | 0.596; 0.920      |
| Effect estimate per comparison | Annualized relapse rate                                                 | Risk reduction           | 17.7%                 | 25.9%             |
| Effect estimate per comparison | Annualized relapse rate                                                 | P value                  | 0.0746                | 0.0067            |
| Effect estimate per comparison | Brain atrophy (PBVC)                                                    | Comparison groups        | Laquinimod vs placebo | Avonex vs placebo |
| Effect estimate per comparison | Brain atrophy (PBVC)                                                    | Adjusted mean difference | 0.284                 | -0.107            |
| Effect estimate per comparison | Brain atrophy (PBVC)                                                    | 95% CI                   | 0.139 ; 0.429         | -0.249 ; 0.035    |
| Effect estimate per comparison | Brain atrophy (PBVC)                                                    | Risk reduction           | 27.6%                 | -10%              |
| Effect estimate per comparison | Brain atrophy (PBVC)                                                    | P value                  | 0.0001                | 0.14              |
|                                | Disability measured by Time to confirmed progression of EDSS (3 months) | Comparison groups        | Laquinimod vs placebo | Avonex vs placebo |
|                                | Disability measured by Time to confirmed progression of EDSS (3 months) | Hazard Ratio             | 0.687                 | 0.742             |
|                                | Disability measured by Time to confirmed progression of EDSS (3 months) | 95% CI                   | 0.462 ; 1.020         | 0.507 ; 1.088     |
|                                | Disability measured by Time to confirmed progression of EDSS (3 months) | Risk reduction           | 31.3%                 | 25.8%             |
|                                | Disability measured by Time to confirmed progression of EDSS (3 months) | P value                  | 0.0628                | 0.1269            |
|                                | Disability as assessed by MSFC score                                    | Comparison group         | Laquinimod vs placebo | Avonex vs placebo |
|                                | Disability as assessed by MSFC score                                    | Adjusted mean difference | 0.104                 | 0.089             |
|                                | Disability as assessed by MSFC score                                    | 95% CI                   | -0.038;0.247          | -0.050; 0.229     |
|                                | Disability as assessed by MSFC score                                    | P value                  | 0.1505                | 0.2083            |

## 2.5.2.4. Analysis performed across trials (pooled analyses and meta-analysis)

Naïve pooling of the raw data from the two pivotal studies (ALLEGRO and BRAVO) has been used to provide combined efficacy estimates for laquinimod and to evaluate whether the overall positive efficacy  results  are  also  evident  in  pre-specified  subgroups  of  patients.  The  analysis  was  preplanned. The population for the pooled analysis was the ITT analysis set. The results on ARR and EDSS  score  were  numerically  similar  in  these  studies  although  these  results  did  not  reach  the statistical significance in the BRAVO study. Taking into account these findings, it is not unexpected that the data pooled analysis led to statistically significant results for ARR (RR= 0.786, 95% CI: 0.686, 0.900, p=0.0005). However the effect of laquinimod 0.6 mg was modest with a reduction in the risk of occurrence of relapses of 21.4% as compared to placebo. The analysis of pooled data for time  to  confirmed  EDSS  progression  yielded  a  hazard  ratio  of  0.658  (95%  CI  0.506,  0.854, p=0.0017) reflecting a reduction of 34.2% in the risk for confirmed EDSS (3 months) progression as compared to placebo. The magnitude of the effect of laquinimod 0.6 mg over placebo on brain atrophy was statistically significant and consistent between the two studies ALLEGRO and BRAVO

<div style=\"page-break-after: always\"></div>

(respectively reduction of brain atrophy of 32.8% and 27.6%). Results of the pooled data showed a slowing of brain atrophy at Month 24 in patients treated with laquinimod 0.6 mg as compared to placebo leading to a 29.7% reduction in brain atrophy (p&lt;0.0001).

In the ALLEGRO study, laquinimod 0.6 mg showed a statistically significant effect over placebo for both  MRI  endpoints  (cumulative  number  of  GdE  T1  lesions  and  cumulative  number  of  New  or Enlarging T2 lesions); in BRAVO the results were numerically similar but did not reach statistical significance. The analysis of pooled data for these MRI endpoints showed a statistically significant effect of laquinimod 0.6 mg.

At the CHMP request, a meta-analysis using the two pivotal studies ALLEGRO and BRAVO, and the phase IIb study LAQ/5062 was conducted. The results showed an effect of laquinimod on ARR with an overall  Risk  Ratio  [95%  CI]  of  0.79  [0.69,  0.89]  suggesting  a  21%  reduction  for  laquinimod versus placebo (p=0.0002). This result was consistent with the results of the pre-planned pooled analysis, previously described. Moreover, a treatment effect on GdE T1 lesions was observed with a rate  ratio  of  0.68  suggesting  a  reduction  of  32%  as  compared  to  placebo.  This  effect  was statistically significant (p&lt;0.00001). The effect on new T2 lesions was also statistically significant with  a  reduction  of  27%  versus  placebo  (RR=  0.73,  p&lt;0.00001).  Regarding  brain  atrophy,  the effect of laquinimod was statistically significant as compared to placebo (difference of 0.31 in % brain  volume  change,  p&lt;0.00001).  Regarding  the  disability  progression,  there  was  a  32% reduction in the risk for 3-month confirmed disease progression (HR= 0.68, 95% CI: 0.52, 0.87, p=0.003).  This  result  was  also  consistent  with  the  results  of  the  pre-planned  pooled  analysis, described previously.

In addition, the CHMP also requested a meta-analysis including ALLEGRO and BRAVO studies on the 6 month sustained disability progression. In this post-hoc analysis, an effect of laquinimod 0.6 mg was observed with a 44% reduction in the risk for 6 month confirmed disability progression (HR= 0.56, 95% CI: 0.41, 0.76, p=0.003). This result was in line with previously reported data showing reduction in 6 months confirmed disability progression in the 2 individual studies (48% in ALLEGRO and 39% in BRAVO, respectively).

In subgroup analyses (according to gender, geographic region, age, EDSS baseline score, disease activity at baseline), results were consistently in favour of laquinimod 0.6 mg efficacy to reduce the relapse  rate  in  all  subgroups.  Some  unexpected  statistical  interactions  between  treatments  and gender on EDSS score and cumulative New/Enlarging T2 lesions were observed.

## 2.5.2.5. Clinical studies in special populations

No trials have been performed in any special MS patient populations.

## 2.5.2.6. Supportive studies

Data from 3 extension studies were initially submitted (studies LAQ/5063, LAQ-301 and LAQ-302). At  the  CHMP  request,  the  applicant  also  provided  data  from  the  ongoing  open  label  study  of LAQ/5063  which  is  a  completed  double  blind  active  extension  study.  The  cut-off  date  for  all ongoing studies was November 2012.

After  completing  the  36  week,  placebo-controlled,  phase  II  study  (LAQ/5062),  91%  of  patients (257 patients) enrolled in a 36 week, randomized, double-blind active extension study (LAQ/5063). Patients in  each  of  the  treatment  arms  continued their  original  dosing  regimen,  while  placebo  treated  patients  were  randomized to  either  laquinimod  0.3  mg  or  0.6  mg  daily  for  a  further  36 weeks  duration.  MRI  scans  were  performed  prior  to  and  after  36  weeks  in  the  extension.  Most patients  continued  directly  into  the  extension  after  the  original  study  ended.    Treatment  with

<div style=\"page-break-after: always\"></div>

Laquinimod 0.6 mg resulted in a higher proportion of lesion-free subjects at the end of LAQ/5062 (50% vs 46.5%). This trend was sustained for the subjects who continued on laquinimod 0.6 mg (46.7%  at  both  baseline  and  termination).  Similar  trend  was  maintained  in  the  subjects  who continued on laquinimod 0.3 mg. In its open label study, as of November 2012, 209 patients were included  and  123  were  followed-up  for  more  than  5  years.  Although  the  efficacy  findings  are considered exploratory in this open label design, the CHMP noted that the ARR and EDSS score remain  low  suggesting  a  maintenance  of  the  effect  since  the  mean  duration  of  exposure  to laquinimod 0.6 mg (core and extension and open label study) was 49.9 months.

Study LAQ-301E was an extension to the 24-month, Phase III study ALLEGRO. All patients who completed the  24-month  core  period  could  continue  in  the  extension  phase.  Patients  who  were treated with laquinimod 0.6 mg in the core study continued on the same dose of study medication in the extension study. Patients who received placebo in the core study switched to laquinimod 0.6 mg in the extension study. Of the 864 patients who completed the core study, 839 entered in the extension phase.  A total of 775 patients completed the year 4 visit, 127 patients discontinued the extension phase, 712 patients are still in the ongoing trial. At the end of the core study, the ARR was 0.305 in the 0.6 mg laquinimod treated group and 0.391 in the placebo group. At Month 48, cumulative ARR for the laquinimod 0.6 mg/laquinimod 0.6 mg was 0.262 compared 0.326 for the placebo/laquinimod 0.6 mg group. The results indicate that patients who started laquinimod earlier show less relapses than those who started later. At Month 48, mean EDSS for the total population was 2.6 ±2.5 and then remained stable. At the end of the core study there was a progression of EDSS sustained for 6 months in 6% of patients on laquinimod as compared to 10.8% of patients of the  placebo  group.  At  Month  48,  18%  of  patients  in  placebo/laquinimod  0.6mg  group  had confirmed disease progression as compared to 13.8% in the laquinimod 0.6 mg/laquinimod 0.6 mg group. Patients who started earlier laquinimod treatment had less disability progression than those started later. No conclusions on long term effect on the MRI parameters could be drawn due to small number of patients who consented to continue with MRI follow-up during the extension study (166 in total).

Study LAQ-302E was an extension to the 24-month Phase III study LAQ-302 (BRAVO). All patients who  completed  the  24-month  core  period  on  study  treatment  could  continue  in  the  extension phase. Patients who were randomized to laquinimod 0.6 mg continued to the same dose in the extension  study  and  patients  randomized  to  placebo  or  Avonex  in  the  core  study  switched  to laquinimod 0.6 mg. One thousand and ninety (1,090) patients completed the core study and 1,047 entered  the  extension  phase.  Taking  into  account  the  small  number  of  patients  who  have completed the Month 48 (only 17), the available results should be interpreted with caution. At the end of the core study, ARR was 0.297 in the laquinimod group and 0.354 in the placebo group. At Month  48,  the  cumulative  ARR  for  the  laquinimod/laquinimod  group  was  0.280  as  compared  to 0.325  for  the  Placebo/laquinimod  group.    For  patients  treated  with  Avonex  in  the  core  study, cumulative ARR was also lower at the end of 2 years (0.269) compared to subjects treated with placebo.  After  switching  from  Avonex  to  laquinimod,  there  was  no  worsening  in  ARR  and  the difference achieved with Avonex during the core study was maintained under laquinimod. At Month 48,  the  cumulative  ARR  for  the  Avonex/laquinimod  group  was  0.269.  Regarding  disability progression, the too small number of patients at Month 48 does not allow to have interpretable results.  Results  at  Month  36  (813  patients)  showed  that  87%  of  patients  did  not  experience confirmed 6-month disability progression.

Overall, the supportive studies suggested maintenance of the effect of laquinimod during long-term treatment regarding ARR and disability progression.

Data after discontinuation of treatment at the end of study LAQ5062 and its extension LAQ5063 were available to evaluate the possible rebound effect. In study LAQ/5062, patients were treated

<div style=\"page-break-after: always\"></div>

with  either  laquinimod  0.3  mg,  laquinimod  0.6  mg  or  placebo  for  36  weeks  and  were  originally planned to immediately continue to an active extension of the study. However, a possible effect of laquinimod  withdrawal  on  MRI  activity  (Gd-enhanced  T1  lesions  and  new  T2  lesions)  could  be examined  in  some  patients  due  to  the  fact  that,  for  some  logistical  reasons  (according  to  the applicant), they had to wait without treatment before enrolling in the extension study. Of the 257 patients who enrolled in the extension study, 86 had a gap of at least 15 days (30 in 0.6 mg group, 29 in 0.3 mg group and 27 in placebo group); 77 of them (26 in 0.6 mg group, 26 in 0.3 mg group and 25 in placebo group) had a MRI scan before or shortly after the beginning of the extension study, providing data on rebound effect. However, only 30 patients treated with 0.6 mg had a gap of at least 15 days between the end of study LAQ/5062 and the beginning of treatment in study LAQ/5063. Patients of the three groups (0.6 mg, 0.3 mg and placebo) were classified as suspected or  not  suspected  of  having  a  post-withdrawal  effect  according  to  the  95th  percentile  of  their individual Poisson distribution for the number of Gd-enhancing lesions. The individual means of the Poisson distribution were estimated using three different calculations: 1) all MRI scans during study LAQ/5062,  2)  LAQ/5062  Post-baseline  MRI  scans,  3)  LAQ/5062  pre-treatment  MRI  scans. Irrespective  of  the  calculation  used,  the  percentage  of  patients  suspected  of  having  a  rebound effect was systematically higher in the laquinimod 0.6 mg group than in the laquinimod 0.3 mg and placebo  groups.  The  percentages  were  similar  in  the  laquinimod  0.3  mg  and  placebo  groups. However, the CHMP noted that the difference between laquinimod 0.6 mg and placebo was derived from a difference of only a few cases between the two groups. There was no correlation between the  lesion  difference  (difference  between  the  post-withdrawal  number  of  gadolinium  (Gd)enhancing T1 lesions and the mean number at pre-treatment) and the gap length. Therefore, these data were considered not conclusive of a rebound effect based on the number of Gd-enhancing T1 lesions. No statistically significant difference between the three groups was observed regarding the number and volume of new T2 lesions and no obvious difference between the three groups was seen  regarding  the  number  of  relapses.  Taking  into  account  the  long  terminal  half-life  of laquinimod (approximatively 80 hours), the duration of action of laquinimod and the kinetics of MRI activity in MS, it seems uncertain that the duration of discontinuation of laquinimod treatment is long enough to ascertain a potential rebound effect.

## 2.5.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The  clinical  development  programme  consisted  of  2  phase  II  placebo  controlled  studies  (study 01506203 and LAQ/5062) and 2 phase III studies, one placebo controlled study (LAQ-301, also called  ALLEGRO)  and  one  placebo  and  active  controlled  (study  LAQ-302,  also  called  BRAVO). However the  latter  study  including  the  active  comparator  (interferon-beta  1a:  Avonex)  was  not designed for a comparison of treatment effects between laquinimod and Avonex. In addition, data from extension studies were provided with a cut-off date of November 2012 since some of them were still ongoing.

The  duration  of  the  phase  II  and  III  studies  (6-9  months  and  2  years,  respectively)  were considered adequate by the CHMP.

All studies were multicentre and multinational and included patients with relapsing-remitting MS. Phase II  study  010506203  also  included  SPMS  patients  (15.3%)  and  used  triple  Gd  dose  which restricts the comparability of results with the other three studies. Diagnosis of MS was based on the  McDonald  criteria.  Inclusion  and  exclusion  criteria  for  the  pivotal  studies  (ALLEGRO  and BRAVO) were closely similar to the exception that the duration of the disease in BRAVO study was not limited to at least 6 months and all subjects with previous use of interferons were excluded

<div style=\"page-break-after: always\"></div>

from the study. These criteria may have contributed to the longer MS disease duration observed in subjects enrolled into ALLEGRO study. The time from first MS symptom was at least 8.6 years in ALLEGRO  study  and  6.6  years  in  BRAVO  study.  Time  from  MS  diagnosis  was  ≥5.0  years  in ALLEGRO study and ≥3.0 years in BRAVO study. Furthermore, a number of exclusion criteria were added to these studies (thyroid disease, history of seizure disorder).

In  each individual study there were inter-group differences with respect to baseline MRI disease activity. In BRAVO, the proportion of subjects with GdE T1 lesions ≥1 at baseline was higher in the laquinimod 0.6 mg group than in the placebo group (39.6% vs. 33.4%; p =0.0548) ; mean (±SD) T2  lesions  volume  was  also  higher  in  the  laquinimod  0.6  mg  group  compared  to  placebo  (9.6 [±10.3] vs. 7.9 [±8.9]; p=0.009). The CHMP also noted that these baseline imbalances were also present in the Avonex group, the mean volume of T2 lesions was 10.4% and proportion of subjects with  T1  Gd-enhancing  lesions≥1  at  baseline  was  38.1%.  In  ALLEGRO,  mean  (±SD)  T2  lesion volume was comparable for both treatment groups (9.8 [±10.4] and 9.7 [±10.5] for laquinimod 0.6  mg  and  placebo,  respectively),  but  the  proportion  of  subjects  with  GdE  T1  lesions  ≥1  at baseline was higher for placebo as compared to the laquinimod 0.6 mg group (45.7% vs. 40.4%, respectively,  p=  0.0766)  suggesting  that  subjects  on  placebo  had  higher  disease  activity  at baseline.

The  population  of  the  two  pivotal  studies  was  representative  of  the  MS  population  (68.5%  of patients were women); 97.4% were Caucasian and the mean age was 38.1. The mean duration of the disease was 8.6 years in LAQ-301 study and 6.8 years in LAQ-302 study. In the two studies the mean number of relapses in the last year and in the last two years was similar (respectively 1.2 and 1.9). The mean EDSS score was similar (2.6) in the two studies. In the LAQ-301, more than 60% of patients were naïve of previous MS therapy and in study LAQ-302, there were more than 90% naïve patients.

Relevant efficacy  endpoints  were  selected  and  were  in  accordance  with  the  guideline  on  Clinical Investigation  of  Medicinal  Products  for  the  Treatment  of  Multiple  Sclerosis  or  MS  Guideline (CPMP/EWP/561/98,  Rev.1).  The  primary  efficacy  endpoint  was  the  total  number  of  confirmed relapses during the treatment period as a mechanism for estimating the treatment effect on annual relapse rate in both studies. Furthermore, the CHMP noted that both studies included in addition to disability progression endpoints, different MRI endpoints related to clinical activity, and for some to long term clinical outcome (cumulative numbers of Gd enhancing lesions, new/enlarging T2 lesions for  ALLEGRO,  brain  atrophy  measure  for  BRAVO)  as  secondary  efficacy  endpoints.  Relapse evaluation was performed in all scheduled as well as unscheduled visits as deemed necessary by the investigator/coordinator. Neurological examination was conducted at each visit. MRI scans (T1 and T2) were performed at baseline, after 12 months, after 24 months (termination) or at early discontinuation visit. Either two separate neurologists or two physicians assessed the subjects. An Examining Neurologist/Physician assessed the subject's neurological status, unaware of subject's well-being and a Treating Neurologist/Physician decided whether a subject experienced a relapse and prescribed steroids or other concomitant medications as needed. In order to maintain reliable evaluation and reduce the potential for bias, the examining neurologist/physician was the only one to  evaluate the  subject  neurologically  and  the  examining  neurologist/Physician  had  no  access  to the subject's file, including previous neurostatus forms and adverse events (AEs).

A confirmed progression of EDSS was defined as a 1 point increase from baseline on EDSS score if baseline EDSS was between 0 and 5.0, or a 0.5 point increase if baseline EDSS was 5.5, confirmed 3 months later. Hence, the six-month sustained disability progression endpoint, as recommended in the MS GL (CPMP/EWP/561/98, Rev.1) was evaluated as a post-hoc analysis.

The statistical methods used for analysis of the primary, secondary and exploratory endpoints and the  data  analysis  sets  are  generally  considered  to  be  appropriate.  Methods  were  similar  in  the

<div style=\"page-break-after: always\"></div>

ALLEGRO and the BRAVO studies, but there were differences for the type I error adjustment for the secondary endpoints and the hierarchy of the endpoints. In addition, according to the hierarchical approach taken for  the  statistical  analysis,  it  is  important  to  note  that  testing  of  the  secondary endpoints does not ensure preservation of the overall type-I error in case the primary endpoint does not meet statistical significance , such as in the case of the BRAVO study. According to the applicant, the borderline p value observed for the primary endpoint in the BRAVO study is partly due to the lack of power in addition to the observed imbalances across group (described further below).    From  the  CHMP  viewpoint,  no  pre-specified  blinded  sample  size  reassessment  was included in the study protocol, which might have addressed this issue. This study focused more on brain atrophy and EDSS  based  disease progression to confirm the applicant's claim on neuroprotective properties of the active substance.

For the model based analyses of the primary endpoints pre-tests for the adequacy of the models were  performed.  The  predefined  set  of  sensitivity  analyses  is  considered  appropriate.  The sensitivity analyses demonstrate that the results of the primary analyses can be considered robust.

## Efficacy data and additional analyses

## Dosing rationale

Although the CHMP supported the choice of 0.6 mg dose for the phase III studies based on the overall findings observed in preclinical and clinical dose ranging studies, the CHMP considered that the optimal dose had not been defined because 0.6 mg dose was the sole dose tested in the phase III  studies.  According  to  the  applicant,  preliminary  findings  from  ascending  dose  evaluation  in healthy volunteers and MS patients (study 99506202) identified 1.2 mg dose of laquinimod as not being the optimal dose due to the applied stopping criteria, although these were based on predefined, laboratory-related threshold stopping criteria (increased CRP and fibrinogen levels) rather than clinical criteria. At the present time, the applicant however considered this study as a failed maximum tolerated dose (MTD) study and planned to investigate higher dose (1.2 mg) in RRMS patients as well as in other patient populations. In the absence of data using higher doses than 0.6 mg,  the  CHMP  concluded  that  the  dose  response  effect  of  laquinimod  has  not  been  sufficiently evaluated to determine the optimal dose in the intended population.

## Effect on relapses

In ALLEGRO study, a statistically significant effect of laquinimod 0.6 mg compared to placebo was demonstrated for the annualised relapse rate (p=0.0024). Whilst this result was consistent with other efficacy endpoints related to relapses and supported by sensitivity analyses, the reduction in ARR for laquinimod over placebo was modest, 23% over 24 months (RR= 0.770, 95% CI: 0.650, 0.911). In BRAVO study including an active comparator (Avonex), laquinimod 0.6 mg dose failed to show  a  statistically  significant  effect  as  compared  to  placebo  on  the  ARR  (RR=0.823,  95%  CI: 0.664, 1.020, p=0.0746) reflecting a reduction of ARR of 17.7%. In contrast, the comparison of the  Avonex  treatment  arm  with  placebo  yielded  a  risk  ratio  of  0.741  (95%  CI:  0.596;  0.920, p=0.0067), demonstrating a 25.9% reduction in the annualized relapse rate.

Whereas BRAVO study was not designed for a direct comparison between laquinimod and Avonex, the applicant conducted a post-hoc exploratory comparison of the ARR of laquinimod 0.6mg and Avonex to further analyse the relative efficacy of laquinimod on ARR. This analysis yielded a risk ratio  of  1.102  (with  a  difference  of  0.03  relapses  a  year)  seemingly  rejecting  the  apparent superiority of Avonex over laquinimod (95%CI - 0.883-1.376, p=0.3887) However the CHMP did not consider such analysis as sufficient to conclude on the relative efficacy of laquinimod versus

<div style=\"page-break-after: always\"></div>

Avonex and relied upon the pre-specified sensitivity analyses that were consistent with the primary analysis.

Due to the imbalances observed at baseline for mean T2 lesions volume and proportion of subjects with  GdE  T1  lesions  ≥1  across  treatment  groups,  additional  post-hoc  analyses  were  performed using these MRI parameters as covariates in a corrected model. Such corrected analysis resulted in an increase in magnitude of effect of laquinimod 0.6 mg compared to placebo on ARR (RR=0.787, 95% CI: 0.637, 0.972, p=0.0264) of statistical significance. However this corrected result was still suggesting  a  modest  reduction  in  ARR  of  21.3%  in  patients  treated  with  laquinimod  0.6  mg  in BRAVO  study.  Importantly,  whilst  these  baseline  imbalances  were  also  present  in  the  Avonex group,  treatment  effect  of  Avonex  over  placebo  was  statistically  significant  (p=0.0067)  in  the primary model due to an observed larger treatment effect size of 25.9% reduction in the ARR (RR= 0.741,  95%  CI:  0.596,  0.920).  Numerically,  the  results  on  ARR  were  in  favour  of  Avonex  as compared to laquinimod.  In addition, laquinimod failed to show statistical significance over placebo on  the  time  to  first  relapse  (HR:  0.813,  95%  CI:0.653,  1.014);  p=0.0659),  questioning  the sensitivity of the results observed for the ARR, after the baseline corrected analysis.

An  additional  post-hoc analysis  employing  propensity  score  also  revealed  the  overall  bias introduced in the predefined primary analysis. The results of this analysis showed that when the primary  analysis  model  was  adjusted  for  the  continuous  propensity  score,  laquinimod  0.6  mg reduced  the  risk  for  relapses  by  23.1%  compared  to  placebo  (risk  ratio=0.769,  nominal  pvalue=0.026).  Similarly,  when  the  primary  analysis  model  was  adjusted  for  the  categorical propensity score, laquinimod 0.6 mg reduced the risk for relapses by 22.4% compared to placebo (risk ratio=0.776, nominal p value= 0.0315).

In a meta-analysis including the 2 pivotal studies and the phase II study LAQ/5062,  an effect of laquinimod on ARR  was  demonstrated suggesting a 21% reduction for laquinimod versus placebo (RR=0.79, 95% CI : 0.69,0.89, p=0.0002). This result was consistent with the initially submitted pooled analysis of the two pivotal studies (reduction of 21.4% in ARR, p=0.0005) and is considered modest.

## Effect on disability progression

ALLEGRO  study  showed  also  that  laquinimod  delayed  the  time  to  3-month  confirmed  disability progression, with a statistically significant reduction of 36% over placebo (HR= 0.641; 95% CI: 0.452,  0.908;  p=0.0122).  BRAVO  study  failed  to  demonstrate  such  effect  with  a  lower  risk reduction  of  31.3%  over  placebo  (HR=0.687,  95%  CI:  0.462,  1,020;  p=0.0628).  However,  the CHMP  noted  that  results  on  disability  progression  were  numerically  in  favour  of  laquinimod  as compared  to  Avonex,  although  the  95%  CIs  for  each  of  the  outcomes  were  overlapping.  In addition,  results  from  the  pooled  analysis  using  both  pivotal  studies,  demonstrated  a  34% reduction  in  the  risk  for  3-month  confirmed  disease  progression  (HR  =  0.66,  p=0.002).  When adding the data from the phase II study LAQ/5062 in this pooled analysis, the effect on disability remain with a reduction of around 32% in the risk of disability progression confirmed at 3 months, although the CHMP noted that study LAQ/5062 on its own failed to show an effect on disability (HR= 1.12, 95%CI: 0.33, 3.74). A 44% reduction of disability progression confirmed at 6-months was also observed based on post-hoc analysis of pooled data provided by the applicant from both pivotal  studies,  data  from  study  LAQ/5062  was  not  included  in  this  analysis  due  to  its  short duration.

In both studies, results on MSFC score were not consistent with the EDSS score as there was no difference between treatment groups at month 24 on this disability progression related endpoint.

In the corrected analysis, results on disability progression were comparable across pivotal studies.

<div style=\"page-break-after: always\"></div>

## Effect on MRI parameters

In  ALLEGRO  study,  there  was  a  statistically  significant  effect  of  laquinimod  on  mean  adjusted number  of  T1  Gd-enhancing  lesions  (RR=0.629,95%  CI:  0.488,  0.809,  p=0.0003)  showing  a reduction of 37% in the mean rate of developing T1 Gd-enhancing lesions on laquinimod 0.6 mg compared to placebo. A statistically significant treatment effect of laquinimod 0.6 mg over placebo was also shown on the cumulative number of New/Enlarging T2 lesions (RR=0.704,95% CI: 0.584, 0.849, p=0.0002) indicating a reduction of 30% in the mean rate of developing New/Enlarging T2 lesions on laquinimod 0.6 mg compared to placebo.

In BRAVO study, statistically significant effects of laquinimod over placebo were demonstrated on brain atrophy from baseline to month 24 (adjusted mean difference=0.284, 95%CI: 0.139, 0.429; p=0.0001).A favourable effect of laquinimod 0.6 mg over placebo was observed for the reduction of  enhancing T1 lesions at Month 24 (RR= 0.611, 95% CI: 0.439, 0.852, p=0.0037) but not at Month 12 (RR= 0.884, 95% CI: 0.658, 1.186, p=0.4099). There was a reduction in the mean rate of  development  of  cumulative  number  of  T1  Gd-enhancing  lesions  on  laquinimod  0.6  mg  over placebo but this was not statistically significant (RR= 0.785, 95% CI: 0.604, 1.019, p=0.0691). In contrast, Avonex showed a reduction versus placebo in the number of enhancing T1 lesions at both Month  12  and  Month  24  measurements  (respectively,  RR=  0.410,  95%  CI:  0.299,  0.562, p&lt;0.0001 and RR=0.336, 95% CI: 0.237, 0.474, p&lt;0.0001) as well as for the cumulative lesion counts  for  Months  12  and  24  and  this  was  statistically  significant  (RR=  0.385,  95%  CI:  0.239, 0.505,  p&lt;0.0001).  An  effect  of  laquinimod  0.6  mg  versus  placebo  was  seen  for  reduction  of new/newly enlarging T2 lesions at Month 12 (RR= 0.813, 95% CI: 0.664, 0.996, p=0.0462). As compared to placebo, Avonex reduced the new T2 lesions at Months 12 and 24 (RR= 0.491, 95% CI:  0.400,  0.602,  p&lt;0.001).  No  differences  between  laquinimod  0.6  mg  and  placebo  were observed for T2 lesions volume, either at Month 12 or Month 24 (respectively mean ratio= 0.996, 95% CI: 0.925, 1.071, p=0.9053 and mean ratio= 1.005, 95% CI: 0.930, 1.085, p=0.9019). A statistically  significant  effect  for  Avonex  over  placebo  was  seen  for  both  endpoints  (respectively p=0.0019 and p=0.0104). No differences between laquinimod 0.6 mg and placebo were observed for  T1  hypointense  lesions  volume,  either  at  Month  12  or  Month  24;  there  was  no  difference between the Avonex and placebo groups for either endpoint.

Laquinimod 0.6 mg demonstrated a reduction in brain atrophy over placebo from baseline to Month 12 (adjusted mean difference=0.221, 95% CI: 0.125, 0.317, p&lt;0.001), whereas no appreciable difference  between  the  two  groups  was  shown  between  Months  12  to  24  (adjusted  mean difference=0.033, 95% CI: -0.062, 0.127, p=0.4972). No treatment effects on reduction in brain atrophy were seen for Avonex over placebo for either measurement period  (Month 12: adjusted mean  difference=-0.134,  95%  CI:  -0.229,-0.040,  p=0.0053  and  Month  24:  adjusted  mean difference=0.018 , 95% CI: -0.074, 0.111, p=0.6975, respectively).

In  the  corrected  analysis  performed  due  to  the  imbalances  observed  at  baseline  for  mean  T2 lesions volume and proportion of subjects with GdE T1 lesions ≥1 across treatment groups, results on brain atrophy were comparable across pivotal studies.

In the meta-analysis using the two pivotal studies ALLEGRO and BRAVO, and the phase IIb study LAQ/5062, a treatment effect on GdE T1 lesions was observed with a rate ratio of 0.68 suggesting a reduction of 32% as compared to placebo. This effect was statistically significant (p&lt;0.00001). The  effect  on  new  T2  lesions  was  also  statistically  significant  with  a  reduction  of  27%  versus placebo (Rate Ratio of 0.73, p&lt;0.00001). Regarding brain atrophy, the effect of laquinimod was statistically  significant  as  compared  to  placebo  (difference  of  0.31  in  %  brain  volume  change, p&lt;0.00001).

<div style=\"page-break-after: always\"></div>

## Indirect comparison with other MS treatments

An indirect comparison between the point estimates of ARR with laquinimod and interferon beta and glatiramer show that, although the 95% CI are overlapping, the effect of laquinimod is modest (see  Figure  10).  The  CHMP  considered  that  other  drugs  (i.e.  Tysabri,  Gilenya)  have  shown substantially larger effects. According to the applicant, the magnitude on the disability effect is only matched by potent immunosuppressive DMTs, mediated by their effect on relapses. However, the presented  data  on  the  effect  on  3-month  disability  progression  suggested  a  similar  effect  as compared to Avonex (see Figure 11).

## Long-term efficacy and withdrawal after discontinuation

Data from 3 extension studies were initially submitted (studies LAQ/5063, LAQ-301 and LAQ-302). At  the  CHMP  request,  the  applicant  also  provided  data  from  the  ongoing  open  label  study  of LAQ/5063  which  is  a  completed  double  blind  active  extension  study.  The  cut-off  date  for  all ongoing studies was November 2012.

Although  the  efficacy  findings  are  considered  exploratory  in  study  LAQ/5063  (open  label),  the CHMP noted that the ARR and EDSS score remain low suggesting a maintenance of the effect since the mean duration of exposure to laquinimod 0.6 mg (core and extension and open label study) was 49.9 months.

In study LAQ-301E, results indicate that patients who started laquinimod earlier show less relapses than those who started later. At Month 48, mean EDSS for the total population was 2.6 ±2.5 and then remained stable. At the end of the core study there was a progression of EDSS sustained for 6 months in 6% of patients on laquinimod as compared to 10.8% of patients of the placebo group. At Month 48, 18% of patients in placebo/laquinimod 0.6mg group had confirmed disease progression as compared to 13.8% in the laquinimod 0.6 mg/laquinimod 0.6 mg group. Patients who started earlier laquinimod treatment had less disability progression than those started later. No conclusions on long term effect on the MRI parameters could be drawn due to small number of patients who consented to continue with MRI follow-up during the extension study (166 in total).

In study LAQ-302E, a small number of patients completed the Month 48 (only 17), and available results  should  be  interpreted  with  caution.  At  the  end  of  the  core  study,  ARR  was  0.297  in  the laquinimod  group  and  0.354  in  the  placebo  group.  At  Month  48,  the  cumulative  ARR  for  the laquinimod/laquinimod group was 0.280 as compared to 0.325 for the Placebo/laquinimod group. For patients treated with Avonex in the core study, cumulative ARR was also lower at the end of 2 years  (0.269)  compared  to  subjects  treated  with  placebo.  After  switching  from  Avonex  to laquinimod, there was no worsening in ARR and the difference achieved with Avonex during the core  study  was  maintained  under  laquinimod.  At  Month  48,  the  cumulative  ARR  for  the Avonex/laquinimod  group  was  0.269.  Regarding  disability  progression,  the  too  small  number  of patients at Month 48 does not allow to have results. Results at Month 36 (813 patients) showed that 87% of patients did not experience confirmed 6-month disability progression.

Overall, the supportive studies suggested maintenance of the effect of laquinimod during long term treatment regarding ARR and disability progression.

In  study  LAQ5062  and  its  extension  LAQ5063,  irrespective  of  the  calculation  method  used,  the percentage  of  patients  suspected  of  having  a  rebound  effect  was  systematically  higher  in  the laquinimod 0.6 mg group than in the laquinimod 0.3 mg and placebo groups. The percentages were similar in the laquinimod 0.3 mg and placebo groups. However, the CHMP noted that the difference between laquinimod 0.6 mg and placebo was derived from a difference of only a few cases between the  two  groups.  There  was  no  correlation  between the  lesion  difference  (difference  between  the post-withdrawal number of Gd-enhancing T1 lesions and the mean number at pre-treatment) and

<div style=\"page-break-after: always\"></div>

the gap length. Therefore, these data were considered not conclusive of a rebound effect based on the  number of Gd-enhancing T1 lesions. No statistically significant difference  between the three groups  was  observed  regarding  the  number  and  volume  of  new  T2  lesions  and  no  obvious difference  between  the  three  groups  was  seen  regarding  the  number  of  relapses.  Taking  into account the long terminal half-life of laquinimod (approximatively 80 hours), the duration of action of  laquinimod  and  the  kinetics  of  MRI  activity  in  MS,  it  seems  uncertain  that  the  duration  of discontinuation of laquinimod treatment is long enough to ascertain a potential rebound effect.

Limited  data  after  discontinuation  of  laquinimod  treatment  are  not  suggestive  of  a  potential rebound effect, however, it cannot be excluded and remain a potential risk.

## Patients previously treated, with high disease activity

Because the BRAVO study excluded all patients with prior use of interferons and the sample size for patients  previously  treated  with  glatiramer  acetate  is  small,  data  in  patients  previously  treated were analysed based ALLEGRO study only. In this study, the effect of laquinimod 0.6 mg was twofold smaller in the subgroup with prior use of interferon than in the subgroup without prior use of interferon for ARR (13% vs 27%), brain atrophy (17.4% vs 34.6%) and time to confirmed EDSS progression-6 month (28.7% vs 58.2%). In patients previously treated with interferons, the effect of treatment for time to confirmed EDSS progression-3 month was much weaker  than in patients without  prior  use  of  interferon  ((3.5%  vs  49.4%).  The  effect  of  laquinimod  was  considered  as similar for cumulative Gd T1 lesions and new/enlarging T2 lesions in the two subgroups of patients (respectively 41.1% vs 35.7% and 28.1% vs 30.3%).In patients with prior glatiramer acetate use, there  was  no  effect  of  laquinimod  on  ARR  as  compared  to  placebo,  however  the  sample  size  is small (n=84 for laquinimod and n=89 for placebo) to conclude on this efficacy finding. For all other endpoints (disability  progression  and  MRI  parameters)  an  effect  of laquinimod  over placebo  was observed but not statistically significant and the treatment effect was similar in both patients with and without prior use of GA.

In pooled data using the pivotal studies, there was a consistent effect of laquinimod over placebo on relapses and disability progression across the subgroups of patients with more or less active disease.

## Overall discussion on the patient population

The  applicant'  s  proposal  for  a    broad  indication  in  RRMS  patients  was  maintained  at  an  Oral Explanation  held  on  17  December  2013.  Considering  the  overall  efficacy  results,  a  number  of subsets of the RRMS population that would benefit from laquinimod were identified by the applicant as follows: patients with RRMS who are treatment-naïve and have positive predictive markers for lower  disease  activity  (based  on  relapse  rate  prior  to  treatment  initiation  and  MRI  markers  of inflammatory activity); patients with RRMS who have been mostly stable on injectable therapies (interferon-beta, GA) and who are seeking non-injectable therapies; and RRMS patients who have shown  disease  progression  largely  independent  of  relapses.  These  subsets  have  been  mainly identified according to the applicant's claim that laquinimod has a more pronounced effect on the degenerative  process  of  the  disease  than  on  its  anti-inflammatory  properties.  This  claim  is supported  by  the  efficacy  data  showing  a  more  pronounced  effect  of  laquinimod  on  disability progression at 3 and 6 months in patients with a lower T2 burden of disease (52% versus 14% as suggested by the HR of 0.475 and 0.864 and 60% versus 26% as suggested by the HR of 0.395 and 0.742 after 3 and 6 months, respectively) and in patients with a lower pre-trial relapse rate (&lt; 2 in the year prior to screening) whereas the degree of baseline EDSS does not modify disease progression. Other supportive efficacy analyses were presented to support these subsets of RRMS patient  population  (see  1.8.2.3).  The  CHMP  was  however  of  the  opinion  that  these  subgroup analyses were of exploratory nature and that it was not appropriate to consider data on specific

<div style=\"page-break-after: always\"></div>

subsets of RRMS population to support a broad indication in the RRMS population, as proposed by the applicant.

Having considered the above and the overall efficacy data, the CHMP remained concerned that the efficacy  of  laquinimod  at  the  proposed  0.6  mg  dose,  was  modest  on  the  relapse  rate  in  the proposed  broad  RRMS  population,  notwithstanding  the  more  encouraging  effect  on  disability progression. The unknown mechanism of action and the rather modest effect on relapses questions the suitability of laquinimod as treatment for the broad population with relapsing remitting multiple sclerosis (RRMS) patients.

## 2.5.4. Conclusions on the clinical efficacy

The CHMP concluded the following:

-Only  modest  efficacy  of  laquinimod  on  relapse  rate  in  adult  patients  with  relapsing remitting multiple sclerosis at the proposed 0.6mg dose has been shown, notwithstanding the more encouraging effect on the disability progression.

## 2.6. Clinical safety

The safety database presented in this dossier included the following cohorts: 1) phase III studies (ALLEGRO  and  BRAVO),  2)  all  placebo-controlled  studies  (99506202,  01506203,  LAQ/5062, ALLEGRO,  BRAVO,  and  MS-LAQ-101),  3)  all  MS  studies  (99506202,  01506203,  03506207, LAQ/5062, LAQ/5063, LAQ/5063OL, ALLEGRO, MS-LAQ-301E, BRAVO, MS-LAQ-302E, and MS-LAQ101)  and  4)  MS  studies  with  patients  exposed  to  laquinimod  0.6  mg  for  at  least  one  year (LAQ/5062, LAQ/5063, LAQ/5063OL, ALLEGRO, MS-LAQ- 301E, BRAVO and MS-LAQ-302E).

In  addition  to  these  data,  safety  experience  in  non-MS  studies  ie,  patients  with  Crohn's  disease (CD-LAQ-201) and systemic lupus erythematosus (SLE, studies LN-LAQ-201 and LA-LAQ-202) was provided. During the evaluation, the applicant also provided another cohort 'cohort 5' with a cutoff date of November 2012 to provide further long term safety data with laquinimod.

## 2.6.1. Patient exposure

As  of  March  2012,  2,632  subjects  with  MS  were  exposed  to  laquinimod  for  a  total  duration  of approximately 4,920 subject-years and 321 volunteers (healthy volunteers and special populations) received various doses of laquinimod in several Phase I studies for a total duration of 6.4 subject-years.  A total of 1,456 MS patients were exposed to laquinimod 0.6 mg for at least one year and the mean exposure to study drug was 2.6± 1.2 years in cohort 4. A total of 2,346 subjects (89.1%) were exposed to the proposed therapeutic daily dose of 0.6 mg.

As of November 2012, a total of 1,009 MS patients who participated in clinical were included in cohort  5  and  were  exposed  to  laquinimod  0.6  mg  for  3683.0  subject-years.  Mean  exposure  to study drug was 3.7 ± 1.0 years. In total, 74.3% (750) of subjects in this long-term cohort were exposed for more than 3 years and 19.2% of subjects (194 subjects) were exposed for more than 4 years.

To date, the maximal duration of exposure to laquinimod was observed in open label extension study LAQ5063OL and is approximately 7 years.

<div style=\"page-break-after: always\"></div>

## 2.6.2. Adverse events

The  AE  profile  for  cohort  1  is  considered  representative  of  the  safety  profile  of  laquinimod  and included the 2 pivotal studies, ALLEGRO and BRAVO.

In cohort 1, the incidence of adverse events was the highest in the system organ class (SOC) of Infections and Infestations and comparable between two groups, laquinimod and placebo (48.7% vs 47%). The incidence of AEs was higher in the group laquinimod for SOC Musculoskeletal and Connective  Tissue  Disorders  (30.4%  vs  25.4%),  SOC  Investigations  (27%  vs  20.8%),  SOC gastrointestinal  or  GI  disorders  (26.9%vs  22.6%),  SOC  Metabolism  disorders  (5.3%  vs  2.9%), Neoplasm (4.6% vs 2.7%) compared to placebo. The common AEs are summarised in Table 19.

Table 19: Cohort  #1:  Common*  Adverse  Events  by  Descending  Order  of Incidence in the Laquinimod 0.6 mg Group

| Cohort #1: Placebo-Controlled Pivotal Studies in MS Patients Treated with Laquinimod 0.6 mg   | Placebo (N=1005)   | Placebo (N=1005)   | Placebo (N=1005)   | Laquinimod 0.6 mg (N=983)   | Laquinimod 0.6 mg (N=983)   | Laquinimod 0.6 mg (N=983)   |
|-----------------------------------------------------------------------------------------------|--------------------|--------------------|--------------------|-----------------------------|-----------------------------|-----------------------------|
|                                                                                               | No. of Reports     | No. of Subjects    | %of Subjects       | No. of Reports              | No. of Subjects             | %of Subjects                |
| Preferred Term                                                                                |                    |                    |                    |                             |                             |                             |
| Headache                                                                                      | 278                | 152                | 15.1               | 319                         | 179                         | 18.2                        |
| Nasopharyngitis                                                                               | 240                | 153                | 15.2               | 225                         | 141                         | 14.3                        |
| Back Pain                                                                                     | 121                | 82                 | 8.2                | 179                         | 134                         | 13.6                        |
| Upper Respiratory Tract Infection                                                             | 105                | 84                 | 8.4                | 102                         | 76                          | 7.7                         |
| Arthralgia                                                                                    | 73                 | 60                 | 6.0                | 89                          | 71                          | 7.2                         |
| Influenza                                                                                     | 83                 | 73                 | 7.3                | 69                          | 60                          | 6.1                         |
| Alanine Aminotransferase Increased                                                            | 28                 | 27                 | 2.7                | 72                          | 58                          | 5.9                         |
| Urinary Tract Infection                                                                       | 61                 | 42                 | 4.2                | 75                          | 56                          | 5.7                         |
| Diarrhoea                                                                                     | 55                 | 48                 | 4.8                | 60                          | 54                          | 5.5                         |
| Depression                                                                                    | 49                 | 47                 | 4.7                | 55                          | 53                          | 5.4                         |
| Insomnia                                                                                      | 62                 | 49                 | 4.9                | 61                          | 53                          | 5.4                         |
| Cough                                                                                         | 35                 | 31                 | 3.1                | 57                          | 51                          | 5.2                         |
| Nausea                                                                                        | 51                 | 44                 | 4.4                | 57                          | 50                          | 5.1                         |
| Abdominal Pain                                                                                | 26                 | 26                 | 2.6                | 54                          | 49                          | 5.0                         |
| Pain In Extremity                                                                             | 68                 | 58                 | 5.8                | 58                          | 47                          | 4.8                         |

* Common AEs: AEs reported by 5% or more of any treatment group.

A comparison of AE in ALLEGRO and BRAVO studies is presented in Table 20. When the incidence of common AEs is compared between ALLEGRO and BRAVO studies, the adverse events that are higher  in  the  laquinimod  groups  in  both  studies  are  abdominal  pain,  ALT  increased,  back  pain, arthralgia and headache.

Table 20:  Comparison of AEs in Studies ALLEGRO and BRAVO by SOC

|                                      | ALLEGRO (N=1106, Subject Years=1933.2)            | ALLEGRO (N=1106, Subject Years=1933.2)                      | BRAVO (N=1324, Subject Years=2365.4)              | BRAVO (N=1324, Subject Years=2365.4)                          | BRAVO (N=1324, Subject Years=2365.4)              |
|--------------------------------------|---------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------|
|                                      | Placebo (N=556, Subject Years=959.3) %of Subjects | Laquinimod 0.6 mg (N=550, Subject Years=973.9) %of Subjects | Placebo (N=449, Subject Years=790.2) %of Subjects | Laquinimod 0.6 mg (N=433, Subject Years=768.7 ) %of Subjects% | Avonex ® (N=442, Subject Years=806.5) of Subjects |
| System Organ Class                   |                                                   |                                                             |                                                   |                                                               |                                                   |
| -ALL                                 | 81.5                                              | 87.3                                                        | 69.7                                              | 74.8                                                          | 82.4                                              |
| Blood And Lymphatic System Disorders | 5                                                 | 7.3                                                         | 4                                                 | 5.3                                                           | 5.7                                               |

<div style=\"page-break-after: always\"></div>

| Cardiac Disorders a                                                 | 4.3   | 4.4   |   2.4 |   2.1 |   3.8 |
|---------------------------------------------------------------------|-------|-------|-------|-------|-------|
| Ear And Labyrinth Disorders                                         | 5     | 6.2   |   3.3 |   3.2 |   3.2 |
| Eye Disorders a                                                     | 6.3   | 8.5   |   4.5 |   2.5 |   2.9 |
| Gastrointestinal Disorders                                          | 26.6  | 32    |  17.6 |  20.3 |  11.3 |
| General Disorders And Administration Site Conditions                | 20.7  | 19.8  |  12.5 |  13.2 |  62.4 |
| Infections And Infestations                                         | 54.9  | 56.5  |  37.2 |  38.8 |  30.5 |
| Injury, Poisoning And Procedural                                    | 14    | 13.3  |   8.9 |   2.3 |   4.8 |
| Complications a Investigations                                      | 21.9  | 28.7  |  19.4 |  24.9 |  20.4 |
| Metabolism And Nutrition Disorders                                  | 4.3   | 6.2   |   1.1 |   4.2 |   1.8 |
| Musculoskeletal And Connective Tissue Disorders                     | 29.9  | 36.9  |  19.8 |  22.2 |  14.5 |
| Nervous System Disorders                                            | 34.2  | 36.2  |  23.4 |  21   |  21.5 |
| Psychiatric Disorders                                               | 17.6  | 18.4  |  10.7 |  12.5 |  12   |
| Renal And Urinary Disorders                                         | 5     | 7.3   |   5.1 |   4.8 |   2.3 |
| Reproductive System And Breast Disorders                            | 9.2   | 11.8  |   5.6 |   7.6 |   2.5 |
| Respiratory, Thoracic And Mediastinal Disorders                     | 17.4  | 15.5  |   6.9 |   8.5 |   6.1 |
| Skin And Subcutaneous Tissue Disorders a                            | 9.9   | 14.9  |  10   |   6.5 |   6.1 |
| Surgical And Medical Procedures a                                   | 9.4   | 9.1   |   2.9 |   4.2 |   3.4 |
| Vascular Disorders a                                                | 4.9   | 6     |   4.9 |   2.5 |   5.7 |
| Hepatobiliary Disorders                                             | 2.9   | 3.3   |   2   |   1.8 |   2.3 |
| Immune System Disorders a                                           | 2.3   | 1.8   |   1.3 |   0.9 |   0.5 |
| Neoplasms Benign, Malignant And Unspecified (Incl Cysts And Polyps) | 3.8   | 5.8   |   1.3 |   3   |   2   |
| Congenital, Familial And Genetic Disorders                          | 0.5   | .     |   0.9 |   0.2 |   0.2 |
| Endocrine Disorders                                                 | 1.3   | 0.7   |   1.1 |   1.6 |   3.4 |
| Social Circumstances a                                              | 0.2   | 0.9   |   0.4 |   0.2 |   0.2 |
| Pregnancy, Puerperium And Perinatal Conditions                      | .     | 0.2   |   0.2 |   0.5 |   0.7 |

a SOC with incidence of AEs higher in laquinimod than placebo and difference between laquinimod groups of the individual studies ≥2 fold.

In the non-MS studies, headache was the most common AE. In study CD-LAQ-201, AEs were more frequent  in  the  high-dose  laquinimod  2mg  group.  Headache  was  dose-dependent  AE  as  the incidence  was  the  highest  in  the  laquinimod  2mg  group  compared  to  less  dosed  groups.  GI disorders  (vomiting,  diarrhoea,  abdominal  pain)  were  very  frequent.  Unexpectedly,  back  pain occurred  in  less  patients  in  2mg  group  (3.4%)  compared  to  10.3%,  10%  and  13.8%  in  other groups (0.5mg, 1mg and 1.5mg); however, the number of patients by group was limited (n=29).

In healthy volunteers, headache and nasopharyngitis were the most common AEs, especially in the high dose group (2.4mg). One subject experienced asymptomatic tachycardia 6 hours after first 1.2mg dose. Even if the  event  was  considered  unlikely  related  to  study  drug,  drug  imputability cannot be excluded. Laboratory markers of inflammation (CRP, ESR, fibrinogen) have been found to  be  increased  in  6  healthy  volunteers.  These  elevations  in  ESR,  CRP  and  fibrinogen  were characterised to be large notably during laquinimod exposure at 2.4 mg/day and were reversible after stopping study drug.

<div style=\"page-break-after: always\"></div>

## 2.6.3. Serious adverse event/deaths/other significant events

## Deaths

A total of 13 deaths were reported during the clinical development programme with 9 deaths in the laquinimod groups. These are presented in table 21.

Table 21. Deaths in all MS studies

|   Age (years) | Gender   | Treatment group   | Preferred term                                                                                                   |
|---------------|----------|-------------------|------------------------------------------------------------------------------------------------------------------|
|            44 | M        | laquinimod        | Sepsis                                                                                                           |
|            33 | M        | placebo           | Accident                                                                                                         |
|            50 | M        | placebo           | Suicide                                                                                                          |
|            39 | M        | Avonex            | Cardiopulmonary failure                                                                                          |
|            46 | F        | laquinimod        | Subdural haematoma, ataxia                                                                                       |
|            29 | M        | laquinimod        | Acute coronary syndrome, diabetic ketoacidosis                                                                   |
|            29 | M        | laquinimod        | Completed suicide, depression                                                                                    |
|            45 | F        | laquinimod        | Acute leukaemia, disseminated intravascular coagulation, cerebral haemorrha                                      |
|            34 | F        | laquinimod        | Rectal cancer, large intestine perforation, colonic obstruction, infectious peritonitis, cardiopulmonary failure |
|            47 | F        | laquinimod        | Cardiac failure acute, cardiovascular insufficiency, respiratory failure                                         |
|            39 | M        | laquinimod        | Myocardial infarction                                                                                            |
|            47 | M        | laquinimod        | Ulcerated gastric adenocarcinoma, acute gastroenteritis, clostridium difficile                                   |
|            38 | F        | placebo           | Pneumonia bacterial, coma, pulmonary edema                                                                       |

Overall, among 9 deaths that occurred with laquinimod treatment, one death (completed suicide) was considered as possibly related to study drug by the investigator. It seems that long placebo period with 4 confirmed MS relapses could have led to severe depression and finally to suicide. Also the  death  accompanied  by  acute  leukaemia,  anemia,  thrombocytopenia  should  be  considered potentially  drug-related,  as  laquinimod  can  cause  hematotoxicity.  Two  sudden  deaths  were reported  due  to cardiovascular insufficiency (within 5 hours  after  taking  laquinimod)  and myocardial infarction (5 months of treatment with laquinimod). The available information for these 2 cases is insufficient to conclude on the causality of laquinimod. Indeed, in both cases, no autopsy was performed, and no ECG was done during the event. Confounding factors for ischaemic heart disease  included  overweight  for  both  cases.  In  addition,  in  one  case  the  subject  was  a  former smoking.  In one case, ECG was previously assessed during clinical trial as abnormal (no further information  was  provided)  by  investigator  but  the  abnormality  was  considered  not  clinically significant. The death occurred 3 weeks after starting the drug treatment and 5 hours after taking laquinimod.

No  deaths  were  initially  reported  in  the  non-MS  studies.  During  the  evaluation,  one  additional death due to pneumonia occurred in a SLE study.

## Serious Adverse Events

The number of SAEs was similar in cohort 1 between the laquinimod and the placebo group: 9.4% vs 8.9%. However, the number of appendicitis was significantly higher in the laquinimod group: 6 cases  vs  1  case  in  the  placebo  group.  Serious  cases  of  peritonitis  occurred  also  but  the  exact number  was  not  presented  in  cohort  1;  the  incidence  of  cellulitis  serious  AEs  was  higher  for laquinimod than for placebo however, these cases had confounding factors suggesting no evidence

<div style=\"page-break-after: always\"></div>

for an increased risk of cellulitis in subject treated with laquinimod (see Table 22). In cohort 3, in all MS patients ever exposed to laquinimod, 12 appendicitis and 6 infectious peritonitis were noted.

Table 22: Cohort #1: SAEs Reported by at Least Two Subjects in any Group by Preferred Term in Descending Order of Incidence in the Laquinimod 0.6 mg Group

| Cohort #1: Placebo- Controlled Pivotal Studies in MS Patients Treated with Laquinimod 0.6 mg   | Placebo (N=1005)   | Placebo (N=1005)   | Laquinimod 0.6 mg (N=983)   | Laquinimod 0.6 mg (N=983)   |
|------------------------------------------------------------------------------------------------|--------------------|--------------------|-----------------------------|-----------------------------|
| Cohort #1: Placebo- Controlled Pivotal Studies in MS Patients Treated with Laquinimod 0.6 mg   | No. of Subjects    | %of Subjects       | No. of Subjects             | %of Subjects                |
| Preferred Term                                                                                 |                    |                    |                             |                             |
| Appendicitis                                                                                   | 1                  | 0.1                | 6                           | 0.6                         |
| Multiple Sclerosis Relapse                                                                     | 7                  | 0.7                | 5                           | 0.5                         |
| Cellulitis                                                                                     | .                  | .                  | 3                           | 0.3                         |
| Hysterectomy                                                                                   | 6                  | 0.6                | 3                           | 0.3                         |
| Anaemia                                                                                        | .                  | .                  | 2                           | 0.2                         |
| Diarrhoea                                                                                      | .                  | .                  | 2                           | 0.2                         |
| Pyrexia                                                                                        | .                  | .                  | 2                           | 0.2                         |
| Oedema Peripheral                                                                              | .                  | .                  | 2                           | 0.2                         |
| Hypokalaemia                                                                                   | .                  | .                  | 2                           | 0.2                         |
| Osteoarthritis                                                                                 | .                  | .                  | 2                           | 0.2                         |
| Cervicobrachial Syndrome                                                                       | .                  | .                  | 2                           | 0.2                         |
| Headache                                                                                       | 1                  | 0.1                | 2                           | 0.2                         |
| Abortion Threatened                                                                            | .                  | .                  | 2                           | 0.2                         |
| Depression                                                                                     | 1                  | 0.1                | 2                           | 0.2                         |
| Cervical Dysplasia                                                                             | .                  | .                  | 2                           | 0.2                         |
| Appendicectomy                                                                                 | .                  | .                  | 2                           | 0.2                         |
| Spinal Fusion Surgery                                                                          | .                  | .                  | 2                           | 0.2                         |
| Gastritis                                                                                      | 3                  | 0.3                | 1                           | 0.1                         |
| Abdominal Pain                                                                                 | 2                  | 0.2                | 1                           | 0.1                         |
| Cholelithiasis                                                                                 | 3                  | 0.3                | 1                           | 0.1                         |
| Pneumonia                                                                                      | 3                  | 0.3                | 1                           | 0.1                         |
| Migraine                                                                                       | 2                  | 0.2                | 1                           | 0.1                         |
| Nephrolithiasis                                                                                | 2                  | 0.2                | 1                           | 0.1                         |
| Renal Colic                                                                                    | 2                  | 0.2                | 1                           | 0.1                         |
| Rehabilitation Therapy                                                                         | 3                  | 0.3                | 1                           | 0.1                         |
| Liver Disorder                                                                                 | 2                  | 0.2                | .                           | .                           |
| Hepatic Enzyme Increased                                                                       | 2                  | 0.2                | .                           | .                           |
| Intervertebral Disc Protrusion                                                                 | 2                  | 0.2                | .                           | .                           |
| Depression Suicidal                                                                            | 1                  | 0.1                | .                           | .                           |
| Endometrial Hyperplasia                                                                        | 2                  | 0.2                | .                           | .                           |
| Dyspnoea                                                                                       | 2                  | 0.2                | .                           | .                           |
| Cholecystectomy                                                                                | 2                  | 0.2                | .                           | .                           |

No  severe  cases  have  been  retrieved  with  worrying  neurological  AEs,  rapid  deterioration  of neurological conditions following infection or atypical MS exacerbation after laquinimod initiation.

Furthermore, two SAEs were reported in the laquinimod 2.4 mg group: severe constipation, and pleuritis with pleural effusion in 61 year-old male with traumatic fracture of rib on the same side. Pleural effusion persisted 6 months later. The applicant did not exclude a relationship with study drug.

## Malignant Tumours

Overall, malignant tumors have been reported in 26 patients (0.6%) treated with laquinimod in all clinical studies; 6 breast carcinomas including one metastatic breast cancer (3 in cohort 1, all in

<div style=\"page-break-after: always\"></div>

ALLEGRO and no case in BRAVO; 1 additional case of breast cancer in study LAQ/5062 have been reported  in  laquinimod  group.  One  breast  cancer  was  reported  in  placebo  group).  Data  on  the frequency and incidence of malignant tumours are presented in Table 23.

Table 23: Cohort #3: Frequency and Incidence of Malignant Tumours (SMQ) and Preferred Term

|                                                                |                                                                | Laquinimod (N=2632, Subject Years=4994.2)   | Laquinimod (N=2632, Subject Years=4994.2)   | Laquinimod (N=2632, Subject Years=4994.2)   | Laquinimod (N=2632, Subject Years=4994.2)   |
|----------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| All MS Patients Ever Exposed to Laquinimod in Clinical Studies | All MS Patients Ever Exposed to Laquinimod in Clinical Studies | No. of Reports                              | No. of Subjects                             | % of Subjects                               | Event Rate per 100 Subject Years            |
| SMQ (3)                                                        | Preferred Term                                                 |                                             |                                             |                                             |                                             |
| -ALL                                                           | -ALL                                                           | 29                                          | 26                                          | 1.0                                         | 0.6                                         |
| Malignant tumours (SMQ)                                        | -ALL                                                           | 29                                          | 26                                          | 1.0                                         | 0.6                                         |
| Malignant tumours (SMQ)                                        | Acute Leukaemia                                                | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
| Malignant tumours (SMQ)                                        | Basal Cell Carcinoma                                           | 5                                           | 4                                           | 0.2                                         | 0.1                                         |
| Malignant tumours (SMQ)                                        | Breast Cancer                                                  | 4                                           | 4                                           | 0.2                                         | 0.1                                         |
| Malignant tumours (SMQ)                                        | Breast Cancer Metastatic                                       | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
| Malignant tumours (SMQ)                                        | Breast Cancer Stage II                                         | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
| Malignant tumours (SMQ)                                        | Chronic Lymphocytic Leukaemia                                  | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
| Malignant tumours (SMQ)                                        | Colon Cancer                                                   | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
| Malignant tumours (SMQ)                                        | Gastric Cancer                                                 | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
| Malignant tumours (SMQ)                                        | Glioblastoma                                                   | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
| Malignant tumours (SMQ)                                        | Keratoacanthoma                                                | 2                                           | 2                                           | 0.1                                         | 0.0                                         |
| Malignant tumours (SMQ)                                        | Lung Neoplasm Malignant                                        | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
| Malignant tumours (SMQ)                                        | Lymphoma                                                       | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
| Malignant tumours (SMQ)                                        | Malignant Melanoma                                             | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
|                                                                | Metastases To Lung                                             | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
|                                                                | Metastatic Neoplasm                                            | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
|                                                                | Oesophageal Adenocarcinoma                                     | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
|                                                                | Rectal Cancer                                                  | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
|                                                                | Renal Cancer                                                   | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
|                                                                | Squamous Cell Carcinoma                                        | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
|                                                                | Squamous Cell Carcinoma Of Skin                                | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
|                                                                | Thyroid Cancer                                                 | 1                                           | 1                                           | 0.0                                         | 0.0                                         |

In  cohort  1,  10  (1%)  patients  in  the  laquinimod  group  vs  6  (0.6%)  patients  with  placebo experienced  a  malignant  tumour  [p=0.2944,  95%  CI  (-0.37,  1.21)].  In  addition  to  3  cases  of breast  cancer,  sporadic  cases  of  glioblastoma  (1),  lung  neoplasm  malignant  (1),  lymphoma  (1), oesophageal adenocarcinoma (1), squamous cell carcinoma (1), thyroid cancer (1) were reported.

One case of thyroid cancer has been reported in BRAVO study in a 32.5 year-old female after 189 days of laquinimod treatment. The AE was considered as moderate and not related to study drug; the subject recovered. One case of thyroid cancer occurred in Avonex group.

Concerning skin malignancy, 2 cases (basal cell carcinoma, squamous cell carcinoma) occurred in cohort 1 compared to one case (basal cell carcinoma) in the placebo group. In total, in cohort 3 (all patients treated with laquinimod), 7 subjects suffered from skin malignancies: basal cell carcinoma (4), malignant melanoma (1) and squamous cell carcinoma (2).

Comparison of malignancies incidences with Surveillance Epidemiology and End Results SEER (ageadjusted SIR=1.4; 95% CI [0.90-2.08]) and CPRD (age-adjusted SIR=1.397; 95% CI [0.97-1.95] for general population; age-adjusted SIR=1.088;  95%  CI  [0.75-1.52]  for  MS  population) databases  did  not  demonstrate  an  increase  in  malignant  tumors  with  laquinimod  therapy.  For breast cancer, incidence comparison did not demonstrate an increased risk with laquinimod therapy when  compared  to  SEER  and  General  Practice  Research  Databases  (GPRD).  According  to  the applicant,  malignant  tumours  are  not  considered  to  constitute  a  safety  signal  of  concern  at  the present time. However, from the CHMP viewpoint, the number of events to date and duration of

<div style=\"page-break-after: always\"></div>

follow-up is too limited to definitively exclude a relationship. In addition, based on available preclinical  data,  there  remain  relevant  uncertainties  on  the  potential  risk  for  malignancies.These uncertainties  currently  represent  an  important  concern  with  long  term  use  of  laquinimod  (see 1.6.6).

## Liver Safety

The events of ALT and AST increased were more important in the laquinimod group for &gt;1 and ≤ 5 x ULN elevation (see Table 24).

Table 24: Cohort # 1: Shift from Normal at Baseline to Highest Value for ALT and AST at any Time during Study

| Test Name   | Category of Abnormality               | Placebo (N=1005)   | Laquinimod 0.6 mg (N=983)   |
|-------------|---------------------------------------|--------------------|-----------------------------|
| AST (IU/l)  | Patients with Normal Test at Baseline | 977                | 950                         |
|             | >1 and ≤3 x ULN                       | 83 (8.5%)          | 159 (16.7%)                 |
|             | > 3 and ≤5 x ULN                      | 6 (0.6%)           | 9 (0.9%)                    |
|             | > 5 and ≤8 x ULN                      | 4 (0.4%)           | 1 (0.1%)                    |
|             | > 8 x ULN                             | 2 (0.2%)           | 0 (0.0%)                    |
| ALT (IU/l)  | Patients with Normal Test at Baseline | 930                | 888                         |
|             | >1 and ≤3 x ULN                       | 165 (17.7%)        | 262 (29.5%)                 |
|             | > 3 and ≤5 x ULN                      | 5 (0.5%)           | 30 (3.4%)                   |
|             | > 5 and ≤8 x ULN                      | 6 (0.6%)           | 5 (0.6%)                    |
|             | > 8 x ULN                             | 7 (0.8%)           | 5 (0.6%)                    |

The following protocols are included: MS-LAQ-301 (ALLEGRO) and MS-LAQ-302 (BRAVO)

Five patients terminated early due to AEs of elevations in liver enzymes. No Hy's law cases or liver failure  have  been  reported.  None  of  ALT/AST  increases  were  accompanied  by  bilirubin  elevation &gt;2x ULN. In both treatment groups, the vast majority of subjects had a baseline bilirubin grade 0 ([93.2%] placebo; [92.9%] laquinimod). Of subjects with normal bilirubin values at baseline, the majority during the course of the study still had normal values, less in the placebo group (93.5% vs.  98.9%,  placebo  vs.  laquinimod).  During  the  course  of  the  study  no  patient  in  both  of  the treatment groups had a bilirubin increase grade 4. Grade 3 increase of bilirubin occurred in one patient in the laquinimod group (at baseline this patient already had a bilirubin grade 2 increase) and none in the placebo group.

Analysis using common toxicity criteria or CTCAE (common terminology criteria for AEs) suggested that laquinimod treatment was associated with elevations from normal to Grade 1 for AST, ALT, GGT and normal to grade 1 and 2 (up to 5xULN) for ALT and gamma glutamyl transferase (GGT). Shifts to grade 3 and 4 were uncommon and reported with a similar incidence in the placebo and laquinimod  groups,  apart  from  GGT  increase  grade  3  which  was  slightly  more  frequent  in  the laquinimod group.

Mostly  mild,  asymptomatic  liver  enzyme  elevations  (AST,  ALT  and  GGT)  were  reported  and generally  occurred  within  6  months  after  initiation  of  treatment.  Overall  in  the  pivotal  placebocontrolled  trials,  4.7%  of  laquinimod  treated  subjects  reached  relevantly  significant  [&gt;  3xULN] levels of ALT. ALT increase was the event that was more notable for male than for female (11.6% vs  3.3%)  in  the  laquinimod  0.6  mg  group.    Laquinimod-treated  subjects  with  elevated  liver parameters while on study-drug returned to baseline under continued treatment within a mean of up to 4 months, partially similar to placebo patients.  ALT elevations persisted for a longer period compared to AST elevations: In the laquinimod-group AST &gt;1 and ≤3x ULN maximally persisted for 209 days and AST &gt;3 and ≤5x ULN maximally persisted for 122 days. Whereas ALT &gt;1 and ≤3x ULN maximally persisted for 448 days, ALT &gt;3 and ≤5x ULN for 149 days and ALT &gt;5 and

<div style=\"page-break-after: always\"></div>

≤8x ULN maximally persisted for 204 days. In 74% of subjects who had elevated levels of ALT on laquinimod, ALT decreased to within the normal range while on laquinimod.

The incidence of drug-related hepatic disorders was similar between laquinimod and Avonex groups (9.9%  vs 8.4%).  The incidence of post-baseline shift changes  from low/normal to high AST/ALT/GGT levels was comparable between laquinimod and Avonex groups.

In cohort 1, more drug-related hepatic disorders were reported among laquinimod-treated subjects (11.2% vs 6.4%) compared to placebo. Analysis of liver- related AEs did not reveal any signal in addition to the laboratory findings.

## Back/Neck Pain

Data are presented in Tables 25 and 26.

Table 25: Cohort #1: Incidence of Grouped Term Back/Neck Pain

|                             | Placebo (N=1005)   | Placebo (N=1005)   | Laquinimod 0.6 mg (N=983)   | Laquinimod 0.6 mg (N=983)   | Difference   | p-value 95% CI Laquinimod 0.6 vs   |
|-----------------------------|--------------------|--------------------|-----------------------------|-----------------------------|--------------|------------------------------------|
|                             | No. of Subjects    | %of Subjects       | No. of Subjects             | %of Subjects                |              | Placebo                            |
| Drug related back/neck pain | 92                 | 9.2                | 144                         | 14.6                        | 5.4%         | 0.0002 [0.0265, 0.0833]            |

## Table 26:

Cohort #1: Grouped Term Back/Neck Pain by Outcome

| Outcomes            | Placebo Subjects with back/neck pain=92   | Laquinimod 0.6 mg Subjects with back/neck pain =144   |
|---------------------|-------------------------------------------|-------------------------------------------------------|
| Not recovered n (%) | 27 (29.3%)                                | 47 (32.6%)                                            |
| Recovered n (%)     | 68 (73.9%)                                | 105 (72.9%)                                           |
| Sequelae n (%)      | 3 (3.3%)                                  | 1 (0.7%)                                              |

More  subjects  experienced  back/neck  pain  in  the  laquinimod  group  compared  to  placebo:  114 (14.6%)  vs  92  (9.2%).  Among  144  subjects  with  back/neck  pain,  44  (32.6%)  subjects  did  not recover in cohort 1 compared to 29.3% in placebo group. Similar number of events was severe in both  groups:  4.9%  vs  5.4%.  One  subject  had  sequelae  in  laquinimod  group  and  3  subjects  in placebo group. In patients reporting back pain a slightly higher percentage (4.4% vs. 2.2%) had both elevated CRP and fibrinogen at the same time.

In addition, a higher frequency of back and neck pain was reported in the laquinimod group in the first months of treatment. After 3 months of laquinimod treatment, use of anti-inflammatory and anti-rheumatic  medications  was  similar  in  the  laquinimod  and  placebo  groups.  However  some peaks in the use of these drugs occur again at 9 and 15 months of treatment by laquinimod that seems to be correlated to increases in musculoskeletal AEs in the laquinimod group between 9 and 18 months of treatment, whereas a decrease was observed between 6 and 9 months.

When compared to Avonex group, the incidence of back/neck pain was significantly higher in the laquinimod group: 10.2% (44 subjects) vs 3.4% (15 subjects).

In cohort 1, three serious AEs of back pain have been reported in the laquinimod group and none in the placebo group. All subjects recovered, 2 with symptomatic treatment and one with invasive fixing treatment at L5-S1. In addition, in cohort 5, back pain continued to be commonly reported with laquinimod (8.9 reports/100 subjects/year), supporting an effect not limited to the first weeks of treatment.

## Infections

<div style=\"page-break-after: always\"></div>

Data are presented in Table 27.

Table 27: Cohort #1: AEs with SOC Infections and Infestations Reported by at Least 1% of Subjects in Any Group by Preferred Term and Descending Order of Incidence in the Laquinimod 0.6 mg Group

| Cohort #1: Placebo-Controlled Pivotal Studies in MS Patients Treated with Laquinimod 0.6 mg   | Placebo (N=1005)   | Placebo (N=1005)   | Placebo (N=1005)   | Laquinimod 0.6 mg (N=983)   | Laquinimod 0.6 mg (N=983)   | Laquinimod 0.6 mg (N=983)   |
|-----------------------------------------------------------------------------------------------|--------------------|--------------------|--------------------|-----------------------------|-----------------------------|-----------------------------|
| Preferred Term                                                                                | No. of Reports     | No. of Subjects    | %of Subjects       | No. of Reports              | No. of Subjects             | %of Subjects                |
| Nasopharyngitis                                                                               | 240                | 153                | 15.2               | 225                         | 141                         | 14.3                        |
| Upper Respiratory Tract Infection                                                             | 105                | 84                 | 8.4                | 102                         | 76                          | 7.7                         |
| Influenza                                                                                     | 83                 | 73                 | 7.3                | 69                          | 60                          | 6.1                         |
| Urinary Tract Infection                                                                       | 61                 | 42                 | 4.2                | 75                          | 56                          | 5.7                         |
| Sinusitis                                                                                     | 50                 | 36                 | 3.6                | 53                          | 42                          | 4.3                         |
| Bronchitis                                                                                    | 39                 | 32                 | 3.2                | 39                          | 34                          | 3.5                         |
| Cystitis                                                                                      | 21                 | 18                 | 1.8                | 28                          | 25                          | 2.5                         |
| Rhinitis                                                                                      | 26                 | 20                 | 2                  | 24                          | 20                          | 2                           |
| Gastroenteritis                                                                               | 10                 | 10                 | 1                  | 19                          | 17                          | 1.7                         |
| Pharyngitis                                                                                   | 43                 | 35                 | 3.5                | 20                          | 17                          | 1.7                         |
| Oral Herpes                                                                                   | 32                 | 22                 | 2.2                | 18                          | 17                          | 1.7                         |
| Respiratory Tract Infection                                                                   | 19                 | 14                 | 1.4                | 19                          | 16                          | 1.6                         |
| Respiratory Tract Infection Viral                                                             | 14                 | 11                 | 1.1                | 17                          | 14                          | 1.4                         |
| Viral Infection                                                                               | 23                 | 20                 | 2                  | 19                          | 14                          | 1.4                         |
| Tonsillitis                                                                                   | 16                 | 15                 | 1.5                | 15                          | 13                          | 1.3                         |
| Tooth Abscess                                                                                 | 13                 | 12                 | 1.2                | 13                          | 12                          | 1.2                         |
| Gastroenteritis Viral                                                                         | 10                 | 9                  | 0.9                | 9                           | 9                           | 0.9                         |
| Ear Infection                                                                                 | 11                 | 11                 | 1.1                | 9                           | 8                           | 0.8                         |
| Acute Tonsillitis                                                                             | 14                 | 13                 | 1.3                | 8                           | 8                           | 0.8                         |
| Pneumonia                                                                                     | 13                 | 11                 | 1.1                | 6                           | 6                           | 0.6                         |
| Vulvovaginal Mycotic Infection                                                                | 13                 | 10                 | 1                  | 6                           | 4                           | 0.4                         |

Overall, the incidence of infections was similar between the laquinimod and the placebo treatment groups  (48.7%  vs  47%).  Although  the  incidence  of  severe  infections  was  low  (1.1  reports/100 subject years), severe cases of appendicitis, infectious peritonitis, cellulitis, pneumonia have been observed. One death was reported due to pneumonia and sepsis in cohort 1. One additional death due to pneumonia occurred in SLE study.

With  regards  to  opportunistic  infections,  4  cases  of  tuberculosis  occurred  during  the  laquinimod clinical trials.

## Red Blood Cells Parameters

Data are presented in Table 28.

Table 28: Cohort #1: Incidence of Post Baseline Shifts to Abnormally Low Red Blood Cells

| Placebo-Controlled Pivotal Studies in MS Patients Treated with Laquinimod 0.6 mg   | Placebo (N=1005)   | Placebo (N=1005)               | Laquinimod 0.6 mg (N=983)   | Laquinimod 0.6 mg (N=983)      |
|------------------------------------------------------------------------------------|--------------------|--------------------------------|-----------------------------|--------------------------------|
| Placebo-Controlled Pivotal Studies in MS Patients Treated with Laquinimod 0.6 mg   | All*               | Change From High/Normal to Low | All*                        | Change From High/Normal to Low |
| Placebo-Controlled Pivotal Studies in MS Patients Treated with Laquinimod 0.6 mg   | N                  | %                              | N                           | %                              |
| HgB                                                                                | 1000               | 25.1                           | 974                         | 36.6                           |
| HCT                                                                                | 999                | 8.11                           | 973                         | 16.2                           |
| RBC                                                                                | 1000               | 12.1                           | 974                         | 25.6                           |
| MCV                                                                                | 999                | 3.7                            | 973                         | 3.2                            |
| MCH                                                                                | 1000               | 8.9                            | 973                         | 5.0                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| MCHC   | 999   | 31.2 973   | 31.8   |
|--------|-------|------------|--------|

Cases  of  haemoglobin  decrease  occurred  more  frequently  in  laquinimod  group  (in  36.6%  of subjects) compared to placebo (25%). In cohort 1, 2 cases of anaemia have been observed in the laquinimod group and none with placebo.

One female patient received a blood transfusion; she had an AE of menorrhagia and underwent a radical hysterectomy 2.5 months later. All other patients returned to normal of their low red blood cell levels without a blood transfusion.

## Photosensitivity

In  cohort 1, one report of photodermatosis and 3 reports of photosensitivity reaction have been reported compared to 1 report (photodermatosis) with placebo, 0.3% vs 0.1%. Overall, 11 reports of  photosensitivity  have  been reported with laquinimod in all clinical studies. Most of the events were of mild severity and related to sun exposure, with a variable drug exposure prior to adverse event  onset  (ranging  from  19  days  to  30  months).  All  cases  resolved  with  no  interruption  in laquinimod  treatment.  Five  of  the  cases  resolved  spontaneously,  3  subjects  required  topical steroids and 2 subjects were treated with oral antihistamines.

Incidence of photosensitivity in cohort 3 is presented in Table 29.

Table 29: Cohort #3: Incidence of Photosensitivity Adverse Events

|                                                                |                                                                | Laquinimod (N=2632, Subject Years=4994.2)   | Laquinimod (N=2632, Subject Years=4994.2)   | Laquinimod (N=2632, Subject Years=4994.2)   | Laquinimod (N=2632, Subject Years=4994.2)   |
|----------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| All MS Patients Ever Exposed to Laquinimod in Clinical Studies | All MS Patients Ever Exposed to Laquinimod in Clinical Studies | No. of Reports                              | No. of Subjects                             | %of Subjects                                | Event Rate per 100 Subject Years            |
| Category Photosensitivity                                      | Preferred Term -ALL                                            | 11                                          | 9                                           | 0.3                                         | 0.2                                         |
|                                                                | Photodermatosis                                                | 1                                           | 1                                           | 0.0                                         | 0.0                                         |
|                                                                | Photosensitivity Allergic Reaction                             | 4                                           | 3                                           | 0.1                                         | 0.1                                         |
|                                                                | Photosensitivity Reaction                                      | 6                                           | 5                                           | 0.2                                         | 0.1                                         |

## Oral Cavity Disorder

One  case  of  oral  leukoplakia  was  reported  occurred  in  a  patient  with  a  predisposing  factor (smoking).  The  event  regressed  spontaneously  within  less  than  two  months  under  continued laquinimod therapy.

## 2.6.4. Laboratory, ECG findings, Vital signs

## Haematological parameters

Data are presented in Table 30.

Table 30: Cohort #1: Incidence* of Post Baseline Shift to Abnormal Haematology

Values

| Cohort #1: Placebo- Controlled Pivotal Studies in MS Patients Treated with Laquinimod 0.6 mg   | Placebo (N=1005)   | Placebo (N=1005)               | Placebo (N=1005)               | Laquinimod 0.6 mg (N=983)   | Laquinimod 0.6 mg (N=983)      | Laquinimod 0.6 mg (N=983)      |
|------------------------------------------------------------------------------------------------|--------------------|--------------------------------|--------------------------------|-----------------------------|--------------------------------|--------------------------------|
| Cohort #1: Placebo- Controlled Pivotal Studies in MS Patients Treated with Laquinimod 0.6 mg   | All a              | Change From High/Normal to Low | Change From Low/Normal to High | All a                       | Change From High/Normal to Low | Change From Low/Normal to High |
| Cohort #1: Placebo- Controlled Pivotal Studies in MS Patients Treated with Laquinimod 0.6 mg   | N                  | %                              | %                              | N                           | %                              | %                              |
| WBC                                                                                            | 996                | 8.23                           | 14.76                          | 967                         | 3.62                           | 27.4                           |

<div style=\"page-break-after: always\"></div>

| Neutrophils   |   994 | 5.63 21.03   |      |   963 |       | 3.32 30.63   | 3.32 30.63   |      |
|---------------|-------|--------------|------|-------|-------|--------------|--------------|------|
| Lymphocytes   |   994 | 9.46         | 2.52 |   963 |       | 4.57         |              | 6.02 |
| Monocytes     |   994 | 6.74 10.66   |      |   963 |       | 5.5          | 22.95        |      |
| HgB           |  1000 | 25.1         | 0.9  |   974 | 36.55 |              |              | 0.31 |
| HCT           |   999 | 8.11 26.03   |      |   973 | 16.24 |              | 14.18        |      |
| RBC           |  1000 | 12.1         | 11.5 |   974 | 25.56 |              |              | 5.03 |
| MCV           |   999 | 3.7 46.05    |      |   973 |       | 3.19         | 50.77        |      |
| Platelet      |   995 | 4.62         | 2.01 |   965 | 12.02 |              |              | 2.69 |

a  Subjects with a measurement at baseline and at least one measurement after baseline

* Incidence :percent out of subjects who had a test baseline and at least one post baseline test, only for tests with at least a 1% higher incidence of shifts in the laquinimod 0.6 mg group; HCT: hematocrite, MCV:Mean Cell Volume, WBC: White Blood Cells

Significantly more subjects experienced a change in WBC from low/normal to high level (including increase of subpopulations, e.g. neutrophils) in the laquinimod group (27.5%) compared to placebo (14.6%)  or  Avonex  (11.2%).  In  the  pivotal  studies  shift  in  WBC  was  generally  mild  and  is  not considered  clinically  significant  (no  grade  3  leucocytosis  occurred).  Nevertheless  in  the  BRAVO extension  study  after  exposure  to  laquinimod  for  more  than  700  days  there  was  one  death  by anemia, thrombocytopenia and acute leucemia.

In  addition,  haemoglobin  level  decreased  in  clearly  more  subjects  in  the  laquinimod  group (36.55%) compared to placebo (25.1%) or Avonex (31.2%). However, only one patient suffering from anemia required transfusion due to menorrhagia.

Platelets also shifted to low level in more patients in the laquinimod group (12%) than in placebo group  (4.6%),  but  was  not  considered  clinically  significant  apart  from  the  fatal  case  described above.

Haematological toxicity was relevant with laquinimod when compared to placebo, with mostly mild increase in leucocyte levels and decrease in red blood cells and platelets. Two cases of anaemia and one case of leukemia in the laquinimod group were considered as serious.

## Chemistry, metabolic parameters

Data are presented in Table 31.

Table 31: Cohort #1: Incidence* of Post Baseline Shift to Abnormal Biochemistry Values at Any Time during Study

| Cohort #1: Placebo- Controlled Pivotal Studies in MS Patients Treated with Laquinimod 0.6 mg   | Placebo (N=1005)   | Placebo (N=1005)               | Placebo (N=1005)               | Laquinimod 0.6 mg (N=983)   | Laquinimod 0.6 mg (N=983)      | Laquinimod 0.6 mg (N=983)      |
|------------------------------------------------------------------------------------------------|--------------------|--------------------------------|--------------------------------|-----------------------------|--------------------------------|--------------------------------|
| Cohort #1: Placebo- Controlled Pivotal Studies in MS Patients Treated with Laquinimod 0.6 mg   | All a              | Change From High/Normal to Low | Change From Low/Normal to High | All a                       | Change From High/Normal to Low | Change From Low/Normal to High |
| Cohort #1: Placebo- Controlled Pivotal Studies in MS Patients Treated with Laquinimod 0.6 mg   | N                  | %                              | %                              | N                           | %                              | %                              |
| Sodium                                                                                         | 999                | 1.1                            | 28.8                           | 973                         | 2.7                            | 27.1                           |
| Potassium                                                                                      | 999                | 4                              | 18.7                           | 974                         | 2.3                            | 21.7                           |
| Calcium                                                                                        | 999                | 66.7                           | 5                              | 974                         | 68.8                           | 3.8                            |
| Creatinine                                                                                     | 999                | 27.9                           | 1.1                            | 974                         | 42.5                           | 0.6                            |
| CPK                                                                                            | 1000               | 17.1                           | 14.5                           | 974                         | 13.4                           | 17.2                           |
| ALP                                                                                            | 999                | 5.1                            | 1.8                            | 974                         | 2.8                            | 3.7                            |
| AST                                                                                            | 999                | 0                              | 9.5                            | 974                         | 0                              | 17.4                           |
| ALT                                                                                            | 999                | 2.9                            | 18.3                           | 974                         | 2.5                            | 31.1                           |
| GGT                                                                                            | 999                | 3                              | 10.2                           | 974                         | 1.3                            | 18                             |
| Total Protein                                                                                  | 999                | 7.3                            | 10.8                           | 974                         | 8.7                            | 9.3                            |
| Fibrinogen                                                                                     | 985                | 4.7                            | 28.4                           | 966                         | 3.7                            | 39.9                           |
| P-Amylase                                                                                      | 997                | 2.9                            | 7.9                            | 975                         | 1.3                            | 14.4                           |

a Subjects with measurement at baseline and at least one post baseline measurement

*Incidence:percent out of subjects who had a test at baseline and at least one post-baseline test, only tests with an incidence higher in the laquinimod group by at least 1%

<div style=\"page-break-after: always\"></div>

During escalating-dose phase I studies (using higher doses than 0.6 mg of laquinimod), laboratory markers  of  inflammation  (CRP,  ESR,  fibrinogen)  have  been  increased  in  healthy  volunteers.  In addition,  a  clear  increase  of  fibrinogen  above  normal  values  was  observed  in  phase  II  study (0350627). Some results have been provided on CRP in ALLEGRO study showing CRP increase in 7.3%  of  subjects  compared  to  5.8%  in  the  placebo  group.    Fibrinogen,  other  marker  of inflammation changed from normal to high level in 40% of patients in laquinimod group in Cohort 1 while it changed in clearly less patients in placebo group (28.4%).

In the pivotal studies, mean CRP elevations (and also percentage of potentially clinically significant CRP) were similar in the laquinimod and placebo group. Nevertheless until month 15 the proportion of patients with elevations in both CRP and fibrinogen was slightly higher (by approximately 1-2%) in  the  laquinimod  group  compared  to  placebo.  At  month  2  this  difference  was  statistically significant (approximately 4.1% vs. 2.3%) and this was considered clinically relevant. Long-term data up to 4 years are available and revealed that at month 48, the percentage of patients with potentially  clinically  significant  CRP  elevation  increased  to  5.4%  in  the  laquinimod  group.  In  the pivotal studies, the incidence of fibrinogen level considered potentially clinically significant (&gt; 6g/l), was higher in the laquinimod group compared to placebo (5.5% vs. 2.6%). Maximal fibrinogen did not exceed the &gt;2.5xULN and was 9.0 g/l in the laquinimod group and 8.4 g/l in the placebo group at  any  time  until  month  24.  Overall,  mean  duration  of  elevated  fibrinogen  or  CRP  tended  to  be longer in the laquinimod group compared to placebo.

In  72%  of  the  potentially  clinical  significant  CRP  elevations  there  was  an  intercurrent  AE  in  the laquinimod group compared to 91% in the placebo-group. There were also some patients with CRP increase and at the same time without a concurrent AE in both placebo and laquinimod groups. There were also patients with AEs in both groups that could not explain the long duration of CRPincrease (e.g. a patient on laquinimod with nasopharyngitis and duration of CRP-increase for 170 days). Laquinimod was also associated with a higher incidence of elevated fibrinogen levels, but according to the presented analyses, these elevations were accompanied by clinical findings in 33% for laquinimod group and 46% for placebo group.

Slightly  more  patients  with  back/neck  pain  in  the  laquinimod  group  (n=4)  as  compared  to  the placebo  group  (n=2)  had  both  increased  CRP  and  fibrinogen,  nevertheless  these  were  small numbers of patients. Regarding appendicitis, for at least 4 subjects in the laquinimod group who had appendicitis and for whom laboratory data were available during the visits of the appendicitis event, concurrent elevations in CRP and fibrinogen were observed (with no record of elevated CRP or fibrinogen prior to the appendicitis report). As suggested by the applicant these elevations are expected,  as  CRP  and  fibrinogen  are  acute  phase  reactants  and  appendicitis  is  an  inflammatory process, thus association cannot be excluded between the events, contrary to applicant conclusion.

Changes that concerned ALT and AST levels occurred also in higher frequency in the laquinimod group  compared  to  placebo  (31%  and  17.4%  vs  18.3%  and  9.5%).  In  cohort  4,  shifts  to abnormally  high  fibrinogen  and  cholesterol  as  well  as  shifts  to  abnormally  low  calcium  and creatinine in a considerable number of patients (more than 40%) have been reported during longterm treatment.

## Electrocardiogram (ECG)

One thorough QT study was performed by the applicant, as requested, comparing two doses of laquinimod (0.6 mg and 1.2 mg) to placebo and moxifloxacin. One hundred and eighteen subjects (59%) reported one adverse event, mainly headache, all of mild to moderate intensity. It seems that no signal of laquinimod effect on heart rate has been detected in this study; nevertheless, it is

<div style=\"page-break-after: always\"></div>

to be noted that T wave changes occurred in 5 subjects in the laquinimod groups (3 in 1.2 mg and 2 in 0.6 mg group) compared to 2 changes in the placebo group. The clinical relevance is unknown.

The  number  of  subjects  with  abnormal  ECG  was  comparable  between  placebo  (0.5%)  and laquinimod groups (0.3%; 3 subjects: one experiencing sinus bradycardia at M3, normal at M6, and 2 subjects with first degree atrioventricular (AV) block and PR prolongation).

## Vital signs

No signal emerged from the review of vital signs such as blood pressure, heart rate and weight in cohort 1.

## 2.6.5. Safety in special populations

No trials have been performed in any special multiple sclerosis patient populations. Patients with significant  cardiovascular,  pulmonary,  gastrointestinal,  psychiatric,  neurologic  (other  than  MS), renal impairment, hepatic conditions as well as HIV patients were excluded from the pivotal trials.

Data for patients with renal, hepatic impairment and other special populations (paediatric, elderly) are discussed under clinical pharmacology (see 2.4.4).

In MS studies, females of child bearing potential were required to practice effective contraception. Nonetheless, 74 pregnancies have been reported in the laquinimod development programme, of which 43 were reported in subjects exposed to laquinimod (38 female patients treated and 5 male subjects reporting pregnancies of partners) as of 1 September 2013. Nineteen pregnancies were reported in the placebo group and 12 in the Avonex group. Of these 38 pregnancies in laquinimodtreated  female  patients,  the  outcome  is  unknown  in  3  cases  (ongoing  pregnancies  or  no information),  6  resulted  in  spontaneous  abortions,  16  normal  newborns,  2  obstetric  or  perinatal complications (one case of premature baby and intrauterine infection, one case low birth weight and neonatal asphyxia), 1 case of microcephaly (later corrected to borderline head circumference) and  10  induced  abortions.  Concerning  the  10  induced  abortions  reported,  reason  of  induced abortion  is  unknown  in  1/3  of  cases  (3  cases)  and  for  the  7  remaining  cases,  regarding  the gestational age at abortion (&lt; week 9), the applicant assumed that abortions were the result of personal choice and not of evidence of fetal defects.

Subgroup  analyses  were  performed  to  evaluate  the  safety  profile  of  laquinimod  according  to demographic  characteristics.  In  general  the  AE  profile  in  MS  did  not  depend  on  gender  or  age, except  for  ALT  increase.  Whilst  two  third  of  female  and  one  third  of  male  were  enrolled  in  MS studies,  the  incidence  of  common  AEs  was  higher  in  laquinimod  groups  for  both,  males  and females. However the ALT increase was a more notable event for male than for female (11.6% vs 3.3%). There was no signal of drug abuse potential or overdose with laquinimod.

## 2.6.6. Safety related to drug-drug interactions and other interactions

No additional data were presented other than those presented in the clinical pharmacology studies.

## 2.6.7. Discontinuation due to adverse events

In the pivotal studies, the overall incidence of AEs leading to early termination was higher in the laquinimod 0.6 mg group than the placebo group (6.4% vs. 4.7%). The most frequent AEs leading to  early  termination  with  a  higher  incidence  in  the  laquinimod  group  than  the  placebo  group included abdominal pain (overall 2.0% vs. 0.1%), AEs of elevated liver enzymes (overall increased ALT  and  GGT,  increased  transaminases  and  abnormal  liver  function  test  :  2.0%  vs.  1.6%),

<div style=\"page-break-after: always\"></div>

headache (0.5% vs 0%) and diarrhoea (0.4% vs 0%). These findings were confirmed by the other analysed safety populations.

In the long-term analysis AEs leading to early termination with a calculated event rate &gt;0 were: pyrexia, pulmonary tuberculosis, asthma, nail discolouration, and thrombocytopenia, and increased ALT, GGT and aspartate aminotransferase (0.1 reports/100 subjects years).

## 2.6.8. Post marketing experience

No post-marketing data are available.

## 2.6.9. Additional analyses

The applicant analysed the AE profile of laquinimod in relation to the safety data of roquinimex, a pharmaceutical compound, structurally related to laquinimod. Serious toxicities (including myocardial infarction, pericarditis and pleuritis, venous thrombotic events) occurred during Phase III  trials  with  roquinimex  and  led  to  early  termination  of  these  trials.  The  mechanism  by  which roquinimex caused these events was not identified, but these were assessed by the applicant as possible  manifestations  of  a  systemic  inflammatory  response,  an  assessment  which  was  also supported quite extensively by roquinimex non-clinical findings.

## Pericarditis and pleuritis

In roquinimex trial, pericarditis was reported in 19 subjects (2%) and pleuritis was observed in 8 subjects (0.8%).With regards to laquinimod cohorts, one case of pleuritis with pleural effusion was reported in healthy 61 year-old male with traumatic fracture of rib on the same side. A relationship with the study drug was not excluded by the applicant. Two cases of pericarditis were reported in laquinimod group. In one case the diagnosis of pericarditis was questionable, and in the second case causality for laquinimod is doubtful.

## Myocardial infarction

Although  low,  the  incidence  of  ischemic  heart  disease  was  higher  in  the  laquinimod  group compared to  placebo  (0.6%  vs  0.1%)  in  the  pivotal  studies.  Overall,  20  reports  in  15  subjects (0.6%) reported ischemic heart disease including 2 subjects that were diagnosed with myocardial infarction  in  the  laquinimod  group.  Two  out  of  9  deaths  in  the  laquinimod  group  were  due  to cardiovascular  failure  (sudden  death  within  5  hours  post  treatment)  and  myocardial  infarction (after 5 months of treatment), respectively. Even if the applicant considers that ischaemic heart disease  (IHD)  does  not  constitute  a  safety  signal  for  laquinimod,  the  relationship  could  not  be completely excluded.

Ten  definite  cases  of  myocardial  infarction  were  reported  in  laquinimod  group  including  9  cases where cardiovascular risk factors including obesity, hypertension, hypercholesterolemia, diabetes, smoking, family  history  of  IHD,  and  evidence  of  IHD  were  reported.  Indirect  comparison  to  the Clinical Practice Reasearch Datalink (CPRD) database found no signal of increased incidence of MI with  laquinimod  exposure  over  time,  however  such  analysis  is  of  limited  relevance  due  to  its methodology.

## Venous Thrombotic Events

Whilst venous thrombotic events were identified as safety concern for roquinimex, a single case of Budd  Chiari  syndrome  in  a  44  year-old  female  with  factor  V  Leiden  mutation  occurred  with laquinimod.

The  applicant  performed  a  literature  search  to  retrieve  the  incidence  rates  of  deep  venous thrombosis (DVT) and pulmonary embolism (PE) and compare them to the incidence rates of these

<div style=\"page-break-after: always\"></div>

events found in the laquinimod development program. A recent study conducted by Christensen et al. reported that the incidence rates of DVT and PE in the MS population were 2 per 1,000 personyears (95% CI: 1.41- 2.76) and 0.94 per 1,000 person-years (95% CI: 0.56-1.49), respectively. In  the  laquinimod  development  program,  the  incidence  rates  of  DVT  and  PE  among  patients exposed to laquinimod were 0.67/ 1000 subject years and 0.17/1000 subject years, respectively. Thus,  these  results  indicate  that  the  incidence  rates  of  DVT  and  PE  among  patients  exposed  to laquinimod  were  lower  than  the  rates  reported  in  MS  patients.  Available  data  to  date  did  not suggest an increased rate of any thrombotic events.

## 2.6.10. Discussion on clinical safety

The safety profile of laquinimod has been characterised with data from a total of 2,632 MS patients that were exposed to different doses of laquinimod, with the majority of the patients (more than 2,300) having taken the intended dose of 0.6 mg. In the pivotal studies (cohort 1), 983 patients in the  laquinimod  0.6  mg  group  had  total  mean  exposure  of  1.8  years,  that  was  comparable  to placebo. In addition, 442 patients were included in active comparator arm (Avonex) with similar mean exposure. These exposure data were considered adequate and the CHMP considered cohort 1 as representative of the AE profile of laquinimod in the intended MS population.

In the pivotal studies, the incidence of adverse events was the highest in the system organ class of  Infections  and  Infestations  and  comparable  between  two  groups,  laquinimod  and  placebo (48.7% vs 47%). The incidence of AEs was higher in the group laquinimod for SOC Musculoskeletal and  Connective  Tissue  Disorders  (30.4%  vs  25.4%),  SOC  Investigations  (27%  vs  20.8%),  SOC gastrointestinal  disorders  (26.9%  vs  22.6%),  SOC  Metabolism  disorders  (5.3%  vs  2.9%), Neoplasm (4.6% vs 2.7%) compared to placebo.

Although the incidence of severe infections was low (1.1 reports/100 subject years), numerically some serious infections have been observed more frequently in the laquinimod group compared to placebo  in  the  pivotal  studies:  appendicitis  (6  vs.  1)  and  cellulitis  (3  vs.  0).  Appendicitis  was partially accompanied by peritonitis, mainly due to delayed time to surgery. Non-SAE urinary tract infections were slightly increased in the laquinimod group compared to placebo.

The number of SAEs was similar in cohort 1 between the laquinimod and the placebo group: 9.4% vs 8.9%. However, the number of appendicitis, as previously described, was significantly higher in the laquinimod. In cohort 3, in all MS patients ever exposed to laquinimod, 12 appendicitis and 6 infectious  peritonitis  were  noted.  Based  on  animal  findings,  a  pro-inflammatory  mechanism underlying these events cannot be excluded.

The safety profile indicated liver enzyme elevations, inflammatory markers  increased (e.g. CRP, fibrinogen), back and neck pain, haematological changes, appendicitis as important identified risks, in  addition  to  the  interaction  with  CYP3A4  inhibitors/inducers  that  was  observed  in  clinical pharmacology.

Laquinimod treatment was associated with elevations from normal to Grade 1 for AST, ALT, GGT and  normal  to  grade  1  and  2  (up  to  5x  ULN)  for  ALT  and  GGT.  Shifts  to  grade  3  and  4  were uncommon and reported with a similar incidence in the placebo and laquinimod groups, apart from GGT increase grade 3 which was slightly more frequent in the laquinimod group. Severe hepatic AEs  were  reported  in  a  slightly  higher  frequency  in  the  laquinimod  group  (1%)  compared  to placebo  (0.5%),  however  these  were  related  to  only  liver  enzyme  elevations  with  no  specific clinical pattern. Liver-related serious AEs were uncommon, and reported with similar incidence and types in the laquinimod and placebo groups. In addition no case of 'hepatitis' was reported with laquinimod  (versus  one  case  in  placebo  group);  increased  blood  bilirubin  was  reported  by  more subjects in the placebo group (0.6%) than in the laquinimod 0.6 mg group (0.1%); no Hy's law or

<div style=\"page-break-after: always\"></div>

liver failure cases were reported throughout the laquinimod clinical development program. Overall, the  effect  of  laquinimod  on  the  liver  appeared  to  be  limited  to  liver  enzyme  elevations,  but  the mechanism  underlying  these  events  is  unknown.  Mostly  mild,  asymptomatic  liver  enzyme elevations  (AST,  ALT  and  GGT)  were  reported  that  generally  occurred  within  6  months  after initiation  of  treatment  Overall  in  the  pivotal  trials,  4.7%  of  laquinimod  treated  subjects  reached clinically significant [&gt; 3x ULN] levels of ALT. This was more notable for male than for female in laquinimod treated subjects. In 74% of subjects who had elevated levels of ALT on laquinimod, ALT decreased to within the normal range while on laquinimod.

The higher incidence of AEs in laquinimod group for SOC Musculoskeletal and Connective Tissue Disorders as compared to placebo group was associated with a higher frequency of back and neck pain  in  the  laquinimod  group  in  the  first  months  of  treatment.  After  3  months  of  laquinimod treatment, use of anti-inflammatory and anti-rheumatic medications was similar in the laquinimod and placebo groups. However some peaks in the use of these drugs occurred again at 9 and 15 months of treatment by laquinimod that seems to be correlated to increases in musculoskeletal AEs in the laquinimod group between 9 and 18 months of treatment, whereas a decrease was observed between 6 and 9 months. Thus, the applicant's claim that the higher incidence of musculoskeletal AEs reported in the laquinimod group appeared to be limited to the first 3 months of treatment after which the incidence declines and becomes similar to the placebo group, was not agreed by the CHMP. In addition, in cohort 5, back pain continued to be commonly reported with laquinimod (8.9 reports/100 subjects/year), supporting an effect not limited to the first weeks of treatment.

Inflammatory  markers  (CRP,  ESR,  fibrinogen)  were  increased  in  healthy  volunteers  in  phase  I studies.  In  pivotal  studies,  fibrinogen  (40%  vs.  28%)  and  WBC  levels  (27%  vs.  15%)  clearly increased to values above ULN in a higher percentage of patients with laquinimod in comparison with  placebo.  Increase  of  fibrinogen  was  apparent  from  month  1.  The  increase  in  WBC  was generally  mild  and  was  not  considered  clinically  significant  (no  grade  3  leucocytosis  occurred). Nevertheless in the extension study MS-LAQ-302E there was one death due to acute leukemia with disseminated  intravascular  coagulation  and  cerebral  haemorrhage,  accompanied  by  anemia  and thrombocytopenia. In contrast, mean CRP elevations (and also percentage of potentially clinically siginificant CRP) were similar in the laquinimod and placebo group in cohort 1. Nevertheless until month 15 the proportion of patients with elevations in both CRP and fibrinogen was slightly higher (by approximately 1-2%) in the laquinimod group compared to placebo. At month 2 this difference was  statistically  significant  (approximately  4.1%  vs.  2.3%)  and  this  was  considered  clinically relevant.  Long-term  data  up  to  4  years  are  available  and  revealed  that,  at  month  48,  the percentage of patients with potentially clinically significant CRP elevation increased to 5.4% in the laquinimod  group.  In  the  pivotal  studies,  the  incidence  of  fibrinogen  level  considered  potentially clinically significant (&gt; 6g/l), was higher in the laquinimod group compared to placebo (5.5% vs. 2.6%). Maximal fibrinogen did not exceed the &gt;2.5x ULN and was 9.0 g/l in the laquinimod group and 8.4 g/l in the placebo group at any time until month 24. Overall, mean duration of elevated fibrinogen or CRP tended to be longer in the laquinimod group compared to placebo. The CHMP acknowledged that the inflammatory markers (including also WBC count) are not specific and that their  measurement  is  supportive  in  the  context  of  inflammatory  diseases.  The  interpretation  of markers  in  the  context  of  MS  as  underlying  inflammatory  disease  or  in  the  case  of  relapse  is therefore  much  more  complicated.  Based  on  the  presented  data,  a  CRP  increase  by  laquinimod could  be  specific  (e.g.  infections)  but  also  unspecific/not  identified  and  could  be  sign  of  an undetected  inflammatory  process.  In  case  of  a  pro-inflammatory  process,  some  uncertainties remain with regard to possible deterioration of MS and long-term carcinogenic effect. Whereas, no evidence of increased risk for malignancy has been found based on the available clinical data of laquinimod at the present time, long term data are limited to ascertain the level of this risk. Since an  increase  in  pro-inflammatory  markers  has  been  observed  in  animal  studies  (dogs)  and

<div style=\"page-break-after: always\"></div>

considering  the  available  clinical  findings,  the  CHMP  considered  that  increased  CRP  is  a  safety concern for laquinimod and further data are required to better understand this identified risk and adverse events related to a possible pro-inflammatory mechanism of laquinimod.

Haematological  toxicity  was  relevant  with  laquinimod  when  compared  to  placebo,  with  mostly increase in leucocyte levels and decrease in red blood cells and platelets. Two cases of anaemia and one case of leukemia in the laquinimod group were considered as serious.

Although  low,  the  incidence  of  ischemic  heart  disease  was  higher  in  the  laquinimod  group compared to  placebo  (0.6%  vs  0.1%)  in  the  pivotal  studies.  Overall,  20  reports  in  15  subjects (0.6%) reported ischemic heart disease including 2 subjects that were diagnosed with myocardial infarction  in  the  laquinimod  group.  Two  out  of  9  deaths  in  the  laquinimod  group  were  due  to cardiovascular  failure  (sudden  death  within  5  hours  post  treatment)  and  myocardial  infarction (after 5 months of treatment), respectively. Patients with significant cardiovascular conditions were excluded from the pivotal trials. On this basis and considering the safety data from roquinimex, a structurally related product, the CHMP considers cardiotoxicity as a potential risk for laquinimod.

Malignant tumours have been reported in 26 patients (0.6%) treated with laquinimod in all clinical studies; 6 breast carcinomas including one metastatic breast cancer (3 in cohort 1, all in ALLEGRO and no case in BRAVO; 1 additional case of breast cancer in study LAQ/5062 has been reported in laquinimod  group.  One  breast  cancer  was  reported  in  placebo  group).  In  cohort  1,  10  (1%) patients  in  the  laquinimod  group  vs  6  (0.6%)  patients  with  placebo  experienced  a  malignant tumour [p=0.2944, 95% CI (-0.37, 1.21)]. In addition to 3 cases of breast cancer, sporadic cases of  glioblastoma  (1),  lung  neoplasm  malignant  (1),  lymphoma  (1),  oesophageal  adenocarcinoma (1), squamous cell carcinoma (1), thyroid cancer (1) were reported.  One case of thyroid cancer has  been  reported  in  BRAVO  study  in  a  32.5  year-old  female  after  189  days  of  laquinimod treatment.  The  AE  was  considered  as  moderate  and  not  related  to  study  drug;  the  subject recovered. One case of thyroid cancer occurred in Avonex group. Concerning skin malignancy, 2 cases (basal cell carcinoma, squamous cell carcinoma) occurred in cohort 1 compared to one case (basal  cell  carcinoma)  in  the  placebo  group.  In  total,  in  cohort  3  (all  patients  treated  with laquinimod),  7  subjects  suffered  from  skin  malignancies:  basal  cell  carcinoma  (4),  malignant melanoma (1) and squamous cell carcinoma (2). Comparison of malignancies incidences with SEER (age-adjusted SIR=1.4; 95% CI [0.90-2.08])and CPRD (age-adjusted SIR=1.397; 95% CI [0.971.95] for  general  population  ;  age-adjusted  SIR=1.088;  95%  CI  [0.75-1.52]  for  MS  population) databases  did  not  demonstrate  an  increase  in  malignant  tumors  with  laquinimod  therapy.  For breast cancer, incidence comparison did not demonstrate an increased risk with laquinimod therapy when compared to SEER and GPRD databases. According to the applicant, malignant tumours are not  considered  to  constitute  a  safety  signal  of  concern  at  the  present  time.  However,  from  the CHMP  viewpoint,  the  number  of  events  to  date  and  duration  of  follow-up  is  too  limited  to definitively exclude a relationship and further long term data are required to ascertain the level of this  potential  risk.  In  addition,  based  on  available  pre-clinical  data,  there  remain  relevant uncertainties  on  the  potential  risk  for  malignancies.  These  uncertainties  currently  represent  an important concern with long term use of laquinimod (see 2.3.6).

In MS studies, females of childbearing potential were required to practice effective contraception. Nonetheless, 74 pregnancies have been reported in the laquinimod development programme, of which 43 were reported in subjects exposed to laquinimod (38 female patients treated and 5 male subjects reporting pregnancies of partners) as of 1 September 2013. The CHMP is of the opinion that a pregnancy rate of 2 % of the exposed women in the 2 pivotal studies in MS (ALLEGRO and BRAVO)  and  their  extensions,  despite  all  the  measures  to  avoid  pregnancy  is  of  concern.  The applicant  explained  this  high  rate  of  pregnancies  by  the  considerable  fraction  of  the  population included  in  clinical  trials  which  consisted  of  females  of  childbearing  potential  and  the  possible

<div style=\"page-break-after: always\"></div>

demographic/cultural attitudes based on the fact that most of the pregnancies were reported in Russia, Ukraine, Poland and Bulgaria. The lack of data on these unexpected pregnancies (e.g. lack of reason for induced abortions in one third of the cases) did not allow a proper evaluation of the level  of  this  risk  by  the  CHMP.  The  potentially  delayed  effects  of  laquinimod  seen  in  preclinical studies (notably on puberty and fertility), which would not be noticeable at birth are of important concern for the CHMP, especially considering the intended use in MS patients (mostly females of child bearing potential) and the absence of an in vivo interaction study investigating the potential effect of laquinimod on the pharmacokinetics of oral contraceptives.

Due to the potential of formation of adducts seen in preclinical studies, the CHMP considered that drug hypersensitivity reactions should be considered as a potential risk for laquinimod, given its intended chronic use.

## 2.6.11. Conclusions on the clinical safety

The CHMP concluded the following:

Laquinimod is associated with a number of important identified risks (e.g. liver enzyme elevations, and  haematological  changes  which  were  mostly  mild,  inflammatory  markers  increased  (e.g. fibrinogen, CRP), back and neck pain, appendicitis) and potential safety concerns (carcinogenicity, teratogenicity,  cardiotoxicity,  hypersensitivity).  While  the  currently  available  clinical  data  did  not show  evidence  of  an  increased  risk  of  malignancies,  immunosuppression  or  infections,    there remain  significant  uncertainties  on  the  mechanism  of  action  of  laquinimod,  in  particular  with regards  to  immunomodulator  or  immunosuppressant  potential,  and  on  the  risks  associated  with long-term use (i.e. cancer, infections, inflammation), contributing to the insufficient characterization of the safety profile of laquinimod in the intended patient population.

## 2.7. Pharmacovigilance

## Detailed description of the pharmacovigilance system

The CHMP considered that the Pharmacovigilance system as described by the applicant fulfils the legislative requirements.

## 2.8. Risk Management Plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

## PRAC Advice

Based  on  the  PRAC  review  of  the  Risk  Management  Plan  version  2.2,  the  PRAC  considered  by consensus  that  the  risk  management  system  for  Laquinimod  (Nerventra)  in  the  treatment  of relapsing  remitting  multiple  sclerosis  (RRMS)  is  not  acceptable  in  the  current  format  since  the documented  proposals  for  pharmacovigilance  activities  and  risk  minimisation  measures  are  not sufficiently robust and should be revised.

The PRAC commented that serious concerns remain on possible risk minimization given the safety profile  of  laquinimod,  notably  regarding  carcinogenicity  for  which  there  are  no  obvious  risk minimisation  measures  and  regarding  potential  endocrine  disrupting  effects,  for  which  the effectiveness of the pregnancy preventive measures is questionable because of the high frequency

<div style=\"page-break-after: always\"></div>

of pregnancy experienced in the context of the clinical development programme and in reason of the delayed effect after in utero exposure.

Specifically:

-  the  PRAC,  was  of  the  opinion  that  the  proposed  post-authorisation  PhV  development  plan  is insufficient to identify and characterise the risks of the product.

- the PRAC was informed of the conclusions of the discussion of the Safety Working Party on the meeting of 3 December 2013 and expressed very serious concerns on the laquinimod safety profile, in particular because of the potential long term effects and of the potential delayed effects with respect to the following hazards:

- Carcinogenicity
- Delayed effect (endocrine disrupting potential effect - need of a long follow up for infants exposed in utero)
- Important information missing (primary mechanism and DDI study with oral contraceptives)

It  should  be  taken  into  account  that  there  are  no  obvious  risk  minimisation  measures  for  the carcinogenic  risk.  Furthermore  the  experience  with  the  clinical  development  programme  of laquinimod has shown poor control of pregnancy in the target population. In such a context the effectiveness  of  pregnancy  prevention  measures  for  the  teratogenic  and  long-term  endocrine disrupting risks is doubtful.

This advice is based on the following content of the Risk Management Plan:

## · Safety concerns

Table 32: Summary of the Safety Concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                        |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Liver enzyme elevations Back and neck pain* Appendicitis* Fibrinogen increased* CRP increased* Haematological changes: • WBC increased • Haemoglobin decreased/Anaemia • Platelets decreased Interactions of laquinimod with: • CYP3A4 strong or moderate Inhibitors • CYP3A4 strong inducers • CYP1A2 substrates |
| Important potential risks    | Teratogenicity (urogenital malformations) Carcinogenicity Hypersensitivity Cardiotoxicity (MI, acute coronary syndrome)                                                                                                                                                                                           |
| Missing information          | • Paediatric patients (below 18) • Elderly patients • Pregnancy • Breastfeeding                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Summary of safety concerns   | Summary of safety concerns                                                           |
|------------------------------|--------------------------------------------------------------------------------------|
|                              | • Patients with renal impairment • Patients with liver impairment • Long-term safety |

* Wording about a possible role for inflammation has been added as 'potential mechanism' for these risks

## · Pharmacovigilance plans

Table 33: Ongoing and planned studies in the PhV development plan

| Activity/Study title(type of activity, study title [if known] category 1-3)*   | Objectives                                                                                                                                                                                    | Safety concerns addressed                                                                                                                                                                                                           | Status Planne d, started   | Date for submission of interim or final reports (planned or actual)                               |
|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|---------------------------------------------------------------------------------------------------|
| PASS, A long term, prospective, observational study [category 1]               | To collect long term safety data, and to further characterise identified and potential safety concerns                                                                                        | Liver enzyme elevations, back and neck pain, appendicitis; Drug- drug interactions; teratogenicity; Missing information on paediatric,elderly, pregnancy, breastfeeding, patient with renal or hepatic impairment, long term safety | Planned                    | Final study report: Within 12 months from end of data collection.                                 |
| Pregnancy registry [category 1]                                                | A pregnancy registry to characterise and assess pregnancy outcomes in clinical practice should a pregnancy occur, to be incorporated into the company's safety database.                      | Potential risk: teratogenicity; missing information: pregnancy                                                                                                                                                                      | Planned                    | Periodic overview in PSUR/PBRER; Final study report: Within 12 months from end of data collection |
| DDI study [category 1]                                                         | A randomized, double-blind, placebo-controlled, crossover study to assess the effect of Laquinimod 0.6 mg on the PK and PD of oral contraceptives (EE+LNG) in healthy young female volunteers |                                                                                                                                                                                                                                     | Planned                    | Final study report: Within 6 months after CHMP opinion                                            |

*Category 1 are imposed activities considered key to the benefit risk of the product.

Category 2 are specific obligations

Category 3 are required additional PhV activity (to address specific safety concerns or to measure effectiveness of risk minimisation measures)

<div style=\"page-break-after: always\"></div>

## · Risk minimisation measures

Table 34: Summary table of Risk Minimisation Measures

| Safety concern                                                                                  | Routine risk minimisation measures                                                                                               | Additional risk minimisation measures                                                                                                                                                                                                    |
|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Liver enzyme elevations                                                                         | Labeling information (SmPC section 4.4 and 4.8, Package Leaflet)                                                                 | None                                                                                                                                                                                                                                     |
| Back and neck pain                                                                              | Labeling information (SmPC section 4.8, Package Leaflet)                                                                         | None                                                                                                                                                                                                                                     |
| Appendicitis                                                                                    | Labeling information (SmPC section 4.8, Package Leaflet)                                                                         | None                                                                                                                                                                                                                                     |
| Fibrinogen and CRP increase                                                                     | Labeling information (SmPC section 4.8, Package Leaflet)                                                                         | None                                                                                                                                                                                                                                     |
| Haematological changes (anaemia, increase white blood cells, decreased platelets)               | Labeling information (SmPC section 4.8, Package Leaflet)                                                                         | None                                                                                                                                                                                                                                     |
| Interaction with; CYP3A4 Strong or moderate inhibitors CYP3A4 strong Inducers CYP1A2 Substrates | Labeling information (SmPC sections 4.4 and 4.5, Package Leaflet)                                                                | None                                                                                                                                                                                                                                     |
| Teratogenicity (urogenital malformations)                                                       | Labeling information (SmPC sections 4.3, 4.6, and 5.3, Package Leaflet)                                                          | Need to use effective contraception and avoid pregnancy will be communicated as follows:  DHPC  Educational m a te ria ls  Other material provide d to patients or HCPs  By fie ld re pre s e n ta tive s  By medical a ctivit ie s |
| Carcinogenicity                                                                                 | Labeling information (SmPC section 5.3)                                                                                          | None                                                                                                                                                                                                                                     |
| Hypersensitivity                                                                                | In the absence of a specific safety signal relating to hypersensitivityno risk minimisation activities are proposed at this time | None                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Safety concern                               | Routine risk minimisation measures                                                                                             | Additional risk minimisation measures                                                                                                                                                                                                     |
|----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cardiotoxicity (MI, acute coronary syndrome) | In the absence of a specific safetysignal relating to cardiotoxicity no risk minimisation activities are proposed at this time | None                                                                                                                                                                                                                                      |
| Paediatric patients                          | Labeling information (SmPC section 4.2, Package Leaflet)                                                                       | None                                                                                                                                                                                                                                      |
| Elderly patients                             | Labeling information (SmPC section 4.2, Package Leaflet)                                                                       | None                                                                                                                                                                                                                                      |
| Pregnancy                                    | Labeling information (SmPC sections 4.3, 4.6, and 5.3, Package Leaflet)                                                        | Need to use effective contraception and avoid pregnancy will be communicated as follows:  DHPC  Educational m a te ria ls  Other material provide d to patients or HCPs  By fie ld re pre s e n ta t iv es  By medical a ctivit ie s |
| Breastfeeding                                | Labeling information (SmPC sections 4.6 and 5.3, Package Leaflet)                                                              | None                                                                                                                                                                                                                                      |
| Patients with renal impairment               | Labeling information (SmPC sections 4.2, 4.4, and 5.2, Package Leaflet)                                                        | None                                                                                                                                                                                                                                      |
| Patients with liver impairment               | Labeling information (SmPC sections 4.2, 4.4, and 5.2, Package Leaflet)                                                        | None                                                                                                                                                                                                                                      |
| Long term safety                             | Labeling information (SmPC section 4.8, Package Leaflet)                                                                       | None                                                                                                                                                                                                                                      |

The applicant presented the details of their proposed Risk Management at the Oral Explanation held on 17 December 2013. No major changes to the pharmacovigilance plan and risk minimisation measures were noted by the CHMP.

The CHMP, having considered the latest PRAC advice and the data submitted in the application is of the opinion that the proposed risk minimisation activities were not able to reduce the risks to an acceptable level.

<div style=\"page-break-after: always\"></div>

## 2.9. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

Laquinimod is a novel orally administered therapy, intended for the treatment of patients suffering from relapsing-remitting multiple sclerosis. Laquinimod is claimed to fulfil an unmet medical need for an oral agent by acting as an immumodulator with CNS protective activity that is at least as effective  as  the  currently  available  first-line  treatments.  The  exact  mechanism  of  action  of laquinimod  is  unknown  but  it  has  shown  beneficial  effects  in  various  types  of  experimental autoimmune encephalomyelitis models as well as in cuprizone induced demyelination, all accepted animal models of multiple sclerosis.

Prevention  and/or  modification  of  relapse  features  as  well  as  prevention  or  delay  of  the accumulation of disability are meaningful goals in the treatment of relapsing multiple sclerosis.

Two large phase 3 pivotal studies (ALLEGRO, BRAVO) over two years were conducted. Both used relapse  rate  as  a  primary  outcome  measure.  Time  to  confirmed  EDSS  progression  was  a  key secondary endpoint.

In ALLEGRO study, a statistically significant effect of laquinimod 0.6 mg compared to placebo was demonstrated for the annualised relapse rate (p=0.0024). Whilst this result was consistent with other efficacy endpoints related to relapses and supported by sensitivity analyses, the reduction in ARR for laquinimod over placebo was modest, 23% over 24 months (RR= 0.770, 95% CI: 0.650, 0.911). In BRAVO study including an active comparator (Avonex), laquinimod 0.6 mg dose failed to show  a  statistically  significant  effect  as  compared  to  placebo  on  the  ARR  (RR=0.823,  95%  CI: 0.664, 1.020, p=0.0746) reflecting a reduction of ARR of 17.7%. In contrast, comparison of the Avonex  treatment  arm  with  placebo  yielded  a  risk  ratio  of  0.741  (95%  CI:  0.596;  0.920, p=0.0067),  demonstrating  a  25.9%  reduction  in  the  annualized  relapse  rate.  The  pre-specified sensitivity analyses were consistent with the primary analysis.

Due to the imbalances observed at baseline for mean T2 lesions volume and proportion of subjects with  GdE  T1  lesions  ≥1  across  treatment  groups,  additional  post-hoc  analyses  were  performed using these MRI parameters as covariates in a corrected model. Such corrected analysis resulted in an increase in magnitude of effect of laquinimod 0.6 mg compared to placebo on ARR (RR=0.787, 95% CI: 0.637, 0.972) of statistically significance (p=0.0264) however this corrected result was still suggesting a modest reduction in ARR of 21.3% in patients treated with laquinimod 0.6 mg in BRAVO  study.  Importantly,  whilst  these  baseline  imbalances  were  also  present  in  the  Avonex group,  treatment  effect  of  Avonex  over  placebo  was  statistically  significant  (p=0.0067)  in  the primary model due to an observed larger treatment effect size of 25.9% reduction in the ARR (RR= 0.741,  95%  CI:  0.596,  0.920).  Numerically,  the  results  on  ARR  were  in  favour  of  Avonex  as compared to laquinimod.  In addition, laquinimod failed to show statistical significance over placebo on  the  time  to  first  relapse  (HR=0.813,  95%  CI:  0.653,  1.014);  p=0.0659),  questioning  the sensitivity of the results observed for the ARR, after the baseline corrected analysis.

<div style=\"page-break-after: always\"></div>

In a meta-analysis including the 2 pivotal studies and the phase II study LAQ/5062, an effect of laquinimod on ARR  was  demonstrated suggesting a 21% reduction for laquinimod versus placebo (RR=0.79, 95% CI : 0.69,0.89, p=0.0002). This result was consistent with  the initially submitted pooled analysis of the two pivotal studies (reduction of 21.4% in ARR, p=0.0005) and is considered modest.

ALLEGRO  study  showed  that  laquinimod  delayed  the  time  to  3-month  confirmed  disability progression, with a statistically significant reduction of 36% over placebo (HR= 0.641; 95% CI: 0.452,  0.908;  p=0.0122).  BRAVO  study  failed  to  demonstrate  such  effect  with  a  lower  risk reduction  of  31.3%  over  placebo  (HR=0.687,  95%  CI:  0.462,  1,020;  p=0.0628).  However,  the CHMP  noted  that  results  on  disability  progression  were  numerically  in  favour  of  laquinimod  as compared  to  Avonex,  although  the  95%  CIs  for  each  of  the  outcomes  were  overlapping.  In addition,  results  from  the  pooled  analysis  using  both  pivotal  studies,  demonstrated  a  34% reduction  in  the  risk  for  3-month  confirmed  disease  progression  (HR  =  0.66,  p=0.002).  When adding the data from the phase II study LAQ/5062 in this pooled analysis, the effect on disability remain with a reduction of around 32% in the risk of disability progression confirmed at 3 months, although the CHMP noted that study LAQ/5062 on its own failed to show an effect on disability (HR= 1.12, 95% CI: 0.33, 3.74). A 44% reduction of disability progression confirmed at 6-months was also observed based on post-hoc analysis of pooled data provided by the applicant from both pivotal  studies,  data  from  study  LAQ/5062  was  not  included  in  this  analysis  due  to  its  short duration.

Different  MRI  endpoints  related  to  clinical  activity  and  for  some  to  long  term  clinical  outcome (cumulative  numbers  of  Gd  enhancing  lesions,  new/enlarging  T2  lesions  for  ALLEGRO,  brain atrophy measure for BRAVO) were also used as secondary efficacy endpoints.

In ALLEGRO study, there was a statistically significant effect of laquinimod as compared to placebo on  mean  adjusted  number  of  T1  Gd-enhancing  lesions  (RR=0.629,95%  CI:  0.488,  0.809, p=0.0003) showing a reduction of 37% in the mean rate of developing T1 Gd-enhancing lesions on laquinimod 0.6 mg compared to placebo. A statistically significant treatment effect of laquinimod 0.6  mg  over  placebo  was  also  shown  on  the  cumulative  number  of  New/Enlarging  T2  lesions (RR=0.704,95% CI: 0.584, 0.849, p=0.0002) indicating a reduction of 30% in the mean rate of developing New/Enlarging T2 lesions on laquinimod 0.6 mg compared to placebo.

In the meta-analysis using the two pivotal studies ALLEGRO and BRAVO, and the phase IIb study LAQ/5062, a treatment effect on GdE T1 lesions was observed with a rate ratio of 0.68 suggesting a reduction of 32% as compared to placebo. This effect was statistically significant (p&lt;0.00001). The  effect  on  new  T2  lesions  was  also  statistically  significant  with  a  reduction  of  27%  versus placebo (Rate Ratio of 0.73, p&lt;0.00001). Regarding brain atrophy, the effect of laquinimod was statistically  significant  as  compared  to  placebo  (difference  of  0.31  in  %  brain  volume  change, p&lt;0.00001).

The  supportive  studies  suggested  maintenance  of  the  effect  of  laquinimod  during  long  term treatment regarding ARR and disability progression.

## Uncertainty in the knowledge about the beneficial effects.

Limited  data  were  provided  regarding  the  pharmacodynamic  effects  of  laquinimod  in  humans. Given  the  mechanism  of  action  has  not  been  sufficiently  investigated  and  the  molecular  target remains unknown, no conclusion could be drawn on the clinical pharmacology of laquinimod.

The optimal dose had not been defined because 0.6 mg dose was the sole dose tested in the phase III studies. In the absence of data using higher doses than 0.6 mg, the CHMP concluded that the

<div style=\"page-break-after: always\"></div>

dose  reponse  effect  of  laquinimod  has  not  been  sufficiently  evaluated  to  determine  the  optimal dose in the intended population.

Limited data after discontinuation of laquinimod treatment are available to evaluate the potential risk of rebound effect.

The  mechanism  of  action  of  laquinimod  is  unknown  and  the  rather  modest  effect  on  relapses questions  the  suitability  of  laquinimod  as  treatment  for  the  broad  population  with  relapsing remitting multiple sclerosis (RRMS) patients.

## Risks

## Unfavourable effects

Liver  enzyme  elevations,  inflammatory  markers  increased  (e.g.  CRP,  fibrinogen),  back  and  neck pain, haematological changes, appendicitis, interaction with CYP3A4 inhibitors/inducers have been identified as important risks.

The effect of laquinimod on the liver appeared to be limited to liver enzyme elevations, but the mechanism  underlying  these  events  is  unknown.  Mostly  mild,  asymptomatic  liver  enzyme elevations (AST, ALT and GGT) were reported that generally occur within 6 months after initiation of treatment. Overall in the pivotal trials, 4.7% of laquinimod treated subjects reached relevantly significant [&gt; 3xULN] levels of ALT. This was more notable for male than for female in laquinimod treated subjects. In 74% of subjects who had elevated levels of ALT on laquinimod, ALT decreased to within the normal range while on laquinimod.

Inflammatory  markers  (CRP,  ESR,  fibrinogen)  were  increased  in  healthy  volunteers  in  phase  I studies.  In  pivotal  studies,  fibrinogen  (40%  vs.  28%)  and  WBC  levels  (27%  vs.  15%)  clearly increased to values above ULN in a higher percentage of patients with laquinimod in comparison with placebo. Increase of fibrinogen was apparent from month 1. In the pivotal studies, until month 15, the proportion of patients with elevations in both CRP and fibrinogen was slightly higher (by approximately 1-2%) in the laquinimod group compared to placebo. At month 2 this difference was statistically  significant  (approximately  4.1%  vs.  2.3%)  and  was  considered  clinically  relevant. Long-term data up to 4 years are available  and  revealed  that,  at  month  48,  the  percentage  of patients  with  potentially  clinically  significant  CRP  elevation  increased  to  5.4%  in  the  laquinimod group.  In  the  pivotal  studies,  the  incidence  of  fibrinogen  level  considered  potentially  clinically significant  (&gt;  6g/l),  was  higher  in  the  laquinimod group  compared to placebo (5.5% vs. 2.6%). Maximal  fibrinogen  did  not  exceed  the  &gt;2.5x  ULN;  maximal  fibrinogen  was  9.0  g/l  in  the laquinimod  group  and  8.4  g/l  in  the  placebo  group  at  any  time  until  month  24.  Overall,  mean duration of elevated fibrinogen or CRP tended to be longer in the laquinimod group compared to placebo.

Haematological toxicity was relevant with laquinimod when compared to placebo, with mostly mild increases in leucocyte levels and decreases in red blood cells and platelets. Two cases of anaemia and one case of acute leukemia in the laquinimod group were considered as serious.

## Uncertainty in the knowledge about the unfavourable effects

There is currently a considerable level of uncertainty on the carcinogenic potential of laquinimod. The  pharmacology  of  laquinimod  is  unclear  thus  making  difficult  the  full  appreciation  of  any pharmacology-driven proliferative or metaplastic processes. Based on pre-clinical data, a potential carcinogenicity  relative  to  oral  cavity  and  uterus  could  not  be  ruled  out.  There  is  a  lack  of mechanistic data to exclude these potential risks in humans. A comparison between laquinimod,

<div style=\"page-break-after: always\"></div>

TCDD and DLCs with regard to major non-neoplastic toxicity, taking all repeat dose toxicity studies of laquinimod into consideration, showed that, although the histopathological findings did not show a  complete  overlap,  it  can  be  concluded  that  laquinimod  shares  a  general  pro-inflammatory, hyperplastic (forestomach, oral cavity and kidney), hepatic and thyroid toxicity profile with TCDD and DLCs. Laquinimod shared also the dioxins class effect of being a potent inducer of CYP1A2. Considering complexity and diversity of AhR-mediated toxic responses, complete overlap between laquinimod  and  TCDD  is  not  expected.  Moreover,  striking  similarities  were  observed  in  the malformation patterns (see below) comparing the teratogenic effects of laquinimod and TCDD in rat, and a mechanism involving the AhR-ER cross-talk pathway could not be excluded. Significant uncertainties also remain with regards to the unknown immunomodulator or immunosuppressant potential, and the potential risks associated with long-term use (i.e. cancer, infections, inflammation),  also  contributing  to  the  insufficient  characterization  of  the  safety  profile  of laquinimod in the intended patient population, although the currently available clinical data did not show evidence of an increased risk of malignancies, immunosuppression or infections.

Malignant tumours have been reported in 26 patients (0.6%) treated with laquinimod in all clinical studies; 6 breast carcinomas including one metastatic breast cancer (3 in cohort 1, all in ALLEGRO and no case in BRAVO; 1 additional case of breast cancer in study LAQ/5062 have been reported in laquinimod  group.  One  breast  cancer  was  reported  in  placebo  group).  In  cohort  1,  10  (1%) patients  in  the  laquinimod  group  vs  6  (0.6%)  patients  with  placebo  experienced  a  malignant tumour (p=0.2944, 95% CI: -0.37, 1.21). In addition to 3 cases of breast cancer, sporadic cases of glioblastoma (1), lung neoplasm malignant (1), lymphoma (1), oesophageal adenocarcinoma (1), squamous cell carcinoma (1), thyroid cancer (1) were reported.  One case of thyroid cancer has been  reported  in  BRAVO  study  in  patient  treated  with  laquinimod.    One  case  of  thyroid  cancer occurred in Avonex group. Concerning skin malignancy, 2 cases (basal cell carcinoma, squamous cell carcinoma) occurred in cohort 1 compared to one case (basal cell carcinoma) in the placebo group. In total,  in  cohort  3  (all  patients  treated  with  laquinimod),  7  subjects  suffered  from  skin malignancies: basal cell carcinoma (4), malignant melanoma (1) and squamous cell carcinoma (2). Overall  incidences  of  malignancies  comparison  with  SEER  Database  did  not  demonstrate  an increase in malignant tumours with laquinimod therapy. However, the number of events to date and duration of follow-up is too limited to definitively exclude a relationship and further long term data are required to ascertain the level of this potential risk. In addition, based on available preclinical  data,  there  remain  relevant  uncertainties  on  the  potential  risk  for  malignancies  .These uncertainties currently represent an important concern with long term use of laquinimod.

Laquinimod was teratogenic in rats, causing hypospadias in females. The most sensitive days for induction  of  these  malformations  were  days  18-21  of  gestation  in  rats,  while  exposure  before implantation or during lactation did not induce this type of malformation. In F1 males, hypospadias were also reported and other findings consisted of dose-dependent delayed growth which persisted up to adult age in the high dose group, a clear dose-dependent delay in onset of puberty, and decreased  fertility  in  spite  of  normal  sperm  parameters.  In  addition,  the  absolute  weight  of prostate and seminal vesicles were decreased at the high dose level. In F1 females, in addition to the urogenital abnormalities, there were also treatment-related effects on growth, delayed vaginal opening at the high dose level only, prolonged estrous cycle length, decreased fertility at the mid and  high  dose  levels.  Treatment  also  had  an  impact  on  F2  generation  as  seen  from  decreased viability of F2 pups born from F1 females (high-dose group). Most of the findings obtained in F1 animals were suggestive of a hormonal effect of laquinimod. An effect of laquinimod on the AhR-ER cross-talk pathway cannot be excluded as possible mechanism underlying its potential endocrinedisrupting effects. No definitive conclusions could be drawn regarding the teratogenic potential of laquinimod in cynomolgus monkeys. In clinical MS studies, females of child bearing potential were required to practice effective contraception. Nonetheless, 74 pregnancies have been reported in the

<div style=\"page-break-after: always\"></div>

laquinimod development programme, of which 43 were reported in subjects exposed to laquinimod (38  female  patients  treated  and  5  male  subjects  reporting  pregnancies  of  partners)  as  of  1 September 2013. The potentially delayed effects of laquinimod seen in preclinical studies (notably on puberty and fertility), which would not be noticeable at birth are of important concern for the CHMP,  especially  considering  the  intended  use  in  MS  patients  (mostly  females  of  child  bearing potential)  and  the  absence  of  an in  vivo interaction  study  investigating  the  potential  effect  of laquinimod on the pharmacokinetics of oral contraceptives.

Although  low,  the  incidence  of  ischemic  heart  disease  was  higher  in  the  laquinimod  group compared to  placebo  (0.6%  vs  0.1%)  in  the  pivotal  studies.  Overall,  20  reports  in  15  subjects (0.6%) reported ischemic heart disease including 2 subjects that were diagnosed with myocardial infarction  in  the  laquinimod  group.  Two  out  of  9  deaths  in  the  laquinimod  group  were  due  to cardiovascular  failure  (sudden  death  within  5  hours  post  treatment)  and  myocardial  infarction (after 5 months of treatment), respectively. Patients with significant cardiovascular conditions were excluded from the pivotal trials. On this basis and considering the safety data from roquinimex, a structurally related product, cardiotoxicity was considered as a potential risk for laquinimod.

Due to the potential of formation of tissue adducts seen in preclinical studies, drug hypersensitivity  reactions  should  be  considered  as  a  potential  risk  for  laquinimod,  given  its intended chronic use.

## Benefit-risk balance

## Importance of favourable and unfavourable effects

Laquinimod is a novel substance, which is proposed as orally administered treatment of relapsing remitting multiple sclerosis. Currently, a number of MS drugs are available in the EU as oral or parenteral formulations and are indicated either as first line or second line therapies. The exact mechanism of action of laquinimod is unknown and the molecular therapeutic target has not been identified. This lack of knowledge raised serious concerns over the pharmacology of laquinimod, especially  given  its  overall  unfavourable  toxicity  profile  (general  toxicity,  carcinogenicity  and reproductive toxicity). Furthermore, the toxicity profile correlates well with what has been shown for AhR agonists such as TCDD (dioxin). The main risks in humans for laquinimod included liver enzyme elevations, inflammatory markers increased (e.g. CRP, fibrinogen), back and neck pain, haematological changes, appendicitis as well as potential risks of carcinogenicity and teratogenicity  based  on  findings  in  animal  studies.  There  are  no  obvious  risk  minimisation measures  for  the  potential  carcinogenic  risk.  The  experience  with  the  clinical  development programme of laquinimod has shown poor control of pregnancy in the target population. In such a context,  the  effectiveness  of  preventive  measures  for  potential  teratogenic  and  long-term endocrine disrupting effects is doubtful. Overall, the proposed risk minimisation measures were considered  not  able  to  reduce  these  risks  to  an  acceptable  level.  Whilst  an  effect  on  disability progression was shown, the effect on relapses was modest at the proposed 0.6 mg dose in the broad adult RRMS population, not outweighing the safety concerns.

## Benefit-risk balance

Having  considered  the  efficacy  of  laquinimod  was  modest  on  relapse  rate  in  the  adult  RRMS population  at  the  proposed  dose,  notwithstanding  the  more  encouraging  effect  on  disability progression, the CHMP concluded that the benefit-risk balance for Nerventra was negative based on the unknown mechanism of action, the unfavourable overall toxicity profile (general toxicity, carcinogenicity and reproductive toxicity) seen in animal studies with potential human risks that cannot be currently excluded, and the absence of obvious risk minimisation measures to ensure

<div style=\"page-break-after: always\"></div>

its safe long term use, for the following indication:

'Nerventra  is  indicated  for  the  treatment  of  adult  patients  with  relapsing  remitting  multiple sclerosis  (RRMS)  (please  refer  to  section 5.1  for  important  information  on  the  populations  for which efficacy has been established)'.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy for Nerventra in the treatment of    adult  patients  with  relapsing  remitting  multiple sclerosis,  the  CHMP  considers  by consensus that:

the safety and  efficacy of the above  mentioned  medicinal  product  are  not  sufficiently demonstrated, and, therefore recommends the refusal of the granting of the  Marketing Authorisation  for the above mentioned medicinal product. The CHMP considers that:

- The overall toxicity profile (general toxicity, carcinogenicity and reproductive toxicity) seen in animal  studies  is  unfavourable  and  a  potential  carcinogenic  risk  with  long  term  use  in  humans cannot currently be excluded, especially considering that the mechanism of action of laquinimod has not been sufficiently investigated and is unknown;
- The modest efficacy of laquinimod on relapse rate in adult patients with relapsing remitting multiple  sclerosis  (RRMS)  at  the  proposed  0.6mg  dose  does  not  outweigh  the  safety  concerns, notwithstanding the more encouraging effect on disability progression;
- The  absence  of  obvious  measures  to  address  the  potential  carcinogenic  risk  and  potential endocrine disrupting effects and consequently to ensure the safe long term use of laquinimod in the RRMS population is of concern. There is also evidence of limited effectiveness of the pregnancy preventive measures in clinical studies to address the potential risk of teratogenicity and delayed effects.

Thus,  the  CHMP  concluded  that  the  benefit-risk  balance  of  laquinimod  was  negative  at  the proposed  dose  of  0.6  mg  in  the  treatment  of  adult  patients  with  relapsing  remitting  multiple sclerosis.

Due to the aforementioned concerns a satisfactory summary of product characteristics, labelling, package leaflet and risk management plan cannot be agreed at this stage.

Furthermore, the CHMP, in light of the negative recommendation, is of the opinion that it is not appropriate to conclude on the new active substance status at this time.

## 5. Re-examination of the CHMP opinion of 23 January 2014

Following  the  CHMP  conclusion  that    the  application  for  marketing  authorisation  of  Nerventra (laquinimod) was not approvable because of the unfavourable toxicity profile seen in animal studies and  the  potential  carcinogenic  risk  with  long  term  use  in  humans  that  cannot  currently  be excluded, especially considering that the mechanism of action is unknown; the modest efficacy of laquinimod on relapse rate at the proposed dose and in the intended population and the absence of

<div style=\"page-break-after: always\"></div>

obvious  measures  to  address  the  potential  carcinogenic  risk  and  potential  endocrine  disrupting effects, the applicant submitted detailed grounds for the re-examination of the grounds for refusal.

## 5.1. Detailed grounds for re-examination submitted by the applicant

The applicant presented in writing and at an oral explanation.

A summary of the applicant's detailed grounds for the re-examination of the grounds for refusal is presented below.

Ground for refusal #1: The overall toxicity profile (general toxicity, carcinogenicity and reproductive toxicity) seen in animal studies is unfavourable and a potential carcinogenic risk with long term use in humans cannot currently be excluded, especially considering  that  the  mechanism  of  action  of  laquinimod  has  not  been  sufficiently investigated and is unknown.

## Applicant responses: grounds for appeal- non clinical considerations

A  major  concern  of  the  CHMP,  as  indicated  in  the  SWP  report,  arises  from  the  association  of \"laquinimod with an overall toxicity profile (general toxicity, immune system effects, reproductive toxicity and carcinogenicity) that correlates well with what has been shown for AhR agonists such as e.g. TCDD.' and that 'it cannot be excluded that the tumours were caused by the interaction of laquinimod or its metabolites with the AhR receptor. Such mechanism(s) can be of relevance for humans'.

Taking into consideration the above, the applicant provided the following arguments:

- Laquinimod is an AhR activator and as such there are some similarities to other AhR-activating compounds,  which  include  drugs  and  dietary  compounds.  In  the  CHMP  negative  opinion,  it  was concluded that laquinimod and AhR-activating  compounds  share  molecular  effects  (CYP1A induction) and some toxicities, and therefore laquinimod may be associated with the toxicities of TCDD  and  DLC.  Based  on  further  analyses  (including  literature,  published  data  and  expert opinions) conducted in order to understand the mechanisms involved, the applicant argued that it is clear that laquinimod is very different from TCDD/DLCs, and does not result in the same toxic effects as this class of compounds. There is a greater similarity between laquinimod and the dietary AhR activator indol-3- carbinol (I3C), a component of broccoli and other cruciferous vegetables.

Laquinimod  and  TCDD  are  both  potent  inducers  of  CYP1A1/2.  However,  CYP1A  induction  is  a dissociated event from dioxin-like toxicity, even if both activities are mediated by AhR activation. The applicant view is that CYP1A induction is considered a biomarker of AhR activation, but not an indicator of AhR toxicity.

Laquinimod and DLCs differ in critical attributes of mode of AhR activation, gene expression, and pharmacological responses. The major differences between laquinimod and TCDD/DLCs include:

- Structural and physicochemical differences: TCDD (like all other DLCs) is a highly lipophilic, nonionized,  planar  molecule  that  distributes  extensively  into  adipose  tissue.  Laquinimod  is  a  nonplanar  molecule,  ionized  at  physiologically  relevant  pH  with  relatively  high  aqueous  solubility. These  differences  may  explain  the  different  AhR  activation  characteristics  noted  for  the  two compounds.

- No sensitivity of laquinimod to a TCDD/DLC antagonist: laquinimod transiently activates AhR by a mechanism other than the canonical direct binding to the TCDD/DLCs binding site.

<div style=\"page-break-after: always\"></div>

-  The pharmacokinetic properties of laquinimod are fundamentally different from those of TCDD, with  the  most  notable  difference  being  the  biological  persistence  of  TCDD.  In  humans,  the elimination half-life of TCDD is 8 to 10 years, compared with an 80-hour half-life of laquinimod.

- Laquinimod and TCDD induce distinct sets of hepatic genes with very little overlap. Laquinimod induces only a small subset of TCDD responsive genes, most of which encode enzymes involved in xenobiotic  metabolism  that  are  not  mediators  of  TCDD  toxicity.  Furthermore,  gene  expression analysis of samples from the ALLEGRO study showed that laquinimod does not induce TCDD/DLCresponsive genes in peripheral blood mononuclear cells (PBMCs) from treated patients.

- Laquinimod lacks the hallmark toxicities characteristic of TCDD and related compounds in animals and humans, namely wasting syndrome, immune suppression, porphyria, progressive liver toxicity and chloracne.

- The laquinimod tumourigenic profile in rodents is different from that of TCDD and DLCs.

<div style=\"page-break-after: always\"></div>

Laquinimod exhibits a toxicity response in animals that is substantially different  from  and  much more benign than that caused by TCDD and DLCs in terms of both non-neoplastic and neoplastic endpoints. Laquinimod in rats does not induce tumours in lung, liver or pancreas. In contrast, the incidence of these tumours with TCDD is very high. See Tables 34 and 35:

Table 34. Comparison of Incidence of Pivotal Non-Neoplastic Lesions Induced by TCDD, I3C and Laquinimod in 2-Year Studies - Female SD Rats

| Organ and lesion                                    | TCDD                                                                                   | I3C                                                                                     | LAQUINIMOD (Study 1028/119)                                                              |
|-----------------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| High Dose (mg/kg)                                   | 0.0001                                                                                 | 300                                                                                     | 1                                                                                        |
| CYP 1A fold induction (liver)                       | 70                                                                                     | 81                                                                                      | 130                                                                                      |
| Liver - Toxic hepatopathy                           | +++                                                                                    | +/-                                                                                     | +/-                                                                                      |
| Liver - Oval cell hyperplasia                       | +++                                                                                    | -                                                                                       | -                                                                                        |
| Bile duct hyperplasia                               | +++                                                                                    | -                                                                                       | -                                                                                        |
| Lungs -metaplasia                                   | +++                                                                                    | -                                                                                       | -                                                                                        |
| Adrenal cortex - Atrophy, vacuolation, degeneration | ++                                                                                     | +                                                                                       | -                                                                                        |
| Pancreas - lesions                                  | +++                                                                                    | +                                                                                       | -                                                                                        |
| Heart - cardiomyopathy                              | +++                                                                                    | ++                                                                                      | -                                                                                        |
| Thyroid gland - lesions                             | +                                                                                      | ++                                                                                      | +                                                                                        |
| Thymus atrophy                                      | 42/42 ( average severity 3.9 ) compared to 36/51in control ( average severity 2.6 ) i) | 38/50 ( average severity 2.3 ) compared to 38/47 in control ( average severity 2.2 ) i) | 39/58 ( average severity 2.5 ) compared to 31/59 in control ( average severity 2.2 ) ii) |
| Oral mucosa -hyperplasia                            | +                                                                                      | +                                                                                       | +                                                                                        |
| Forestomach -hyperplasia/ hyperkeratosis            | +                                                                                      | +                                                                                       | ++                                                                                       |
| Uterus -cystic hyperplasia, metaplasia              | -                                                                                      | ++                                                                                      | -                                                                                        |
| Nose -epithelium hyperplasia                        | -                                                                                      | +                                                                                       | -                                                                                        |
| Larynx - metaplasia                                 | -                                                                                      | -                                                                                       | +/-                                                                                      |
| Kidney - nephropathy                                | -                                                                                      | +++                                                                                     | -                                                                                        |
| Kidney - hyperplasia                                | ++                                                                                     | ++                                                                                      | +                                                                                        |
| Urinary bladder - hyperplasia, metaplasia           | -                                                                                      | -                                                                                       | +/-                                                                                      |

i)  Severity scale: 1-minimal 2-mild 3-moderate 4-marked

ii) Severity scale: 1-minimal 2-slight 3-moderate 4-moderately severe

Table 35. Comparison of Incidence (%) of Pivotal Neoplastic Lesions Induced by TCDD, I3C and Laquinimod in 2-Year Studies - Female SD Rats

<!-- image -->

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Neoplasm                                       | TCDD   | I3C   | LAQUINIMOD (Study 1028/119)   |
|------------------------------------------------|--------|-------|-------------------------------|
| High Dose (mg/kg)                              | 0.0001 | 300   | 1                             |
| CYP 1A fold induction (liver)                  | 70     | 81    | 130                           |
| Cholangiocarcinoma                             | 47     | -     | -                             |
| Hepatocellular adenoma                         | 24.5   | -     | -                             |
| Hepatocholangioma                              | 4      | -     | -                             |
| Lung - Cystic keratinizing epithelioma         | 17     | 2     | -                             |
| Oral Mucosa - Gingival squamous cell carcinoma | 19     | 4     | 3.3                           |
| Uterus-adenoma/carcinomas                      | - i)   | 8     | 11                            |
| Pancreas- acinar adenoma/carcinoma             | 6      | -     | -                             |

i) Equivocal results are reported for TCDD. In one study, there was a reduced incidence and in a second study, there was an increase but not in the highest dose tested.

The  applicant  claimed  that  experts  in  the  field  clearly  dissociate  laquinimod  from  TCDD  and conclude that it does not fulfil the toxicity equivalence criteria set by the WHO for DLCs. According to the criteria of the World Health Organization (WHO), laquinimod and its minor metabolite DELAQ cannot be classified as DLCs, and laquinimod is not expected to have a similar toxicity risk as DLCs.

According to the applicant, there is a clear distinction between DLCs and non-DLCs that activate AhR  in  as  much  as  there  is  no  evidence  that  any  non-DLC,  the  class  of  compounds  to  which laquinimod belongs, can elicit the spectrum of effects characteristic of TCDD toxicity.

Therefore,  it  is  the  applicant's  view  that  risk  assessment  for  laquinimod  should  be  done independent  of  DLCs,  based  on  the  safety  signals  identified  in  the  development  program  of laquinimod.

With  regard  to  rat  carcinogenicity  findings,  the  applicant  indicated  that  the  hallmarks  of  TCDD carcinogenicity in rats, namely liver and lung tumours, were not seen with laquinimod. The uterine tumours are not considered characteristic of the carcinogenicity profile of DLCs. Thus, only the oral tumours can be considered similar between laquinimod and DLCs. Notably, this type of tumour was also demonstrated in rats for the dietary AhR activator, I3C, a component of broccoli and other cruciferous vegetables.

Laquinimod induced a low incidence of tumours in the oral cavity and in the uterus of female rats and  thyroid  tumours  in  male  rats.The  applicant  maintains  that  the  carcinogenicity  findings  are species-specific and do not imply an elevated carcinogenicity risk in humans.

The  uterine  adenocarcinomas  seen  with  laquinimod  likely  involve  mechanisms  specific  to  aged female  rats.  An  involvement  of  the  AhR  pathway  activation  for  the  oral  mucosa  squamous  cell tumours in rats is plausible. The mode of administration and the high local concentration are likely to  separate  this  mechanism  from  the  human  condition.  It  should  be  noted  that  in  humans,  no significant  increase  in  oral  tumours  is  associated  with  exposure  to  TCDD.  Furthermore,  gene expression data indicate that rats are a more sensitive species to laquinimod than humans.

<div style=\"page-break-after: always\"></div>

With  regard  to    the  CHMP  concern  of  laquinimod's  endocrine  disruption  potential,  the  applicant argued that laquinimod is distinctly different from endocrine disruptors like diethylstilbestrol (DES) as  neither  laquinimod  nor  its  trace  metabolite,  DELAQ,  bind  or  activate  the  oestrogen  receptor. Even  though  DELAQ  displayed  indirect  anti-estrogenic  effects  in  an  in  vitro  assay,  it  did  so  at concentrations higher than those in the plasma of laquinimod-treated patients. In any case, antiestrogenic effects would be expected to protect against, rather than cause uterine tumours.

Regarding  the  CHMP  concern  related  to  developmental  and  reproductive  toxicity,  the  applicant acknowledged that AhR involvement in these findings remains a possibility in view of an AhR role in developmental processes in animals. The applicant pointed out the species specificity of the noted malformations  and  presents  epidemiological  data  indicating  that  the  risk  of  birth  defects  is  not increased in populations exposed to TCDD. This notwithstanding, to mitigate the potential human teratogenic risk, the applicant committed  to implement a rigorous pregnancy prevention programme in clinical trials and in the post-marketing program to prevent exposure to laquinimod during pregnancy.

To  address  the  CHMP  concerns  regarding  lack  of  understanding  of  laquinimod  pharmacological mode of action and the possible involvement of AhR, the applicant has  summarised (i) studies that have  been  performed  to  further  explore  the  mechanism  underlying  the  immunomodulatory  and neuroprotective  properties  of  laquinimod  and  (ii)  demonstrate  that  key  elements  in  laquinimod mode of action are different from other AhR activators and that laquinimod elicits only a subset of AhR-mediated biological responses. The applicant argued that the pharmacological mode of action of laquinimod was extensively investigated and concluded that laquinimod and other AhR activators (including TCDD/DLCs) share a number of biological effects on the immune system. However, there are  marked  differences  in  the  cellular  mechanisms  involved:  whilst  laquinimod  targets  Antigen Presenting  Cells  (APCs)  which  lead  to  T-cell  modulation,  with  no  direct  effect  on  T-cells,  high affinity AhR ligands such as TCDD/DLCs target both T-cells and APCs. Although it is plausible that AhR  may  be  involved  in  the  biological/pharmacological  mode  of  action  of  laquinimod,  there  is currently  no  molecular  proof  for  this  hypothesis.  The  applicant  committed  to  continue  the investigations  on  the  mode  of  action  of  laquinimod,  as  well  as  to  investigate  the  mechanisms involved in the adverse signals seen in animals to further elucidate possible human relevance.

The applicant concluded that the overall properties and toxicity profile of laquinimod are markedly different  from  those  of  DLCs.  Laquinimod  cannot  be  considered  a  DLC  and  risk  assessment  of laquinimod  should  be  independent  of  this  group  of  chemicals.  The  carcinogenicity  findings  are species-specific  and  do  not  imply  an  elevated  carcinogenicity  risk  in  humans.  In  terms  of  the teratogenicity findings, the applicant proposes a comprehensive pregnancy prevention programme that incorporates all measures suggested by the CHMP.

## Ground  for  refusal  #2:  The  modest  efficacy  of  laquinimod  on  relapse  rate  in  adult patients with relapsing remitting multiple sclerosis (RRMS) at the proposed 0.6mg dose does not outweigh the safety concerns, notwithstanding the more encouraging effect on disability progression

## Applicant responses: risk and benefit statement

The  applicant  was  of  the  view  that  laquinimod  has  demonstrated  efficacy  on  relapse-based outcomes in line with other standard therapies for RRMS. The effects of laquinimod on disability progression are large, consistent, maintained over increasingly rigorous confirmation time intervals and demonstrated across the spectrum of baseline EDSS.

A published analysis using mediation modelling showed that the disability effect was substantially mediated  by  the  effect  on  relapses  in  the  first  year  for  fingolimod,  the  proportion  of  treatment effect (PTE) was 60% (Sormani 2013), a similar analysis was performed on the pooled ALLEGRO

<div style=\"page-break-after: always\"></div>

and BRAVO laquinimod data set, the relapse contribution to the effect on disability was only 11%. In other words, while, the processes which contribute to fingolimod's disability reduction overlap substantially  with  those  which  lead  to  its  relapse  suppression,  most  of  laquinimod's  disability reduction  is  likely  explained  by  other  mechanisms.  On  this  basis,  the  applicant  argued  that laquinimod likely has a direct effect on CNS processes related to disability progression outside of relapses.

The applicant noted that the clinical profile corresponds to non-clinical findings related to diffuse changes  in  the  normal  appearing  brain  tissue,  chronic  white  matter  changes  and  grey  matter. Further corroboration of the effect on brain tissue loss come from an ALLEGRO MRI ancillary study showing  a  decrease  in  whole  brain  atrophy,  regional  thalamic  atrophy,  preservation  of  MTR  in whole brain as well as in normal appearing white matter (NAWM), and reduction in the evolution of permanent T1 hypointense lesions.

Such a mechanism may offer an alternative treatment approach in RRMS patients and may be of specific value for MS patients in whom the impact of relapses and relapse frequency are expected to be clinically less significant and the reduction of CDP via an alternate pathway is sought.

The  applicant  therefore  proposed  that  laquinimod  will  be  indicated  for  patients  with  RRMS  who have  demonstrated  disease  worsening  and  have  reached  an  EDSS  above  3.  A  summary  of  the baseline characteristics and post hoc analyses of this subgroup of RRMS population is presented below. See Tables 36 and 37.

<div style=\"page-break-after: always\"></div>

## Table 36. Baseline characteristics

| Pooled ALLEGRO and BRAVO                         | EDSS≤3.0 (N=1335)   | EDSS>3.0 (N=655)   |
|--------------------------------------------------|---------------------|--------------------|
| Age (Years) Mean ± SD                            | 36.5± 9.1           | 41.3± 8.7          |
| Weight (kg) Mean ± SD                            | 71.0± 15.9          | 70.4± 15.7         |
| BMI (kg/m^2) Mean ± SD                           | 24.8± 5.2           | 24.8± 5.0          |
| Female Gender N (%)                              | 910 ( 68.2%)        | 452 ( 69.0%)       |
| Previous MS Treatment N (%)                      | 325 ( 24.3%)        | 163 ( 24.9%)       |
| EDSS at Baseline Mean ± SD                       | 1.9± 0.7            | 4.1± 0.7           |
| Time from MS Diagnosis (Years) Mean ± SD         | 3.7± 4.6            | 5.2± 5.3           |
| Time from First Symptom (Years) Mean ± SD        | 6.9± 6.1            | 9.7± 7.2           |
| # of Relapses in 1y Prior to Screening Mean ± SD | 1.2± 0.7            | 1.3± 0.7           |
| # of Relapses in 2y Prior to Screening Mean ± SD | 1.8± 0.9            | 2.0± 1.0           |
| # of GdE-T1 Lesions Mean ± SD                    | 1.5± 4.2            | 2.2± 6.7           |
| Volume of T2 Lesions (cm^3) Mean ± SD            | 7.8± 8.7            | 12.3± 12.0         |
| Baseline Brain Volume Mean ± SD                  | 1601± 90.0          | 1547± 90.8         |
| GdE lesions>0 at Baseline N (%)                  | 538 ( 40.3%)        | 259 ( 39.5%)       |

<div style=\"page-break-after: always\"></div>

Table 37: Results of Key Clinical Outcomes by EDSS at Baseline

|                                                    |                        | EDSS ≤3.0 LAQ 0.6 mg, n=656 (66.7%) Placebo, n=679 (67.5%)   | EDSS >3.0 LAQ 0.6 mg, n=328 (33.3%) Placebo, n=327 (32.5%) 0.751 [0.601;   |
|----------------------------------------------------|------------------------|--------------------------------------------------------------|----------------------------------------------------------------------------|
| Annualized Relapse Rate                            | Risk Ratio [CI]        | 0.798 [0.672; 0.948]                                         | 0.939]                                                                     |
| Annualized Relapse Rate                            | laquinimod Effect      | 20%                                                          | 25%                                                                        |
| Annualized Relapse Rate                            | p-value                | 0.0103                                                       | 0.0119                                                                     |
| Time To 3-month CDP                                | Hazard Ratio [CI]      | 0.692 [0.501; 0.956]                                         | 0.595 [0.381; 0.931]                                                       |
| Time To 3-month CDP                                | laquinimod Effect      | 31%                                                          | 40%                                                                        |
| Time To 3-month CDP                                | p-value                | 0.0256                                                       | 0.0229                                                                     |
| Time To 6-month CDP                                | Hazard Ratio [CI]      | 0.600 [0.410; 0.879]                                         | 0.468 [0.266; 0.823]                                                       |
| Time To 6-month CDP                                | laquinimod Effect      | 40%                                                          | 53%                                                                        |
| Time To 6-month CDP                                | p-value                | 0.0088                                                       | 0.0083                                                                     |
| Disability As Assessed By MSFC Z-Score At Month 24 | Adj. Mean Diff. [CI]   | -0.016 [- 0.116;0.                                           | 0.245 [0.101; 0.389]                                                       |
| Disability As Assessed By MSFC Z-Score At Month 24 | p-value                | 0.7614                                                       | 0.0009                                                                     |
| Brain Atrophy As Defined                           | Adj. Mean Diff. [CI]   | 0.338 [0.208; 0.469]                                         | 0.393 [0.208; 0.578]                                                       |
| By PBVC                                            | p-value                | <.0001                                                       | <.0001                                                                     |
| Cumulative GdE T1 Lesions                          | Rate Ratio             | 0.662 [0.533; 0.822]                                         | 0.829 [0.607; 1.133]                                                       |
| At Months 12 and 24                                | laquinimod Effect [CI] | 34%                                                          | 17%                                                                        |
| At Months 12 and 24                                | p-value                | 0.0002                                                       | 0.2390                                                                     |
| Cumulative New/Enlarging                           | Rate Ratio [CI]        | 0.772 [0.653; 0.912]                                         | 0.753 [0.592; 0.959]                                                       |
| T2 Lesions At Months 12                            | laquinimod Effect      | 23%                                                          | 25%                                                                        |
| and 24                                             | p-value                | 0.0024                                                       | 0.0214                                                                     |

For the proposed  population, the importance  of reducing further disability progression is heightened,  as  the  next  steps  in  their  progression  have  clinically  significant  functional  and especially ambulation impact. These patients are older, have longer disease duration, largely will have received prior DMTs in the member states and developed moderate disability and brain tissue loss in  spite  of  treatment  with  available  DMTs.  The  point  estimates of  the  efficacy  profile  in this

<div style=\"page-break-after: always\"></div>

group  include  a  25%  reduction  in  relapse  rate,  a  53%  reduction  in  6  months  CDP,  as  well  as reduced brain atrophy. Overall, while the above table shows no differential treatment effects on key clinical and MRI endpoints between these two EDSS subgroups, the MSFC is an exception. In the EDSS&gt;3 subgroup, a significant MSFC effect of laquinimod (mean z-score difference of 0.25; p=0.0009)  is  noted.  The  interaction  for  this  MSFC  treatment  effect  by  subgroup  is  statistically significant  (p=  0.0037).  As  shown  in  Table  38,  there  was  a  significant  treatment  benefit  on  the T25FW, which appears to drive the MSFC effect in the EDSS&gt;3 subgroup. A treatment effect on the T25FW is also evident in the individual studies (ALLEGRO and BRAVO). There was no significant PASAT or 9HPT difference between laquinimod and placebo treated subjects in either  subgroup, although the directions of change were consistent with a laquinimod effect.

Table 38: ALLEGRO and BRAVO Efficacy Results: MSFC Components by EDSS at Baseline

|                                        |                      | EDSS ≤3.0 LAQ 0.6 mg, n=656 (66.7%) Placebo, n=679 (67.5%)   | EDSS >3.0 LAQ 0.6 mg, n=328 (33.3%) Placebo, n=327 (32.5%)   |
|----------------------------------------|----------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| PASAT Change from Baseline to Month 24 | Adj. Mean Diff. [CI] | 0.302 [-0.467; 1.071]                                        | 0.586 [-0.515; 1.687]                                        |
| PASAT Change from Baseline to Month 24 | p-value              | 0.4411                                                       | 0.2967                                                       |
| 9HPT Change from Baseline to Month 24  | Adj. Mean Diff. [CI] | -1.108 [-3.041; 0.681]                                       | -1.590 [-4.257; 1.077]                                       |
| 9HPT Change from Baseline to Month 24  | p-value              | 0.2137                                                       | 0.2425                                                       |
| T25FW Change from Baseline to Month 24 | Adj. Mean Diff. [CI] | 0.055 [-1.250; 1.359]                                        | -2.79 [-4.664; - 0.917]                                      |
| T25FW Change from Baseline to Month 24 | p-value              | 0.9342                                                       | 0.0035                                                       |

* Adj Mean Diff: adjusted mean difference

According  to  the  applicant,  these  patients  experienced  a  significant  59%  effect  on  the  T25FW, denoting an important benefit to motor activity and substantiation of the profound CDP effect.

The identified clinical  and  laboratory  risks  with laquinimod are generally mild and do not pose a concern  in  this  specific  population  in  the  applicant's  opinion.  The  potential  risks  of  human teratogenicity  and  potential  carcinogenicity,  which  may  be  associated  with  long  term  treatment, are  expected  by  the  applicant  to  be  mitigated  in  the  newly  identified  targeted  subpopulation through  considerably  lower  pregnancy  rates  expected  in  this  population  and  overall  shorter potential exposure during the RRMS phase, as these patients start treatment later in the disease. According  to  the  applicant,  this  is  specifically  pertinent  as  laquinimod  has  no  mutagenic  or clastogenic potential.

While the precise molecular target of laquinimod remains unknown, key elements in the laquinimod mode of action are different from other AhR activators and laquinimod elicits only a subset of AhRmediated  biological  responses.  Laquinimod  is  clearly  characterized  as  a  non-DLC  AhR  pathway activator with substantial  differentiation  from  TCDD  and  other  DLCs  on  organ  toxicology, carcinogenicity  in  target  organs,  and  gene  expression  profiling.  Transcriptome  analyses  only demonstrate minimal overlap, predominantly in CYP1 genes.

Regarding  the  potential  carcinogenicity  risk,  the  applicant  maintains  that  the  carcinogenicity findings from rodent studies are species-specific and do not imply an elevated carcinogenicity risk in humans.

<div style=\"page-break-after: always\"></div>

Warnings  are  proposed  to  be  implemented  in  the  SmPC.  According  to  the  applicant,  additional measures to determine whether the hypothetical carcinogenicity poses a risk to humans, include an adequately powered PASS aligned with EMA expectations.

Regarding the potential teratogenicity risk, the mechanism underlying the findings in rat offspring is unknown and AhR involvement in the teratogenic findings in rats remains a possibility in view of its role in developmental processes in many experimental animals. Laquinimod is contraindicated during pregnancy. The applicant has adopted a comprehensive pregnancy prevention program for ongoing clinical trials and the postmarketing setting.

Taking  into  consideration  laquinimod's  modest  effect  on  relapses,  its  larger  effect  on  disability progression and the potential risks, the applicant considered that the benefit and risk balance in the targeted population of patients that reached an EDSS greater than 3 is positive.

Ground #3: The absence of obvious measures to address the potential carcinogenic risk and potential endocrine disrupting effects and consequently to ensure the safe long-term use of laquinimod in the RRMS population is of concern. There is also evidence of limited effectiveness  of  the  pregnancy  preventive  measures  in  clinical  studies  to  address  the potential risk of teratogenicity and delayed effects.

## Applicant responses: measures to address the potential risks

The  applicant  acknowledges  that  a  potential  long  term  carcinogenic  risk  to  humans  cannot  be excluded, because an increase in the incidence of oral mucosa cancers and uterine adenocarcinomas  was  observed  in  rats  treated  with  laquinimod.  However,  it  is  the  applicant's contention  that  the  carcinogenicity  findings  from  rodent  studies  are  species-specific  and  do  not imply an elevated carcinogenicity risk in humans. The uterine adenocarcinomas are not considered characteristic of the carcinogenicity profile of DLCs, and likely involve mechanisms specific to aged female  rats.  An  involvement  of  the  AhR  pathway  activation  for  the  oral  mucosa  squamous  cell tumours in rats is plausible. The mode of administration and the high local concentration that occur with  rodents  does  not  occur  during  the  treatment  of  humans  and  thus,  this  mechanism  is  not relevant  to  any  risk  associated  with  administration  of  laquinimod  to  humans.  Furthermore,  the absence of a signal for an increased risk of cancer from the extensive clinical trial program, the fact that  laquinimod  activates  the  AhR  pathway  in  a  non-DLC  manner,  as  well  as  the  significant uncertainty  regarding  an  observable  human  cancer  risk  even  for  DLCs  in  exposed  individuals, mitigates the concern of this potential long-term risk. Furthermore, for the populations of RRMS patients with EDSS greater than 3, exposure will be substantially reduced. The absence of obvious clinical or laboratory measures to address potential carcinogenicity is inherent in this type of risk, which is in line with similar issues with other products demonstrating animal carcinogenicity. The applicant  proposed  to  implement  similar  measures  to  those  that  have  been  proposed  for  other products with a potential or identified cancer risk, including a PASS to further characterise the risk. This PASS will be aligned with all CHMP recommendations. Further changes to labelling, including an additional warning related to the potential carcinogenic risk were suggested.

The  applicant  also  agreed  that  the  human  relevance  of  potential  teratogenicity  and  long  term effects  cannot  be  excluded  for  laquinimod,  and  that  a  comprehensive  pregnancy  prevention program should be in place. The mechanism underlying the findings in rat offspring is unknown and AhR  involvement  in  these  findings  remains  a  possibility  in  view  of  its  role  in  developmental processes in many experimental animals. An anti-estrogenic effect on the fetus (through ER-AhR cross talk) cannot be excluded, but the \"endocrine disrupting\" effect of the compounds listed by the CHMP (ethinyl estradiol, 17β-estradiol, diethylstilbestrol, tamoxifen and testosterone) and the clinical consequences of exposure to these compounds are not relevant for laquinimod. In regards to the concern about an AhR-related effect in humans, lack of malformations in subjects who were

<div style=\"page-break-after: always\"></div>

exposed to TCDD, in the Seveso cohort, is somewhat reassuring. The applicant is committed to prevent  foetal  exposure  to  laquinimod,  and  is  implementing  all  components  of  the  pregnancy prevention program in the clinical studies. For the proposed indicated population as a whole, the attributable risk of potential teratogenicity in this older, more disabled population is substantially reduced due to the significant drop in expected pregnancy rates.

## 5.2. Additional expert consultation

Following a request from the applicant at the time of the re-examination, the CHMP convened a Scientific Advisory Group (SAG) inviting the experts to provide their views on the CHMP grounds for refusal, taking into account the applicant's response.

In addition, during the re-examination, the CHMP requested, at their April 2014 Plenary meeting, the Safety Working Party (SWP) and the PRAC to address a number of questions related to the applicant's detailed grounds for the re-examination.

## Report from the SWP

The CHMP questions to be addressed by the SWP were as follows:

1) Given the new arguments developed by the applicant in the grounds for the re-examination, in particular that laquinimod would be a non-toxic AhR activator, different from TCDD or DLCs (e.g. transient effects, different gene activation pattern), does SWP consider that its previous position on the safety of laquiminod should be amended?

2)  Considering the non-clinical findings of teratogenicity in rats and the presence of laquinimod in the  semen  measured  in  the  monkey  study,  what  is  the  SWP  position  regarding  a  risk  of  maletransmitted malformations in human?'

The SWP discussion and main conclusions are summarised below:

- Laquinimod has similarities and dissimilarities with TCDD and I3C as AhR activators.
- o It  is  dissimilar  in  having  a  shorter  duration  (TCDD  effect  is  very  persistent),  but  the intended daily administration weakens this aspect.
- o Humans are less sensitive  to  TCDD  (10  x  lower  affinity  to  the  human  AhR  than  the  rat AhR),  but  it  is  not  proven  that  this  is  true  for  AhR-mediated  effects  of  laquinimod  or  DELAQ (human metabolite). Data do exist mainly for liver cells, and not for other tissues, whereas these differences might be essential
- o Gene  expression  data  show  only  a  very  small  overlap  between  laquinimod  and  TCDD. However, these data are only  present  for  hepatic  cells.  Data  on  other  gene  expression  was  not documented and therefore was not further discussed.
- o There  is  a  major  point  of  discussion  regarding  the  comparison  of  the  toxicity  profile  of laquinimod  and  TCDD/DLCs.  The  company  has  emphasized  that  there  are  differences  in  target organs and effects, as well as in the degrees of severity and incidences. SWP members indicate that  the  company  still  is  selective  in  discussing  the  similarity  and  dissimilarity  of  the  toxicity profiles.  Especially  the  general  pro-inflammatory,  hyperplastic  and  hepatic  profile  is  shared  with TCDD.
- Regarding  carcinogenicity,  particularly  uterine  and  oral  cavity  tumors  observed  in  rats, most of SWP members were not convinced by the new argumentation of the company.
- o With respect to the uterine tumors, the lack of prolactin measurement, and inconsistencies in the explanation by the company are a stumbling block to accept the hypothesis of the company.
- o With  respect  to  oral  cavity  tumours  it  is  stated  that  the  NTP  report  on  I3C  is  not  yet available. The similarity between laquinimod and I3C can therefore not be assessed. In addition, tumour incidence is difficult to compare between studies conducted at different laboratories. There

<div style=\"page-break-after: always\"></div>

were no increased inflammatory changes in the oral cavity caused by laquinimod, which would be expected following local irritation. Regardless the mode of action, if the local exposure of the oral tissues  is  causing  the  lesions  there  is  a  sufficient  safety  margin,  but  when  it  is  a  tissue  specific response to systemic exposure the exposure margin at the NOAEL is less than two. The human relevance of the laquinimod-induction of oral cavity tumors if caused by Ah Receptor stimulation cannot be assessed as the activation by laquinimod of the human Ah receptor is unknown and thus far only subject to speculation.

Regarding question 1, the SWP supported by majority that the general toxicity remains an issue, especially  because  the  underlying  mechanism  of  action  is  unknown.  The  SWP  supported  the conclusion that laquinimod is a multi-site carcinogen as well as a teratogenic product in rats and the  underlying  mechanism  of  action  for  these  toxic  effects  remains  unknown  regardless  the mechanism of toxicity. Therefore, its relevance to humans cannot be excluded.

Taken together, it was concluded that there is no new evidence that justify an amendment of the previous SWP position on the safety of laquiminod.

The SWP considers that further mechanistic studies may be helpful to understand better the safety of laquiminod in humans, although doubts that additional mechanistic data can help in excluding a human risk remain. Reference was made to the SWP position made during the initial evaluation.

Regarding  question  2,  the  company  has  made  a  calculation  of  the  potential  the  exposure  of women, based on the concentration of laquinimod measured in semen in animals and concluded that this exposure via semen is negligible.The SWP agreed by consensus with the company that the potential exposure of women via semen is negligible. Therefore the use of a condom during sexual intercourse for males treated with laquinimod is not deemed necessary.

## PRAC advice

The CHMP questions to be addressed by the PRAC were as follows:

The views of PRAC are sought on:

- the acceptability and feasibility of the proposed additional risk minimisation measures for pregnancy prevention (as submitted in the re-examination package).
- the acceptability and feasibility of the submitted PASS and registry protocols (to adequately address/characterise the potential risks of carcinogenicity and teratogenicity/endocrine-disrupting effects- as submitted in the re-examination package)

The PRAC discussion and main conclusions are summarised below:

## Proposed additional risk minimisation measures for pregnancy prevention.

The RMP (version 2.2) submitted by the applicant during the initial submission proposed routine pharmacovigilance activities with a PASS and pregnancy registry as additional measures to manage the  safety  concerns  of  pregnancy  and  teratogenicity.  The  routine  risk  minimisation  measures included  a  contraindication  in  pregnancy,  effective  contraception  in  women  of  child-bearing potential,  pregnancy  testing  before  initiation  of  laquinimod  or  if  pregnancy  suspected,  and counselling  on  all  elements  of  the  laquinimod  pregnancy  prevention  programme  and  potential teratogenicity  for  females  of  child-bearing  potential.  The  potential  risk  of  teratogenicity  was summarised in sections 4.3, 4.6 and 5.3 of the SmPC and also in the Package Leaflet. Educational materials for healthcare providers (including a prescription guide and counselling verification guide) and a direct healthcare professional letter at launch were also proposed to address the teratogenic risk and long-term effects on puberty and fertility in children after in utero exposure (infant follow-

<div style=\"page-break-after: always\"></div>

up  to  18  years).  The  effectiveness  of  these  proposed  activities  was  to  be  measured  by  the frequency of pregnancies on laquinimod.

Additional  activities  proposed  by  the  applicant  in  this  re-examination  submission  include  regular pregnancy  testing  during  laquinimod  therapy,  male  contraceptive  measures  if  their  partner  is female and of childbearing potential (and provision of counselling materials for them) and section 4.6  of  the  SmPC  was  updated  to  include  'relevance  of  these  findings  to  humans  cannot  be excluded'.

The  effectiveness  of  the  pregnancy  prevention  programme  is  doubtful  because  of  the  high frequency  of  pregnancy  experienced  in  the  context  of  the  clinical  development  programme,  the population to be exposed and the long term nature of treatment.

The  PRAC  commented  that  no  information  had  been  presented  by  the  applicant  that  provided reassurance about adherence  to the pregnancy  prevention programme.  Therefore,  it  was recommended  that  a  continuation  form  that  confirms  the  ongoing  acceptance  of  the  conditions associated  with  laquinimod  treatment  should  be  completed  and  signed  by  the  neurologist  and women of child bearing potential at regular appropriate intervals.

The PRAC noted the consensus position of the SWP that there was negligible risk of exposure to laquinimod through semen. However, a concern was raised that the amount in human semen is unknown and no observed adverse effect level can be determined and on that basis a risk to the foetus cannot totally be excluded. Overall by a majority, the PRAC supported the views of the SWP and the PRAC Rapporteurs that contraceptive measures for males treated with laquinimod was no longer considered necessary.

## Proposed additional Pharmacovigilance (PhV) activities for teratogenicity (i.e Pregnancy Registry)

There are serious questions on the feasibility of long-term follow up through the pregnancy registry due to inadequate reassurance from the information in the re-examination submission.  Even with a proposed restricted use, these concerns still remain.

## Proposed additional risk minimisation measures for carcinogenicity.

In addition, the PRAC maintains their position that there are no obvious risk minimisation measures to  address  the  potential  risk  of  carcinogenicity  which  is  perceived  as  a  general  risk  without  any specific target tissue identified.  Screening for early or pre-cancerous lesions, avoiding genetic or environmental risk factors and counselling are not appropriate or feasible.

## Proposed additional PhV activities for carcinogenicity (i.e PASS)

The RMP (version 2.2) submitted by the applicant during the initial application proposed routine pharmacovigilance  and  a  PASS  for  the  carcinogenicity  safety  concern..The  applicant  also  now additionally  proposes  in  the  re-examination  submission  that  long  term  extension  studies  and changes  in  SmPC  labelling  will  also  be  implemented  to  address  the  potential  carcinogenicity  of laquinimod. Given the absence of any new data relating to the safety concern of carcinogenicity, numerous issues with the PASS synopsis and lack of any detailed PASS protocol, the PRAC has serious doubts that the proposed study will serve to clarify the uncertainty regarding the long-term risk of laquinimod and also provide the necessary information to improve risk characterization and identification.

## General discussion on impact of proposed new indication on RMP

The  PRAC  noted  that  in  their  response  to  the  grounds  for  refusal  the  applicant  has  proposed  a restricted indication of adult patients with relapsing remitting MS (RRMS), who have demonstrated

<div style=\"page-break-after: always\"></div>

disease worsening and have reached an EDSS above 3, however, it is unclear the extent to which the applicant proposes to revise the content of the RMP. Furthermore no major changes have been proposed regarding the details of the additional risk minimisation measures  (information related to prescription guide, counselling verification form and DHPC).

## General discussion on adequacy of additional risk minimisation measures and PhV activities

The PRAC also noted that no major updates have been proposed in relation to the draft synopses for the PASS and pregnancy registry. On this basis, the PRAC maintains its initial position that the documented proposals for PV activities and risk minimisation measures are not sufficiently robust and consequently considered that the feasibility of the studies cannot be established at the present time. A detailed list of deficiencies is annexed in the PRAC advice.

Overall, pending the SAG consultation, the PRAC maintains their serious concerns over the safety profile of laquinimod and therefore concluded that the proposed risk minimisation activities would not be able to reduce the risks to an acceptable level.

In  summary,  the  PRAC  concluded  that  this  submission  provided  with  the  grounds  for  reexamination  is  deficient  in  a  number  of  areas.  Based  on  the  submission  of  the  grounds  for  reexamination, the PRAC considers that i) with regards to carcinogenicity there are no obvious risk minimisation measures to address the potential risk given that this appears to be a general risk for which no specific target tissue or clear mechanism has been identified.

ii)  there  remain  important  concerns  about  the  effectiveness  and  feasibility  of  the  proposed additional risk minimisation measures for pregnancy prevention iii)  the  submitted  PASS  and  registry  protocol  synopses  are  not  approvable  since  there  is  no reassurance that they will allow for adequate and timely further characterisation of the important risks and any emerging safety signals.

## Report from the SAG

The CHMP questions to be addressed by the SAG were as follows:

1. The non-clinical SAG experts are invited to discuss the safety concerns related to the findings seen in animals (general toxicity, carcinogenicity and reproductive toxicity, presence of laquinimod in monkey semen and potential teratogenicity) and their relevance for humans in the context of a long-term use of laquinimod.

2.  Bearing  in  mind  the  grounds  for  negative  opinion  and  re-examination,  the  potential  safety concerns and the newly proposed indication for laquinimod in the \"treatment of RRMS patients who have demonstrated disease worsening and have reached an EDSS above 3\", the experts are asked to discuss:

a) whether a clearly defined target population within the broad RRMS could be identified, in whom the benefit/risk balance of laquinimod would be considered positive.

b) whether the population as defined by the applicant represents a valid clinical entity (i.e. whether the chosen cut-off of EDSS above three is based on clinical reasoning)

c) whether the robustness of the presented data on relapses and disability is considered sufficient, bearing in mind that the effect seen on disability seems to be mainly driven by ambulation (and not in other dimensions of Multiple Sclerosis), and that no patient with EDSS &gt; 5.5 was included in the Phase III studies.

<div style=\"page-break-after: always\"></div>

3. The views of the SAG are sought on the acceptability/feasibility of the proposed additional risk minimisation measures for pregnancy prevention (as submitted in the re-examination package).

The main SAG conclusions were the following:

- The SAG experts agreed that laquinimod, while activating AhR seems different from dioxin-like compounds.    However,  differences  with  I3C-like  compounds  are  difficult  to  ascertain.  The  nonclinical experts suggested that applicant should present changes in global gene expression, preferentially in the form of heat maps. This would allow a direct comparison of gene expression patterns produced by laquinimod, TCDD and I3C and help to decide whether laquinimod is  different  with  respect to  its  activity  on  AhR.  It  was  agreed  that  laquiminod  is  clearly  a  multicarcinogenic  compound  in  animals  as  indicated  in  the  SWP  report.  Considering  the  overall carcinogenicity findings and the probable non-genotoxic mechanism of carcinogenicity this is not considered however as a major concern in humans. Concerns still remain due to the difficulty to predict the relevance to humans because of the lack of mechanistic understanding of the animal findings. These risks could be acceptable in the context of clear clinical benefits.

Laquinimod is a clear teratogenic compound and would need a strict pregnancy control. However the practical feasibility will have to be appropriately addressed.

The  SAG  agreed  that  there  was  no  concern  about  exposure  of  female  partners  through  the quantities of laquinimod in semen which are negligible.

- The SAG considered that according to the available data there was no sub-group of patients that stood  out  on  the  basis  of  the  observed  efficacy.  The  drug  did  not  seem  to  perform  differently according to baseline EDSS or other characteristics of the RRMS population.

The SAG also made the comment that the studied dose may not be the most appropriate one.

-SAG and the patient representatives were not convinced that the proposed population (patients with  EDSS&gt;3)  represented  a  clearly  defined,  real-life  entity  that  could  be  considered  a  valid therapeutic target group.  It includes a very heterogenous group of patients according to clinical features and to future evolution. Additionally, the vast majority of these patients would already be on treatment with other compounds. Available data indicate that efficacy could be lower (as much as by two fold) in this category of patients as compared to previously untreated patients.

The SAG made the observation that a more appropriate target population would have been the PPMS  or  SPMS  population,  in order to validate a mechanism  of  action more  active on neurodegeneration and less dependent on inflammation. In a second step, patients who are in the transitional window from RRMS to SPMS could be a relevant population.

-In both the phase III randomised clinical trials presented, the effect size of the medication on the primary outcome measure (relapses) was modest. The observed effect size on disability, although meaningful, should only be considered as exploratory as the trials had methodological shortcomings, the most prominent one being the fact that in both pivotal studies disability was only a pre-specified secondary end point. Additionally, in the BRAVO study the statistical significance of the difference of the effect on disability vs placebo was borderline and the overall data on disability were at least in part based on a  post-hoc meta-analysis of the two studies.

Because of the methodological shortcomings described above, the SAG considered that the data were not robust from a methodological point of view for the whole RRMS population included.

<div style=\"page-break-after: always\"></div>

-  The  SAG's  position  was  that  the  proposed  measures  were  certainly  wide  and  useful,  however uncertainties  remain  regarding  their  feasibility  and  implementation  in  clinical  practice,  rendering their effectiveness doubtful.

## Additional information provided by the applicant

The applicant submitted written documents for the Oral Explanation held on Monday 19 May 2014, which included revised SmPC and RMP.

Of  note,  the  limited  MS  population  as  proposed  as  revised  indication  within  the  re-examination package  was  finally  not  pursued  by  the  applicant  in  their  latest  SmPC  proposal;  a  decision reportedly made  in view of the Neurology SAG meeting outcome and latest available assessment on the grounds for re-examination.

Therefore, the revised SmPC and RMP were submitted to support the following indication:

'Nerventra  is  indicated  for  the  treatment  of  adult  patients  with  relapsing  remitting  multiple sclerosis (RRMS) (see section 5.1).'

## 5.3. Overall conclusion on grounds for re-examination

The CHMP assessed all the detailed grounds for re-examination and argumentations presented by the applicant and considered the views of the Scientific Advisory Group, the SWP and the PRAC.

## CHMP position on Ground for refusal #1

The CHMP maintains its view that the mechanism of action of laquinimod had not been sufficiently investigated  and  is  unknown.    This  contributes  to  the  insufficient  characterisation  of  the  safety profile,  considering  that  laquinimod  is  a  multi-  site  carcinogenic  and  teratogenic  compound  in animals. The CHMP was still of the opinion that a potential carcinogenic risk with long term use in humans cannot be currently excluded. Although the animal findings may not be seen as a major concern because of a probable non-genotoxic mechanism of carcinogenicity, such concerns remain due  to  the  difficulty  to  predict  the  relevance  of  toxicity  to  humans  because  of  the  lack  of mechanistic  understanding  of  the  animal  findings,  as  indicated  by  the  SAG  and  the  SWP.  The indirect evidence provided by the applicant to explain the mechanisms underlying the carcinogenic finding (oral cavity tumors and uterine adenocarcinoma) was also not particularly convincing and further mechanistic data would be necessary to exclude these safety concerns.

Although  the  CHMP  acknowledged  the  SAG  view  that  laquinimod  while  activating  AhR  seems different  from  dioxin-like  compounds,  the  CHMP  did  not  consider  the  comparison  of  the  toxicity profile  of  laquinimod,  TCDD  and  I3C  as  sufficient  evidence  to  support  the  conclusions  that laquinimod is a non-toxic AhR agonist. As indicated by the SWP, the comparison of the toxicity profile  of  laquinimod,  TCDD/DLCs,  as  presented  by  the  applicant,  was  considered  selective.  The CHMP considered more appropriate a comparison using the overall toxicity data for laquinimod, as presented in the previous SWP report during the initial evaluation. Laquinimod shares a general pro-inflammatory, hyperplastic (forestomach, oral cavity and kidney), hepatic and thyroid toxicity profile  with  TCDD  and  DLCs.  It  should  be  noted  that  inflammatory  adverse  reactions  have  been observed in clinical trials with laquinimod, based on the occurrence of peritonitis, appendicitis and increased  fibrinogen  and  CRP  levels.  Other  adverse  events  in  clinical  trials  include  liver  enzyme elevations, haematological changes and higher frequency of back and neck pain. In line with these concerns,  the  CHMP  also  noted  that  the  incidence  of  appendicitis  was  significantly  increased  in workers  exposed  to  TCDD  following  a  1953  chemical  reactor  incident,  thus  questioning  the comparative data, as presented by the applicant. Presentation of all the results of gene expression

<div style=\"page-break-after: always\"></div>

studied  by  the  applicant,  preferentially  in  the  form  of  heat  maps,  would  have  allowed  a  direct comparison  of  gene  expression  patterns  produced  by  laquinimod,  TCDD  and  I3C  and  could  be helpful to understand the mechanism of action and toxicity of laquiminod which remain unknown, although the CHMP overall agreed that laquinimod toxicity profile should be evaluated on its own.In addition, as commented by the SAG, differences with I3C-like compounds are difficult to ascertain. No conclusions could be drawn on the data presented to support the similarity between I3C and laquinimod in the absence of submission of the referred National Toxicology Program (NTP) report on I3C.

Furthermore,  there  are  potential  endocrine  disruptive  effects,  in  particular  in  view  of  the teratogenicity findings in rats. These effects could be related to AhR activation following treatment with laquinimod,  but  cannot  be  further  evaluated  due  to  insufficient investigation  on  the mechanism of action of laquinimod.

Taking into consideration the uncertainties related to the mechanism of action, the CHMP remains concerned  on  the  overall  toxicity  profile  of  laquinimod  seen  in  animal  studies,  in  particular  the potential for carcinogenicity and teratogenicity.

The  CHMP  noted  the  SAG  conclusions  regarding  the  teratogenicity  and  carcinogenicity  findings, notably that the carcinogenic risk could be acceptable in the context of a clear clinical benefit and that a strict pregnancy control would be required since laquinimod is a clear teratogenic compound. As sufficient benefits were not considered to be shown in the main clinical studies submitted for this application, the CHMP considered that the safety concerns remained unbalanced at the present time.

## CHMP position on Ground for refusal #2

During the re-examination, the applicant proposed to restrict the indication to 'adult patients with worsening relapsing remitting MS and at least moderate neurological disability (such as EDSS over 3).  Nerventra is not indicated for patients with primary or secondary progressive MS'. In line with the SAG conclusions, the CHMP was of the opinion that such RRMS population was not a clearly defined  target  population.  The  CHMP  further  noted  that  the  applicant  proposal  was  based  on  a clinical reference, yet to be published. The applicant based their proposal on post-hoc analyses on this  particular  subset  of  patients,  which  can  be  considered  as  a  subgroup  within  the  global population included in the clinical studies. As such, the subgroup analyses need to be interpreted with  caution  and  their  validity  needs  to  be  ensured,  as  recommended  by  the  'Guideline  on  the investigation of subgroups in confirmatory clinical trials' (EMA/CHMP/539146/2013). Given that the mechanism of  action  of  laquinimod  remains  undetermined,  it  is  uncertain  whether  a  differential effect might be expected based on the EDSS value at baseline.

The Phase III programme for Nerventra included RRMS patients with EDSS of 0 to 5.5 hence no data is available in patients with more severe disability; the median EDSS score at baseline was 2.5. Patients are fully ambulatory up to a score of 4.5 with ability to walk 500 meters with a score of 4.0 when the walking distance is reduced to 100 meters for a score of 5.5 (but with disability severe enough to preclude full daily activities; Kurtze JF, 1983). It has been reported that from scores of 3.0 the EDSS is weighted heavily toward ambulatory disability and is less sensitive to other  dimensions  of  MS  such  as  arm  and  cognitive  function  (Polman  CH  et  al.,  2010);  also  the EDSS  is  less  responsive  to  changes  in  more  severely  ill  patients.  Disability  in  MS  comprises  a number of  functional  systems  and  includes  symptoms  other  than    impaired  ambulation  such  as fatigue, pain, cognitive impairment, bowel and bladder disturbances and the benefits in all of these symptoms remain unclear.

The treatment effect was slightly better in patients with EDSS above 3.0 as opposed to EDSS 3.0 and below, whether for ARR (25 % vs. 20 %), time to 3-month CDP (40 % vs. 31 %), time to 6-

<div style=\"page-break-after: always\"></div>

month CDP (53 % vs. 40 %) and MSFC z-score. However little difference is seen for brain atrophy or  T2  lesions  and  the  effect  on  Gd-enhanced  T1  lesions  is  halved.  The  lesser  effect  on  Gd-T1 enhanced lesions was observed in patients with more disability, which might be of concern in the long term therapy.

Data provided are indeed indicative of a rather consistent effect throughout the spectrum of EDSS from 0 to 5.5. Laquinimod did not seem to perform differently according to baseline EDSS or other characteristics of the RRMS population as also noted by the SAG.

Subgroup analyses of  6-month CDP showed  little numerical difference whether a cut-off point of 2 or 3 was chosen for the EDSS score. See Table 39.

Table 39. Subgroup Analysis of CDP (6 months)

<!-- image -->

|                                                                                                                                                                                                                                                                                                    | CDP 6 Months                                                                                                                                                                                                                                                                                       | CDP 6 Months                                                                                                                                                                                                                                                                                       | CDP 6 Months                                                                                                                                                                                                                                                                                       | CDP 6 Months                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Subgroup                                                                                                                                                                                                                                                                                           | No.of Patients (%)                                                                                                                                                                                                                                                                                 | No.of Patients (%)                                                                                                                                                                                                                                                                                 | No.of Patients (%)                                                                                                                                                                                                                                                                                 | Treatment Effect                                                                                                                                                                                                                                                                                   | Treatment Effect                                                                                                                                                                                                                                                                                   |
|                                                                                                                                                                                                                                                                                                    | LAQ                                                                                                                                                                                                                                                                                                | PLC                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                    | HR (95% CI)                                                                                                                                                                                                                                                                                        | P-Value*                                                                                                                                                                                                                                                                                           |
| Relapses(>=2) 1yr Prior SC                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    | 0.2758                                                                                                                                                                                                                                                                                             |
| >=2 Relapses                                                                                                                                                                                                                                                                                       | 257( 26)                                                                                                                                                                                                                                                                                           | 273( 27)                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                    | 0.723 ( 0.408, 1.282)                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                    |
| <2 Relapses                                                                                                                                                                                                                                                                                        | 727( 74)                                                                                                                                                                                                                                                                                           | 733( 73)                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                    | 0.493 ( 0.336, 0.722)                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                    |
| Relapses(>=2) 1yr Prior SC and GdE at BL                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    | 0.9253                                                                                                                                                                                                                                                                                             |
| >=2 Relapses and GdE at BL                                                                                                                                                                                                                                                                         | 117(12)                                                                                                                                                                                                                                                                                            | 120(12)                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                    | 0.568 ( 0.222, 1.451)                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                    |
| Otherwise                                                                                                                                                                                                                                                                                          | 864( 88)                                                                                                                                                                                                                                                                                           | 885(88)                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                    | 0.541 (0.386,0.759)                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                    |
| Relapses(>=1) 1yr Prior SC and GdE at BL                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    | 0.5349                                                                                                                                                                                                                                                                                             |
| >=1 Relapse and GdE at BL                                                                                                                                                                                                                                                                          | 370( 38)                                                                                                                                                                                                                                                                                           | 380(38)                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                    | 0.480 (0.286,0.803)                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                    |
| Otherwise                                                                                                                                                                                                                                                                                          | 611(62)                                                                                                                                                                                                                                                                                            | 625( 62)                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                    | 0.590 (0.394,0.884)                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                    |
| Median T2 Lesion Volume at BL                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    | 0.0568                                                                                                                                                                                                                                                                                             |
| >=Median T2 Volume at BL                                                                                                                                                                                                                                                                           | 508( 52)                                                                                                                                                                                                                                                                                           | 485( 48)                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                    | 0.742 ( 0.477, 1.155)                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                    |
| <Median T2 Volume at BL                                                                                                                                                                                                                                                                            | 473( 48)                                                                                                                                                                                                                                                                                           | 520(52)                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                    | 0.395( 0.246, 0.634)                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                    |
| Number of GdE Lesions at BL                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    | 0.5858                                                                                                                                                                                                                                                                                             |
| >=2 GdE Lesions at BL                                                                                                                                                                                                                                                                              | 247( 25)                                                                                                                                                                                                                                                                                           | 239( 24)                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                    | 0.471 ( 0.257, 0.864)                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                    |
| < 2 GdE Lesions at BL                                                                                                                                                                                                                                                                              | 734( 75)                                                                                                                                                                                                                                                                                           | 766( 76)                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                    | 0.575( 0.395,0.835)                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                    |
| EDSS(>=2) at BL                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    | 0.9512                                                                                                                                                                                                                                                                                             |
| >=2 EDSS                                                                                                                                                                                                                                                                                           | 697( 71)                                                                                                                                                                                                                                                                                           | 734( 73)                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                    | 0.556 (0.384,0.804)                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                    |
| <2 EDSS                                                                                                                                                                                                                                                                                            | 287( 29)                                                                                                                                                                                                                                                                                           | 272( 27)                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                    | 0.544 ( 0.295, 1.003)                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                    |
| EDSS(>=3) at BL                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    | 0.9389                                                                                                                                                                                                                                                                                             |
| >=3 EDSS                                                                                                                                                                                                                                                                                           | 430( 44)                                                                                                                                                                                                                                                                                           | 452( 45)                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                    | 0.558(0.353,0.881)                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                    |
| <3 EDSS                                                                                                                                                                                                                                                                                            | 554( 56)                                                                                                                                                                                                                                                                                           | 554( 55)                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                    | 0.544 (0.351,0.844)                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                    |
| 0.1 <.--FavorsLAQ----.--FavorsPLC--->                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    | 1                                                                                                                                                                                                                                                                                                  | 10                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                    |
| Results are generated by Cox regression analysis adjusted to: Log(No. of Relapses in 2 years prior SC), EDSS at BL,Country/Geographical Region, Treatment group, Subgroup Variable and Treatment by Subgroup Interaction * P-Value is from the test statistic of Treatment by Subgroup Interaction | Results are generated by Cox regression analysis adjusted to: Log(No. of Relapses in 2 years prior SC), EDSS at BL,Country/Geographical Region, Treatment group, Subgroup Variable and Treatment by Subgroup Interaction * P-Value is from the test statistic of Treatment by Subgroup Interaction | Results are generated by Cox regression analysis adjusted to: Log(No. of Relapses in 2 years prior SC), EDSS at BL,Country/Geographical Region, Treatment group, Subgroup Variable and Treatment by Subgroup Interaction * P-Value is from the test statistic of Treatment by Subgroup Interaction | Results are generated by Cox regression analysis adjusted to: Log(No. of Relapses in 2 years prior SC), EDSS at BL,Country/Geographical Region, Treatment group, Subgroup Variable and Treatment by Subgroup Interaction * P-Value is from the test statistic of Treatment by Subgroup Interaction | Results are generated by Cox regression analysis adjusted to: Log(No. of Relapses in 2 years prior SC), EDSS at BL,Country/Geographical Region, Treatment group, Subgroup Variable and Treatment by Subgroup Interaction * P-Value is from the test statistic of Treatment by Subgroup Interaction | Results are generated by Cox regression analysis adjusted to: Log(No. of Relapses in 2 years prior SC), EDSS at BL,Country/Geographical Region, Treatment group, Subgroup Variable and Treatment by Subgroup Interaction * P-Value is from the test statistic of Treatment by Subgroup Interaction |

The CHMP agreed that the main difference seemed to lay in the improvement of the MSFC z-score where a statistically significant difference is seen from a baseline EDSS score of 3.5. The MSFC is a 3-part quantitative instrument that measures arm, leg, and cognitive function with the 9-Hole Peg Test (9HPT, arm/hand dexterity), the Timed 25-Foot Walk (T25FW, leg function), and the Paced Auditory Serial Addition Test (3-second version, PASAT3; cognition). In the overall population the results on the MSFC score at month 24 did not show a statistically significant difference between laquinimod  and  placebo  (p=0.5893);  this  was  deemed  inconsistent  with  the  effect  seen  for  the EDSS score and brain atrophy.

The improvement of the MSFC z-score for patients with EDSS &gt; 3 was 0.245. However there is no accepted clinically meaningful change for MSFC z-score (Polman JC et al., 2010). This effect seems to  be  mainly  due  to  an  improvement in  T25FW  and  very  little  difference  is  seen  for  PASAT  and 9HPT. Baseline T25FW was 8.29 +/- 6.81 seconds in patients with EDSS &gt;3.0.  After 24 months the T25FW was 4.732 seconds longer in the placebo group but only 1.941 seconds longer in the laquinimod 0.6mg group. However no responder data (increase of 20 % or greater in the T25FW) have been submitted which would have been useful to assess the clinical relevance. Nevertheless the main contribution to improvement of CDP with laquinimod 0.6 mg was seen for the Pyramidal (37%), cerebellar (33%) and ambulation Functional System Scores (41%) of the EDSS score. Also

<div style=\"page-break-after: always\"></div>

the improvement in ambulation was independent of a disability progression during the Phase III studies.

The  exact  mechanism  for  the  effect  on  T25FW  is  unknown  and  the  fact  that  no  parallel improvement (e.g on vision, quality of life) was discussed, makes it difficult to put these changes into  context  or  to  make  assumptions  in  the  long  term  therapy,  especially  when  only  a  modest effect was seen on relapses and MRI T1 and T2 lesions. Also the T25FW is a short test and the results  are  not  confirmed  by  other  ambulatory  tests  such  as  longer  walking  test  or  the  Multiple Sclerosis Walking Scale. Altogether the absence of similar positive results in dimensions other than ambulation for patients with a baseline EDSS &gt; 3 adds to the argument that such population was not a properly defined and clinical justified subgroup of the RRMS population. In addition, based on the natural history of this disease, once a certain degree of disability has been reached in RRMS, some patients would enter into a phase where disease progression seems to be less dependent of the early inflammation/relapses, which otherwise tend to decrease/disappear over time, and more dependent of the degenerative component of the disease. This is the so call 'secondary progressive multiple sclerosis' form. However, this is highly variable within patients and does not occur at a given point in time, but rather is a continuous transitional process. There is not agreed definition to identify patients who will progress into a SPMS and the degree of accumulated disability measured by the EDSS on its own is not considered enough to properly define those patients. In fact, from a clinical  point  of  view,  a  clear  'cut-off'  point  in  the  EDSS  cannot  be  established  and  the  3-point score appears rather arbitrary.  To identify patients on the 'verge' of progressive disability might not be feasible.

The  CHMP  recognised  the  fact  that  patients  transitioning  into  a  progressive  form  might  likely benefit from therapies targeting the degenerative component of the disease, but so far laquinimod has not demonstrated that it has such an effect on patients with true progressive MS forms, as clearly required in the guideline on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis or MS Guideline (CPMP/EWP/561/98, Rev.1).

Patients with 'disease worsening and an EDSS&gt;3', is not an agreed definition for patients whose disease  progresses  independently  of  relapses  and  does  not  define  a  homogeneous  subset  of patients.  In  fact,  RRMS  patients  with  an  EDSS&gt;3  might  well  have  progressed  and  continue progressing in close relation to relapses. Given that in the EU, RRMS patients with an EDSS&gt;3 will universally be on treatment, in case of lack of response to a DMT ('disease worsening') a number of  therapeutic  alternatives  exist  with  a  well  defined  benefit-risk  ratio  in  RRMS,  being  thus candidates  to  any  of  the  available  treatment  options.  Furthermore,  data  from  the  previous procedure indicated that the effect of laquinimod on ARR, brain atrophy and disability progression was not statistically significant as compared to placebo for patients previously treated with IFNs (only the effect on MRI parameters was statistically significant). In fact, the effect of laquinimod 0.6 mg was 2-fold smaller than in the subgroup without prior use of interferon for ARR (13% vs 27%), brain atrophy (17.4% vs 34.6%) and time to confirmed EDSS progression-6 month (28.7% vs  58.2%). In the small subgroup of patients with prior GA use (n=84), there was no effect of laquinimod on ARR as compared to placebo (n=89). For all other endpoints (disability progression and  MRI  parameters),  an  effect  of  laquinimod  over  placebo  was  observed  but  not  statistically significant. These findings question the adequacy of laquinimod treatment in a subgroup of RRMS patients with disease worsening despite treatment.

In addition no extrapolation can be made to patients with more severe disability with regards to ambulation  as  no  patient  with  EDSS  6  and  above  was  included  in  the  main  clinical  studies submitted for the present application.

The  proposed  mode of  action  relates  to  pre-clinical  findings  of  neuroprotective  effects  and  antiinflammatory effects. In that respect the CHMP noted that an increase of white blood cells has been

<div style=\"page-break-after: always\"></div>

reported together with increased C-reactive protein following treatment with laquinimod questioning such claim. Back and neck pain and appendicitis have been clearly identified as clinical risks.  Increased  liver  enzymes,  fibrinogen  levels,  erythrocyte  sedimentation  rate  and  CRP  have been noted and proposed to be included in sections  4.4  and  4.8  of  the  SmPC.  With  regards  to increased  inflammatory  markers,  fibrinogen  and  CRP  have  been  studied  in  detail  in  relation  to cardiovascular  events  and  mortality.  In  the  clinical  studies,  a  shift  from  normal  to  elevated fibrinogen occurred in more laquinimod-treated patients compared to placebo (42.9% vs. 33.8%), whereas the change from normal to high CRP was similar in the laquinimod and placebo group (16.5  vs.  17.8%).  The  majority  of  the  patients  had  no  change  in  their  baseline  CRP  condition (80.4% vs. 79.4%).

During  the  Oral  Explanation  held  on  19  May  2014,  the  applicant  did  not  pursue  the  proposed restricted indication 'adult patients with worsening relapsing remitting MS and at least moderate neurological disability (such as EDSS over 3).  Nerventra is not indicated for patients with primary or  secondary  progressive  MS'.  The  applicant  proposed  to  revert  back  to  the  broad  indication  in RRMS  patients  as  initially  applied  for.  Based  on  the  latest  available  assessment  and  the  SAG conclusions,  the  applicant  maintained  their  position  regarding  the  suitability  of  laquinimod  as treatment for the broad population with relapsing remitting multiple sclerosis (RRMS), as according to  the  applicant,  the  SAG  assessed  that  the  non-clinical  risk  does  not  pose  a  major  concern  to humans. The applicant remained also committed to considering a restrictive labelling indication to mitigate the raised potential safety concern, including e.g. a second line indication.

Having considered the above and the overall efficacy data, the CHMP remained concerned that the efficacy  of  laquinimod  at  the  proposed  0.6  mg  dose,  was  modest  on  the  relapse  rate  in  the proposed broad RRMS population. A more encouraging effect was seen on disability progression but this  requires  confirmation.  The  unknown  mechanism  of  action  and  the  rather  modest  effect  on relapses  questions  the  suitability  of  laquinimod  as  treatment  for  the  broad  population  with relapsing remitting multiple sclerosis (RRMS) patients.

<div style=\"page-break-after: always\"></div>

## CHMP position on Ground for refusal #3

The CHMP maintains its view that the potential carcinogenic risk and potential endocrine disrupting effects  cannot  be  currently  excluded  and  that  there  are  no  obvious  measures  to  address  these concerns.  As  commented  by  the  PRAC  and  SAG  during  the  re-examination  procedure,  the uncertainties  on  the  effectiveness  of  the  pregnancy  preventive  measures  in  clinical  practice  to address the potential risk of teratogenicity, do not alleviate the concerns. Overall, these potential risks  were  considered by the  CHMP to outweigh the modest benefit on relapses shown with the proposed 0.6 mg dose of laquinimod in the intended RRMS population, notwithstanding the more encouraging effect on disability progression.

As sufficient benefits were not considered to be shown in the main clinical studies submitted for this application, the CHMP was of the opinion that the proposed risk minimisation activities do not alleviate the concerns raised by the non-clinical findings and therefore were not able to reduce the risks to an acceptable level at the present time.

## 5.4. Updated Benefit-Risk Balance

## Benefits

## Beneficial effects

Laquinimod is a novel orally administered therapy, intended for the treatment of patients suffering from relapsing-remitting multiple sclerosis. Laquinimod is claimed to fulfil an unmet medical need for an oral agent by acting as an immumodulator with CNS protective activity that is at least as effective  as  the  currently  available  first-line  treatments.  The  exact  mechanism  of  action  of laquinimod  is  unknown  but  it  has  shown  beneficial  effects  in  various  types  of  experimental autoimmune encephalomyelitis models as well as in cuprizone induced demyelination, all accepted animal models of multiple sclerosis.

Prevention  and/or  modification  of  relapse  features  as  well  as  prevention  or  delay  of  the accumulation of disability are meaningful goals in the treatment of relapsing multiple sclerosis.

Two large phase 3 pivotal studies (ALLEGRO, BRAVO) over two years were conducted. Both used relapse  rate  as  a  primary  outcome  measure.  Time  to  confirmed  EDSS  progression  was  a  key secondary endpoint.

In ALLEGRO study, a statistically significant effect of laquinimod 0.6 mg compared to placebo was demonstrated for the annualised relapse rate (p=0.0024). Whilst this result was consistent with other efficacy endpoints related to relapses and supported by sensitivity analyses, the reduction in ARR for laquinimod over placebo was modest, 23% over 24 months (RR= 0.770, 95% CI: 0.650, 0.911). In BRAVO study including an active comparator (Avonex), laquinimod 0.6 mg dose failed to show  a  statistically  significant  effect  as  compared  to  placebo  on  the  ARR  (RR=0.823,  95%  CI: 0.664, 1.020, p=0.0746) reflecting a reduction of ARR of 17.7%. In contrast, comparison of the Avonex  treatment  arm  with  placebo  yielded  a  risk  ratio  of  0.741  (95%  CI:  0.596;  0.920, p=0.0067),  demonstrating  a  25.9%  reduction  in  the  annualized  relapse  rate.  The  pre-specified sensitivity analyses were consistent with the primary analysis.

Due to the imbalances observed at baseline for mean T2 lesions volume and proportion of subjects with  GdE  T1  lesions  ≥1  across  treatment  groups,  additional  post-hoc  analyses  were  performed using these MRI parameters as covariates in a corrected model. Such corrected analysis resulted in an increase in magnitude of effect of laquinimod 0.6 mg compared to placebo on ARR (RR=0.787,

<div style=\"page-break-after: always\"></div>

95% CI: 0.637, 0.972) of statistically significance (p=0.0264) however this corrected result was still suggesting a modest reduction in ARR of 21.3% in patients treated with laquinimod 0.6 mg in BRAVO  study.  Importantly,  whilst  these  baseline  imbalances  were  also  present  in  the  Avonex group,  treatment  effect  of  Avonex  over  placebo  was  statistically  significant  (p=0.0067)  in  the primary model due to an observed larger treatment effect size of 25.9% reduction in the ARR (RR= 0.741,  95%  CI:  0.596,  0.920).  Numerically,  the  results  on  ARR  were  in  favour  of  Avonex  as compared to laquinimod.  In addition, laquinimod failed to show statistical significance over placebo on  the  time  to  first  relapse  (HR=0.813,  95%  CI:  0.653,  1.014);  p=0.0659),  questioning  the sensitivity of the results observed for the ARR, after the baseline corrected analysis.

In a meta-analysis including the 2 pivotal studies and the phase II study LAQ/5062, an effect of laquinimod on ARR  was  demonstrated suggesting a 21% reduction for laquinimod versus placebo (RR=0.79, 95% CI : 0.69,0.89, p=0.0002). This result was consistent with  the initially submitted pooled analysis of the two pivotal studies (reduction of 21.4% in ARR, p=0.0005) and is considered modest.

ALLEGRO  study  showed  that  laquinimod  delayed  the  time  to  3-month  confirmed  disability progression, with a statistically significant reduction of 36% over placebo (HR= 0.641; 95% CI: 0.452,  0.908;  p=0.0122).  BRAVO  study  failed  to  demonstrate  such  effect  with  a  lower  risk reduction  of  31.3%  over  placebo  (HR=0.687,  95%  CI:  0.462,  1,020;  p=0.0628).  However,  the CHMP  noted  that  results  on  disability  progression  were  numerically  in  favour  of  laquinimod  as compared  to  Avonex,  although  the  95%  CIs  for  each  of  the  outcomes  were  overlapping.  In addition,  results  from  the  pooled  analysis  using  both  pivotal  studies,  demonstrated  a  34% reduction  in  the  risk  for  3-month  confirmed  disease  progression  (HR  =  0.66,  p=0.002).  When adding the data from the phase II study LAQ/5062 in this pooled analysis, the effect on disability remain with a reduction of around 32% in the risk of disability progression confirmed at 3 months, although the CHMP noted that study LAQ/5062 on its own failed to show an effect on disability (HR= 1.12, 95% CI: 0.33, 3.74). A 44% reduction of disability progression confirmed at 6-months was also observed based on post-hoc analysis of pooled data provided by the applicant from both pivotal  studies,  data  from  study  LAQ/5062  was  not  included  in  this  analysis  due  to  its  short duration. It is noted that given the mild status of the studied population, this 44% risk reduction for 6 month confirmed disability progression (CDP) translated just into a 4% difference over the placebo in the absolute reduction for the incidence of CDP.

Different  MRI  endpoints  related  to  clinical  activity  and  for  some  to  long  term  clinical  outcome (cumulative  numbers  of  Gd  enhancing  lesions,  new/enlarging  T2  lesions  for  ALLEGRO,  brain atrophy measure for BRAVO) were also used as secondary efficacy endpoints.

In ALLEGRO study, there was a statistically significant effect of laquinimod as compared to placebo on  mean  adjusted  number  of  T1  Gd-enhancing  lesions  (RR=0.629,95%  CI:  0.488,  0.809, p=0.0003) showing a reduction of 37% in the mean rate of developing T1 Gd-enhancing lesions on laquinimod 0.6 mg compared to placebo. A statistically significant treatment effect of laquinimod 0.6  mg  over  placebo  was  also  shown  on  the  cumulative  number  of  New/Enlarging  T2  lesions (RR=0.704,95% CI: 0.584, 0.849, p=0.0002) indicating a reduction of 30% in the mean rate of developing New/Enlarging T2 lesions on laquinimod 0.6 mg compared to placebo.

In the meta-analysis using the two pivotal studies ALLEGRO and BRAVO, and the phase IIb study LAQ/5062, a treatment effect on GdE T1 lesions was observed with a rate ratio of 0.68 suggesting a reduction of 32% as compared to placebo. This effect was statistically significant (p&lt;0.00001). The  effect  on  new  T2  lesions  was  also  statistically  significant  with  a  reduction  of  27%  versus placebo (Rate Ratio of 0.73, p&lt;0.00001). Regarding brain atrophy, the effect of laquinimod was statistically  significant  as  compared  to  placebo  (difference  of  0.31  in  %  brain  volume  change, p&lt;0.00001).

<div style=\"page-break-after: always\"></div>

The  supportive  studies  suggested  maintenance  of  the  effect  of  laquinimod  during  long  term treatment regarding ARR and disability progression.

## Uncertainty in the knowledge about the beneficial effects.

Limited data were provided regarding the pharmacodynamic effects of laquinimod in humansIt is hypothesised  that  the  disability  reduction  is  likely  explained  by  mechanisms  unrelated  to  the suppression  of  acute  inflammation  and  that  are  different  to  other  DMTs,  possibly  taking  place within the central nervous system and acting directly on the degenerative process . However, since the mechanism of action has not been sufficiently investigated and the molecular target remains unknown, no conclusion could be drawn on the clinical pharmacology of laquinimod.

The optimal dose had not been defined because 0.6 mg dose was the sole dose tested in the phase III studies. In the absence of data using higher doses than 0.6 mg, the CHMP concluded that the dose  reponse  effect  of  laquinimod  has  not  been  sufficiently  evaluated  to  determine  the  optimal dose in the intended population.

Limited data after discontinuation of laquinimod treatment are available to evaluate the potential risk of rebound effect.

The  mechanism  of  action  of  laquinimod  is  unknown  and  the  rather  modest  effect  on  relapses questions  the  suitability  of  laquinimod  as  treatment  for  the  broad  population  with  relapsing remitting multiple sclerosis (RRMS) patients.

## Risks

## Unfavourable effects

Liver  enzyme  elevations,  inflammatory  markers  increased  (e.g.  CRP,  fibrinogen),  back  and  neck pain, haematological changes, appendicitis, interaction with CYP3A4 inhibitors/inducers have been identified as important risks.

The effect of laquinimod on the liver appeared to be limited to liver enzyme elevations, but the mechanism  underlying  these  events  is  unknown.  Mostly  mild,  asymptomatic  liver  enzyme elevations (AST, ALT and GGT) were reported that generally occur within 6 months after initiation of treatment. Overall in the pivotal trials, 4.7% of laquinimod treated subjects reached relevantly significant [&gt; 3xULN] levels of ALT. This was more notable for male than for female in laquinimod treated subjects. In 74% of subjects who had elevated levels of ALT on laquinimod, ALT decreased to within the normal range while on laquinimod.

Inflammatory  markers  (CRP,  ESR,  fibrinogen)  were  increased  in  healthy  volunteers  in  phase  I studies.  In  pivotal  studies,  fibrinogen  (40%  vs.  28%)  and  WBC  levels  (27%  vs.  15%)  clearly increased to values above ULN in a higher percentage of patients with laquinimod in comparison with placebo. Increase of fibrinogen was apparent from month 1. In the pivotal studies, until month 15, the proportion of patients with elevations in both CRP and fibrinogen was slightly higher (by approximately 1-2%) in the laquinimod group compared to placebo. At month 2 this difference was statistically  significant  (approximately  4.1%  vs.  2.3%)  and  was  considered  clinically  relevant. Long-term data up to 4 years are available  and  revealed  that,  at  month  48,  the  percentage  of patients  with  potentially  clinically  significant  CRP  elevation  increased  to  5.4%  in  the  laquinimod group.  In  the  pivotal  studies,  the  incidence  of  fibrinogen  level  considered  potentially  clinically significant  (&gt;  6g/l),  was  higher  in  the  laquinimod group  compared to placebo (5.5% vs. 2.6%).

<div style=\"page-break-after: always\"></div>

Maximal  fibrinogen  did  not  exceed  the  &gt;2.5x  ULN;  maximal  fibrinogen  was  9.0  g/l  in  the laquinimod  group  and  8.4  g/l  in  the  placebo  group  at  any  time  until  month  24.  Overall,  mean duration of elevated fibrinogen or CRP tended to be longer in the laquinimod group compared to placebo.

Haematological toxicity was relevant with laquinimod when compared to placebo, with mostly mild increases in leucocyte levels and decreases in red blood cells and platelets. Two cases of anaemia and one case of acute leukemia in the laquinimod group were considered as serious.

## Uncertainty in the knowledge about the unfavourable effects

There is currently a considerable level of uncertainty on the carcinogenic potential of laquinimod. The  pharmacology  of  laquinimod  is  unclear  thus  making  difficult  the  full  appreciation  of  any pharmacology-driven proliferative or metaplastic processes. Based on pre-clinical data, a potential carcinogenicity  relative  to  oral  cavity  and  uterus  could  not  be  ruled  out.  There  is  a  lack  of mechanistic  data  to  exclude  these  potential  risks  in  humans.  At  the  present  time,  there  is  also insufficient  evidence  to  conclude  that  laquinimod  can  be  considered  as  a  non-toxic  AhR  agonist. Significant uncertainties also remain with regards to the unknown immunomodulator or immunosuppressant potential, and the potential risks associated with long-term use (i.e. cancer, infections, inflammation), also contributing to the insufficient characterization of the safety profile of laquinimod in the intended patient population, although the currently available clinical data did not show evidence of an increased risk of malignancies, immunosuppression or infections.

Malignant tumours have been reported in 26 patients (0.6%) treated with laquinimod in all clinical studies; 6 breast carcinomas including one metastatic breast cancer (3 in cohort 1, all in ALLEGRO and no case in BRAVO; 1 additional case of breast cancer in study LAQ/5062 have been reported in laquinimod  group.  One  breast  cancer  was  reported  in  placebo  group).  In  cohort  1,  10  (1%) patients  in  the  laquinimod  group  vs  6  (0.6%)  patients  with  placebo  experienced  a  malignant tumour (p=0.2944, 95% CI: -0.37, 1.21). In addition to 3 cases of breast cancer, sporadic cases of glioblastoma (1), lung neoplasm malignant (1), lymphoma (1), oesophageal adenocarcinoma (1), squamous cell carcinoma (1), thyroid cancer (1) were reported.  One case of thyroid cancer has been  reported  in  BRAVO  study  in  patient  treated  with  laquinimod.    One  case  of  thyroid  cancer occurred in Avonex group. Concerning skin malignancy, 2 cases (basal cell carcinoma, squamous cell carcinoma) occurred in cohort 1 compared to one case (basal cell carcinoma) in the placebo group. In total,  in  cohort  3  (all  patients  treated  with  laquinimod),  7  subjects  suffered  from  skin malignancies: basal cell carcinoma (4), malignant melanoma (1) and squamous cell carcinoma (2). Overall  incidences  of  malignancies  comparison  with  SEER  Database  did  not  demonstrate  an increase in malignant tumours with laquinimod therapy. However, the number of events to date and duration of follow-up is too limited to definitively exclude a relationship and further long term data are required to ascertain the level of this potential risk. In addition, based on available preclinical  data,  there  remain  relevant  uncertainties  on  the  potential  risk  for  malignancies  .These uncertainties currently represent an important concern with long term use of laquinimod.

Laquinimod was teratogenic in rats, causing hypospadias in females. The most sensitive days for induction  of  these  malformations  were  days  18-21  of  gestation  in  rats,  while  exposure  before implantation or during lactation did not induce this type of malformation. In F1 males, hypospadias were also reported and other findings consisted of dose-dependent delayed growth which persisted up to adult age in the high dose group, a clear dose-dependent delay in onset of puberty, and decreased  fertility  in  spite  of  normal  sperm  parameters.  In  addition,  the  absolute  weight  of prostate and seminal vesicles were decreased at the high dose level. In F1 females, in addition to the urogenital abnormalities, there were also treatment-related effects on growth, delayed vaginal opening at the high dose level only, prolonged estrous cycle length, decreased fertility at the mid and  high  dose  levels.  Treatment  also  had  an  impact  on  F2  generation  as  seen  from  decreased

<div style=\"page-break-after: always\"></div>

viability of F2 pups born from F1 females (high-dose group). Most of the findings obtained in F1 animals were suggestive of a hormonal effect of laquinimod. An effect of laquinimod on the AhR-ER cross-talk pathway cannot be excluded as possible mechanism underlying its potential endocrinedisrupting  effects.  These  effects  could  be  related  to  AhR  activation  following  treatment  with laquinimod but cannot be further evaluated due to insufficient investigation on the mechanim of action of laquinimod. No definitive conclusions could be drawn regarding the teratogenic potential of  laquinimod  in  cynomolgus  monkeys.  In  clinical  MS  studies,  females  of  child  bearing  potential were required to practice effective contraception. Nonetheless, 74 pregnancies have been reported in  the  laquinimod  development  programme,  of  which  43  were  reported  in  subjects  exposed  to laquinimod (38 female patients treated and 5 male subjects reporting pregnancies of partners) as of  1  September  2013.  The  potentially  delayed  effects  of  laquinimod  seen  in  preclinical  studies (notably on puberty and fertility), which would not be noticeable at birth are of important concern for  the  CHMP,  especially  considering  the  intended  use  in  MS  patients  (mostly  females  of  child bearing potential) and the absence of an in vivo interaction study investigating the potential effect of laquinimod on the pharmacokinetics of oral contraceptives.

Although  low,  the  incidence  of  ischemic  heart  disease  was  higher  in  the  laquinimod  group compared to  placebo  (0.6%  vs  0.1%)  in  the  pivotal  studies.  Overall,  20  reports  in  15  subjects (0.6%) reported ischemic heart disease including 2 subjects that were diagnosed with myocardial infarction  in  the  laquinimod  group.  Two  out  of  9  deaths  in  the  laquinimod  group  were  due  to cardiovascular  failure  (sudden  death  within  5  hours  post  treatment)  and  myocardial  infarction (after 5 months of treatment), respectively. Patients with significant cardiovascular conditions were excluded from the pivotal trials. On this basis and considering the safety data from roquinimex, a structurally related product, cardiotoxicity was considered as a potential risk for laquinimod.

Due to the potential of formation of tissue adducts seen in preclinical studies, drug hypersensitivity  reactions  should  be  considered  as  a  potential  risk  for  laquinimod,  given  its intended chronic use.

## Benefit-risk balance

## Importance of favourable and unfavourable effects

Laquinimod is a novel substance, which is proposed as orally administered treatment of relapsing remitting multiple sclerosis. Currently, a number of MS drugs are available in the EU as oral or parenteral formulations and are indicated either as first line or second line therapies. The exact mechanism of action of laquinimod is unknown and the molecular therapeutic target has not been identified. This lack of knowledge raised serious concerns over the pharmacology of laquinimod, particularly considering the potential for carcinogenicity and teratogenicity seen in animal studies and possibly related to AhR activation. According to the SAG conclusions, the carcinogenic risk could be acceptable in the context of a clear clinical benefit and that a strict pregnancy control would be required since laquinimod is a clear teratogenic compound. As  sufficient benefits were not considered to be shown in the main clinical studies submitted for this application, the CHMP considered  that  the  safety  concerns  remained  unbalanced  at  the  present  time  for  the  RRMS population.The main risks in humans for laquinimod included liver enzyme elevations, inflammatory  markers  increased  (e.g.  CRP,  fibrinogen),  back  and  neck  pain,  haematological changes,  appendicitis  as  well  as  potential  risks  of  carcinogenicity  and  teratogenicity  based  on findings  in  animal  studies.  There  are  no  obvious  risk  minimisation  measures  for  the  potential carcinogenic risk and potential endocrine disrupting effect.These potential risks were considered to outweigh the modest benefits on relapses shown with the proposed 0.6 mg dose of laquinimod in the intended RRMS population. In line with the PRAC and SAG conclusions, the CHMP was of the view that laquinimod is a clear teratogenic compound and uncertainties remain regarding the

<div style=\"page-break-after: always\"></div>

feasibility  and  implementation  of  the  proposed  pregnancy  prevention  programme  in  clinical practice.

In this context, the modest efficacy of laquinimod on relapse rate in adult patients with relapsing remitting  multiple  sclerosis  (RRMS)  at  the  proposed  0.6mg  dose is  not  considered  sufficient  to outweigh the safety concerns.

## Benefit-risk balance

The demonstrated efficacy of laquinimod on relapse rate in adult patients with relapsing remitting multiple sclerosis (RRMS) at the proposed 0.6mg dose is considered modest. A more encouraging effect  was  seen  on  disability  progression  but  this  requires  confirmation.  The  toxicity  profile  (in particular carcinogenicity but also reproductive toxicity) seen in animal studies is of concern, given the difficulty in predicting the relevance to humans in the absence of mechanistic understanding of the  animal  findings.There  are  concerns  regarding  the  adequacy  of  the  pregnancy  prevention measures  to  minimise  the  potential  risk  of  teratogenicity  in  clinical  practice.  There  is  a  lack  of available  measures  to  minimise  a  potential  carcinogenic  risk.  The  proposed  risk  management measures  therefore  do  not  alleviate  the  concerns  raised  by  the  non-clinical  findings.  In  this context, the modest efficacy of laquinimod on relapse rate in adult patients with relapsing remitting multiple sclerosis (RRMS) at the proposed 0.6mg dose is not considered sufficient to outweigh the safety concerns.

Therefore, the CHMP concluded that the benefit/risk balance for Nerventra was negative for the following indication:

'Nerventra  is  indicated  for  the  treatment  of  adult  patients  with  relapsing  remitting  multiple sclerosis (RRMS) (see section 5.1)'.

## 5.5. Recommendations following re-examination

Based on the arguments of the applicant and all the supporting data on quality, safety and efficacy, the CHMP re-examined its initial opinion and in its final opinion concluded by consensus that:

the safety and  efficacy of the above  mentioned  medicinal  product  are  not  sufficiently demonstrated, and, therefore recommends the refusal of the granting of the  Marketing Authorisation  for the above mentioned medicinal product:

The CHMP considers that:

· The demonstrated efficacy of laquinimod on relapse rate in adult patients with relapsing remitting  multiple  sclerosis  (RRMS)  at  the  proposed  0.6mg  dose  is  considered  modest.  A  more encouraging effect was seen on disability progression but this requires confirmation.

The  toxicity  profile  (in  particular  reproductive  toxicity  but  also  carcinogenicity)  seen  in  animal studies is of concern, given the difficulty in predicting the relevance to humans in the absence of mechanistic understanding of the animal findings. There are concerns regarding the adequacy of the  pregnancy  prevention  measures  to  minimise  the  potential  risk  of  teratogenicity  in  clinical practice.  There  is  a  lack  of  available  measures  to  minimise  a  potential  carcinogenic  risk.  The proposed risk management measures therefore do not alleviate the concerns raised by the nonclinical findings.

<div style=\"page-break-after: always\"></div>

In this context, the modest efficacy shown for laquinimod in RRMS is not considered sufficient to outweigh the safety concerns. The benefit-risk balance in the studied RRMS population is therefore considered negative at the present time.

Thus,  the  CHMP  concluded  that  the  benefit-risk  balance  of  laquinimod  was  negative  at  the proposed  dose  of  0.6  mg  in  the  treatment  of  adult  patients  with  relapsing  remitting  multiple sclerosis.

Due to the aforementioned concerns a satisfactory summary of product characteristics, labelling, package leaflet and risk management plan cannot be agreed at this stage.

Furthermore, the CHMP, in light of the negative recommendation, is of the opinion that it is not appropriate to conclude on the new active substance status at this time.